



United
Healthcare®
Community Plan

UNITEDHEALTHCARE® COMMUNITY PLAN:
RADIOLOGY IMAGING COVERAGE DETERMINATION GUIDELINE

Adult Oncology Imaging Guidelines (For Ohio Only)

V2.0.2024

Guideline Number: CSRAD0100H.C

Effective Date: November 15, 2024

Application (for Ohio Only)

This Medical Policy only applies to the state of Ohio. Any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-1-01.

Table of Contents

Guideline

Related Community Plan Policies

Application (For Ohio Only)

Guideline Development (Preface-1)

Benefits, Coverage Policies, and Eligibility Issues (Preface-2)

Clinical Information (Preface-3)

Coding Issues (Preface-4)

Whole-Body Imaging (Preface-5)

References (Preface-6)

Copyright Information (Preface-7)

Trademarks (Preface-8)

General Guidelines (ONC-1)

Primary Central Nervous System Tumors (ONC-2)

Squamous Cell Carcinomas of the Head and Neck (ONC-3)

Salivary Gland Cancers (ONC-4)

Melanomas and Other Skin Cancers (ONC-5)

Thyroid Cancer (ONC-6)

Small Cell Lung Cancer (ONC-7)

Non-Small Cell Lung Cancer (ONC-8)

Esophageal and GE Junction Cancer (ONC-9)

Other Thoracic Tumors (ONC-10)

Breast Cancer (ONC-11)

Sarcomas – Bone, Soft Tissue, and GIST (ONC-12)

Pancreatic Cancer (ONC-13)

Upper GI Cancers (ONC-14)

Neuroendocrine Cancers and Adrenal Tumors (ONC-15)

Colorectal and Small Bowel Cancer (ONC-16)

Renal Cell Cancer (RCC) (ONC-17)

Transitional Cell Cancer (ONC-18)

Prostate Cancer (ONC-19)

Testicular, Ovarian and Extragonadal Germ Cell Tumors (ONC-20)

Ovarian Cancer (ONC-21)

Uterine Cancer (ONC-22)

Cervical Cancer (ONC-23)

Anal Cancer & Cancers of the External Genitalia (ONC-24)

Multiple Myeloma and Plasmacytomas (ONC-25)

Leukemias, Myelodysplasia and Myeloproliferative Neoplasms (ONC-26)

Non-Hodgkin Lymphomas (ONC-27)
Hodgkin Lymphoma (ONC-28)
Hematopoietic Stem Cell Transplantation (ONC-29)
Medical Conditions with Cancer in the Differential Diagnosis (ONC-30)
**Metastatic Cancer, Carcinoma of Unknown Primary Site, and Other Types of
Cancer (ONC-31)**
Policy History and Instructions for Use

Related Community Plan Policies

Guideline

Related Community Plan Policies

Related Community Plan Policies

Related Community Plan Policies v2.0.2024

General Policies

- Abdomen Imaging Guidelines
- Breast Imaging Guidelines
- Cardiac Imaging Guidelines
- Chest Imaging Guidelines
- Neck Imaging Guidelines
- Pelvis Imaging Guidelines
- Spine Imaging Guidelines

Pediatric Policies

- Pediatric and Special Populations Oncology Imaging Guidelines

Application (For Ohio Only)

Guideline

Application (For Ohio Only)

Application (For Ohio Only)

Application for Ohio OH UHC v2.0.2024

- This Medical Policy only applies to the state of Ohio. Any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-1-01.

Guideline Development (Preface-1)

Guideline

Guideline Development (Preface-1.1)

Guideline Development (Preface-1.1)

PRF.GG.0001.1.UOH

v2.0.2024

- The UnitedHealthcare's evidence-based, proprietary clinical guidelines evaluate a range of advanced imaging and procedures, including NM, US, CT, MRI, PET, Radiation Oncology, Sleep Studies, as well as Cardiac, musculoskeletal and Spine interventions.
- UnitedHealthcare reserves the right to change and update the guidelines. The guidelines undergo a formal review annually. UnitedHealthcare's guidelines are based on current evidence supported by major national and international association and society guidelines and criteria, peer-reviewed literature, major treatises as well as, input from health plans, and practicing academic and community-based physicians.
- These guidelines are not intended to supersede or replace sound medical judgment, but instead, should facilitate the identification of the most appropriate imaging or other designated procedure given the individual's clinical condition. These guidelines are written to cover medical conditions as experienced by the majority of individuals. However, these guidelines may not be applicable in certain clinical circumstances, and physician judgment can override the guidelines.
- These guidelines provide evidence-based, clinical benefits with a focus on health care quality and patient safety.
- Clinical decisions, including treatment decisions, are the responsibility of the individual and his/her provider. Clinicians are expected to use independent medical judgment, which takes into account the clinical circumstances to determine individual management decisions.
- UnitedHealthcare supports the Choosing Wisely initiative (<https://www.choosingwisely.org/>) by the American Board of Internal Medicine (ABIM) Foundation and many national physician organizations, to reduce the overuse of diagnostic tests that are low value, no value, or whose risks are greater than the benefits.

Benefits, Coverage Policies, and Eligibility Issues (Preface-2)

Guideline

Benefits, Coverage Policies, and Eligibility Issues (Preface-2.1)
References (Preface-2)

Benefits, Coverage Policies, and Eligibility Issues (Preface-2.1)

PRF.BC.0002.1.UOH

v2.0.2024

Investigational and Experimental Studies

- Certain studies, treatments, procedures, or devices may be considered experimental, investigational, or unproven for any condition, illness, disease, injury being treated if one of the following is present:
 - if there is a paucity of supporting evidence;
 - if the evidence has not matured to exhibit improved health parameters;
 - if clinical utility has not been demonstrated in any condition; OR
 - if the study, treatment, procedure, or device lacks a collective opinion of support
- Supporting evidence includes standards that are based on credible scientific evidence published in peer-reviewed medical literature (such as well conducted randomized clinical trials or cohort studies with a sample size of sufficient statistical power) generally recognized by the relevant medical community. Collective opinion of support includes physician specialty society recommendations and the views of physicians practicing in relevant clinical areas when physician specialty society recommendations are not available.

Clinical and Research Trials

- Similar to investigational and experimental studies, clinical trial imaging requests will be considered to determine whether they meet UnitedHealthcare's evidence-based guidelines.
- Imaging studies which are inconsistent with established clinical standards, or are requested for data collection and not used in direct clinical management are not supported.

Legislative Mandate

- State and federal legislations may need to be considered in the review of advanced imaging requests.

References (Preface-2)

v2.0.2024

1. Coverage of Clinical Trials under the Patient Protection and Affordable Care Act; 42 U.S.C.A. § 300gg-8.

Clinical Information (Preface-3)

Guideline

Clinical Information (Preface-3.1)
References (Preface-3)

Clinical Information (Preface-3.1)

PRF.CL.0003.1.UOH

v2.0.2024

Clinical Documentation and Age Considerations

- UnitedHealthcare's guidelines use an evidence-based approach to determine the most appropriate procedure for each individual, at the most appropriate time in the diagnostic and treatment cycle. UnitedHealthcare's guidelines are framed by:
 - Clinical presentation of the individual, rather than the studies requested
 - Adequate clinical information that must be submitted to UnitedHealthcare in order to establish medical necessity for advanced imaging or other designated procedures includes, but is not limited to, the following:
 - Pertinent clinical evaluation should include a recent detailed history, physical examination²⁰ since the onset or change in symptoms, and/or laboratory and prior imaging studies.
 - Condition-specific guideline sections may describe additional clinical information which is required for a pertinent clinical evaluation.
 - The Spine and Musculoskeletal guidelines require x-ray studies from when the current episode of symptoms has started or changed; x-ray imaging does not have to be within the past 60 days.
 - Advanced imaging or other designated procedures should not be ordered prior to clinical evaluation of an individual by the physician treating the individual. This may include referral to a consultant specialist who will make further treatment decisions.
 - Other meaningful technological contact (telehealth visit, telephone or video call, electronic mail or messaging) since the onset or change in symptoms by an established individual can serve as a pertinent clinical evaluation.
 - Some conditions may require a face-to-face evaluation as discussed in the applicable condition-specific guideline sections.
 - A recent clinical evaluation may be unnecessary if the individual is undergoing a guideline-supported, scheduled follow-up imaging or other designated procedural evaluation. Exceptions due to routine surveillance indications are addressed in the applicable condition-specific guideline sections.
 - UnitedHealthcare's evidence-based approach to determine the most appropriate procedure for each individual requires submission of medical records pertinent to the requested imaging or other designated procedures.
- Many conditions affecting the pediatric population are different diagnoses than those occurring in the adult population. For those diseases which occur in both pediatric and adult populations, minor differences may exist in management due to individual

age, comorbidities, and differences in disease natural history between children and adults.

- Individuals who are 18 years old or younger¹⁹ should be imaged according to the Pediatric Imaging Guidelines if discussed in the condition-specific guideline sections. Any conditions not specifically discussed in the Pediatric Imaging Guidelines should be imaged according to the General Imaging Guidelines. Individuals who are >18 years old should be imaged according to the General Imaging Guidelines, except where directed otherwise by a specific guideline section.
- The terms “male” and “female” used in these guidelines refer to anatomic-specific diseases and disease predispositions associated with the individual's sex assigned at birth rather than their gender identity. It should be noted that gender identity and anatomic-specific diseases as well as disease predispositions are not always linked. As such, these guidelines should be applied to the individual's corresponding known or suspected anatomic-specific disease or disease predisposition. At UnitedHealthcare, we believe that it is important to understand how all individuals, including those who are gender-diverse, choose to identify themselves. To ensure that gender-diverse individuals are treated with respect and that decisions impacting their healthcare are made correctly and with sensitivity, UnitedHealthcare recognizes all individuals with the following gender marker options: Male, Female, Transgender Male, Transgender Female, “X”, and “Not Specified.”

General Imaging Information

- “Standard” or “conventional” imaging is most often performed in the initial and subsequent evaluations of malignancy. Standard or conventional imaging includes plain film, CT, MRI, or US.
 - Often, further advanced imaging is needed when initial imaging, such as ultrasound, CT, or MRI does not answer the clinical question. Uncertain, indeterminate, inconclusive, or equivocal may describe these situations.
- Appropriate use of contrast is a very important component of evidence-based advanced imaging use.
 - The appropriate levels of contrast for an examination (i.e., without contrast, with contrast, without and with contrast) is determined by the evidence-based guidance reflected in the condition-specific guideline sections.
 - If, during the performance of a non-contrast imaging study, there is the unexpected need to use contrast in order to evaluate a possible abnormality, then that is appropriate.¹

Ultrasound

- Diagnostic ultrasound uses high-frequency sound waves to evaluate soft tissue structures and vascular structures utilizing grey scale and Doppler techniques.
- Ultrasound allows for dynamic real-time imaging at the bedside.

- Ultrasound is limited in areas where there is dense bone or other calcification.
- Ultrasound also has a relatively limited imaging window so may be of limited value in evaluating very large abnormalities.
- In general, ultrasound is highly operator-dependent, and proper training and experience are required to perform consistent, high-quality evaluations.
- Indications for ultrasound may include, but are not limited to, the following:
 - Obstetric and gynecologic imaging
 - Soft tissue and visceral imaging of the chest, abdomen, pelvis, and extremities
 - Brain and spine imaging when not obscured by dense bony structures
 - Vascular imaging when not obscured by dense bony structures
 - Procedural guidance when not obscured by dense bony structures
 - Initial evaluation of ill-defined soft tissue masses or fullness and differentiating adenopathy from mass or cyst. Prior to advanced imaging, ultrasound can be very beneficial in selecting the proper modality, body area, image sequences, and contrast level that will provide the most definitive information for the individual.
- More specific guidance for ultrasound usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

Computed Tomography (CT)

- The AMA CPT[®] manual does not describe nor assign any minimum or maximum number of sequences for any CT study. CT imaging protocols are often influenced by the individual's clinical situation and additional sequences are not uncommon. There are numerous CT protocols that may be performed to evaluate specific clinical questions, and this technology is constantly undergoing development.
- CT utilizes ionizing radiation to create cross-sectional and volumetric images of the body.
 - Advantages over ultrasound include a much larger field of view and faster completion time in general. Disadvantages compared to ultrasound include lack of portability and exposure to ionizing radiation.
 - Advantages over MRI include faster imaging and a more spacious scanner area limiting claustrophobia. Disadvantages compared to MRI include decreased soft tissue definition, especially with non-contrast imaging, and exposure to ionizing radiation.
- CT can be performed without, with, or without and with intravenous (IV) contrast depending on the clinical indication and body area.
 - In general, non-contrast imaging is appropriate for evaluating structures with significant tissue density differences such as lung parenchyma and bony structures, or when there is a contraindication to contrast.
 - In general, CT with contrast is the most common level of contrast and can be used when there is need for improved vascular or soft tissue resolution, including better

- characterization of known or suspected malignancy, as well as infectious and inflammatory conditions.
- CT without and with contrast has a limited role as the risks of doubling the ionizing radiation exposure rarely outweigh the benefits of multiphase imaging, though there are some exceptions which include, but are not limited to, the following:
 - Characterization of a mass
 - Characterization of arterial and venous anatomy
 - CT with contrast may be used to better characterize findings on a very recent (within two weeks) inconclusive non-contrast CT where the guidelines would support CT without and with contrast.
 - More specific guidance for CT contrast usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.
 - Shellfish allergy:
 - It is commonly assumed that an allergy to shellfish indicates iodine allergy, and that this implies an allergy to iodinated contrast media used with CT. However, this is NOT true. Shellfish allergy is due to tropomyosins. Iodine plays no role in these allergic reactions. Allergies to shellfish do not increase the risk of reaction to iodinated contrast media any more than that of other allergens.¹
 - Enteric contrast (oral or rectal) is sometimes used in abdominal imaging. There is no specific CPT[®] code which refers to enteric contrast.
 - The appropriate contrast level and anatomic region in CT imaging is specific to the clinical indication, as listed in the condition-specific guideline sections.
 - CT should not be used to replace MRI in an attempt to avoid sedation unless it is listed as a recommended study the appropriate condition-specific guideline.
 - There are significant potential adverse effects associated with the use of iodinated contrast media. These include hypersensitivity reactions, thyroid dysfunction, and contrast-induced nephropathy (CIN). Individuals with impaired renal function are at increased risk for CIN.²
 - Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR <30 mL/min).
 - The use of CT contrast should proceed with caution in pregnant and breastfeeding individuals. There is a theoretical risk of contrast toxicity to the fetal and infant thyroid. The procedure can be performed if the specific need for that contrast-enhanced procedure outweighs risk to the fetus. Breastfeeding individuals may reduce this risk by choosing to pump and discard breast milk for 12-24 hours after the contrast injection.
 - CT without contrast may be appropriate if clinical criteria for CT with contrast are met AND the individual has:
 - Elevated blood urea nitrogen (BUN) and/or creatinine
 - Renal insufficiency
 - Allergies to iodinated contrast

- Thyroid disease which could be treated with I-131
- Diabetes
- Very elderly
- Urgent or emergent settings due to availability
- Trauma
- CT is superior to other imaging modalities in certain conditions including, but not limited to, the following:
 - Screening following trauma
 - Imaging pulmonary disease
 - Imaging abdominal and pelvic viscera
 - Imaging of complex fractures
 - Evaluation of inconclusive findings on Ultrasound or MRI, or if there is a contraindication to MRI
- More specific guidance for CT usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

Magnetic Resonance Imaging (MRI)

- The AMA CPT[®] manual does not describe nor assign any minimum or maximum number of sequences for any MRI study. MRI protocols are often influenced by the individual's clinical situation and additional sequences are not uncommon. There are numerous MRI sequences that may be performed to evaluate specific clinical questions, and this technology is constantly undergoing development.
- Magnetic Resonance Imaging (MRI) utilizes the interaction between the intrinsic radiofrequency of certain molecules in the body (hydrogen in most cases) and a strong external magnetic field.
 - MRI is often superior for advanced imaging of soft tissues and can also define physiological processes in some instances (e.g., edema, loss of circulation [AVN], and increased vascularity [tumors]).
 - MRI does not use ionizing radiation and even non-contrast images have much higher soft tissue definition than CT or Ultrasound.
 - MRI typically takes much longer than either CT or Ultrasound, and for some individuals may require sedation. It is also much more sensitive to individual motion that can degrade image quality than either CT or Ultrasound.
- MRI Breast and MRI Chest are not interchangeable, as they focus detailed sequences on different adjacent body parts.
- MRI may be utilized either as the primary advanced imaging modality, or when further definition is needed based on CT or ultrasound imaging.
- Most orthopedic and dental implants are not magnetic. These include hip and knee replacements; plates, screws, and rods used to treat fractures; and cavity fillings. Yet,

all of these metal implants can distort the MRI image if near the part of the body being scanned.

- Other implants, however, may have contraindications to MRI. These include the following:
 - Pacemakers
 - ICD or heart valves
 - Metal implants in the brain
 - Metal implants in the eyes or ears
 - Infusion catheters and bullets or shrapnel
- CT can therefore be an alternative study to MRI in these scenarios.
- The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.
- MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.
- MRI is commonly performed without, without and with contrast.
 - Non-contrast imaging offers excellent tissue definition.
 - Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.
 - Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.
 - Some specialized gadolinium and non-gadolinium contrast agents are available, and most commonly used for characterizing liver lesions.
 - MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.
 - MRI contrast is contraindicated in pregnant individuals.
 - More specific guidance for MRI contrast usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.
- MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.
 - Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR <30 mL/min).²
 - Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), the greater the chance of individuals developing NSF.
 - Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.^{3,4,5,6,7} The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadolinium retention in the brain is harmful and restricting

gadolinium-based contrast agents (GBCAs) use is not warranted at this time. It has been recommended that GBCA use should be limited to circumstances in which additional information provided by the contrast agent is necessary and the necessity of repetitive MRIs with GBCAs should be assessed.⁸

- A CT may be approved in place of an MRI when clinical criteria are met for MRI AND there is a contraindication to having an MRI (pacemaker, ICD, insulin pump, neurostimulator, etc.).
 - When replacing MRI with CT, contrast level matching should occur as follows:
 - MRI without contrast → CT without contrast
 - MRI without and with contrast → CT with contrast or CT without and with contrast
- The following situations may impact the appropriateness for MRI and or MR contrast:
 - Caution should be taken in the use of gadolinium in individuals with renal failure.
 - The use of gadolinium contrast agents is contraindicated during pregnancy unless the specific need for that procedure outweighs risk to the fetus.
 - MRI can be performed for non-ferromagnetic body metals (i.e., titanium), although some imaging facilities will consider it contraindicated if recent surgery, regardless of the metal type.
- MRI should not be used as a replacement for CT for the sole reason of avoidance of ionizing radiation when MRI is not supported in the condition-based guidelines, since it does not solve the problem of overutilization.
- MRI is superior to other imaging modalities in certain conditions including, but not limited to, the following:
 - Imaging the brain and spinal cord
 - Characterizing visceral and musculoskeletal soft tissue masses
 - Evaluating musculoskeletal soft tissues including ligaments and tendons
 - Evaluating inconclusive findings on ultrasound or CT
 - Individuals who are pregnant or have high radiation sensitivity
 - Suspicion, diagnosis, or surveillance of infections
- More specific guidance for MRI usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

Positron Emission Tomography (PET)

- PET is a nuclear medicine study that uses a positron emitting radiotracer to create cross-sectional and volumetric images based on tissue metabolism.
- Conventional imaging (frequently CT, sometimes MRI or bone scan) of the affected area(s) drives much of initial and restaging and surveillance imaging for malignancy and other chronic conditions. PET is not indicated for surveillance imaging unless specifically stated in the condition-specific guideline sections.
- PET/MRI is generally not supported, see **PET-MRI (Preface-5.3)**.

- PET is rarely performed as a single modality, but is typically performed as a combined PET/CT.
 - The unbundling of PET/CT into separate PET and diagnostic CT CPT[®] codes is not supported, because PET/CT is done as a single study.
- PET/CT lacks the tissue definition of CT or MRI, but is fairly specific for metabolic activity based on the radiotracer used.
- Indications for PET/CT may include the following:
 - Oncologic Imaging for evaluation of tumor metabolic activity
 - Cardiac Imaging for evaluation of myocardial metabolic activity
 - Brain Imaging for evaluation of metabolic activity for procedural planning
- More specific guidance for PET usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

Overutilization of Advanced Imaging

- A number of recent reports describe overutilization in many areas of advanced imaging and other procedures, which may include the following:
 - High-level testing without consideration of less invasive, lower cost options which may adequately address the clinical question at hand
 - Excessive radiation and costs with unnecessary testing
 - Defensive medical practice
 - CT without and with contrast (so called "double contrast studies") requests, which have few current indications
 - MRI requested in place of CT to avoid radiation without considering the primary indication for imaging
 - Adult CT settings and protocols used for smaller people and children
 - Unnecessary imaging procedures when the same or similar studies have already been conducted
- A review of the imaging or other relevant procedural histories of all individuals presenting for studies has been recognized as one of the more important processes that can be significantly improved. By recognizing that a duplicate or questionably indicated examination has been ordered for individuals, it may be possible to avoid exposing them to unnecessary risks.^{9,10} To avoid these unnecessary risks, the precautions below should be considered:
 - The results of initial diagnostic tests or radiologic studies to narrow the differential diagnosis should be obtained prior to performing further tests or radiologic studies.
 - The clinical history should include a potential indication such as a known or suspected abnormality involving the body part for which the imaging study is being requested. These potential indications are addressed in greater detail within the applicable guidelines.

- The results of the requested imaging procedures should be expected to have an impact on individual management or treatment decisions.
- Repeat imaging studies are not generally necessary unless there is evidence of disease progression, recurrence of disease, and/or the repeat imaging will affect an individual's clinical management.
- Pre-operative imaging/pre-surgical planning imaging/pre-procedure imaging is not indicated if the surgery/procedure is not indicated. Once the procedure has been approved or if the procedure does not require prior authorization, the appropriate pre-procedural imaging may be approved.

References (Preface-3)

v2.0.2024

1. Bettmann MA. Frequently Asked Questions: Iodinated Contrast Agents. *RadioGraphics*. 2004;24(suppl_1):S3-S10. doi: 10.1148/rg.24si045519.
2. Andreucci M, Solomon R, Tasanarong A. Side Effects of Radiographic Contrast Media: Pathogenesis, Risk Factors, and Prevention. *BioMed Res Int*. 2014;2014:1-20. doi: 10.1155/2014/741018.
3. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. *Radiology*. 2015;275(3):772-782. doi: 10.1148/radiol.15150025.
4. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-weighted MR Images: Relationship with Increasing Cumulative Dose of a Gadolinium-based Contrast Material. *Radiology*. 2014;270(3):834-841. doi: 10.1148/radiol.13131669.
5. Olchowy C, Cebulski K, Łasecki M, et al. The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review. Mohapatra S, ed. *PLOS ONE*. 2017;12(2):e0171704. doi: 10.1371/journal.pone.0171704.
6. Ramalho J, Castillo M, AlObaidy M, et al. High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear Gadolinium-based Contrast Agents. *Radiology*. 2015;276(3):836-844. doi:10.1148/radiol.2015150872.
7. Radbruch A, Weberling LD, Kieslich PJ, et al. Intraindividual Analysis of Signal Intensity Changes in the Dentate Nucleus After Consecutive Serial Applications of Linear and Macrocyclic Gadolinium-Based Contrast Agents. *Invest Radiol*. 2016;51(11):683-690. doi: 10.1097/rni.0000000000000308.
8. FDA Warns That Gadolinium-Based Contrast Agents (GBCAs) Are Retained in the Body; Requires New Class Warnings. <https://www.fda.gov/media/109825/download>.
9. Amis ES, Butler PF, Applegate KE, et al. American College of Radiology White Paper on Radiation Dose in Medicine. *J Am Coll Radiol*. 2007;4(5):272-284. doi: 10.1016/j.jacr.2007.03.002.
10. Powell AC, Long JW, Kren EM, Gupta AK, Levin DC. Evaluation of a Program for Improving Advanced Imaging Interpretation. *J Patient Saf*. 2019;15(1):69-75. doi: 10.1097/PTS.000000000000034.5.
11. FDA. White Paper: Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging. Page Last Updated: 06/14/2019. <https://www.fda.gov/Radiation-EmittingProducts/RadiationSafety/RadiationDoseReduction/ucm199994.htm>.
12. Update on FDA approach to safety issue of gadolinium retention after administration of gadolinium-based contrast agents. <https://www.fda.gov/media/116492/download>.
13. Blumfield E, Swenson DW, Iyer RS, Stanescu AL. Gadolinium-based contrast agents — review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients. *Pediatr Radiol*. 2019;49(4):448-457. doi: 10.1007/s00247-018-4304-8.
14. American College of Radiology. ACR – SPR – SRU Practice Parameter for the Performing and Interpreting Diagnostic Ultrasound Examinations. Revised 2017. (Resolution 32). Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/US-Perf-Interpret.pdf>.
15. American College of Radiology. ACR–SPR Practice Parameter for Performing FDG-PET/CT in Oncology. Revised 2021. (Resolution 20). Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/FDG-PET-CT.pdf>.
16. American College of Radiology. ACR Practice Parameter for Performing and Interpreting Magnetic Resonance Imaging (MRI). Revised 2017. (Resolution 10). Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Perf-Interpret.pdf>.
17. American College of Radiology. ACR Practice Parameter for Performing and Interpreting Diagnostic Computed Tomography (CT). Revised 2017. (Resolution 22). Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Perf-Interpret.pdf>.
18. Lohrke J, Frenzel T, Endrikat J, et al. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. *Adv Ther*. 2016;33(1):1-28. doi: 10.1007/s12325-015-0275-4.
19. Implementation Guide: Medicaid State Plan Eligibility Eligibility Groups Mandatory Coverage Infants and Children under Age 19. Available at: <https://www.hhs.gov/guidance/document/implementation-guide-medicaid-state-plan-eligibility-eligibility-groups-aeu-mandatory-2>.

20. History and Physicals - Understanding the Requirements. Available at: <https://www.jointcommission.org/standards/standard-faqs/hospital-and-hospital-clinics/provision-of-care-treatment-and-services-pc/000002272/>.
21. Mammarrappallil JG, Rankine L, Wild JM, Driehuys B. New Developments in Imaging Idiopathic Pulmonary Fibrosis With Hyperpolarized Xenon Magnetic Resonance Imaging. *J Thorac Imaging*. 2019;34(2):136-150. doi: 10.1097/rti.0000000000000392.
22. Wang JM, Robertson SH, Wang Z, et al. Using hyperpolarized ¹²⁹Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis. *Thorax*. 2017;73(1):21-28. doi: 10.1136/thoraxjnl-2017-210070.

Coding Issues (Preface-4)

Guideline

3D Rendering (Preface-4.1)

CT-, MR-, or Ultrasound-Guided Procedures (Preface-4.2)

Unlisted Procedures/Therapy Treatment Planning (Preface-4.3)

CPT[®] 76380 Limited or Follow-up CT (Preface-4.5)

SPECT/CT Imaging (Preface-4.6)

CPT[®] 76140 Interpretation of an Outside Study (Preface-4.7)

Quantitative MR Analysis of Tissue Composition (Preface-4.8)

HCPCS Codes (Preface-4.9)

References (Preface-4)

3D Rendering (Preface-4.1)

PRF.CD.0004.1.UOH

v2.0.2024

CPT[®] 76376 and CPT[®] 76377

- Both codes require concurrent supervision of the image post-processing 3D manipulation of the volumetric data set and image rendering.
 - Concurrent supervision is defined as active physician participation in and monitoring of the reconstruction process including design of the anatomic region that is to be reconstructed; determination of the tissue types and actual structures to be displayed (e.g., bone, organs, and vessels); determination of the images or cine loops that are to be archived; and, monitoring and adjustment of the 3D work product. The American College of Radiology (ACR) recommends that it is best to document the physician's supervision or participation in the 3D reconstruction of images.
- These two codes differ in the need for and use of an independent workstation for post-processing.
 - CPT[®] 76376 reports procedures not requiring image post-processing on an independent workstation.
 - CPT[®] 76377 reports procedures that require image post-processing on an independent workstation.
- These 3D rendering codes should not be used for 2D reformatting.
- Two-dimensional reconstruction (e.g., reformatting an axial scan into the coronal plane) is now included in all cross-sectional imaging base codes and is not separately reimbursable.
- The codes used to report 3D rendering for ultrasound and echocardiography are also used to report the 3D post processing work on CT, MRI, and other tomographic modalities.
- Providers may be required to obtain prior authorization on these 3D codes even if prior authorization is not required for the echocardiography and/or ultrasound procedure codes. It may appear that UnitedHealthcare pre-authorizes echocardiography and/or ultrasound when, in fact, it may only be the 3D code that needs the prior authorization.
- CPT[®] codes for 3D rendering should not be billed in conjunction with computer-aided detection (CAD), MRA, CTA, nuclear medicine SPECT studies, PET, PET/CT, Mammogram, MRI Breast, US Breast, CT Colonography (virtual colonoscopy), Cardiac MRI, Cardiac CT, or Coronary CTA studies.

- CPT[®] 76377 (3D rendering requiring image post-processing on an independent workstation) or CPT[®] 76376 (3D rendering not requiring image post-processing on an independent workstation) can be considered in the following clinical scenarios:
 - Bony conditions:
 - Evaluation of congenital skull abnormalities in newborns, infants, and toddlers (usually for pre-operative planning)
 - Complex fractures (comminuted or displaced)/dislocations of any joint (for pre-operative planning when conventional imaging is insufficient)
 - Spine fractures, pelvic/acetabulum fractures, intra-articular fractures (for pre-operative planning when conventional imaging is insufficient)
 - Pre-operative planning for other complex surgical cases
 - Complex facial fractures
 - Pre-operative planning for other complex surgical cases
 - Cerebral angiography
 - Pelvis conditions:
 - Uterine intra-cavitary lesion when initial US is equivocal: See **Abnormal Uterine Bleeding (AUB) (PV-2.1)** and **Leiomyoma/Uterine Fibroids (PV-12.1)** in the Pelvis Imaging Guidelines.
 - Hydrosalpinxes or peritoneal cysts when initial US is indeterminate: See **Complex Adnexal Masses (PV-5.3)** in the Pelvis Imaging Guidelines.
 - Lost IUD (inability to feel or see IUD string) with initial US: See **Intrauterine Device (PV-10.1)** in the Pelvis Imaging Guidelines.
 - Uterine anomalies with initial US: See **Uterine Anomalies (PV-14.1)** in the Pelvis Imaging Guidelines.
 - Infertility: See **Initial Infertility Evaluation, Female (PV-9.1)** in the Pelvis Imaging Guidelines.
 - Abdomen conditions:
 - CT Urogram: See **Hematuria and Hydronephrosis (AB-39)** in the Abdomen Imaging Guidelines.
 - MRCP: See **MR Cholangiopancreatography (MRCP) (AB-27)** in the Abdomen Imaging Guidelines.

CT-, MR-, or Ultrasound-Guided Procedures (Preface-4.2)

PRF.CD.0004.2.A

v2.0.2024

- CT-, MR-, and Ultrasound-guidance procedure codes contain all of the imaging necessary to guide a needle or catheter. It is inappropriate to routinely bill a diagnostic procedure code in conjunction with a guidance procedure code.
- Imaging studies performed as part of a CT-, MR-, or Ultrasound-guided procedure should be reported using the CPT[®] codes in the following table:

TABLE: Imaging Guidance Procedure Codes

CPT [®]	Description
19085	Biopsy, breast, with placement of breast localization device(s), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including MR guidance
19086	Biopsy, breast, with placement of breast localization device(s), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including MR guidance
75989	Imaging guidance for percutaneous drainage with placement of catheter (all modalities)
76942	Ultrasonic guidance for needle placement
77011	CT guidance for stereotactic localization
77012	CT guidance for needle placement
77013	CT guidance for, and monitoring of parenchymal tissue ablation
77021	MR guidance for needle placement
77022	MR guidance for, and monitoring of parenchymal tissue ablation

CPT® 19085 and CPT® 19086

- The proper way to bill an MRI-guided breast biopsy is CPT® 19085 (Biopsy, breast, with placement of breast localization device(s), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including MR guidance). Additional lesions should be billed using CPT® 19086.
 - **CPT® 77021** (MR guidance for needle placement) is not an appropriate code for a breast biopsy.

CPT® 75989

- This code is used to report imaging guidance for a percutaneous drainage procedure in which a catheter is left in place.
- This code can be used to report whether the drainage catheter is placed under fluoroscopy, Ultrasound-, CT-, or MR-guidance modality.

CPT® 77011

- A stereotactic CT localization scan is frequently obtained prior to sinus surgery. The dataset is then loaded into the navigational workstation in the operating room for use during the surgical procedure. The information provides exact positioning of surgical instruments with regard to the individual's 3D CT images.³
- In most cases, the pre-operative CT is a technical-only service that does not require interpretation by a radiologist.
 - The imaging facility should report CPT® 77011 when performing a scan not requiring interpretation by a radiologist.
 - If a diagnostic scan is performed and interpreted by a radiologist, the appropriate diagnostic CT code (e.g., CPT® 70486) should be used.
 - It is not appropriate to report both CPT® 70486 and CPT® 77011 for the same CT stereotactic localization imaging session.
 - 3D Rendering (CPT® 76376 or CPT® 76377) should not be reported in conjunction with CPT® 77011 (or CPT® 70486 if used). The procedure inherently generates a 3D dataset.

CPT® 77012 (CT) and CPT® 77021 (MR)

- These codes are used to report imaging guidance for needle placement during biopsy, aspiration, and other percutaneous procedures.
- They represent the radiological supervision and interpretation of the procedure and are often billed in conjunction with surgical procedure codes.
 - For example, CPT® 77012 is reported when CT guidance is used to place the needle for a conventional arthrogram.
 - Only codes representing percutaneous surgical procedures should be billed with CPT® 77012 and CPT® 77021. It is inappropriate to use with surgical codes for open, excisional, or incisional procedures.

- **CPT[®] 77021** (MR guidance for needle placement) is not an appropriate code for breast biopsy.
 - CPT[®] 19085 would be appropriate for the first breast biopsy site and CPT[®] 19086 would be appropriate for additional concurrent biopsies.

CPT[®] 77013 (CT) and CPT[®] 77022 (MR)

- These codes include the initial guidance to direct a needle electrode to the tumor(s), monitoring for needle electrode repositioning within the lesion, and as necessary for multiple ablations to coagulate the lesion and confirmation of satisfactory coagulative necrosis of the lesion(s) and comparison to pre-ablation images.
 - **NOTE:** CPT[®] 77013 should only be used for non-bone ablation procedures.
 - CPT[®] 20982 includes CT guidance for bone tumor ablations.
 - Only codes representing percutaneous surgical procedures should be billed with CPT[®] 77013 and CPT[®] 77022. It is inappropriate to use with surgical codes for open, excisional, or incisional procedures.
- CPT[®] 77012 and CPT[®] 77021 (as well as guidance codes CPT[®] 76942 [US], and CPT[®] 77002 - CPT[®] 77003 [fluoroscopy]) describe radiologic guidance by different modalities.
 - Only one unit of any of these codes should be reported per individual encounter (date of service). The unit of service is considered to be the individual encounter, not the number of lesions, aspirations, biopsies, injections, or localizations.

Unlisted Procedures/Therapy Treatment Planning (Preface-4.3)

PRF.CD.0004.3.UOH

v2.0.2024

CPT [®]	Description
76497	Unlisted CT procedure (e.g., diagnostic or interventional)
76498	Unlisted MR procedure (e.g., diagnostic or interventional)
78999	Unlisted procedure, diagnostic nuclear medicine

- These unlisted codes should be reported whenever a diagnostic or interventional CT or MR study is performed in which an appropriate anatomic site-specific code is not available.
 - A Category III code that describes the procedure performed must be reported rather than an unlisted code if one is available.
- CPT[®] 76497 or CPT[®] 76498 (Unlisted CT or MRI procedure) can be considered in the following clinical scenarios:
 - Studies done for navigation and planning for neurosurgical procedures (i.e., Stealth or Brain Lab Imaging)^{1,2}
 - Custom joint arthroplasty planning (not as an alternative recommendation): See **Osteoarthritis (MS-12.1)** in the Musculoskeletal Imaging Guidelines.
 - Any procedure/surgical planning if thinner cuts or different positional acquisition (than those on the completed diagnostic study) are needed. These could include navigational bronchoscopy: See **Navigational Bronchoscopy (CH-1.7)** in the Chest Imaging Guidelines.

Therapy Treatment Planning

- Radiation Therapy Treatment Planning: See **Unlisted Procedure Codes in Oncology (ONC-1.5)** in the Oncology Imaging Guidelines.

CPT[®] 76380 Limited or Follow-up CT (Preface-4.5)

PRF.CD.0004.5.UOH

v2.0.2024

- CPT[®] 76380 describes a limited or follow-up CT scan. The code is used to report any CT scan, for any given area of the body, in which the work of a full diagnostic code is not performed.
- Common examples include, but are not limited to, the following:
 - Limited sinus CT imaging protocol
 - Limited or follow-up slices through a known pulmonary nodule
 - Limited slices to assess a non-healing fracture (such as the clavicle)
- Limited CT (CPT[®] 76380) is not indicated for treatment planning purposes. See **Unlisted Procedure Codes in Oncology (ONC-1.5)** in the Oncology Imaging Guidelines.
- It is inappropriate to report CPT[®] 76380, in conjunction with other diagnostic CT codes, to cover 'extra slices' in certain imaging protocols.
 - There is no specific number of sequences or slices defined in any CT CPT[®] code definition.
 - The AMA, in *CPT[®] 2019*, does not describe nor assign any minimum or maximum number of sequences or slices for any CT study.
 - A few additional slices or sequences are not uncommon.
 - CT imaging protocols are often influenced by the individual's clinical situation. Sometimes the protocols require more time and sometimes less.

SPECT/CT Imaging (Preface-4.6)

PRF.CD.0004.6.A

v2.0.2024

- SPECT/CT involves SPECT (Single Photon Emission Computed Tomography) nuclear medicine imaging and CT for optimizing location, accuracy, and attenuation correction and combines functional and anatomic information.
 - Common studies using this modality include ^{123}I - or ^{131}I -Metaiodobenzylguanidine (MIBG) and octreotide scintigraphy for neuroendocrine tumors.
- Hybrid Nuclear/CT scan can be reported as CPT[®] 78830 (single area and single day), CPT[®] 78831 (2 or more days), or CPT[®] 78832 (2 areas with one day and 2-day study).
- CPT[®] 78072 became effective January 1, 2013 for SPECT/CT parathyroid nuclear imaging.

CPT[®] 76140 Interpretation of an Outside Study (Preface-4.7)

PRF.CD.0004.7.UOH

v2.0.2024

- It is inappropriate to use diagnostic imaging codes for interpretation of a previously performed exam that was completed at another facility.
 - If the outside exam is being used for comparison with a current exam, the diagnostic code for the current examination includes comparison to the prior study.⁴
 - CPT[®] 76140 is the appropriate code to use for an exam which was completed elsewhere and a secondary interpretation of the images is requested.⁵

Quantitative MR Analysis of Tissue Composition (Preface-4.8)

PRF.CD.0004.8.A

v2.0.2024

- Category III CPT[®] codes for quantitative analysis of multiparametric-MR (mp-MRI) data with and without an associated diagnostic MRI have been established. Quantitative mp-MRI uses software to analyze tissue physiology of visceral organs and other anatomic structures non-invasively. At present, these procedures are primarily being used in clinical trials and there is no widely recommended indications in clinical practice. As such, these procedures are considered to be investigational and experimental for coverage purposes.
 - CPT[®] 0648T (without diagnostic MRI) and CPT[®] 0649T (with diagnostic MRI) refer to data analysis with and without associate imaging of a single organ, with its most common use being LiverMultiScan (LMS).
 - See **Fatty Liver (AB-29.2)** in the Abdomen Imaging Guidelines.
 - CPT[®] 0697T (without diagnostic MRI) and CPT[®] 0698T (with diagnostic MRI) refer to data analysis with and without associate imaging of a multiple organs, with its most common use being CoverScan.

HCPCS Codes (Preface-4.9)

PRF.CD.0004.9.UOH

v2.0.2024

- Healthcare Common Procedure Coding System (HCPCS) codes are utilized by some hospitals in favor of the typical Level-III CPT[®] codes. These codes are typically 4 digits preceded by a C or S.⁶
 - Many of these codes have similar code descriptions to Level-III CPT[®] codes (i.e., C8931 – MRA with dye, Spinal Canal; and, CPT[®] 72159 – MRA Spinal Canal).
 - If cases are submitted with HCPCS codes with similar code descriptions to the typical Level-III CPT[®] codes, those procedures should be managed in the same manner as the typical CPT[®] codes.
 - HCPCS code management is discussed further in the applicable guideline sections.
- Requests for many Healthcare Common Procedure Coding System (HCPCS) codes, including non-specific codes such as S8042 (Magnetic resonance imaging [MRI], low-field), should be redirected to a more appropriate and specific CPT[®] code. Exceptions are noted in the applicable guideline sections.

References (Preface-4)

v2.0.2024

1. Society of Nuclear Medicine and Molecular Imaging Coding Corner. Available at: <http://www.snmmi.org/ClinicalPractice/CodingCornerPT.aspx?ItemNumber=1786>.
2. Intraoperative MR. Brainlab. Available at: <https://www.brainlab.com/surgery-products/overview-neurosurgery-products/intraoperative-mr/>
3. Experience the Advanced 3D Sinus Surgery Planning with Scopis Building Blocks planning software. Scopis Planning. Available at: <http://planning.scopis.com/>.
4. ACR Radiology Coding Source™ March-April 2007 Q and A. Available at: <https://www.acr.org/Advocacy-and-Economics/Coding-Source/ACR-Radiology-Coding-Source-March-April-2007-Q-and-A>.
5. Chung CY, Alson MD, Duszak R, Degnan AJ. From imaging to reimbursement: what the pediatric radiologist needs to know about health care payers, documentation, coding and billing. *Pediatr Radiol*. 2018;48(7):904-914. doi: 10.1007/s00247-018-4104-1.
6. HCPCS - General Information from CMS.gov. Available at: www.cms.gov/medicare/coding/medhcpcsgeninfo.

Whole-Body Imaging (Preface-5)

Guideline

Whole-Body CT Imaging (Preface-5.1)
Whole-Body MR Imaging (Preface-5.2)
PET-MRI (Preface-5.3)
References (Preface-5)

Whole-Body CT Imaging (Preface-5.1)

PRF.WB.0005.1.UOH

v2.0.2024

- Whole-body CT or LifeScan (CT Brain, Chest, Abdomen, and Pelvis) for screening of asymptomatic individuals is not indicated. The performance of whole-body screening CT examinations in healthy individuals does not meet any of the current validity criteria for screening studies and there is no clear documentation of benefit versus radiation risk.
- Whole-body low-dose CT is supported for oncologic staging in Multiple Myeloma. See **Multiple Myeloma and Plasmacytomas (ONC-25)** in the Oncology Imaging Guidelines.

Whole-Body MR Imaging (Preface-5.2)

PRF.WB.0005.2.A

v2.0.2024

- Whole-body MRI (WBMRI) is, with the exception of select cancer predisposition syndromes and autoimmune conditions discussed below, generally not supported at this time due to lack of standardization in imaging technique and lack of evidence that WBMRI improves outcome for any individual disease state.
 - While WBMRI has the benefit of whole-body imaging and lack of radiation exposure, substantial variation still exists in the number of images, type of sequences (STIR vs. diffusion weighting, for example), and contrast agent(s) used.
- Coding considerations:
 - There are no established CPT[®] or HCPCS codes for reporting WBMRI.
 - WBMRI is at present only reportable using CPT[®] 76498. All other methods of reporting whole-body MRI are inappropriate including the following:
 - Separate diagnostic MRI codes for multiple individual body parts
 - MRI Bone Marrow Supply (CPT[®] 77084)
- Disease-specific considerations:
 - Cancer screening:
 - Interval WBMRI is recommended for cancer screening in individuals with select cancer predisposition syndromes. Otherwise, WBMRI has not been shown to improve outcomes for cancer screening.
 - For additional information, see **Li-Fraumeni Syndrome (LFS) (PEDONC-2.2)**, **Hereditary Paraganglioma-Pheochromocytoma (HPP) Syndromes (PEDONC-2.13)**, or **Constitutional Mismatch Repair Deficiency (CMMRD or Turcot Syndrome) (PEDONC-2.15)** in the Pediatric Oncology Imaging Guidelines.
 - Cancer staging and restaging:
 - While the feasibility of WBMRI has been established, data remain conflicting on whether WBMRI is of equivalent diagnostic accuracy compared with standard imaging modalities such as CT, scintigraphy, and PET imaging.
 - Evidence has not been published establishing WBMRI as a standard evaluation for any type of cancer.
 - Autoimmune disease:
 - WBMRI can be approved in some situations for individuals with chronic recurrent multifocal osteomyelitis.
 - For additional information, see **Chronic Recurrent Multifocal Osteomyelitis (PEDMS-10.2)** in the Pediatric Musculoskeletal Imaging Guidelines.

PET-MRI (Preface-5.3)

PRF.WB.0005.3.A

v2.0.2024

- PET-MRI is generally not supported for a vast majority of oncologic and neurologic conditions due to lack of standardization in imaging technique and interpretation. However, it may be appropriate in select circumstances when the following criteria are met:
 - The individual meets condition-specific guidelines for PET-MRI OR
 - The individual meets ALL of the following:
 - The individual is a pediatric patient or being treated under a pediatric guideline and treatment plan AND
 - The individual meets guideline criteria for PET-CT, AND
 - PET-CT is not available at the treating institution, AND
 - The provider requests PET-MRI in lieu of PET-CT
- When the above criteria are met, PET-MRI may be reported using the code combination of PET Whole-Body (CPT[®] 78813) and MRI Unlisted (CPT[®] 76498). All other methods of reporting PET-MRI are inappropriate.
 - When clinically appropriate, diagnostic MRI codes may be indicated at the same time as the PET-MRI code combination.
- For more information, see **PET Imaging in Pediatric Oncology (PEDONC-1.4)** in the Pediatric Oncology Imaging Guidelines, and **PET Brain Imaging (PEDHD-2.3)** and **Special Imaging Studies in Evaluation for Epilepsy Surgery (PEDHD-6.3)** in the Pediatric Head Imaging Guidelines.

References (Preface-5)

v2.0.2024

1. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. *Lancet Oncol.* 2011;12(6):559-567. doi: 10.1016/S1470-2045(11)70119-X.
2. Siegel MJ, Acharyya S, Hoffer FA, et al. Whole-Body MR Imaging for Staging of Malignant Tumors in Pediatric Patients: Results of the American College of Radiology Imaging Network 6660 Trial. *Radiology.* 2013;266(2):599-609. doi: 10.1148/radiol.12112531.
3. Antoch G. Whole-Body Dual-Modality PET/CT and Whole-Body MRI for Tumor Staging in Oncology. *JAMA.* 2003;290(24):3199. doi: 10.1001/jama.290.24.3199.
4. Lauenstein TC, Semelka RC. Emerging techniques: Whole-body screening and staging with MRI. *J Magn Reson Imaging.* 2006;24(3):489-498. doi: 10.1002/jmri.20666.
5. Khanna G, Sato TSP, Ferguson P. Imaging of Chronic Recurrent Multifocal Osteomyelitis. *RadioGraphics.* 2009;29(4):1159-1177. doi: 10.1148/rg.294085244.
6. Ferguson PJ, Sandu M. Current Understanding of the Pathogenesis and Management of Chronic Recurrent Multifocal Osteomyelitis. *Curr Rheumatol Rep.* 2012;14(2):130-141. doi: 10.1007/s11926-012-0239-5.
7. National Comprehensive Cancer Network[®] (NCCN[®]). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]): Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2023. February 13, 2023. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V.3.2023. ©National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed July 10, 2023. The NCCN Guidelines[®] and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines[®], go online to NCCN.org.

References (Preface-6)

Guideline

References (Preface-6.1)

References (Preface-6.1)

PRF.RF.0006.1.A

v2.0.2024

- Complete reference citations for the journal articles are embedded within the body of the guidelines and/or may be found on the Reference pages at the end of some guideline sections.
- The website addresses for certain references are included in the body of the guidelines but are not hyperlinked to the actual website.
- The website address for the American College of Radiology (ACR) Appropriateness Criteria[®] is <http://www.acr.org>.

Copyright Information (Preface-7)

Guideline

Copyright Information (Preface-7.1)

Copyright Information (Preface-7.1)

PRF.CI.0007.1.UOH

v2.0.2024

- ©2024 United HealthCare Services, Inc. All rights reserved. No part of these materials may be changed, reproduced, or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording, or in any information storage or retrieval system, without the prior express written permission of United HealthCare Services, Inc.

Trademarks (Preface-8)

Guideline

Trademarks (Preface-8.1)

Trademarks (Preface-8.1)

PRF.TM.0008.1.A

v2.0.2024

- **CPT® (Current Procedural Terminology)** is a registered trademark of the American Medical Association (AMA). **CPT®** five-digit codes, nomenclature, and other data are copyright 2024 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values, or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

General Guidelines (ONC-1)

Guideline

Abbreviations for Oncology Imaging Guidelines

General Guidelines (ONC-1.0)

Key Principles (ONC-1.1)

Phases of Oncology Imaging and General Phase-Related Considerations (ONC-1.2)

Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)

PET Imaging in Oncology (ONC-1.4)

Unlisted Procedure Codes in Oncology (ONC-1.5)

Predisposition Syndromes (ONC-1.6)

References (ONC-1)

Abbreviations for Oncology Imaging Guidelines

ON.GG.Abbreviations.A

v2.0.2024

Abbreviations for Oncology Imaging Guidelines

ACTH	adrenocorticotrophic hormone
AFP	alpha-fetoprotein
ALKP	alkaline phosphatase
AP	anteroposterior
betaHCG	beta human chorionic gonadotropin
CA 125	cancer antigen 125 test
CA 19-9	cancer antigen 19-9
CA 15-3	cancer antigen 15-3
CA 27-29	cancer antigen 27-29
CBC	complete blood count
CEA	carcinoembryonic antigen
CNS	central nervous system
CR	complete response
CTA	computed tomography angiography
DCIS	ductal carcinoma in situ
DLBCL	diffuse large B cell lymphomas
DRE	digital rectal exam
EGD	esophagogastroduodenoscopy
ENT	ear, nose, throat
EOT	end of therapy
ERCP	endoscopic retrograde cholangiopancreatography
ESR	erythrocyte sedimentation rate

Abbreviations for Oncology Imaging Guidelines

EUA	exam under anesthesia
EUS	endoscopic ultrasound
FDG	fluorodeoxyglucose
FNA	fine needle aspiration
FUO	fever of unknown origin
GE	gastroesophageal
GI	gastrointestinal
GU	genitourinary
GTR	gross total resection
HG	high-grade
HIV	human immunodeficiency disease
HRPC	hormone refractory prostate cancer
hypermet	hypermetabolic
IFRT	involved field radiation therapy
inv	invasive
LAR	low anterior resection
LCIS	lobular carcinoma in situ
LDH	lactate dehydrogenase
LFT	liver function tests
LND	lymph node dissection
MALT	mucosa associated lymphoid tissue
maint	maintenance
MEN	multiple endocrine neoplasia
MG	myasthenia gravis
MGUS	monoclonal gammopathy of unknown significance
MIBG	I-123 metaiodobenzylguanidine scintigraphy
MRA	magnetic resonance angiography

Abbreviations for Oncology Imaging Guidelines

MRI	magnetic resonance imaging
MUGA	'multiple gated acquisition' cardiac nuclear scan
MWA	microwave ablation
NaF	sodium fluoride
NET	neuroendocrine tumor
NCCN [®]	National Comprehensive Cancer Network
NHL	non-Hodgkin's lymphoma
NPC	nasopharyngeal carcinoma
NSABP	National Surgical Adjuvant Breast and Bowel Project
NSAIDS	nonsteroidal anti-inflammatory drugs
NSCLC	non-small cell lung cancer
NSGCT	non-seminomatous germ cell tumor
PA	posteroanterior
PCI	prophylactic cranial irradiation
PET	positron emission tomography
COG	Children's Oncology Group
PSA	prostate specific antigen
RFA	radiofrequency ablation
RPLND	retroperitoneal lymph node dissection
SqCCa	squamous cell carcinoma
SCLC	small cell lung cancer
SIADH	syndrome of inappropriate secretion of antidiuretic hormone
TCC	transitional cell carcinoma
TLH	total laparoscopic hysterectomy
TNM	tumor node metastasis staging system
TSH	thyroid-stimulating hormone
TURBT	trans-urethral resection of bladder tumor

Abbreviations for Oncology Imaging Guidelines

VIPoma	vasoactive intestinal polypeptide
WLE	wide local incision
WB-MRI	whole body MRI
WM	Waldenstrom's macroglobulinemia
WBXRT	whole brain radiation therapy

General Guidelines (ONC-1.0)

ON.GG.0001.0.UOH

v2.0.2024

- A recent clinical evaluation (within 60 days) or meaningful contact (telephone call, electronic mail or messaging) should be performed prior to considering advanced imaging, unless the individual is undergoing guideline-supported scheduled off therapy surveillance evaluation or cancer screening. The clinical evaluation may include a relevant history and physical examination, including biopsy, appropriate laboratory studies, and results of non-advanced or advanced imaging modalities.
- Unless otherwise stated in the disease-specific guideline, a histological confirmation of malignancy (or recurrence) and the stage of disease is required to perform a medical necessity review of the requested imaging.
- Generally, the studies listed in the disease-specific sections reflect the studies supported by current literature and research for that condition. If a study is not listed, then it is not supported.
- Routine imaging of brain, spine, neck, chest, abdomen, pelvis, bones, or other body areas is not indicated except where explicitly stated in a diagnosis-specific guideline section, or if one of the following applies:
 - Known prior disease involving the requested body area
 - New or worsening symptoms or physical exam findings involving the requested body area (including non-specific findings such as ascites or pleural effusion)
 - New finding on basic imaging study such as plain x-ray or ultrasound
 - New finding on adjacent body area CT/MRI study (i.e., pleural effusion observed on CT abdomen)
- Unless otherwise stated in the disease-specific guideline, advanced imaging of asymptomatic individuals is not routinely supported without signs or symptoms of systemic involvement of cancer.
- Repeat imaging studies are not generally necessary unless there is evidence of disease progression, recurrence of disease, and/or the repeat imaging will affect an individual's clinical management.
- Conventional imaging performed prior to diagnosis should not be repeated unless there is a delay of at least 6 weeks since previous imaging and treatment initiation or there are new or significantly worsening clinical signs or symptoms

Phase	Imaging Timeframe
After definitive local therapy of primary tumor (surgery or radiation therapy)	<ul style="list-style-type: none"> Follow surveillance guidelines
During adjuvant chemotherapy	<ul style="list-style-type: none"> Follow surveillance guidelines
After ablative therapy	<ul style="list-style-type: none"> See disease-specific guidelines
During chemotherapy or immunotherapy for measurable disease	<ul style="list-style-type: none"> Every 2 cycles (generally every 6 to 8 weeks)
During endocrine/hormonal therapy for measurable disease	<ul style="list-style-type: none"> Every 3 months (12 weeks)
Measurable metastatic disease being monitored off therapy	<ul style="list-style-type: none"> Every 3 months (12 weeks)
Minimal metastatic disease on maintenance therapy	<ul style="list-style-type: none"> Every 3 months (12 weeks)
Surveillance for history of metastatic disease with complete response and being observed off-therapy	<ul style="list-style-type: none"> Imaging typically not indicated beyond 5 years from completion of treatment for metastatic disease

- Advanced imaging is not indicated for evaluation of in situ or non-invasive cancers or cancer surveillance after complete surgical removal of primary disease unless otherwise stated in the cancer-specific guidelines.
- Advanced imaging is not indicated for monitoring disease in individuals who choose to not receive standard oncologic therapy, but may be receiving alternative therapies or palliative care and/or hospice. All advanced imaging indicated for initial staging of the specific cancer type can be approved once when the individual is considering initiation of a standard therapeutic approach (surgery, chemotherapy, or radiation therapy).
- Brain imaging is performed for signs or symptoms of brain disease
 - MRI Brain without and with contrast (CPT[®] 70553) is the recommended study for evaluation of suspected or known brain metastases. If a non-contrast CT head shows suspicious lesion, MRI brain may be obtained to further characterize the lesion
 - CT without and with contrast (CPT[®] 70470) can be approved when MRI is contraindicated or not available, or if there is skull bone involvement

- Certain malignancies including, but not limited to melanoma and lung cancer have indications for brain imaging for asymptomatic individuals
- If stage IV disease is demonstrated elsewhere or if systemic disease progression is noted, refer to disease specific guidelines
- Initiation of angiogenesis therapy is not an indication for advanced imaging of the brain in asymptomatic individuals (Avastin/Bevacizumab; < 3% risk of bleeding and < 1% risk of serious bleeding)
- Bone Scan:
 - Primarily used for evaluation of bone metastases in individuals with solid malignancies.
 - Indications for bone scan in individuals with history of malignancy include – bone pain, rising tumor markers, elevated alkaline phosphatase or in individuals with primary bone tumor.
 - For evaluation of suspected or known bony metastases, CPT[®] 78306 (Nuclear bone scan whole body), may be approved.
 - Radiopharmaceutical Localization scan SPECT (CPT[®] 78803 or CPT[®] 78831) or SPECT/CT (CPT[®] 78830 or CPT[®] 78832) may be approved as an add-on test for further evaluation of a specific area of interest.
 - CPT[®] codes 78300 (Nuclear bone scan limited), 78305 (Nuclear bone scan multiple areas) or 78315 do not have any indications in oncology nuclear medicine imaging.
- Bone scan supplemented by plain x-rays are the initial imaging modalities for suspected malignant bone pain. For specific imaging indications, see also:
 - **Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)**
 - **Bone (Non-Vertebral) Metastases (ONC-31.5)**
 - **Spinal/Vertebral Metastases (ONC-31.6)**
 - **Carcinoma of Unknown Primary Site (ONC-31.7)**
- Advanced imaging used for radiation therapy treatment planning should not be authorized using any of the diagnostic imaging codes for CT, MRI, or PET.
 - In the absence of written payor guidelines, advanced imaging performed in support of radiation therapy treatment planning should be reported with CPT[®] 76498 for Unlisted MRI or CPT[®] 76497 for Unlisted CT scan
- Delay PET/CT for at least 12 weeks after completion of radiation treatment, unless required sooner for imminent surgical resection.
- PET/CT may be considered prior to biopsy in order to determine a more favorable site for biopsy when a prior biopsy was nondiagnostic or a relatively inaccessible site is contemplated which would require invasive surgical intervention for biopsy attempt.
- PET/CT may be indicated if:
 - Conventional imaging (CT, MRI or bone scan) reveals findings that are inconclusive or negative, with continued suspicion for recurrence

- Unless specified in diagnosis-specific guideline section PET/CT Imaging is NOT indicated for:
 - Infection, inflammation, trauma, post-operative healing, granulomatous disease, rheumatological conditions
 - Concomitantly with separate diagnostic CT studies
 - Conclusive evidence of distant or diffuse metastatic disease on recent conventional imaging studies
 - Metastatic disease in the central nervous system (CNS)
 - Lesions less than 8 mm in size
 - Follow up after localized therapy (i.e. radiofrequency ablation, embolization, stereotactic radiation, etc.)
 - Rare malignancies, due to lack of available evidence regarding the diagnostic accuracy of PET in rare cancers
 - Surveillance
 - Serial monitoring of individuals who are not currently receiving anti-tumor treatment or are receiving maintenance treatment
 - Serial monitoring of FDG avidity until resolution.
 - PET/CT avidity in a residual mass at the end of planned therapy is not an indication for PET/CT imaging during surveillance.
 - Residual mass that has not changed in size since the last conventional imaging does not justify PET imaging
- Unless otherwise specified for a specific cancer type, once PET has been documented to be negative for a given individual's cancer or all PET-avid disease has been surgically resected, PET should not be used for continued disease monitoring or surveillance.
- PET/MRI is generally not supported by UnitedHealthcare for imaging adults with a vast majority of oncologic conditions due to lack of standardization in imaging technique and interpretation.
 - However, it may be indicated in certain pediatric oncologic conditions. See: **PET Imaging in Pediatric Oncology (PEDONC-1.4)** for indications.
- The specific radiotracer planned to be used with PET/CT imaging is required to perform a medical necessity review. Indications for PET/CT imaging using non-FDG radiotracers are listed in diagnosis-specific guidelines.
 - Supported radiotracers:
 - ¹⁸F-FDG
 - ⁶⁸Gallium DOTATATE (NETSPOT[®]) for low-grade neuroendocrine tumors and medullary thyroid cancer
 - ⁶⁴Cu-DOTATATE (DETECTNET[®]) for low-grade neuroendocrine tumors
 - ⁶⁸Ga-DOTA-TOC for low-grade neuroendocrine tumors
 - ¹¹C Choline for prostate cancer

- ¹⁸F-Fluciclovine (AXUMIN[®]) for prostate cancer
- ⁶⁸Ga PSMA-11 for prostate cancer
- ¹⁸F Piflufolastat (Pylarify[®]) for prostate cancer
- ⁶⁸Ga Gozetotide (Illuccix[®] and Locametz[®]) for prostate cancer
- ¹⁸F Flotufolastat (Posluma[®]) for prostate cancer
- ¹⁸F Fluoroestradiol (Cerianna[®]) for breast cancer
- Unsupported radiotracers:
 - ¹⁸F-Na Fluoride PET bone scan
 - PET/CT imaging using isotopes other than those specified above
- Octreotide scan:
 - Specific for low and intermediate grade neuroendocrine tumors which express specific cell surface somatostatin receptors. See cancer specific guidelines for recommended use.
 - One of the following codes may be approved when Octreotide scan is requested:
 - CPT[®] 78802 (Radiopharmaceutical localization of tumor whole-body single day study)
 - CPT[®] 78804 (Radiopharmaceutical localization of tumor whole-body two or more days)
 - In addition to one of the above CPT codes, CPT[®] 78803 (Radiopharmaceutical localization of tumor SPECT), SPECT CPT[®] 78831, or hybrid SPECT/CT (CPT[®] 78830 or 78832) may be approved as an add-on test for further evaluation of a specific area of interest.

Clinical Trials

- Similar to investigational and experimental studies, clinical trial imaging requests will be considered to determine whether they meet UnitedHealthcare's evidence-based guidelines.
- Imaging studies which are inconsistent with established clinical standards, or are requested for data collection and not used in direct clinical management are not supported.

Key Principles (ONC-1.1)

ON.GG.0001.1.A
v2.0.2024

AGE APPROPRIATE GUIDELINES	
Age of Individual	Appropriate Imaging Guidelines
≥18 years old at initial diagnosis	<ul style="list-style-type: none"> General Oncology Imaging Guidelines, except where directed otherwise by a specific guideline section
<18 years old at initial diagnosis	<ul style="list-style-type: none"> Pediatric and Special Populations Oncology Imaging Guidelines, except where directed otherwise by a specific guideline section
15 to 39 years old at initial diagnosis (defined as Adolescent and Young Adult (AYA) oncology individuals)	<ul style="list-style-type: none"> When unique guidelines for a specific cancer type exist only in either General Oncology or Pediatric and Special Populations Oncology, AYA individuals should be imaged according to the guideline section for their specific cancer type, regardless of the individual's age When unique guidelines for a specific cancer type exist in both General Oncology and Pediatric and Special Populations Oncology, AYA individuals should be imaged according to the age rule in the previous bullet

- Conventional Imaging (mostly CT, sometimes MRI or bone scan) of the affected area(s) drives much of initial and re-staging and surveillance. PET is not indicated for surveillance imaging unless specifically stated in the diagnosis-specific guideline sections
- Brain imaging is performed for signs or symptoms of brain disease
 - MRI Brain without and with contrast (CPT[®] 70553) is the recommended study for evaluation of suspected or known brain metastases.
 - MRI Brain without and with contrast (CPT[®] 70553) may be obtained if a non-contrast CT Head shows suspicious lesion.
 - CT Head without and with contrast (CPT[®] 70470) can be approved when MRI is contraindicated or not available, or if there is skull bone involvement.
 - Initiation of angiogenesis therapy is not an indication for advanced imaging of the brain in asymptomatic individuals (Avastin/Bevacizumab; <3% risk of bleeding and <1% risk of serious bleeding)

- Individuals receiving cardiotoxic chemotherapy (such as doxorubicin, trastuzumab, pertuzumab, mitoxantrone, etc.) may undergo cardiac evaluation – at baseline and for monitoring while on active therapy.
 - Echocardiography (CPT[®] 93306, CPT[®] 93307, or CPT[®] 93308) rather than MUGA scan for determination of LVEF and/or wall motion.
 - MUGA Scan may be performed instead of ECHO in individuals who have a low LV ejection fraction of <50% on a prior ECHO or MUGA, pre-existing left ventricular wall motion abnormalities from ischemic or non-ischemic cardiomyopathies, congestive heart failure or when ECHO is technically limited and prevents accurate assessment of LV function.
 - A prior MUGA is not a reason to approve another MUGA (it is not necessary to compare LVEF by the same modality)
 - The timeframe for monitoring the ejection fraction should be determined by the provider, but no more often than baseline and at every 6 weeks.
 - May repeat every 4 weeks if cardiotoxic chemotherapeutic drug is withheld for significant left ventricular cardiac dysfunction.
 - See: **Oncologic Indications for Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD) (CD-12.1)** in the Cardiology Imaging Guidelines
- CTA or MRA of a specific anatomic region is indicated when requested for surgical planning when there is suspected vascular proximity to proposed resection margin.
- Adults (≥18 years) with a diagnosis of Li-Fraumeni Syndrome (LFS) may be screened for malignancy with a Whole-Body MRI (CPT[®] 76498) on an annual basis. Annual Brain MRI (CPT[®] 70553) may be performed as part of Whole-Body MRI or as a separate exam. Due to lack of standardization of technique, interpretation, and availability of Whole-Body MRI, individuals with LFS are encouraged to participate in clinical trials.

Use of Contrast

- CT imaging should be performed with contrast for known or suspected body regions, unless contraindicated.
 - Shellfish allergy is not a contraindication to contrast. Individuals with known shellfish allergy do not have contrast reaction any more often than other atopic individuals or individuals with other food allergies.
 - For iodinated contrast dye allergy, either CT scans without contrast or MRI scans without and with contrast are indicated.
 - If CT scanning is considered strongly indicated in an individual with known contrast allergy, CT with contrast may be considered to be safely performed following prednisone premedication over a 24-hour period prior to the study.
- For individuals with renal insufficiency which precludes contrast use, CT without contrast appropriate disease-specific areas should be offered. Further imaging (such as MRI) may be indicated if non-contrast CT results are inconclusive.

- Severe renal insufficiency, i.e. an eGFR less than 30, is a contraindication for an MRI using a gadolinium-based contrast agent (GBCA) as well. In individuals with eGFR greater than 40, GBCA administration can be safely performed. GBCA administered to individuals with acute kidney injury or severe chronic kidney disease can result in a syndrome of nephrogenic systemic fibrosis (NSF), but GBCAs are not considered nephrotoxic at dosages approved for MRI.
- Gadolinium deposition has been found in individuals with normal renal function following the use of gadolinium based contrast agents (GBCAs).
 - The U.S. Food and Drug Administration (FDA) is investigating the risk of brain deposits following repeated use of GBCAs.
 - The FDA has noted that, “It is unknown whether these gadolinium deposits are harmful or can lead to adverse health effects.” and have recommended:
 - To reduce the potential for gadolinium accumulation, health care professionals should consider limiting GBCA use to clinical circumstances in which the additional information provided by the contrast is necessary.
 - Health care professionals are also urged to reassess the necessity of repetitive GBCA MRIs in established treatment protocols.

Radiation Exposure

- The use of MRI in place of CT scans to reduce risk of secondary malignancy from radiation exposure during CT is not supported by the peer-reviewed literature. Unless otherwise specified in the Guidelines, MRI in place of CT scans for this purpose alone is not indicated. In some instances (i.e., testicular cancer surveillance), MRI may be considered inferior to CT scans.

Phases of Oncology Imaging and General Phase-Related Considerations (ONC-1.2)

ON.GG.0001.2.A
v2.0.2024

Phases of Oncology Imaging	Definition
Screening	Imaging requested for individuals at increased risk for a particular cancer in the absence of known clinical signs or symptoms
Suspected Diagnosis	Imaging requested to evaluate a suspicion of cancer, prior to histological confirmation
Initial work-up and Staging	Imaging requested after biopsy confirmation and prior to starting specific treatment
Treatment response or Interim Restaging	Imaging performed during active treatment with chemotherapy, targeted therapy, immunotherapy, or endocrine therapy
Restaging of locally treated lesions	Imaging performed to evaluate primary or metastatic lesions with ablation using cryoablation, radiofrequency, radioactive isotope, microwave or chemotherapy
Restaging / Suspected Recurrence	Imaging requested when there is suspicion for progression or recurrence of known cancer based on clinical signs/symptoms, laboratory tests or basic imaging studies
Surveillance	Imaging performed in individuals who: <ul style="list-style-type: none"> • Are asymptomatic or have chronic stable symptoms, and • Have no clinical suspicion of change in disease status, and • Are not receiving active anti-tumor treatment or are receiving maintenance treatment

General Phase-Related Considerations

- Conventional imaging performed prior to diagnosis should not be repeated unless there is a delay of at least 6 weeks since previous imaging and treatment initiation or there are new or significantly worsening clinical signs or symptoms

Phase	Imaging Timeframe
After definitive local therapy of primary tumor (surgery or radiation therapy)	<ul style="list-style-type: none"> • Follow surveillance guidelines
During adjuvant chemotherapy or endocrine therapy	<ul style="list-style-type: none"> • Follow surveillance guidelines
After ablative therapy	<ul style="list-style-type: none"> • See disease-specific guidelines
During chemotherapy or immunotherapy for measurable disease	<ul style="list-style-type: none"> • Every 2 cycles (generally every 6 to 8 weeks)
During endocrine/hormonal therapy for measurable disease	<ul style="list-style-type: none"> • Every 3 months (12 weeks)
Metastatic disease on maintenance therapy	<ul style="list-style-type: none"> • Every 3 months (12 weeks)
Measurable metastatic disease being monitored off therapy	<ul style="list-style-type: none"> • Every 3 months (12 weeks) for up to 5 years after completion of treatment for metastatic disease

Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)

ON.GG.0001.3.A

v2.0.2024

- This section does not apply to PET imaging. PET imaging considerations can be found in **PET Imaging in Oncology (ONC-1.4)**
- Bone Scan:
 - Primarily used for evaluation of bone metastases in individuals with solid malignancies.
 - Indications for bone scan in individuals with history of malignancy include – bone pain, rising tumor markers, elevated alkaline phosphatase or in individuals with primary bone tumor.
 - For evaluation of suspected or known bony metastases, CPT[®] 78306 (Nuclear bone scan whole-body), may be approved.
 - Radiopharmaceutical Localization scan SPECT (CPT[®] 78803 or CPT[®] 78831) or SPECT/CT (CPT[®] 78830 or CPT[®] 78832) may be approved as an add-on test for further evaluation of a specific area of interest with prior positive whole-body scan or documented bone metastasis.
 - CPT[®] codes 78300 (Nuclear bone scan limited), 78305 (Nuclear bone scan multiple areas) or 78315 do not have any indications in oncology nuclear medicine imaging.
- Octreotide scan:
 - Specific for low and intermediate grade neuroendocrine tumors which express specific cell surface somatostatin receptors. See cancer specific guidelines for recommended use.
 - One of the following codes may be approved when Octreotide scan is requested:
 - CPT[®] 78802 (Radiopharmaceutical localization of tumor whole-body single day study)
 - CPT[®] 78804 (Radiopharmaceutical localization of tumor whole-body two or more days)
 - In addition to one of the above CPT codes, CPT[®] 78803 (Radiopharmaceutical localization of tumor SPECT), SPECT CPT[®] 78831, or hybrid SPECT/CT (CPT[®] 78830 or 78832) may be approved as an add-on test for further evaluation of a specific area of interest.
- Bone marrow imaging:
 - This study is rarely performed for evaluation of the entire bone marrow in conditions like myeloproliferative disorders, sickle cell bone infarct or ischemia, avascular necrosis or myeloma

- The correct CPT code for this study is CPT[®] 78104 (Diagnostic Nuclear Medicine Procedures on the Hematopoietic, Reticuloendothelial and Lymphatic System)
- Brain imaging SPECT with Technetium-99m or thallium-201 (CPT[®] 78803):
 - Immunocompromised individuals with mass lesion detected on CT or MRI for differentiation between lymphoma and infection
 - In distinguishing recurrent brain tumor from radiation necrosis
- Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s):
 - CPT[®] 78800, CPT[®] 78801, CPT[®] 78802, CPT[®] 78804, CPT[®] 78803, CPT[®] 78831 (SPECT), or CPT[®] 78830 or CPT[®] 78832 (SPECT/CT)
 - For evaluation of fever of unknown origin and osteomyelitis
 - For suspected infections such as infected central lines, grafts or shunts
- Gallium Isotope Scan:
 - Radiopharmaceutical Localization of tumor (CPT[®] 78800, CPT[®] 78801, CPT[®] 78802, CPT[®] 78803, or CPT[®] 78804), SPECT CPT[®] 78831, or hybrid SPECT/CT CPT[®] 78830 or 78832
 - This may be rarely used in place of PET/CT scan when PET/CT scan not available and PET/CT is indicated by guidelines for lymphoma, sarcoma, melanoma or myeloma

PET Imaging in Oncology (ONC-1.4)

ON.GG.0001.4.UOH

v2.0.2024

- CPT codes:
 - PET imaging in oncology should use PET/CT fusion (CPT[®] 78815 or CPT[®] 78816) Unbundling PET/CT imaging into separate PET and diagnostic CT codes is otherwise not supported.
 - The decision whether to use skull base to mid-femur (“eyes to thighs”) procedure code for PET (CPT[®] 78812 or CPT[®] 78815) or whole-body PET (CPT[®] 78813 or CPT[®] 78816) is addressed in the diagnosis-specific guideline sections.
 - “Limited area” protocol is done infrequently, but may be considered, and is reported with PET (CPT[®] 78811) or for PET/CT (CPT[®] 78814).
- Radiotracers:
 - Unless specified otherwise, the term “PET” refers to ¹⁸F-FDG-PET and PET/CT fusion studies
 - Indications for PET/CT imaging using non-FDG radiotracers are listed in diagnosis-specific guidelines. The indications may be as follows:
- Supported radiotracers:
 - ¹⁸F-FDG
 - ⁶⁸Gallium DOTATATE (NETSPOT[®]) for low-grade neuroendocrine tumors and medullary thyroid cancer
 - ⁶⁴Cu-DOTATATE (DETECTNET[®]) for low-grade neuroendocrine tumors
 - ⁶⁸Ga-DOTA-TOC for low-grade neuroendocrine tumors
 - ¹¹C Choline for prostate cancer
 - ¹⁸F-Fluciclovine (AXUMIN[®]) for prostate cancer
 - ⁶⁸Ga PSMA-11 for prostate cancer
 - ¹⁸F Piflufolastat (Pylarify[®]) for prostate cancer
 - ⁶⁸Ga Gozetotide (Illuccix[®] and Locametz[®]) for prostate cancer
 - ¹⁸F Flotufolastat (Posluma[®]) for prostate cancer
 - ¹⁸F Fluoroestradiol (Cerianna[®]) for breast cancer
- Unsupported radiotracers:
 - ¹⁸F-Na Fluoride PET bone scan
 - PET/CT imaging using isotopes other than those specified above

CPT/ HCPCS Code	Code Description	Brand or common name	Guideline Section and Cancer Type
A9552	¹⁸ F Fluoro deoxyglucose	FDG	Various guideline sections where PET is indicated
A9580	¹⁸ F Sodium fluoride	N/A	ONC-1
A9587	⁶⁸ Ga-68 Dotatate	NETSPOT [®]	ONC-15: Low-grade neuroendocrine tumors, ONC-6: Medullary thyroid cancer
A9515	¹¹ C Choline	N/A	ONC-19, Prostate Cancer
A9588	¹⁸ F-Fluciclovine	AXUMIN [®]	ONC-19, Prostate Cancer
A9593 A9594	⁶⁸ Ga PSMA-11	N/A	ONC-19, Prostate Cancer
A9595	¹⁸ F Piflufolastat	Pylarify [®]	ONC-19, Prostate Cancer
A9596	⁶⁸ Ga Gozetotide	Illuccix [®]	ONC-19, Prostate Cancer
A9800	⁶⁸ Ga Gozetotide	Locametz [®]	ONC-19, Prostate Cancer
A9608	¹⁸ F Flotufolastat	Posluma [®]	ONC-19, Prostate Cancer
A9591	¹⁸ F Fluoroestradiol	Cerianna [®]	ONC-11, Breast Cancer
A9592	⁶⁴ Cu Copper dotatate	Detectnet [®]	ONC-15, Low-grade neuroendocrine tumors
C9067	⁶⁸ Ga Gallium-DOTA-TOC	N/A	ONC-15, Low-grade neuroendocrine tumors

- Unless specified in diagnosis-specific guideline section PET/CT Imaging is NOT indicated for:
 - Infection, inflammation, trauma, post-operative healing, granulomatous disease, rheumatological conditions
 - Concomitantly with separate diagnostic CT studies

- Conclusive evidence of distant or diffuse metastatic disease on recent conventional imaging studies
- Metastatic disease in the central nervous system (CNS)
- Lesions less than 8 mm in size
- Follow up after localized therapy (i.e. radiofrequency ablation, embolization, stereotactic radiation, etc.)
- Rare malignancies, due to lack of available evidence regarding the diagnostic accuracy of PET in rare cancers
- Surveillance
 - Serial monitoring of individuals who are not currently receiving anti-tumor treatment or are receiving maintenance treatment
 - Serial monitoring of FDG avidity until resolution.
 - PET/CT avidity in a residual mass at the end of planned therapy is not an indication for PET/CT imaging during surveillance.
 - Residual mass that has not changed in size since the last conventional imaging does not justify PET imaging
- Unless otherwise specified for a specific cancer type, once PET has been documented to be negative for a given individual's cancer or all PET-avid disease has been surgically resected, PET should not be used for continued disease monitoring or surveillance.

PET/CT may be indicated if:

- Conventional imaging (CT, MRI or bone scan) reveals findings that are inconclusive or negative, with continued suspicion for recurrence
- The individual is undergoing salvage treatment for a recurrent solid tumor with residual measurable disease on conventional imaging and confirmed repeat negative PET imaging will allow the individual to transition from active treatment to surveillance.
- PET/CT may be considered prior to biopsy in order to determine a more favorable site for biopsy when a prior biopsy was nondiagnostic or a relatively inaccessible site is contemplated which would require invasive surgical intervention for biopsy attempt.

PET/CT for rare malignancies is not covered by UnitedHealthcare guidelines due to lack of available evidence regarding diagnostic accuracy of PET/CT in the majority of rare cancers. Conventional imaging studies should be used for initial staging and treatment response for these diagnoses. PET/CT can be approved if all of the following apply:

- Conventional imaging (CT, MRI or bone scan) reveals equivocal or suspicious findings
- No other specific metabolic imaging (MIBG, octreotide, technetium, etc.) is appropriate for the disease type

- The submitted clinical information describes a specific decision regarding the individual's care that will be made based on the PET/CT results
- Delay PET/CT for at least 12 weeks after completion of radiation treatment, unless required sooner for imminent surgical resection.
- PET mammography (PEM, generally reported with CPT[®] 78811) is considered experimental and investigational at this time.

Unlisted Procedure Codes in Oncology (ONC-1.5)

ON.GG.0001.5.UOH

v2.0.2024

- UnitedHealthcare does not routinely authorize requests for PET associated with image-directed biopsy or radiation therapy treatment planning.
- There is often no unique procedure code for a service performed solely for treatment planning purposes. AMA instructions in the CPT state that if no specific code exists for a particular service, the service is reported with an unlisted code.
- Advanced imaging being used for radiation therapy treatment planning should not be authorized using any of the diagnostic imaging codes for CT, MRI or PET. Advanced imaging performed in support of radiation therapy treatment planning should be reported with:
 - **CPT[®] 76498 for Unlisted MRI** – when MRI will be used for treatment planning of radiation therapy to be delivered ONLY to the brain, prostate and cervix. The use of this code for radiation treatment planning of any other cancers/body parts not listed above may be reviewed on a case-by-case basis.
 - **CPT[®] 76497 for Unlisted CT** – may NOT be used for radiation treatment planning. CT imaging performed in support of radiation therapy treatment planning is bundled in with the concurrent radiation treatment authorization codes and a separate authorization for treatment planning is not required.
 - Imaging associated with image-directed biopsy should be reported with the corresponding interventional codes. See also: **CT-, MR-, or Ultrasound-Guided Procedures (Preface-4.2)** in the Preface Imaging Guidelines.
 - For advanced imaging used solely for the purpose of Surgical planning, see: **Unlisted Procedures/Therapy treatment planning (Preface-4.3)** in the Preface Imaging Guidelines

Predisposition Syndromes (ONC-1.6)

ON.GG.0001.6.A

v2.0.2024

- For predisposition syndrome screening in adult individuals, see: **Screening Imaging in Cancer Predisposition Syndromes (PEDONC-2)** in the Pediatric Oncology Imaging Guidelines

References (ONC-1)

v2.0.2024

1. ACR Committee on Drugs and Contrast Media. *ACR Manual on Contrast Media, version 10.3*. Reston, VA: American College of Radiology; 2018.
2. The American College of Radiology. *Practice parameter for the performance of skeletal scintigraphy (bone scan)*. Rev. 2017.
3. The American College of Radiology. *Practice parameter for performing FDG-PET/CT in oncology*. Rev. 2016.
4. The American College of Radiology. *Practice parameter for the performance of tumor scintigraphy with gamma cameras*. Rev. 2015.
5. Erdi YE. Limits of tumor detectability in nuclear medicine and PET. *Mol Imaging Radionucl Ther*. 2012;21(1):23-28. doi:10.4274/Mirt.128.
6. Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. *Oncology*. 2010;79(1):27-38. doi:10.1159/000314980.
7. ACR Appropriateness Criteria. *Pretreatment planning of Invasive cancer of Cervix*. Rev. 2015.
8. ACR Appropriateness Criteria. *External Beam Radiation therapy treatment planning for clinically localized prostate cancer*. Rev. 2016.
9. Metcalfe P, Liney GP, Holloway L, et al. The potential for an enhanced role for MRI in radiation-therapy treatment planning. *Technol Cancer Res Treat*. 2013;12(5):429-46. doi:10.7785/tcrt.2012.500342.
10. Daly MB, Pal T, AlHilli Z, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 – February 13, 2023, Genetic/Familial High Risk Assessment: Breast and Ovarian, available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Genetic/Familial High Risk Assessment: Breast and Ovarian V3.2023 – February 13, 2023 ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
11. Coverage of Clinical Trials under the Patient Protection and Affordable Care Act; 42 U.S.C.A. § 300gg-8.
12. Shah MH, Goldner WS, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2022 – December 21, 2022. Neuroendocrine tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Neuroendocrine tumors V2.2022 – December 21, 2022. ©2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.

Primary Central Nervous System Tumors (ONC-2)

Guideline

Primary Central Nervous System Tumors – General Considerations (ONC-2.1)
Low Grade Gliomas (ONC-2.2)
High Grade Gliomas (ONC-2.3)
Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumors (sPNET) (ONC-2.4)
Ependymoma (ONC-2.5)
Central Nervous System Germ Cell Tumors (ONC-2.6)
CNS Lymphoma (Also Known as Microglioma) (ONC-2.7)
Meningiomas (Intracranial and Intraspinal) (ONC-2.8)
Spinal Cord Tumors (Benign and Malignant) (ONC-2.9)
Choroid Plexus Tumors (ONC-2.10)
References (ONC-2)

Primary Central Nervous System Tumors – General Considerations (ONC-2.1)

ON.CN_0002.1.UOH

v2.0.2024

- This guideline section applies to primary CNS tumors only. For imaging guidelines in metastatic brain cancer, see the appropriate diagnosis-specific section or **Brain Metastases (ONC-31.3)** for imaging guidelines.
- Primary brain tumors presenting only with uncomplicated headache are very uncommon. Most primary brain tumors present with specific CNS symptoms.
- Histologic confirmation is critical. Therapeutic decisions should not be made on radiographic findings alone, except for ANY of the following:
 - Medically fragile individuals for whom attempted biopsy carries excess medical risk, as stated in writing by both the attending physician and surgeon.
 - Brain stem tumors or other sites where the imaging findings are pathognomonic and the risk of permanent neurological damage is excessive with even a limited biopsy attempt.
- For evaluation of known or suspected spinal cord compromise, see: **Spinal/Vertebral Metastases (ONC-31.6)**
- For suspected brain tumors in neurofibromatosis, see: **Screening Imaging in Cancer Predisposition Syndromes (PEDONC-2)** in the Pediatric Oncology Imaging Guidelines
- Rare tumors occurring more commonly in the pediatric population should be imaged according to the imaging guidelines in: **Pediatric Central Nervous System Tumors (PEDONC-4)** in the Pediatric Oncology Imaging Guidelines

Indication	Imaging Study
Characterization and follow up of all brain tumors	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) • CT Head without and with contrast (CPT[®] 70470) can be approved when MRI is contraindicated or not available, or there is skull bone involvement • CT Head (contrast as requested) can be approved for preoperative planning when requested by the operating surgeon

Indication	Imaging Study
Preoperative planning or to clarify inconclusive findings on MRI or CT	<ul style="list-style-type: none"> • MRA Head (CPT[®] 70544) or CTA Head (CPT[®] 70496)
Within 24 to 72 hours following brain tumor surgery	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)
Clinical deterioration or development of new neurological features	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) • MRI Spine without and with contrast (Cervical-CPT[®] 72156, Thoracic-CPT[®] 72157, Lumbar-CPT[®] 72158) for signs/symptoms of spinal involvement or if spinal involvement is suspected

MR Spectroscopy in Brain Tumors (MRS, CPT[®] 76390)

- MRS is only supported for use in brain tumors of specified histologies where diagnostic accuracy has been established in peer-reviewed literature
 - See diagnosis-specific guidelines for MRS indications
- MRS is considered investigational/experimental for all other histologies and indications not listed in a diagnosis-specific guideline section.

PET Brain Imaging (CPT[®] 78608 and CPT[®] 78609)

- PET Brain Metabolic Imaging (CPT[®] 78608) is only supported for use in brain tumors of specified histologies where diagnostic accuracy has been established in peer-reviewed literature
- PET Brain metabolic imaging (CPT[®] 78608) is considered investigational/experimental for all other histologies and indications not listed in a diagnosis-specific guideline section.
- PET Brain perfusion imaging (CPT[®] 78609) is not indicated in the evaluation or management of primary CNS tumors
- Body PET studies (CPT[®] 78811, CPT[®] 78812, and CPT[®] 78813) and fusion PET/CT studies (CPT[®] 78814, CPT[®] 78815, or CPT[®] 78816) are not indicated in the evaluation or management of primary CNS tumors
- See: **Other Imaging Studies (HD-24)** in the Head Imaging Guidelines for details on other advanced neuro-imaging studies

Low Grade Gliomas (ONC-2.2)

ON.CN.0002.2.A

v2.0.2024

- These tumors are defined as having a WHO histologic grade of I or II (out of IV), can occur anywhere in the CNS, and includes the following tumors:
 - Pilocytic Astrocytoma
 - Fibrillary (or Diffuse) Astrocytoma
 - Optic Pathway Gliomas
 - Pilomyxoid Astrocytoma
 - Oligodendroglioma
 - Oligoastrocytoma
 - Oligodendrocytoma
 - Subependymal Giant Cell Astrocytoma (SEGA)
 - Ganglioglioma
 - Gangliocytoma
 - Dysembryoplastic infantile astrocytoma (DIA)
 - Dysembryoplastic infantile ganglioglioma (DIG)
 - Dysembryoplastic neuroepithelial tumor (DNT)
 - Tectal plate gliomas
 - Cervicomedullary gliomas
 - Pleomorphic xanthoastrocytoma (PXA)
 - Any other glial tumor with a WHO grade of I or II

Indication	Imaging Study
Initial Staging	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) if not already done • MRI Spine without and with contrast (Cervical-CPT[®] 72156, Thoracic-CPT[®] 72157, Lumbar-CPT[®] 72158) <ul style="list-style-type: none"> ◦ MRI Spine with contrast only (Cervical-CPT[®] 72142, Thoracic-CPT[®] 72147, Lumbar-CPT[®] 72149) can be approved if being performed immediately following a contrast-enhanced MRI Brain

Indication	Imaging Study
After initial resection or other treatment (radiation therapy, etc.)	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)
For individuals undergoing chemotherapy treatment	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) every 2 cycles • Individuals with spinal cord involvement at diagnosis can have MRI without and with contrast of the involved spinal region on the same schedule as MRI brain
<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Determine need for biopsy when transformation to high-grade glioma is suspected based on clinical symptoms or recent MRI findings • Evaluate a brain lesion of indeterminate nature when the study will be used to determine whether biopsy/resection can be safely postponed 	<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • PET Brain Metabolic Imaging (CPT[®] 78608) • MRI Perfusion imaging (CPT[®] 70553)
<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Distinguish low-grade from high-grade gliomas • Evaluate a brain lesion of indeterminate nature when the study will be used to determine whether biopsy/resection can be safely postponed • Distinguish radiation-induced tumor necrosis from progressive disease within 18 months of completing radiotherapy 	<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • MR Spectroscopy (CPT[®] 76390) • MRI Perfusion imaging (CPT[®] 70553)
Suspected intracranial or intraspinal recurrence	<ul style="list-style-type: none"> • All imaging supported for initial staging may be repeated

Indication	Imaging Study
Surveillance	<ul style="list-style-type: none">• MRI Brain without and with contrast (CPT[®] 70553) every 3 months for 2 years, then every 6 months thereafter• Individuals with spinal cord involvement at diagnosis can have MRI Spine without and with contrast (Cervical-CPT[®] 72156, Thoracic-CPT[®] 72157, Lumbar-CPT[®] 72158) on the same schedule as MRI Brain

High Grade Gliomas (ONC-2.3)

ON.CN.0002.3.A

v2.0.2024

- These tumors are defined as having a WHO histologic grade of III or IV (out of IV can occur anywhere in the CNS (though the majority occur in the brain), and include the following tumors:
 - Anaplastic astrocytoma
 - Glioblastoma multiforme
 - Diffuse intrinsic pontine glioma (DIPG, or “brainstem glioma”)
 - Gliomatosis cerebri
 - Gliosarcoma
 - Anaplastic oligodendroglioma
 - Anaplastic ganglioglioma
 - Anaplastic mixed glioma
 - Anaplastic mixed ganglioneuronal tumors
 - Any other glial tumor with a WHO grade of III or IV

Indication	Imaging Study
Initial Staging	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) if not already done • MRI Spine without and with contrast (Cervical-CPT[®] 72156, Thoracic-CPT[®] 72157, Lumbar-CPT[®] 72158) <ul style="list-style-type: none"> ◦ MRI Spine with contrast only (Cervical-CPT[®] 72142, Thoracic-CPT[®] 72147, Lumbar-CPT[®] 72149) can be approved if being performed immediately following a contrast-enhanced MRI Brain
Immediately following partial or complete resection	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)
Immediately following radiation therapy (XRT)	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) once within 2 to 6 weeks following completion of treatment, and then go to surveillance imaging

Indication	Imaging Study
<p>For individuals undergoing chemotherapy treatment</p>	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) every 2 cycles • Individuals with spinal cord involvement at diagnosis can have MRI without and with contrast of the involved spinal region on the same schedule as MRI Brain
<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Distinguish low-grade from high-grade gliomas • Evaluate a brain lesion of indeterminate nature when the study will be used to determine whether biopsy/resection can be safely postponed • Distinguish radiation-induced tumor necrosis from progressive disease within 18 months of completing radiotherapy 	<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • MR Spectroscopy (CPT[®] 76390) • MRI Perfusion imaging (CPT[®] 70553)
<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Distinguish radiation-induced tumor necrosis from progressive disease • Evaluate inconclusive MRI findings when the study will be used to determine need for biopsy or change in therapy, including a change from active therapy to surveillance • Evaluate a brain lesion of indeterminate nature when the study will be used to determine whether biopsy/resection can be safely postponed 	<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • MRI Perfusion imaging (CPT[®] 70553) • PET Brain metabolic imaging (CPT[®] 78608) <ul style="list-style-type: none"> ◦ PET Brain is not indicated in gliomas occurring in the brain stem due to poor uptake and lack of impact on individual outcomes
<p>Suspected intracranial or intraspinal recurrence</p>	<ul style="list-style-type: none"> • All imaging supported for initial staging may be repeated

Indication	Imaging Study
Surveillance	<ul style="list-style-type: none">• MRI Brain without and with contrast (CPT[®] 70553) every 3 months for 3 years and every 6 months thereafter• Individuals with spinal cord involvement at diagnosis can have MRI Spine without and with contrast (Cervical-CPT[®] 72156, Thoracic-CPT[®] 72157, Lumbar-CPT[®] 72158) on the same schedule as MRI Brain

Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumors (sPNET) (ONC-2.4)

ON.CN.0002.4.A

v2.0.2024

- Medulloblastoma and sPNET imaging indications in adult individuals are identical to those for pediatric individuals. See: **Medulloblastoma (MDB), Supratentorial Primitive Neuroectodermal Tumors (sPNET), and Pineoblastoma (PEDONC-4.4)** in the Pediatric Oncology Imaging Guidelines.

Ependymoma (ONC-2.5)

ON.CN.0002.5.A

v2.0.2024

- Ependymoma imaging indications in adult individuals are identical to those for pediatric individuals. See: **Ependymoma (PEDONC-4.8)** in the Pediatric Oncology Imaging Guidelines.

Central Nervous System Germ Cell Tumors (ONC-2.6)

ON.CN.0002.6.A

v2.0.2024

- Central nervous system germ cell tumor imaging indications in adult individuals are identical to those for pediatric individuals. See: **CNS Germinomas and Non-Germinomatous Germ Cell Tumors (NGGCT) (PEDONC-4.7)** in the Pediatric Oncology Imaging Guidelines.

CNS Lymphoma (Also Known as Microglioma) (ONC-2.7)

ON.CN.0002.7.A

v2.0.2024

Indication	Imaging Study
Initial Staging	<p><u>ALL of the following are indicated:</u></p> <ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) • MRI Cervical Spine without and with contrast (CPT[®] 72156) • MRI Thoracic Spine without and with contrast (CPT[®] 72157) • MRI Lumbar Spine without and with contrast (CPT[®] 72158)
<p>Extra-neural evaluation to confirm CNS primary</p> <p>*Individuals with CNS Lymphoma that is metastatic should be imaged according to:</p> <ul style="list-style-type: none"> • <u>Non-Hodgkin Lymphomas (ONC-27)</u> for individuals age ≥18 years • <u>Pediatric Aggressive Mature B-Cell Non-Hodgkin Lymphomas (NHL) (PEDONC-5.3)</u> in the Pediatric Oncology Imaging Guidelines for individuals age ≤17 years 	<p><u>ANY or ALL of the following are indicated:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • PET/CT (CPT[®] 78815) can be approved for evaluation of inconclusive findings on CT imaging
Treatment Response	<ul style="list-style-type: none"> • MRI without and with contrast of all positive disease sites every 2 cycles
Suspected intracranial or intraspinal recurrence	<ul style="list-style-type: none"> • All imaging supported for initial staging may be repeated

Indication	Imaging Study
Surveillance	<ul style="list-style-type: none">• MRI without and with contrast of all positive disease sites every 3 months for 2 years, then every 6 months for 3 years, then annually thereafter

Meningiomas (Intracranial and Intraspinal) (ONC-2.8)

ON.CN.0002.8.A

v2.0.2024

Indication	Imaging Study
Initial Staging of Intracranial Meningioma	<p>ANY or ALL of the following are indicated:</p> <ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) • CT Head (contrast as requested)
Initial staging of Intraspinal Meningioma	<p>ONE of the following:</p> <ul style="list-style-type: none"> • MRI without and with contrast of appropriate spinal region (Cervical CPT[®] 72156, Thoracic CPT[®] 72157, and Lumbar CPT[®] 72158) <p>OR</p> <ul style="list-style-type: none"> • CT without and with contrast of the appropriate spinal region (Cervical CPT[®] 72127, Thoracic CPT[®] 72130, and Lumbar CPT[®] 72133)
Treatment Response	<ul style="list-style-type: none"> • MRI without and with contrast of all positive disease sites every 2 cycles
Suspected recurrence of intracranial or intraspinal disease	<ul style="list-style-type: none"> • All imaging supported for initial staging may be repeated
Suspected recurrence with inconclusive findings on MRI	<p>Any ONE of the following studies:</p> <ul style="list-style-type: none"> • Octreotide SPECT Brain (CPT[®] 78803) • Octreotide SPECT/CT Brain (CPT[®] 78830) • Dotatate PET/CT Brain (CPT[®] 78814)
<p>Surveillance for Grade I (low-grade) and Grade II (atypical) intracranial meningioma</p> <p>(completely resected, partially resected, and unresected)</p>	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) at 3, 6, and 12 months, then annually for 5 years <ul style="list-style-type: none"> ◦ Imaging beyond 5 years is only indicated for evaluation of new signs or symptoms

Indication	Imaging Study
<p>Surveillance for Grade I (low-grade) and Grade II (atypical) intraspinal meningioma (completely resected, partially resected, and unresected)</p>	<p><u>ONE of the following at 3, 6, and 12 months, and then annually for 5 years:</u></p> <ul style="list-style-type: none"> • MRI without and with contrast (CPT[®] 72156 [Cervical spine], CPT[®] 72157 [Thoracic spine], CPT[®] 72158 [Lumbar spine]) of the involved spinal level <p>OR</p> <ul style="list-style-type: none"> • CT without and with contrast (CPT[®] 72127 [Cervical spine], CPT[®] 72130 [Thoracic spine], CPT[®] 72133 [Lumbar spine]) of the involved spinal level • Imaging beyond 5 years is only indicated for evaluation of new signs or symptoms
<p>Surveillance for Grade III (malignant or anaplastic) Meningioma</p>	<ul style="list-style-type: none"> • <u>Intracranial Meningioma:</u> MRI Brain without and with contrast (CPT[®] 70553) every 3 months for 3 years, and then every 6 months thereafter • <u>Intraspinal Meningioma:</u> MRI or CT without and with contrast of the involved spinal region every 3 months for 3 years and then every 6 months thereafter

Spinal Cord Tumors (Benign and Malignant) (ONC-2.9)

ON.CN.0002.9.A

v2.0.2024

- See: **Low Grade Gliomas (ONC-2.2)** and **High Grade Gliomas (ONC-2.3)** for imaging guidelines of low-grade and high-grade gliomas of the spinal cord
- See: **Malignant Tumors of the Spinal Cord (PEDONC-4.9)** in the Pediatric Oncology Imaging Guidelines for other malignant spinal cord tumors
- See: **Neurofibromatosis 1 and 2 (NF1 and NF2) (PEDONC-2.3)** in the Pediatric Oncology Imaging Guidelines for spinal tumors in individuals with Neurofibromatosis 1 or 2
- See: **Spinal/Vertebral Metastases (ONC-31.6)** for known secondary malignancy involving the spine/spinal canal/spinal cord

Choroid Plexus Tumors (ONC-2.10)

ON.CN.0002.10.A

v2.0.2024

- Choroid Plexus Tumor imaging indications in adult individuals are identical to those for pediatric individuals. See: **Choroid Plexus Tumors (PEDONC-4.13)** in the Pediatric Oncology Imaging Guidelines.

References (ONC-2)

v2.0.2024

1. Nabors LB, Portnow J, Baehring J, et. al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – March 24, 2023 Central Nervous System Cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Central Nervous System Tumors Cancer V1.2023. – March 24, 2023 ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Brandão LA, Castillo M. Adult brain tumors: clinical applications of magnetic resonance spectroscopy. *Magn Reson Imaging Clin N Am*. 2016;24(4):781-809. doi:10.1016/j.mric.2016.07.005.
3. Pasquier D, Bijmolt S, Veninga T, et al. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. *Int J Radiat Oncol Biol Phys*. 2008;71(5):1388. doi:10.1016/j.ijrobp.2007.12.020.
4. Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. *Neurosurgery*. 2005;57(3):538-550.
5. Horská A, Barker PB. Imaging of brain tumors: MR spectroscopy and metabolic imaging. *Neuroimaging Clin N Am*. 2010;20(3):293-310. doi:10.1016/j.nic.2010.04.003.
6. Sundgren PC. MR Spectroscopy in radiation Injury. *Am J Neuroradiol*. 2009;30(8):1469-1476. doi:10.3174/ajnr.A1580.
7. American College of Radiology. ACR–ASNR–SPR practice parameter for the performance of intracranial magnetic resonance perfusion imaging. 2017; Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Perfusion.pdf?la=en>.

Squamous Cell Carcinomas of the Head and Neck (ONC-3)

Guideline

Squamous Cell Carcinomas of the Head and Neck – General Considerations (ONC-3.0)

Squamous Cell Carcinomas of the Head and Neck – Suspected/Diagnosis (ONC-3.1)

Squamous Cell Carcinomas of the Head and Neck – Initial Work-up/Staging (ONC-3.2)

Squamous Cell Carcinomas of the Head and Neck – Restaging/Recurrence (ONC-3.3)

Squamous Cell Carcinomas of the Head and Neck – Surveillance/Follow-up (ONC-3.4)

References (ONC-3)

Squamous Cell Carcinomas of the Head and Neck – General Considerations (ONC-3.0)

ON.HN.0003.0.A

v2.0.2024

- Individuals with esthesioneuroblastoma should be imaged according to this guideline section
- Stage III/IV disease encompasses any primary tumor larger than 4 cm or documented lymph node positive disease

Squamous Cell Carcinomas of the Head and Neck – Suspected/Diagnosis (ONC-3.1)

ON.HN.0003.1.A

v2.0.2024

- See: **Neck Masses - Imaging (NECK-5.1)** in the Neck Imaging Guidelines for evaluation of suspected malignancy in the neck
- PET may be considered prior to biopsy in order to determine a more favorable site for biopsy when:
 - A prior biopsy was nondiagnostic or
 - A relatively inaccessible site is contemplated which would require invasive surgical intervention for biopsy attempt

Squamous Cell Carcinomas of the Head and Neck – Initial Work-up/Staging (ONC-3.2)

ON.HN.0003.2.A
v2.0.2024

Indication	Imaging Study
All Stages of Disease	<ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) or MRI Orbits/Face/Neck (OFN) without and with contrast (CPT[®] 70543) • CT Chest with contrast (CPT[®] 71260)
For sentinel lymph node evaluation when nodes are not clinically positive	<ul style="list-style-type: none"> • Lymph system imaging (lymphoscintigraphy, CPT[®] 78195) <ul style="list-style-type: none"> ◦ SPECT/CT (CPT[®] 78830) is indicated as an add on code if requested
Nasal cavity and paranasal sinuses (bony erosion or skull base and intracranial involvement)	<p><u>ONE of the following studies is indicated:</u></p> <ul style="list-style-type: none"> • CT Maxillofacial with contrast (CPT[®] 70487) • CT Neck with contrast (CPT[®] 70491) • MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543)
Nasopharyngeal (NPC) Cancer	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815) • MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) is the preferred study <ul style="list-style-type: none"> ◦ CT Neck (CPT[®] 70491) and/or CT Maxillofacial (CPT[®] 70487) with contrast can be approved if contraindication to MRI • CT Chest with contrast (CPT[®] 71260)

Indication	Imaging Study
<p>For ANY of the following:</p> <ul style="list-style-type: none"> • Known stage III or IV disease • Prior to start of primary chemoradiotherapy and have not undergone definitive surgical resection • Inconclusive findings on conventional imaging (CT, MRI) • In order to direct laryngoscopy/exam under anesthesia for biopsy • Pulmonary nodule(s) ≥8 mm in size • Cervical lymph node biopsy positive for squamous cell carcinoma and no primary site identified on CT or MRI Neck and Chest • Inconclusive findings suggestive of disease outside the head and neck area 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)
<p>Signs or symptoms of abdominal metastatic disease, including elevated liver function tests</p>	<ul style="list-style-type: none"> • CT Abdomen with contrast (CPT[®] 74160)
<p>Any head and neck cancer with neurological findings or suspicion of skull base invasion</p>	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)

Squamous Cell Carcinomas of the Head and Neck – Restaging/Recurrence (ONC-3.3)

ON.HN.0003.3.A
v2.0.2024

Indication	Imaging Study
Following complete resection and/or radical neck dissection	See: Surveillance/Follow-up (ONC-3.4)
Following primary chemoradiotherapy or radiation therapy in individuals who have not undergone surgical resection of primary tumor or neck dissection	<p>ONE of the following:</p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491); or • MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543); or • PET/CT (CPT[®] 78815) no sooner than 12 weeks (3 months) post completion of radiation therapy <ul style="list-style-type: none"> ◦ If post-treatment PET/CT scan is negative, further surveillance imaging is not routinely indicated.
Induction chemotherapy response	<ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) or MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) • PET not indicated to assess response to induction chemotherapy
Measurable or metastatic disease undergoing active treatment	<p>Every 2 cycles (6-8 weeks):</p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) <p>OR</p> <ul style="list-style-type: none"> • MRI Orbits/ Face/Neck without and with contrast (CPT[®] 70543) <p>AND</p> <ul style="list-style-type: none"> • CT with contrast of involved body sites
Suspected local recurrence	<ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) or MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) • CT Chest with contrast (CPT[®] 71260)

Indication	Imaging Study
Biopsy proven local recurrence	<p>ONE of the following:</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815) <p>or</p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) or MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) and CT Chest with contrast (CPT[®] 71260)
Inconclusive conventional imaging (CT or MRI)	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)
If new pulmonary symptoms or chest previously involved	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260)

Squamous Cell Carcinomas of the Head and Neck – Surveillance/Follow-up (ONC-3.4)

ON.HN.0003.4.A
v2.0.2024

Indications	Imaging Study
Individuals treated with surgical resection of primary site and/or neck dissection (with or without postoperative radiation therapy)	<p><u>Once within 6 months of completing all treatment:</u></p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) or MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) • CT with contrast of any other involved body area
Individuals treated with definitive radiation therapy or combined chemoradiation, and post-treatment imaging is negative	Further surveillance imaging is not routinely indicated
If post-treatment imaging shows residual abnormalities	<p><u>ONE of the following, once within 6 months of prior imaging:</u></p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) OR • MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543)
<p><u>After initial post-treatment study, for ANY of the following:</u></p> <ul style="list-style-type: none"> • Nasopharyngeal primary site • Physical exam unable to visualize deep-seated primary site 	<p><u>Annually for 3 years:</u></p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) or MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543)
<ul style="list-style-type: none"> • CT Chest is not indicated for surveillance. Individuals with smoking history may undergo annual low dose CT cancer screening if criteria are met (See: Lung Cancer Screening (CH-33) in the Chest Imaging Guidelines) 	

References (ONC-3)

v2.0.2024

1. Pfister DG, Spencer S, Adkins D, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2024 – February 29, 2024 Head and Neck Cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Head and Neck Cancer V3.2024 – February 29, 2024 ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Goel R, Moore W, Sumer B, Khan S, Sher D, Subramaniam RM. Clinical practice in PET/CT for the management of head and neck squamous cell cancer. *AJR Am J Roentgenol*. 2017;209(2):289-303. doi:10.2214/AJR.17.18301.
3. Moncrieff M, Pywell S, Snelling A, et. al. Effectiveness of SPECT/CT imaging for sentinel node biopsy staging of primary cutaneous melanoma and patient outcomes. *Ann Surg Oncol*. 2022;29(2):767-775. doi:10.1245/s10434-021-10911-4.
4. Quartuccio N, Garau LM, Arnone A, et. al. Comparison of 99mTc-labeled colloid SPECT/CT and planar lymphoscintigraphy in sentinel lymph node detection in patients with melanoma: a meta-analysis. *J Clin Med*. 2020;9(6):1680. doi:10.3390/jcm9061680.
5. Bennie G, Vorster M, Buscombe J, Sathekge M. The added value of a single-photon emission computed tomography-computed in sentinel lymph node mapping in patients with breast cancer and malignant melanoma. *World J Nucl Med*. 2015;14(01):41-46. doi:10.4103/1450-1147.150543.

Salivary Gland Cancers (ONC-4)

Guideline

Salivary Gland Cancers – General Considerations (ONC-4.0)

Salivary Gland Cancers – Suspected/Diagnosis (ONC-4.1)

Salivary Gland Cancers – Initial Work-up/Staging (ONC-4.2)

Salivary Gland Cancers – Restaging/Recurrence (ONC-4.3)

Salivary Gland Cancers – Surveillance/Follow-up (ONC-4.4)

References (ONC-4)

Salivary Gland Cancers – General Considerations (ONC-4.0)

ON.SG.0004.0.A

v2.0.2024

- Salivary gland tumors may originate within the parotid, submandibular, sublingual or minor salivary glands in the mouth.
- Histological subtypes include:
 - Mucoepidermoid
 - Acinic
 - Adenocarcinoma
 - Adenoid cystic carcinoma
 - Malignant myoepithelial tumors
 - Squamous cell carcinoma
 - Lymphoma and metastatic squamous carcinoma can occur in the parotid gland
- Over 80% of parotid gland tumors are benign. A bilateral parotid tumor is most likely Warthin's tumor.
- The role of PET in salivary gland tumors is considered experimental, investigational, or unproven.

Salivary Gland Cancers – Suspected/ Diagnosis (ONC-4.1)

ON.SG.0004.1.A

v2.0.2024

- See: **Salivary Gland Disorders (NECK-11)** and **Neck Masses – Imaging (NECK-5.1)** in the Neck Imaging Guidelines for evaluation of salivary gland masses, salivary gland stones and neck masses.

Salivary Gland Cancers – Initial Work-up/ Staging (ONC-4.2)

ON.SG.0004.2.A
v2.0.2024

Indication	Imaging Study
Biopsy-proven malignancy	<p><u>ONE of the following can be approved:</u></p> <ul style="list-style-type: none"> • MRI Orbits/Face/Neck without and with contrast (CPT® 70543) • CT Neck with contrast (CPT® 70491) • CT Neck without contrast (CPT® 70490)
Skull base invasion	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT® 70553)
<ul style="list-style-type: none"> • Adenoid cystic carcinoma • Lymphadenopathy in the neck • Pulmonary signs or symptoms • Abnormal chest x-ray 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT® 71260)

Salivary Gland Cancers – Restaging/ Recurrence (ONC-4.3)

ON.SG.0004.3.A

v2.0.2024

Indication	Imaging Study
After complete surgical resection	See: Salivary Gland Cancers - Surveillance (ONC-4.4)
Individuals with unresected disease receiving systemic therapy (chemotherapy)	<p><u>ONE of the following may be approved every 2 cycles:</u></p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) and any other sites of disease • MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) and any other sites of disease
Recurrence or progression suspected based on new or worsening signs or symptoms	<p><u>ONE of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) • MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) <p><u>In addition, for all individuals:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260)
All other individuals	<ul style="list-style-type: none"> • No routine advanced imaging indicated

Salivary Gland Cancers – Surveillance/ Follow-up (ONC-4.4)

ON.SG.0004.4.A

v2.0.2024

Indication	Imaging Study
Total surgical resection	<ul style="list-style-type: none"> No routine advanced imaging indicated
Unresectable or partially resected disease, including those treated with radiation therapy	<ul style="list-style-type: none"> Either CT Neck with contrast (CPT[®] 70491) or MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) once within 6 months of completion of treatment
Adenoid cystic carcinoma	<p><u>ANY of the following, annually for up to 10 years:</u></p> <ul style="list-style-type: none"> CT Neck with contrast (CPT[®] 70491) or MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250)

References (ONC-4)

v2.0.2024

1. Pfister DG, Spencer S, Adkins D et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2023 – May 15, 2023 Head and Neck Cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Head and Neck Cancer V2.2023 – May 15, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Palacios E, Ellis M, Lam EC, Neitzschman H, Haile M. Pitfalls in imaging the submandibular glands with PET/CT. *Ear Nose Throat J*. 2015;94(10-11):E37-E39.
3. Seo YL, Yoon DY, Baek S, et al. Incidental focal FDG uptake in the parotid glands on PET/CT in patients with head and neck malignancy. *Eur Radiol*. 2015;25(1):171-177. doi:10.1007/s00330-0140339701.
4. Park HL, Yoo le R, Lee N, et al. The value of F-18 FDG PET for planning treatment and detecting recurrence in malignant salivary gland tumors: comparison with conventional imaging studies. *Nucl Med Mol Imaging*. 2013;47(4):242-248. doi:10.1007/s13139-013-0222-8.
5. Bertagna F, Nicolai P, Maroldi R. Diagnostic role of 18F-FDG-PET or PET/CT in salivary gland tumors: a systematic review. *Rev Esp Med Nucl Imagen Mol*. 2015;34(5):295-302.
6. Garg M, Tudor-Green B, Bisase B. Current thinking in the management of adenoid cystic carcinoma of the head and neck. *British Journal of Oral and Maxillofacial Surgery*. 2019;57(8):716-721. doi:10.1016/j.bjoms.2019.07.021.
7. Geiger JL, Ismaila N, Beadle B, et al. Management of salivary gland malignancy: ASCO guideline. *Journal of Clinical Oncology*. 2021;39(17):1909-1941. doi:10.1200/JCO.21.00449.

Melanomas and Other Skin Cancers (ONC-5)

Guideline

- Melanoma – General Considerations (ONC-5.0)
- Melanoma – Suspected/Diagnosis (ONC-5.1)
- Melanoma – Initial Work-up/Staging (ONC-5.2)
- Melanoma – Restaging/Recurrence (ONC-5.3)
- Melanoma – Surveillance/Follow-up (ONC-5.4)
- Non-Melanoma Skin Cancers – General Considerations (ONC-5.5)
- Non-Melanoma Skin Cancers – Initial Work-up/Staging (ONC-5.6)
- Non-Melanoma Skin Cancers – Restaging/Recurrence (ONC-5.7)
- Non-Melanoma Skin Cancers – Surveillance/Follow-up (ONC-5.8)
- Ocular Melanoma (ONC-5.9)
- References (ONC-5)

Melanoma – General Considerations (ONC-5.0)

ON.SC.0005.0.A

v2.0.2024

- Melanomas can metastasize in an unpredictable fashion.

Melanoma – Suspected/Diagnosis (ONC-5.1)

ON.SC.0005.1.A
v2.0.2024

Indication	Imaging Study
All	<ul style="list-style-type: none">Imaging is not indicated until histologic diagnosis is confirmed

Melanoma – Initial Work-up/Staging (ONC-5.2)

ON.SC.0005.2.A

v2.0.2024

Indication	Imaging Study
Stage 0 or IA (in situ or disease <1 mm)	<ul style="list-style-type: none"> Routine advanced imaging is not indicated
<ul style="list-style-type: none"> Stage IB (<0.8 mm with ulceration or 0.8-1 mm without or with ulceration) Stage II (lesions >1 mm thick, but node negative) 	<ul style="list-style-type: none"> CT with contrast or MRI without and with contrast of specific areas, only if signs or symptoms indicate need for further evaluation
For sentinel lymph node evaluation in stages IB and II	<ul style="list-style-type: none"> Lymph system imaging (lymphoscintigraphy, CPT[®] 78195) <ul style="list-style-type: none"> SPECT/CT (CPT[®] 78830) is indicated as an add on code if requested
<p>Any of the following:</p> <ul style="list-style-type: none"> Stage III (sentinel node positive, palpable regional nodes) Stage IV (metastatic) 	<ul style="list-style-type: none"> PET/CT (CPT[®] 78815 or CPT[®] 78816) <p>OR</p> <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177) MRI Brain without and with contrast (CPT[®] 70553)
<ul style="list-style-type: none"> Head or neck primary site Palpable lymphadenopathy in the neck Mucosal melanoma of the head or neck region 	<p>In addition to above initial staging imaging, if PET/CT not performed:</p> <ul style="list-style-type: none"> CT Neck with contrast (CPT[®] 70491)
<ul style="list-style-type: none"> Primary site of melanoma is unknown and CT Chest, Abdomen, and Pelvis are negative 	<ul style="list-style-type: none"> PET/CT (CPT[®] 78815 or CPT[®] 78816)

Melanoma – Restaging/Recurrence (ONC-5.3)

ON.SC.0005.3.A

v2.0.2024

- All recurrences should be confirmed histologically, except when excessive morbidity from a biopsy may occur, such as a biopsy requiring craniotomy.

Indication	Imaging Study
Individuals receiving chemotherapy, with measurable disease, every 2 cycles (commonly every 6 to 8 weeks)	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260); and CT Abdomen and Pelvis with contrast (CPT[®] 74177)
All in situ recurrences	<ul style="list-style-type: none"> • Restaging imaging is not needed after adequate aggressive local therapy (See Surveillance below)
<p><u>Documented or clinically suspected (See top of page regarding biopsy morbidity) recurrence at:</u></p> <ul style="list-style-type: none"> • Primary site • In-transit disease • Regional lymph nodes • Metastatic site 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260); and CT Abdomen and Pelvis with contrast (CPT[®] 74177) <p><u>In addition, for all individuals:</u></p> <ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Inconclusive findings on conventional imaging • Isolated metastatic site found on conventional imaging 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)

Indication	Imaging Study
<p><u>Brain imaging is indicated for:</u></p> <ul style="list-style-type: none">• New discovery of metastatic disease or progression of metastatic disease• Signs or symptoms of CNS disease• If considering Interleukin (IL-2) therapy	<ul style="list-style-type: none">• MRI Brain without and with contrast (CPT[®] 70553)

Melanoma – Surveillance/Follow-up (ONC-5.4)

ON.SC.0005.4.A

v2.0.2024

Indication	Imaging Study
Stage 0, IA, IB and IIA Melanomas	<ul style="list-style-type: none"> No routine advanced imaging indicated
Stage IIB, IIC, IIIA and IIIB Melanomas	<ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast every 6 months for 2 years, then annually for 3 years For melanoma arising from extremities, advanced imaging of the primary site is not routinely indicated for surveillance in asymptomatic individuals.
Stage IIIC and IV Melanomas	<ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast every 3 months for 2 years, then every 6 months for 3 years MRI Brain without and with contrast (CPT[®] 70553) annually for 3 years For melanoma arising from extremities, advanced imaging of the primary site is not routinely indicated for surveillance in asymptomatic individuals.
Mucosal Melanoma of the head or neck region	<p>In addition to above stage-based surveillance imaging, the following may be obtained ONCE within 6 months of completing all treatment:</p> <ul style="list-style-type: none"> CT Neck with contrast (CPT[®] 70491) or MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) CT with contrast of any other involved body area
Liver metastases treated with focal therapy	<ul style="list-style-type: none"> See: <u>Liver Metastases (ONC-31.2)</u>

Non-Melanoma Skin Cancers – General Considerations (ONC-5.5)

ON.SC.0005.5.A

v2.0.2024

- Advanced imaging is generally not indicated for basal cell and squamous cell skin cancers
- PET/CT scan is not indicated for evaluation of non-melanoma skin cancers unless specified within the guidelines below (e.g. Merkel cell carcinoma)
- Merkel cell carcinoma is an unusual skin cancer with neuroendocrine-like histologic features, which has a high propensity (25% to 33%) for regional lymph node spread and occasionally, metastatic spread to lungs.
- Merkel cell carcinoma may present as a primary cancer or as a skin metastasis from a non-cutaneous primary neuroendocrine carcinoma (i.e., small cell lung cancer), therefore conventional imaging is indicated initially to confirm the absence of metastasis prior to considering PET scan.

Non-Melanoma Skin Cancers – Initial Work-up/Staging (ONC-5.6)

ON.SC.0005.6.A

v2.0.2024

Indication	Imaging Study
Body area with unexplained signs or symptoms	<ul style="list-style-type: none"> • CT with contrast of that body area
Perineural invasion or local regional extension (i.e. bone; deep soft tissue) involvement	<p><u>ONE of the following may be approved of the primary site:</u></p> <ul style="list-style-type: none"> • MRI without contrast or without and with contrast • CT (contrast as requested)
Skin lesion may be a dermal metastasis from distant primary	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast • PET/CT (CPT[®] 78815 or CPT[®] 78816) is indicated if conventional imaging (CT or MRI) is unable to identify a primary site
Squamous cell carcinoma head or neck skin with regional lymphadenopathy	<ul style="list-style-type: none"> • CT Neck (CPT[®] 70491) and CT Chest (CPT[®] 71260) with contrast
Merkel Cell carcinoma	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of other involved body area(s) • PET/CT (CPT[®] 78815 or CPT[®] 78816) if inconclusive conventional imaging • Lymph system imaging (lymphoscintigraphy, CPT[®] 78195) for sentinel lymph node evaluation <ul style="list-style-type: none"> ◦ SPECT/CT (CPT[®] 78830) is indicated as an add on code if requested

Indication	Imaging Study
Signs or symptoms of CNS involvement	<ul style="list-style-type: none"><li data-bbox="738 296 1421 373">• MRI Brain with and without contrast (CPT[®] 70553)

Non-Melanoma Skin Cancers – Restaging/Recurrence (ONC-5.7)

ON.SC.0005.7.A

v2.0.2024

- All recurrences should be confirmed histologically, except when excessive morbidity from a biopsy may occur, such as a biopsy requiring craniotomy.

Indication	Imaging Study
Recurrence where planned therapy is more extensive than simple wide local excision	<ul style="list-style-type: none"> • CT with contrast of the primary and recurrent site(s)
Suspected or biopsy-proven recurrence of Merkel cell carcinoma	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast • CT with contrast of other symptomatic body area(s)
Inconclusive findings on conventional imaging	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or 78816)
Signs or symptoms of CNS involvement	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)

Non-Melanoma Skin Cancers – Surveillance/Follow-up (ONC-5.8)

ON.SC.0005.8.A

v2.0.2024

Indication	Imaging Study
Merkel cell cancer – only if node positive	<ul style="list-style-type: none">• CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast every 6 months for 5 years• Add CT Neck with contrast (CPT[®] 70491) if known prior neck disease or scalp/facial/neck disease
All others	<ul style="list-style-type: none">• Routine advanced imaging for surveillance is not indicated• Imaging indicated only for signs and symptoms of recurrent disease

Ocular Melanoma (ONC-5.9)

ON.SC.0005.9.A
v2.0.2024

General Considerations

- Approximately 95% of ocular melanomas arise from the uvea (iris, ciliary body and choroid) and 5% arise from the conjunctiva or orbit.
- Biopsy is usually not necessary for initial diagnosis of uveal melanoma but may be useful in cases when diagnosis is uncertain (e.g. amelanotic tumors, retinal detachment) or for prognostic analysis and risk stratification.
- Treatment is directed to the affected eye with systemic therapy reserved only for known metastatic disease.
- The most common site of metastatic disease is the liver.
- Surveillance of the affected eye is with clinical examination only; advanced imaging is supported for surveillance of systemic metastatic disease based on individual risk factors. See risk categories below for surveillance recommendations.

Table 1: Ocular Melanoma Risk Categories

Low Risk	Medium Risk	High-Risk
T1	T2 and T3	T4
Class IA	Class IB	Class 2
Spindle cell histology	Mixed Spindle and Epitheloid cells	Epitheloid cell histology
No extraocular extension	No extraocular extension	Extraocular extension present
No ciliary body involvement	No ciliary body involvement	Ciliary body involvement present

Low Risk	Medium Risk	High-Risk
<p>Chromosome mutations:</p> <ul style="list-style-type: none"> • Disomy 3 • EIF1AX mutation • Gain of chromosome 6p 	<p>Chromosome mutations:</p> <ul style="list-style-type: none"> • SF3B1 mutation 	<p>Chromosome mutations:</p> <ul style="list-style-type: none"> • BAP1 mutation • PRAME mutation • Monosomy 3 • Gain of chromosome 8q

Indication	Imaging Study
Initial staging of suspected or biopsy-proven uveal melanoma	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543)
Neurological signs/symptoms	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)
Restaging/Suspected Recurrence	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) • MRI Brain without and with contrast (CPT[®] 70553)
Surveillance for Low Risk disease	<p><u>Annually for 10 years:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen with contrast (CPT[®] 74160) or MRI Abdomen without and with contrast (CPT[®] 74183)
Surveillance for Medium Risk disease	<p><u>Every 6 months for 2 years and then annually up to year 10:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen with contrast (CPT[®] 74160) or MRI Abdomen without and with contrast (CPT[®] 74183)

Indication	Imaging Study
Surveillance for High-risk disease	<p>Every 3 months for 2 years, every 6 months for 3 years, then annually up to year 10:</p> <ul style="list-style-type: none">• CT Chest with contrast (CPT[®] 71260)• CT Abdomen with contrast (CPT[®] 74160) or MRI Abdomen without and with contrast (CPT[®] 74183)

References (ONC-5)

v2.0.2024

1. Swetter SM, Johnson D, Thompson JA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2023 – March 10, 2023 Cutaneous Melanoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Cutaneous Melanoma V2.2023 – March 10, 2023 ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Swetter S, Johnson D, Thompson JA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – May 4, 2023 Melanoma: Uveal, available at: https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Melanoma: Uveal V1.2023 – May 4, 2023 ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Schmults CD, Blitzblau R, Aasi SZ, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – April 10, 2023 Merkel Cell Carcinoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Merkel Cell Carcinoma V1.2023 – April 10, 2023 ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org .
4. Schmults CD, Blitzblau R, Aasi SZ, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – March 10, 2023 Basal Cell Skin Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Basal Cell Skin Cancer 1.2023 – March 10, 2023 ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org .
5. Schmults CD, Blitzblau R, Aasi SZ, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – May 10, 2023 Squamous Cell Skin Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Squamous Cell Skin Cancer V1.2023 – May 10, 2023 ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org .
6. Schröer-Günther MA, Wolff RF, Westwood ME, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. *Syst Rev.* 2012;1:62. doi:10.1186/2046-4053-1-62.
7. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. *J Natl Cancer Inst.* 2011;103(2):129-142. doi:10.1093/jnci/djq455.
8. Rodriguez Rivera AM, Alabbas H, Ramjuan A, Meguerditchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. *Surg Oncol.* 2014;23(1):11-16. doi: 10.1016/j.suronc.2014.01.002.
9. Nathan P, Cohen V, Coupland S, et al. Uveal melanoma UK national guidelines. *European Journal of Cancer.* 2015;51(16):2404-2412. doi:10.1016/j.ejca.2015.07.013.
10. Moncrieff M, Pywell S, Snelling A, et al. Effectiveness of SPECT/CT imaging for sentinel node biopsy staging of primary cutaneous melanoma and patient outcomes. *Ann Surg Oncol.* 2022;29(2):767-775. doi:10.1245/s10434-021-10911-4.

11. Bennie G, Vorster M, Buscombe J, Sathekge M. The added value of a single-photon emission computed tomography-computed in sentinel lymph node mapping in patients with breast cancer and malignant melanoma. *World J Nucl Med.* 2015;14(01):41-46. doi:10.4103/1450-1147.150543
12. Quartuccio N, Garau LM, Arnone A, et. al. Comparison of 99mTc-labeled colloid SPECT/CT and planar lymphoscintigraphy in sentinel lymph node detection in patients with melanoma: a meta-analysis. *J Clin Med.* 2020;9(6):1680. doi:10.3390/jcm9061680.

Thyroid Cancer (ONC-6)

Guideline

- Thyroid Cancer – General Considerations (ONC-6.0)
- Thyroid Cancer – Suspected/Diagnosis (ONC-6.1)
- Thyroid Cancer – Initial Work-up/Staging (ONC-6.2)
- Thyroid Cancer – Restaging/Recurrence (ONC-6.3)
- Thyroid Cancer – Surveillance/Follow-up (ONC-6.4)
- References (ONC-6)

Thyroid Cancer – General Considerations (ONC-6.0)

ON.TC.0006.0.A

v2.0.2024

- Individuals of all ages with thyroid cancer are imaged according to this guideline.
- Whole-Body Thyroid Nuclear scan (also known as whole-body radioiodine scan) is coded with CPT[®] 78018. If CPT[®] 78018 is obtained and found to be positive, CPT[®] 78020 may be approved as an add-on test to evaluate the degree of iodine uptake.
- Single photon emission computed tomography (SPECT) imaging – Radiopharmaceutical Localization of Tumor SPECT (CPT[®] 78803 or CPT[®] 78831) or SPECT/CT Hybrid study (CPT[®] 78830 or CPT[®] 78832) may complement planar and pinhole imaging and can be approved as an add-on wherever radioiodine (RAI) scans are indicated.
- Whole-Body Thyroid Nuclear scan (also known as whole-body RAI scan) is the imaging modality of choice for differentiated thyroid cancers, as these are usually not well visualized on FDG-PET/CT scans. Individuals who have RAI-diagnostic scan negative and PET-positive disease will generally not respond to RAI treatment, whereas individuals who have PET-negative and RAI-diagnostic scan negative disease may still be candidates for empiric RAI treatment.
- Radioiodine (RAI) refractory disease is defined as: (i) the malignant/metastatic tissue does not ever concentrate RAI (no uptake outside the thyroid bed at the first therapeutic WBS), (ii) the tumor tissue loses the ability to concentrate RAI after previous evidence of RAI-avid disease (in the absence of stable iodine contamination), (iii) RAI is concentrated in some lesions but not in others, and (iv) metastatic disease progresses despite significant concentration of RAI⁶.

Thyroid Cancer – Suspected/Diagnosis (ONC-6.1)

ON.TC.0006.1.A

v2.0.2024

- See: **Thyroid Nodule (NECK-8.1)** in the Neck Imaging Guidelines for suspected thyroid malignancies

Thyroid Cancer – Initial Work-up/Staging (ONC-6.2)

ON.TC.0006.2.A
v2.0.2024

Follicular, Papillary and Hürthle Cell Carcinomas	Imaging Study
<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Locally advanced disease or fixation suggested by clinical exam and/or ultrasound • Substernal or bulky disease • Disease precluding full ultrasound examination • Vocal cord paresis 	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • MRI Neck without contrast (CPT[®] 70540) • MRI Neck without and with contrast (CPT[®] 70543) • CT Neck without contrast (CPT[®] 70490) • CT Neck with contrast (CPT[®] 70491) can be approved if contrast study is necessary for complete pre-operative assessment and use of IV contrast will not delay post-operative use of RAI therapy.
<p><u>Post-thyroidectomy to assess thyroid remnant and to look for iodine-avid metastases for ONE of the following:</u></p> <ul style="list-style-type: none"> • Extent of thyroid remnant cannot be accurately ascertained from the surgical report or neck ultrasound • When the results may alter the decision to treat • Prior to administration of RAI therapy 	<ul style="list-style-type: none"> • Whole-Body Thyroid Nuclear scan (CPT[®] 78018) • The following may be approved as an add-on test: <ul style="list-style-type: none"> ◦ CPT[®] 78020 to evaluate the degree of iodine uptake AND/OR ◦ SPECT (CPT[®] 78803, or CPT[®] 78831), OR SPECT/CT Hybrid study (CPT[®] 78830, or CPT[®] 78832)

Follicular, Papillary and Hürthle Cell Carcinomas	Imaging Study
Skeletal pain	<ul style="list-style-type: none"> • Bone scan <p>See also: Nuclear Medicine (NM) Imaging (ONC-1.3) in Oncology</p> <ul style="list-style-type: none"> • Whole-Body Thyroid Nuclear scan (CPT[®] 78018) • The following may be approved as an add-on test: <ul style="list-style-type: none"> ◦ CPT[®] 78020 to evaluate the degree of iodine uptake AND/OR ◦ SPECT (CPT[®] 78803 or CPT[®] 78831), OR SPECT/CT Hybrid study (CPT[®] 78830, or CPT[®] 78832)
Suspicious findings on chest x-ray, US, or substernal extension of mass	<ul style="list-style-type: none"> • CT Chest without contrast (CPT[®] 71250)
All other individuals	<ul style="list-style-type: none"> • Routine preoperative advanced imaging is not indicated

Medullary Thyroid Carcinomas	Imaging Study
<p><u>ANY</u> of the following:</p> <ul style="list-style-type: none"> • Elevated CEA levels • Calcitonin level >400pg/mL • Positive lymph nodes 	<p>ANY or ALL of the following:</p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) • CT Chest with contrast (CPT[®] 71260) • CT Abdomen with contrast (CPT[®] 74160) or CT Abdomen without and with contrast (CPT[®] 74170) • Bone scan see also: Nuclear Medicine (NM) Imaging (ONC-1.3) in Oncology
Skeletal pain	<ul style="list-style-type: none"> • Bone scan see also: Nuclear Medicine (NM) Imaging (ONC-1.3) in Oncology
Inconclusive findings on conventional imaging	<ul style="list-style-type: none"> • ⁶⁸Gallium-labeled PET/CT (CPT[®] 78815)

Anaplastic Thyroid Carcinomas	Imaging Study
All	<p>ONE of the following combinations, not both:</p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491), CT Chest with contrast (CPT[®] 71260), CT Abdomen and Pelvis with contrast (CPT[®] 74177) <p>OR</p> <ul style="list-style-type: none"> • FDG PET/CT (CPT[®] 78815) <p>In addition to one of the above studies:</p> <ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)
Skeletal pain	<ul style="list-style-type: none"> • Bone scan see also: Nuclear Medicine (NM) Imaging (ONC-1.3) in Oncology

Thyroid Cancer – Restaging/Recurrence (ONC-6.3)

ON.TC.0006.3.A

v2.0.2024

Follicular, Papillary and Hürthle Cell Carcinomas	Imaging Study
Gross residual disease found in the neck post-thyroidectomy	<p>ANY one of the following:</p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) • MRI Neck without and with contrast (CPT[®] 70543)
Within 2 weeks (ideally 7 to 10 days) following the administration of Radioactive Iodine therapy	<ul style="list-style-type: none"> • Whole-body thyroid nuclear scan (CPT[®] 78018) • The following may be approved as an add-on test: <ul style="list-style-type: none"> ◦ CPT[®] 78020 to evaluate the degree of iodine uptake ◦ SPECT (CPT[®] 78803, or CPT[®] 78831), or SPECT/CT Hybrid study (CPT[®] 78830, or CPT[®] 78832)
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Recurrence documented by biopsy • Increasing thyroglobulin level without Thyrogen[®] stimulation • Thyroglobulin level >2 ng/mL or higher than previous after Thyrogen[®] stimulation • Anti-thyroglobulin antibody present • Evidence of residual thyroid tissue on ultrasound or physical exam after thyroidectomy or ablation 	<p>ALL of the following:</p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) or MRI Neck without and with contrast (CPT[®] 70543) • CT Chest with contrast (CPT[®] 71260) • CT with contrast of any symptomatic body area • Whole-body Thyroid Nuclear Scan (CPT[®] 78018) <ul style="list-style-type: none"> ◦ The following may be approved as an add-on test: <ul style="list-style-type: none"> ▪ CPT[®] 78020 to evaluate the degree of iodine uptake ▪ SPECT (CPT[®] 78803 or CPT[®] 78831), or SPECT/CT Hybrid study (CPT[®] 78830, or CPT[®] 78832)

Follicular, Papillary and Hürthle Cell Carcinomas	Imaging Study
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Rising thyroglobulin level with negative CT scans AND radioiodine scan • Inconclusive findings on conventional imaging (CT scans and radioiodine scan) • Known radioiodine-refractory disease and CT scans are negative or inconclusive 	<ul style="list-style-type: none"> • FDG PET/CT (CPT[®] 78815)
<p>Measurable metastatic disease on systemic therapy (no more often than every 2 cycles)</p>	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT with contrast of affected or symptomatic body area

Medullary Thyroid Carcinoma	Imaging Study
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Elevated CEA levels • Calcitonin level ≥150 pg/mL • Signs or symptoms of recurrence 	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) • CT Chest with contrast (CPT[®] 71260) • CT Abdomen either with (CPT[®] 74160) or without and with contrast (CPT[®] 74170) • Bone scan <p>See also: Nuclear Medicine (NM) Imaging (ONC-1.3) in Oncology</p>
<p>Inconclusive conventional imaging with calcitonin ≥150 pg per mL</p>	<ul style="list-style-type: none"> • ⁶⁸Gallium-labeled DOTATATE PET/CT (CPT[®] 78815)

Anaplastic Thyroid Carcinoma	Imaging Study
Measurable metastatic disease on systemic treatment	<p><u>Any of the following every 2 cycles (usually every 6-8 weeks):</u></p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT of any other involved/symptomatic sites
Signs or symptoms of recurrence	<p><u>ONE of the following combinations, not both:</u></p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491), CT Chest with contrast (CPT[®] 71260), CT Abdomen and Pelvis with contrast (CPT[®] 74177) OR • FDG PET/CT (CPT[®] 78815) <p><u>In addition to one of the above studies:</u></p> <ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)

Thyroid Cancer – Surveillance/Follow-up (ONC-6.4)

ON.TC.0006.4.A

v2.0.2024

Follicular, Papillary and Hürthle Cell Carcinomas	Imaging Study
Individuals being monitored on active surveillance	<ul style="list-style-type: none"> • Neck ultrasound (CPT[®] 76536) every 6 months for 2 years, and then annually thereafter
All other individuals post-treatment	<ul style="list-style-type: none"> • Neck ultrasound (CPT[®] 76536) once at 6-12 months post-treatment, and then annually thereafter
<p>For individuals with ANY of the following:</p> <ul style="list-style-type: none"> • Node positive disease • RAI-avid metastases 	<ul style="list-style-type: none"> • Whole-body Thyroid Nuclear Scan annually (CPT[®] 78018) <ul style="list-style-type: none"> ◦ The following may be approved as an add-on test: <ul style="list-style-type: none"> ▪ CPT[®] 78020 to evaluate the degree of iodine uptake ▪ SPECT (CPT[®] 78803, or CPT[®] 78831), OR SPECT/CT Hybrid study (CPT[®] 78830, or CPT[®] 78832)

Medullary Carcinomas	Imaging Study
All individuals	<ul style="list-style-type: none"> • CEA and calcitonin are required for monitoring medullary carcinomas • Routine surveillance imaging is not indicated

Anaplastic Thyroid Carcinomas	Imaging Study
All individuals	<p><u>Every 3 months for 2 years:</u></p> <ul style="list-style-type: none">• CT Neck with contrast (CPT[®] 70491)• CT Chest with contrast (CPT[®] 71260)• CT Abdomen and Pelvis with contrast (CPT[®] 74177)• MRI Brain without and with contrast (CPT[®] 70553)

References (ONC-6)

v2.0.2024

1. Haddad RH, Bischoff L, Ball D, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 – July 27, 2023 Thyroid carcinoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Thyroid carcinoma V3.2023 – July 27, 2023 ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Slough CM, Randolph GW. Workup of well-differentiated thyroid carcinoma. *Cancer Control*. 2006;13(2):99-105. doi:10.1177/107327480601300203.
3. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. *Thyroid*. 2012;22(11):1104-1139. doi:10.1089/thy.2012.0302.
4. Wells SA Jr, Asa SL, Dralle H, et al. American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid*. 2015;25(6):567-610. doi:10.1089/thy.2014.0335.
5. Yeh MW, Bauer AJ, Bernet VA, et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. *Thyroid*. 2015;25:3-14. doi:10.1089/thy.2014.0096.
6. Haugen BR, Alexander EK, Bible KB, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid*. 2016;26(1):1-133. doi:10.1089/thy.2015.0020.
7. Silberstein EB, Alavi A, Balon HR, et al. The SNMMI Practice Guideline for therapy of thyroid disease with ¹³¹I. *J Nucl Med*. 2012;53(10):1633-1651. doi:10.2967/jnumed.112.105148.
8. Avram AM, Fig LM, Frey KA, Gross MD, Wong KK. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? *J Clin Endocrinol Metab*. February 21, 2013 [Epub ahead of print].

Small Cell Lung Cancer (ONC-7)

Guideline

Small Cell Lung Cancer – General Considerations (ONC-7.0)

Small Cell Lung Cancer – Suspected/Diagnosis (ONC-7.1)

Small Cell Lung Cancer – Initial Work-up/Staging (ONC-7.2)

Small Cell Lung Cancer – Restaging/Recurrence (ONC-7.3)

Small Cell Lung Cancer – Surveillance/Follow-up ONC-7.4

References (ONC-7)

Small Cell Lung Cancer – General Considerations (ONC-7.0)

ON.SL.0007.0.A

v2.0.2024

- Combined histologies of Small and Non-Small cell are considered Small cell lung cancer. Use this guideline for imaging recommendations for small and large cell high-grade (poorly differentiated) neuroendocrine tumors of the lung.
- Imaging is presently guided by traditional staging of limited or extensive disease.
 - Extensive stage is either metastatic disease or an extent which cannot be encompassed by a single radiotherapy portal.
 - Limited staging is confined to one side of the chest.
- Individuals treated curatively for SCLC are at increased risk for developing a second lung cancer. If new lung nodule is seen on imaging without any evidence of other systemic disease, follow **Lung Metastases (ONC-31.1)** for work-up of nodule.
- For carcinoid (low-grade neuroendocrine tumors) of the lung, see: **Neuroendocrine Cancers and Adrenal Tumors (ONC-15)**

Small Cell Lung Cancer – Suspected/ Diagnosis (ONC-7.1)

ON.SL.0007.1.A

v2.0.2024

Indication	Imaging Study
<ul style="list-style-type: none"> Abnormal chest x-ray or clinical suspicion remains high despite a normal chest x-ray in symptomatic individual 	<ul style="list-style-type: none"> CT Chest without contrast (CPT[®] 71250) or CT Chest with contrast (CPT[®] 71260)
<ul style="list-style-type: none"> Pulmonary nodule <8 mm in size noted on CT Chest 	<ul style="list-style-type: none"> See: <u>Incidental Pulmonary Nodules Detected on CT Images (CH-16.2)</u> in the Chest Imaging Guidelines
<ul style="list-style-type: none"> Pulmonary nodule 8 mm (0.8 cm) to 30 mm (3 cm) seen on CT Chest or MRI Chest 	<ul style="list-style-type: none"> See: <u>PET (CH-16.4)</u> in the Chest Imaging Guidelines If PET is Positive: Qualifies as initial staging PET/CT Biopsy is indicated prior to PET imaging for pulmonary masses ≥31 mm (3.1 cm) in size
<ul style="list-style-type: none"> Mediastinal/Hilar Mass 	<ul style="list-style-type: none"> See: <u>Lymphadenopathy (CH-2)</u> in the Chest Imaging Guidelines
<ul style="list-style-type: none"> Paraneoplastic syndrome suspected 	<ul style="list-style-type: none"> See: <u>Paraneoplastic Syndromes (ONC-30.3)</u>

Small Cell Lung Cancer – Initial Work-up/ Staging (ONC-7.2)

ON.SL.0007.2.A

v2.0.2024

Indication	Imaging Study
Initial staging	<p>ANY or ALL of the following:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Brain without and with contrast (CPT[®] 70553) • Bone scan, if PET/CT not being done (See also: Nuclear Medicine (NM) Imaging (ONC-1.3) in Oncology)
To confirm the extent of disease when initial CT and MRI indicate limited stage disease (confined to one side of the chest)	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Small Cell Lung Cancer – Restaging/ Recurrence (ONC-7.3)

ON.SL.0007.3.A

v2.0.2024

Indication	Imaging study
<p><u>Treatment Response:</u></p> <ul style="list-style-type: none"> • After every 2 cycles of chemotherapy • Following completion of chemoradiation 	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Brain without and with contrast (CPT[®] 70553) for measurable brain metastases being treated with systemic therapy • Bone scan (See also: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)) • PET is not indicated for evaluation of treatment response in SCLC, but can be considered on a case-by-case basis.
<p>Restaging (suspected recurrence)</p>	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Brain without and with contrast (CPT[®] 70553) • Bone scan (See: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)) • PET is not indicated for evaluation of recurrent SCLC but can be considered on a case-by-case basis.
<p>Complete or partial response to initial treatment, if prophylactic cranial irradiation (PCI) is planned</p>	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)

Small Cell Lung Cancer – Surveillance/ Follow-up ONC-7.4

ON.PC.0007.4.A
v2.0.2024

Indication	Imaging Study
Limited stage SCLC	<p><u>Every 3 months for one year, every 6 months for two years, and then annually:</u></p> <ul style="list-style-type: none"> • CT Chest without (CPT[®] 71250) or CT Chest with (CPT[®] 71260) contrast • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • For new nodules, see: Lung Metastases (ONC-31.1)
Extensive stage SCLC	<p><u>Every 2 months for one year, every 4 months for two years, every 6 months for two years, and then annually:</u></p> <ul style="list-style-type: none"> • CT Chest without (CPT[®] 71250) or CT Chest with (CPT[®] 71260) contrast • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • For new nodules, see: Lung Metastases (ONC-31.1)
Screening for brain metastases, regardless of PCI status	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) every 4 months for 1 year and then every 6 months thereafter

References (ONC-7)

v2.0.2024

1. Ganti AKP, Loo Jr. BW, Bassetti M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024 – November 21, 2023 Small Cell Lung Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Small Cell Lung Cancer V2.2024 – November 21, 2023 ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Lu YY, Chen JH, Liang JA, Chu S, Lin WY, Kao CH. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. *Nucl Med Commun*. 2014;35(7):697-703. doi:10.1097/MNM.000000000000122.
3. Carter BW, Glisson BS, Truong MT, Erasmus JJ. Small cell lung carcinoma: staging, imaging, and treatment considerations. *Radiographics*. 2014;34(6):1707-1721. doi:10.1148/rg.346140178.
4. Kalemkerian G. Staging and imaging of small cell lung cancer. *Cancer Imag*. 2011;11(1):253-258.doi:10.1102/1470-7330.2011.0036.

Non-Small Cell Lung Cancer (ONC-8)

Guideline

- Non-Small Cell Lung Cancer – General Considerations (ONC-8.0)
- Non-Small Cell Lung Cancer – Asymptomatic Screening (ONC-8.1)
- Non-Small Cell Lung Cancer – Suspected/Diagnosis (ONC-8.2)
- Non-Small Cell Lung Cancer – Initial Work-up/Staging (ONC-8.3)
- Non-Small Cell Lung Cancer – Restaging/Recurrence (ONC-8.4)
- Non-Small Cell Lung Cancer – Surveillance/Follow-up (ONC-8.5)
- References (ONC-8)

Non-Small Cell Lung Cancer – General Considerations (ONC-8.0)

ON.NL.0008.0.A

v2.0.2024

- Non-small cell lung cancer includes adenocarcinoma, squamous cell carcinoma, adenosquamous and large cell tumors.
- See: **Bronchopulmonary or Thymic Carcinoid – Initial Staging (ONC-15.6)** for evaluation of low-grade neuroendocrine tumors (carcinoid) of the lung.
- See: **Small Cell Lung Cancer (ONC-7)** for evaluation of high-grade small cell and large cell neuroendocrine tumors of the lung.
- PET/CT scan is generally not indicated for initial staging or restaging of NSCLC when multiple sites of extra-pulmonary metastases are found on conventional imaging (i.e., liver, bone and adrenal metastases, etc.).
- PET/CT may be considered to confirm solitary focus of extra-pulmonary metastatic disease (i.e., brain or adrenal) if the individual is being considered for an aggressive treatment for oligometastatic disease.

Non-Small Cell Lung Cancer – Asymptomatic Screening (ONC-8.1)

ON.NL.0008.1.A

v2.0.2024

- See: **Lung Cancer Screening (CH-33)** in the Chest Imaging Guidelines for criteria for Low-dose CT Chest for lung cancer screening.

Non-Small Cell Lung Cancer – Suspected/Diagnosis (ONC-8.2)

ON.NL.0008.2.A

v2.0.2024

Indication	Imaging Study
Abnormal chest x-ray or clinical suspicion remains high despite a normal chest x-ray in symptomatic individual	<ul style="list-style-type: none"> • CT Chest without contrast (CPT[®] 71250) <li style="text-align: center;">or • CT Chest with contrast (CPT[®] 71260)
Pulmonary nodule <8 mm in size noted on CT Chest	<ul style="list-style-type: none"> • See: <u>Incidental Pulmonary Nodules Detected on CT Images (CH-16.2)</u> in the Chest Imaging Guidelines
Pulmonary nodule 8 mm (0.8 cm) to 30 mm (3 cm) seen on CT Chest or MRI Chest	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815) • See: <u>PET (CH-16.4)</u> in the Chest Imaging Guidelines • If PET is Positive: Qualifies as initial staging PET/CT
Pulmonary mass 31 mm (3.1 cm) or greater seen on CT or MRI	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815) can be approved prior to biopsy if ONE or MORE of the following applies: <ul style="list-style-type: none"> ◦ Definitive treatment with resection or radiation will be utilized instead of biopsy if PET confirms limited disease ◦ Multiple possible biopsy options are present within the chest and PET findings will be used to determine the most favorable biopsy site • Biopsy is indicated prior to PET imaging for all other indications in pulmonary masses ≥31 mm (3.1 cm) in size
Mediastinal/Hilar Lymphadenopathy	See: <u>Mediastinal Lymphadenopathy (CH-2.3)</u> in the Chest Imaging Guidelines
Mediastinal/Hilar Mass	See: <u>Mediastinal Mass (CH-20)</u> in the Chest Imaging Guidelines
Paraneoplastic syndrome suspected	See: <u>Paraneoplastic Syndromes (ONC-30.3)</u>

Non-Small Cell Lung Cancer – Initial Work-up/Staging (ONC-8.3)

ON.NL.0008.3.A

v2.0.2024

Indication	Imaging Study
All individuals	<p>ANY or ALL of the following:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen with contrast (CPT[®] 74160) <ul style="list-style-type: none"> ◦ CT Abdomen may be omitted if CT Chest report clearly documents upper abdomen through level of adrenals • Bone scan, if PET/CT not being done <p>See also: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)</p>
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Stage I-III B • Stage IV confined to the chest region (including pleural/pericardial effusion) • Stage IV with oligometastatic disease on conventional imaging and individual is a candidate for aggressive surgical resection or other localized treatment of metastases with a curative intent • Conventional imaging is inconclusive 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815) (if not already completed prior to histological diagnosis)
<p>ANY of the following:</p> <ul style="list-style-type: none"> • All Stage II-IV disease • Stage I disease and considering surgical resection as primary therapy 	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)

Indication	Imaging Study
Superior sulcus (Pancoast) tumor suspected	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none">• MRI Chest without and with contrast (CPT[®] 71552)• MRI Cervical Spine without and with contrast (CPT[®] 72156)• MRI Thoracic Spine without and with contrast (CPT[®] 72157)

Non-Small Cell Lung Cancer – Restaging/Recurrence (ONC-8.4)

ON.NL.0008.4.A

v2.0.2024

Indication	Imaging Study
Stage I or II individuals who undergo definitive local treatment with surgery, radiation, or radiosurgery	<ul style="list-style-type: none"> Restaging imaging is not indicated. See: <u>Surveillance/Follow-up (ONC-8.5)</u>
Measurable disease, undergoing active treatment	<p><u>ANY or ALL of the following every 2 cycles:</u></p> <ul style="list-style-type: none"> CT Chest with (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) CT Abdomen with contrast (CPT[®] 74160) <ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) may be substituted for known pelvic disease or pelvic symptoms MRI Brain without and with contrast (CPT[®] 70553) for measurable brain metastases being treated with systemic therapy
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> After neoadjuvant treatment for evaluation of surgical resectability Prior to starting adjuvant therapy Inadequately resected disease 	<ul style="list-style-type: none"> CT Chest with (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250)

Indication	Imaging Study
Suspected recurrence	<p>ANY or ALL of the following:</p> <ul style="list-style-type: none"> • CT Chest with (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) • CT Abdomen with contrast (CPT[®] 74160) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) may be substituted for known pelvic disease or pelvic symptoms
Newly identified lung nodule(s)	<ul style="list-style-type: none"> • See: Lung Metastases (ONC-31.1) for new nodule evaluation
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Suspected/biopsy proven recurrence localized to the chest cavity • Inconclusive findings conventional imaging • To differentiate tumor from radiation scar/fibrosis • Stage IV with oligometastatic disease on conventional imaging and individual is a candidate for aggressive surgical resection or other localized treatment of metastases with a curative intent 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Following a demonstrated adequate response to neoadjuvant therapy if intracranial disease will preclude surgery • Documented recurrence/progression • New or worsening neurological signs or symptoms 	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)

Non-Small Cell Lung Cancer – Surveillance/Follow-up (ONC-8.5)

ON.NL.0008.5.A
v2.0.2024

Indication	Study
Stage I-II	<ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) every 6 months for 3 years and then annually <p>***Individuals treated with radiation therapy and residual abnormality on imaging may undergo CT Chest every 3 months for the first year after therapy, every 6 months for 2 years, and then annually thereafter</p>
Stage III-IV (metastatic sites treated with definitive intent)	<ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) every 3 months for 2 years, every 6 months for 3 years and then annually
New lung nodule	<ul style="list-style-type: none"> See: <u>Lung Metastases (ONC-31.1)</u>

References (ONC-8)

v2.0.2024

1. Ettinger DS, Wood DE, Aisner DL, et al, National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 – April 13, 2023. Non small cell lung cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Non-small cell lung cancer V3.2023 – April 13, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Scheider BJ, Ismaila N, Aerts J, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. *J Clin Oncol*. 2020;38(7):753-766. doi:10.1200/JCO.19.02748.
3. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. *Radiology*. 2017;284(1):228-243. doi:10.1148/radiol.2017161659.
4. Calman L, Beaver K, Hind D, Lorigan P, Roberts C, Lloyd-Jones M. Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis. *J Thorac Oncol*. 2011;6(12):1993-2004. doi:10.1097/JTO.0b013e31822b01a1.
5. Lou F, Huang J, Sima CS et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. *J Thorac Cardiovasc Surg*. 2013;145:75-81. <https://www.ncbi.nlm.nih.gov/pubmed/23127371> .
6. Colt HG, Murgu SD, Korst RJ, et al. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143:e437S-454S. <https://www.ncbi.nlm.nih.gov/pubmed/23649451> .
7. Dane B, Grechushkin V, Plank A, et al. PET/CT vs. non-contrast CT alone for surveillance 1-year post lobectomy for stage I non-small cell lung cancer. *Am J Nucl Med Mol Imaging*. 2013; 3:408-416. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784804/> .
8. Zhao L, He ZY, Zhong XN, et al. (18)FDG-PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer: a meta-analysis. *Surg Oncol*. 2012;21(3):230-236. <https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0049561/> .
9. Li J, Xu W, Kong F, et al. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis in lung cancer patients. *Surg Oncol*. 2013;22(3):151-155. <https://www.ncbi.nlm.nih.gov/pubmed/23664848> .
10. Ravenel JG. Evidence-based imaging in lung cancer: a systematic review. *J Thorac Imaging*. 2012; 27(5):315-324. http://journals.lww.com/thoracicimaging/Abstract/2012/09000/Evidence_based_Imaging_in_Lung_Cancer__A.8.aspx .
11. Bille A, Pelosi E, Skanjeti A, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. *Eur J Cardiothorac Surg*. 2009;36(3):440-445. <https://academic.oup.com/ejcts/article-lookup/doi/10.1016/j.ejcts.2009.04.003> .

Esophageal and GE Junction Cancer (ONC-9)

Guideline

- Esophageal and GE Junction Cancer – General Considerations (ONC-9.0)
- Esophageal and GE Junction Cancer – Suspected/Diagnosis (ONC-9.1)
- Esophageal and GE Junction Cancer – Initial Work-up/Staging (ONC-9.2)
- Esophageal and GE Junction Cancer – Restaging/Recurrence (ONC-9.3)
- Esophageal and GE Junction Cancer – Surveillance/Follow-up (ONC-9.4)
- References (ONC-9)

Esophageal and GE Junction Cancer – General Considerations (ONC-9.0)

ON.EJ.0009.0.A

v2.0.2024

- Imaging for esophageal cancer is determined by cell type and in which third of the esophagus it occurs.
- Cancers of the upper and middle third are usually squamous cell and are highly associated with tobacco and alcohol abuse.
- Cancers of the gastroesophageal (GE) junction are treated as lower third cancers. Lower third cancers are usually adenocarcinomas; 62% of these arise in the setting of Barrett's esophagus, a condition associated with high body mass index (BMI).

Esophageal and GE Junction Cancer – Suspected/Diagnosis (ONC-9.1)

ON.EJ.0009.1.A

v2.0.2024

- See: **Dysphagia and Esophageal Disorders (NECK-3.1)** in the Neck Imaging Guidelines for evaluation of suspected esophageal malignancy.

Esophageal and GE Junction Cancer – Initial Work-up/Staging (ONC-9.2)

ON.EJ.0009.2.A
v2.0.2024

Indication	Imaging Study
Biopsy proven	<ul style="list-style-type: none">• CT Chest (CPT[®] 71260) and CT Abdomen (CPT[®] 74160) with contrast<ul style="list-style-type: none">◦ CT Abdomen and Pelvis with contrast (CPT[®] 74177) may be approved instead of CT Abdomen if there are pelvic signs or symptoms
Upper 1/3 or neck mass	<ul style="list-style-type: none">• CT Neck with contrast (CPT[®] 70491)
If no evidence of metastatic disease on conventional imaging	<ul style="list-style-type: none">• PET/CT (CPT[®] 78815)

Esophageal and GE Junction Cancer – Restaging/Recurrence (ONC-9.3)

ON.EJ.0009.3.A

v2.0.2024

Indication	Imaging Study
After primary chemoradiation therapy prior to surgery	<p>Any ONE of the following, not both:</p> <ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen (CPT[®] 74160) with contrast OR • PET/CT (CPT[®] 78815) no sooner than 8 weeks post completion of radiation therapy
Post-surgical resection	<ul style="list-style-type: none"> • See: Surveillance/Follow-up (ONC-9.4)
Monitoring response to chemotherapy for stage IV/ metastatic disease	<p>Every 2 cycles of treatment (~every 6-8 weeks):</p> <ul style="list-style-type: none"> • CT Abdomen with contrast (CPT[®] 74160) • CT Chest with contrast (CPT[®] 71260)
<ul style="list-style-type: none"> • If conventional imaging is inconclusive or • Salvage surgical candidate with recurrence and no metastatic disease documented by conventional imaging 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)
<p>For ANY of the following:</p> <ul style="list-style-type: none"> • Signs or symptoms of recurrence • Biopsy proven on follow-up endoscopy • Recurrence suggested by other imaging (i.e. chest x-ray or barium swallow) 	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen (CPT[®] 74160) with contrast
If previously involved or new signs or symptoms	<ul style="list-style-type: none"> • CT Pelvis with contrast (CPT[®] 72193) and/or CT Neck with contrast (CPT[®] 70491)

Esophageal and GE Junction Cancer – Surveillance/Follow-up (ONC-9.4)

ON.EJ.0009.4.A
v2.0.2024

Indication	Imaging Study
Stage 0-IA (Tis, T1a) disease	<ul style="list-style-type: none">No routine advanced imaging indicated
Stage IB (T1b)-III disease	<ul style="list-style-type: none">CT Chest (CPT[®] 71260) and CT Abdomen (CPT[®] 74160) with contrast every 6 months for 2 years and then annually for 3 more years
Stage IV disease	<ul style="list-style-type: none">See: <u>Phases of Oncology Imaging and General Phase-Related Considerations (ONC-1.2)</u>

References (ONC-9)

v2.0.2024

1. Ajani JA, D'Amico TA, Barzi A, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – March 7, 2024. Esophageal and esophagogastric junction cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Esophageal and esophagogastric junction cancers V1.2024 – March 7, 2024. © 2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Klaeser B, Nitzsche E, Schuller JC, et al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). *Onkologie*. 2009;32(12):724-730. doi:10.1159/000251842.
3. Malik V, Lucey JA, Duffy GJ, et al. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. *J Nucl Med*. 2010;51(12):1863-1869. doi:10.2967/jnumed.110.079566.
4. Stiekema J, Vermeulen D, Vegt E, et al. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer. *Clin Nucl Med*. 2014;39(10):862-867. doi:10.1097/RLU.0000000000000517.
5. Sudo K, Xiao L, Wadhwa R, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. *J Clin Oncol*. 2014;32(30):3400-3405. doi:10.1200/JCO.2014.56.7156.
6. Lou F, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. *J Thorac Oncol*. 2013;8(12):1558–1562. doi:10.1097/JTO.0000437420.38972.fb.
7. Goense L, van Rossum PS, Reitsma JB, et al. Diagnostic performance of 18F-FDG PET and PET/CT for the detection of recurrent esophageal cancer after treatment with curative intent: a systematic review and meta-analysis. *J Nucl Med*. 2015;56(7):995-1002. doi:10.2967/jnumed.115.155580.

Other Thoracic Tumors (ONC-10)

Guideline

Malignant Pleural Mesothelioma – Suspected/Diagnosis (ONC-10.1)

Malignant Pleural Mesothelioma – Initial Work-up/Staging (ONC-10.2)

Malignant Pleural Mesothelioma – Restaging (ONC-10.3)

Malignant Pleural Mesothelioma – Surveillance (ONC-10.4)

Thymoma and Thymic Carcinoma – Suspected/Diagnosis (ONC-10.5)

Thymoma and Thymic Carcinoma – Initial Work-up/Staging (ONC-10.6)

Thymoma and Thymic Carcinoma – Restaging (ONC-10.7)

Thymoma and Thymic Carcinoma – Surveillance (ONC-10.8)

References (ONC-10)

Malignant Pleural Mesothelioma – Suspected/Diagnosis (ONC-10.1)

ON.OT.0010.1.A

v2.0.2024

- See: **Asbestos Exposure (CH-9.1)** in the Chest Imaging Guidelines for evaluation of suspected mesothelioma.

Malignant Pleural Mesothelioma – Initial Work-up/Staging (ONC-10.2)

ON.OT.0010.2.A
v2.0.2024

Indication	Imaging Study
Cytologically or pathologically proven	<ul style="list-style-type: none">• CT Chest (CPT[®] 71260) and CT Abdomen (CPT[®] 74160) with contrast<ul style="list-style-type: none">◦ CT Abdomen and Pelvis with contrast (CPT[®] 74177) may be approved instead of CT Abdomen if there are pelvic signs or symptoms• PET/CT (CPT[®] 78815) if no evidence of metastatic disease or inconclusive conventional imaging
Preoperative planning	<ul style="list-style-type: none">• MRI Chest without and with contrast (CPT[®] 71552)

Malignant Pleural Mesothelioma – Restaging (ONC-10.3)

ON.OT.0010.3.A
v2.0.2024

Indication	Imaging Study
Signs or symptoms of recurrence	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen (CPT[®] 74160) with contrast <ul style="list-style-type: none"> ◦ CT Abdomen and Pelvis with contrast (CPT[®] 74177) may be approved instead of CT Abdomen if there are pelvic signs or symptoms
Treatment with chemotherapy	<p><u>Every 2 cycles:</u></p> <ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen (CPT[®] 74160) with contrast <ul style="list-style-type: none"> ◦ CT Abdomen and Pelvis with contrast (CPT[®] 74177) may be approved instead of CT Abdomen if there are pelvic signs or symptoms
Following induction chemotherapy prior to surgical resection	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen (CPT[®] 74160) with contrast <ul style="list-style-type: none"> ◦ CT Abdomen and Pelvis with contrast (CPT[®] 74177) may be approved instead of CT Abdomen if there are pelvic signs or symptoms • PET/CT (CPT[®] 78815) if no evidence of metastatic disease
Inconclusive CT Chest	<ul style="list-style-type: none"> • MRI Chest without and with contrast (CPT[®] 71552)

Malignant Pleural Mesothelioma – Surveillance (ONC-10.4)

ON.OT.0010.4.A

v2.0.2024

Indication	Imaging Study
All	<ul style="list-style-type: none">• CT Chest with contrast (CPT[®] 71260) and previously involved regions every 3 months for 2 years, then annually thereafter

Thymoma and Thymic Carcinoma – Suspected/Diagnosis (ONC-10.5)

ON.OT.0010.5.A

v2.0.2024

- See: **Mediastinal Mass (CH-20.1)** in the Chest Imaging Guidelines for evaluation of suspected thymic malignancies.
- See: **Bronchopulmonary or Thymic Carcinoid – Initial Staging (ONC-15.6)** for imaging guidelines for thymic carcinoid.

Thymoma and Thymic Carcinoma – Initial Work-up/Staging (ONC-10.6)

ON.OT.0010.6.A

v2.0.2024

Indication	Imaging Study
Encapsulated or invasive limited disease	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260)
Extensive mediastinal involvement on CT Chest	<ul style="list-style-type: none"> • CT Abdomen with contrast (CPT[®] 74160) • CT Neck with contrast (CPT[®] 70491)
Inconclusive finding on CT	<p>ONE of the following:</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815) • MRI Chest without and with contrast (CPT[®] 71552)
Preoperative planning	<ul style="list-style-type: none"> • MRI Chest without and with contrast (CPT[®] 71552)
Thymic Carcinomas	<ul style="list-style-type: none"> • Image according to Non-Small Cell Lung Cancer - Initial Work-up/Staging (ONC-8.3)

Thymoma and Thymic Carcinoma – Restaging (ONC-10.7)

ON.OT.0010.7.A

v2.0.2024

Indication	Study
Adjuvant therapy following surgical resection	<ul style="list-style-type: none"> Follow surveillance imaging
Following induction chemotherapy prior to surgical resection, if no evidence of metastatic disease	<ul style="list-style-type: none"> PET/CT (CPT[®] 78815)
For suspected recurrence	<ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260)
Recurrence with extensive mediastinal involvement on CT Chest	<ul style="list-style-type: none"> CT Abdomen with contrast (CPT[®] 74160) CT Neck with contrast (CPT[®] 70491)
Inconclusive finding on CT	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> PET/CT (CPT[®] 78815) MRI Chest without and with contrast (CPT[®] 71552)
Metastatic disease on chemotherapy	<ul style="list-style-type: none"> CT Neck (CPT[®] 70491), CT Chest (CPT[®] 71260), and CT Abdomen (CPT[®] 74160) with contrast, every 2 cycles of therapy
Thymic carcinomas	<ul style="list-style-type: none"> See: <u>Non-Small Cell Lung Cancer Restaging/ Recurrence (ONC-8.4)</u>

Thymoma and Thymic Carcinoma – Surveillance (ONC-10.8)

ON.OT.0010.8.A

v2.0.2024

Indication	Study
Thymoma	<ul style="list-style-type: none">CT Chest with contrast (CPT[®] 71260) and previously involved regions every 6 months for 2 years, then annually for next 10 years
Thymic carcinomas	<ul style="list-style-type: none">CT Chest with contrast (CPT[®] 71260) every 6 months for 2 years and then annually for next 5 years

References (ONC-10)

v2.0.2024

1. Ettinger DS, Wood DE, Stevenson J, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – December 15, 2022. Mesothelioma: Pleural, available at: https://www.nccn.org/professionals/physician_gls/pdf/meso_pleural.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Mesothelioma: Pleural V1.2023 – December 15, 2022. ©2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Ettinger DS, Wood DE, Stevenson J, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2023 – July 20, 2023. Mesothelioma: Peritoneal, available at: https://www.nccn.org/professionals/physician_gls/pdf/meso_peritoneal.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Mesothelioma: Peritoneal V2.2023 – July 20, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Ettinger DS, Wood DE, Riely GJ, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – December 15, 2022. Thymoma and Thymic carcinoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Thymoma and Thymic carcinoma, V1.2023 – December 15, 2022. ©2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
4. Sørensen JB, Ravn J, Loft A, Brenøe J, Berthelsen AK, Nordic Mesothelioma Group. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computer tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. *Eur J Cardiothorac Surg*. 2008;34:1090-1096. doi:10.1016/j.ejcts.2008.07.050.
5. Wilcox BE, Subramaniam RM, Peller PJ, et al. Utility of computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. *Clin lung cancer*. 2009;10:244-248. doi: 10.3816/CLC.2009.n.033.
6. Marom EM. Imaging thymoma. *J Thorac Oncol*. 2010;5(10 Suppl 4):S296-S303. doi:10.1097/JTO.0b013e3181f209ca.
7. Marom EM. Advances in thymoma imaging. *J Thorac Imaging*. 2013;28(2):69-80. doi:10.1097/RTI.0b013e31828609a0.
8. Hayes SA, Huang J, Plodkowski AJ, et al. Preoperative computed tomography findings predict surgical resectability of thymoma. *J Thorac Oncol*. 2014;9(7):1023-1030. doi:10.1097/JTO.000000000000204.
9. Mineo TC, Ambrogio V. Malignant pleural mesothelioma: factors influencing the prognosis. *Oncology*. 2012;26(12):1164-75.

Breast Cancer (ONC-11)

Guideline

- Breast Cancer – General Considerations (ONC-11.0)
- Breast Cancer – Suspected/Diagnosis (ONC-11.1)
- Breast Cancer – Initial Work-up/Staging (ONC-11.2)
- Breast Cancer – Restaging/Recurrence (ONC-11.3)
- Breast Cancer – Surveillance/Follow-up (ONC-11.4)
- References (ONC-11)

Breast Cancer – General Considerations (ONC-11.0)

ON.BC.0011.0.A

v2.0.2024

- This guideline applies to invasive and pre-invasive (lobular and ductal carcinoma in-situ) histologies of breast cancer.
- MRI Breast is not routinely indicated for all individuals with newly diagnosed breast cancer or carcinoma in situ. The use of MRI has not shown to increase the likelihood of negative surgical margins, decrease the rate of mastectomy, reduce local recurrence rates or improve long-term survival.
- Advanced imaging to evaluate for distant metastases is not indicated for asymptomatic individuals with invasive or pre-invasive or in-situ breast cancer (histologies such as DCIS and LCIS).
- Bone scan has a high concordance rate with PET for detecting bone metastases.
- Scintimammography and Breast Specific Gamma Imaging (BSGI) are considered experimental, investigational, or unproven.

Breast Cancer – Suspected/Diagnosis (ONC-11.1)

ON.BC.0011.1.A

v2.0.2024

- See: **Breast MRI Indications (BR-5)** in the Breast Imaging Guidelines for evaluation of suspected breast cancer.

Breast Cancer – Initial Work-up/Staging (ONC-11.2)

ON.BC.0011.2.A

v2.0.2024

Indication	Imaging Study
<p>Newly diagnosed breast cancer or carcinoma in situ</p>	<ul style="list-style-type: none"> • Diagnostic bilateral mammogram and/or Ultrasound Breast (CPT[®] 76641 or CPT[®] 76642) are imaging modalities of choice • MRI Breast is not routinely indicated for all individuals with newly diagnosed breast cancer or carcinoma in situ^{1, 11, 12, 13, 14}
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Multifocal or multicentric breast cancer • Before neoadjuvant systemic therapy • High risk histologies: atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), or invasive lobular carcinoma (ILC) • Paget's disease of the breast • Inconclusive findings on both mammogram and ultrasound • Extremely dense breast tissue (breast density category D) on mammography • Adenocarcinoma in axillary lymph node without a breast primary site identified on mammogram/ultrasound 	<ul style="list-style-type: none"> • MRI Breast Bilateral without and with contrast (CPT[®] 77049)

Indication	Imaging Study
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Ductal carcinoma in situ • Stage I-III 	<ul style="list-style-type: none"> • For planned sentinel lymph node (SLN) biopsy: Lymph system imaging (lymphoscintigraphy, CPT[®] 78195) <ul style="list-style-type: none"> ◦ SPECT/CT (CPT[®] 78830) is indicated as an add on code if requested
<p>Stages I, II, and III</p>	<ul style="list-style-type: none"> • Routine systemic imaging is not indicated for initial staging of non-metastatic breast cancer in the absence of signs or symptoms
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Clinically suspected or biopsy proven metastatic/Stage IV disease • Signs or symptoms of systemic disease • Elevated liver function tests or tumor markers • Inflammatory breast cancer (stage T4d) • 4 or more axillary lymph nodes positive for cancer involvement 	<p>ANY or ALL of the following:</p> <ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast • Bone scan <p>See: <u>Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)</u></p>
<p>Inconclusive CT and/or bone scan</p>	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)
<p>Bone pain</p>	<ul style="list-style-type: none"> • Bone scan (see: <u>Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)</u>) • See: <u>Bone (Non-Vertebral) Metastases (ONC-31.5)</u> • See: <u>Spinal/Vertebral Metastases (ONC-31.6)</u>

Breast Cancer – Restaging/Recurrence (ONC-11.3)

ON.BC.0011.3.A

v2.0.2024

Indication	Imaging Study
<p>ANY of the following:</p> <ul style="list-style-type: none"> • End of planned neoadjuvant chemotherapy to determine resectability • Biopsy proven local recurrence • Suspicion of recurrence with inconclusive mammogram and/or ultrasound (BIRADS 0) • Mammogram and ultrasound conflicts with physical exam 	<ul style="list-style-type: none"> • MRI Breast Bilateral without and with contrast (CPT[®] 77049)
<p>After neoadjuvant chemotherapy, if sentinel node evaluation is planned</p>	<ul style="list-style-type: none"> • Lymph system imaging (lymphoscintigraphy, CPT[®] 78195) <ul style="list-style-type: none"> ◦ SPECT/CT (CPT[®] 78830) is indicated as an add on code if requested
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Assessing for residual disease after surgery • Assessing response to neoadjuvant chemotherapy • After lumpectomy or mastectomy, prior to adjuvant therapy 	<ul style="list-style-type: none"> • Neither PET nor CT are indicated for systemic restaging after neoadjuvant chemotherapy or after surgery
<ul style="list-style-type: none"> • Treatment response in individuals with metastatic disease and measurable disease on imaging <ul style="list-style-type: none"> ◦ For individuals receiving chemotherapy, imaging is indicated after every 2 cycles 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260); and CT Abdomen and Pelvis with contrast (CPT[®] 74177) • Bone scan (see also: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)) <p>In addition to the above options, for individuals receiving systemic treatment for brain metastases:</p>

Indication	Imaging Study
<ul style="list-style-type: none"> For individuals receiving hormonal or endocrine therapy, imaging is indicated every 3 months 	<ul style="list-style-type: none"> MRI Brain without and with contrast (CPT® 70553)
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> Elevated LFTs Elevated tumor markers Signs or symptoms of recurrence Biopsy proven recurrence 	<p><u>Any or all of the following:</u></p> <ul style="list-style-type: none"> CT Chest (CPT® 71260) and CT Abdomen and Pelvis (CPT® 74177) with contrast Bone scan (See also: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3))
<ul style="list-style-type: none"> Inconclusive CT, MRI, and/or bone scan for suspected recurrence, and further characterization is needed to make treatment decisions Bone metastasis as the only site of stage IV disease (excluding brain metastases) and a prior bone scan has not been performed for serial comparison 	<ul style="list-style-type: none"> ¹⁸F-FDG PET/CT (CPT® 78815)
<p><u>To determine the ER-status of suspected/known metastatic recurrence noted on CT/bone scan and any one of the following:</u></p> <ul style="list-style-type: none"> Biopsy of metastatic site is non-diagnostic/inconclusive Biopsy of metastatic site is risky & cannot be performed (metastatic sites in the brain, spine or near vascular structures) 	<ul style="list-style-type: none"> ¹⁸F-FES (fluoroestradiol) PET/CT scan (CPT® 78815 or CPT® 78816)

Breast Cancer – Surveillance/Follow-up (ONC-11.4)

ON.BC.0011.4.U

v2.0.2024

Indication	Imaging Study
Measurable metastatic disease on maintenance therapy or being monitored off therapy	<p>ANY or ALL of the following, every 3 months for up to 5 years after completion of active treatment:</p> <ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast • Bone scan (see also: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3))
<ul style="list-style-type: none"> • Asymptomatic non-metastatic disease • Individuals receiving post-operative adjuvant therapy 	<ul style="list-style-type: none"> • No advanced imaging indicated
Individuals with a personal history of breast cancer (not treated with bilateral mastectomy)	<ul style="list-style-type: none"> • Annual MRI Breast Bilateral without and with contrast (CPT[®] 77049)

References (ONC-11)

v2.0.2024

1. Gradishar WJ, Moran MS, Abraham J, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024 – March 11, 2024. Breast cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Breast Cancer V2.2024 – March 11, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). *Ann Oncol*. 2014;25(10):1871-1888. doi:10.1093/annonc/mdu385.
3. Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2013;31:961-965. doi:10.1200/JCO.2012.45.9859.
4. Puglisi F, Follador A, Minisini AM, et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. *Ann Oncol*. 2005;16(2):263-266. doi:10.1093/annonc/mdi063.
5. Rong J, Wang S, Ding Q, Yun M, Zheng Z, Ye S. Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. *Surg Oncol*. 2013;22(2):86-91. doi:10.1016/j.suronc.2013.01.002.
6. Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. *Surg Oncol*. 2013;22(2):139-143. doi:10.1016/j.suronc.2013.03.001.
7. Cheng X, Li Y, Liu B, Xu Z, Bao L, Wang J. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. *Acta Radiol*. 2012;53(6):615-627. doi:10.1258/ar.2012.110603.
8. Simos D, Catley C, van Walraven C, et al. Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. *CMAJ*. 2015;187(12):E387-E397. doi:10.1503/cmaj.150003.
9. Crivello ML, Ruth K, Sigurdson ER, et al. Advanced imaging modalities in early stage breast cancer: preoperative use in the United States Medicare population. *Ann Surg Oncol*. 2013;20(1):102-110. doi:10.1245/s10434-012-2571-4.
10. Heller SL, Lourenco AP, Niell BL, et al. ACR Appropriateness Criteria® - Imaging after Mastectomy and Breast Reconstruction. Available at <https://acsearch.acr.org/docs/3155410/Narrative/>. American College of Radiology.
11. Landercasper J, Bailey L, Berry TS, et al. Don't routinely order breast MRI in new breast cancer patients. American Society of Breast Surgeons. <https://www.choosingwisely.org/clinician-lists/breast-surgeons-mris-in-new-breast-cancer-patients/>
12. Chagpar AB, Howard-McNatt M, Chiba A, et al. Factors affecting time to surgery in breast cancer patients. *Am Surg*. 2022;88(4):648-652. doi:10.1177/00031348211054714.
13. Peters NHGM, van Esser S, van den Bosch MAAJ, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET – randomized controlled trial. *Eur J Cancer*. 2011;47(6):879-886. doi:10.1016/j.ejca.2010.11.035
14. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomized controlled trial. *Lancet*. 2010;375(9714):563-571. doi:10.1016/S0140-6736(09)62070-5.
15. Daly MB, Pal T, AlHilli Z, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2024 – February 12, 2024. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V3.2023 – February 12, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.

16. Moncrieff M, Pywell S, Snelling A, et. al. Effectiveness of SPECT/CT imaging for sentinel node biopsy staging of primary cutaneous melanoma and patient outcomes. *Ann Surg Oncol.* 2022;29(2):767-775. doi:10.1245/s10434-021-10911-4.
17. Quartuccio N, Garau LM, Arnone A, et. al. Comparison of 99mTc-labeled colloid SPECT/CT and planar lymphoscintigraphy in sentinel lymph node detection in patients with melanoma: a meta-analysis. *J Clin Med.* 2020;9(6):1680. doi:10.3390/jcm9061680.
18. Bennie G, Vorster M, Buscombe J, Sathekge M. The added value of a single-photon emission computed tomography-computed in sentinel lymph node mapping in patients with breast cancer and malignant melanoma. *World J Nucl Med.* 2015;14(01):41-46. doi:10.4103/1450-1147.150543
19. Ulaner GA, Mankoff DA, Clark AS, et al. Appropriate use criteria for estrogen receptor-targeted pet imaging with 16 α -18f-fluoro-17 β -fluoroestradiol. *J Nucl Med.* 2023;64(3):351-354. doi:10.2967/jnumed.123.265420.

Sarcomas – Bone, Soft Tissue, and GIST (ONC-12)

Guideline

- Bone and Soft Tissue Sarcomas – General Considerations (ONC-12.1)
- Soft Tissue Sarcomas – Initial Work-up/Staging (ONC-12.2)
- Soft Tissue Sarcomas – Restaging/Recurrence (ONC-12.3)
- Soft Tissue Sarcomas Surveillance/Follow-up (ONC-12.4)
- Gastrointestinal Stromal Tumor (GIST) (ONC-12.5)
- Bone Sarcomas – Initial Work-up/Staging (ONC-12.6)
- Bone Sarcomas – Restaging/Recurrence (ONC-12.7)
- Bone Sarcomas – Surveillance/Follow-up (ONC-12.8)
- Benign Bone Tumors – General Considerations (ONC-12.9)
- Benign Bone Tumors – Initial Work-up/Staging (ONC-12.10)
- Benign Bone Tumors – Restaging/Recurrence (ONC-12.11)
- Benign Bone Tumors – Surveillance/Follow-up (ONC-12.12)
- References (ONC-12)

Bone and Soft Tissue Sarcomas – General Considerations (ONC-12.1)

ON.SS.0012.1.A

v2.0.2024

- Sarcomas are tumors of mesenchymal origin, classified as high-, intermediate-, and low-grade (G) tumors (sometimes described as “spindle cell” cancers). They can arise in any bony, cartilaginous, smooth muscle, skeletal muscle, or cardiac muscle tissue.
- Malignant nerve sheath tumor cell types should be imaged as high-grade sarcoma.
- Sarcomas occur in both adult and pediatric individuals, but some are more common in one age group than the other. Unless specified below, individuals age ≥ 18 years old should be imaged according to this guideline section.
- Exceptions include:
 - Rhabdomyosarcoma in individuals of all ages should be imaged according to guidelines in **Rhabdomyosarcoma (RMS) (PEDONC-8.2)** in the Pediatric Oncology Imaging Guidelines
 - Osteogenic sarcoma (Osteosarcoma) in individuals of all ages should be imaged according to guidelines in **Osteogenic Sarcoma (OS) (PEDONC-9.3)** in the Pediatric Oncology Imaging Guidelines
 - Ewing sarcoma and Primitive Neuroectodermal Tumor in individuals of all ages should be imaged according to guidelines in **Ewing Sarcoma and Primitive Neuroectodermal Tumors (ESFT) (PEDONC-9.4)** in the Pediatric Oncology Imaging Guidelines
 - Kaposi’s sarcoma in individuals of all ages should be imaged according to guidelines in **Kaposi’s Sarcoma (ONC-31.10)**
 - See: **Uterine Cancer (ONC-22)** for imaging recommendations for uterine sarcoma
 - Desmoplastic small round cell tumor in individuals of all ages should be imaged according to guidelines in **Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) (PEDONC-8.3)**

Soft Tissue Sarcomas – Initial Work-up/ Staging (ONC-12.2)

ON.SS.0012.2.A
v2.0.2024

Indication	Imaging Study
Retroperitoneal or intra-abdominal primary site	<p>ANY or ALL of the following:</p> <ul style="list-style-type: none"> • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • Either CT Abdomen and Pelvis with contrast (CPT[®] 74177) or MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Extremity or trunk primary site • Head or neck primary site 	<p>ANY or ALL of the following:</p> <ul style="list-style-type: none"> • MRI without and with contrast of involved area • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Angiosarcoma • Alveolar soft part sarcoma • Clear cell sarcoma • Epithelioid sarcoma • Hemangiopericytoma • Leiomyosarcoma • Other histologies documented to have propensity for lymphatic spread and deep-seated tumors 	<p>ANY or ALL of the following:</p> <ul style="list-style-type: none"> • MRI without and with contrast of involved area • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • Either CT Abdomen and Pelvis with contrast (CPT[®] 74177) or MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast

Indication	Imaging Study
Myxoid round cell liposarcoma	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none"> • MRI without and with contrast of involved area • CT Chest with (CPT[®] 71260) or without contrast (CPT[®] 71250) • Either CT Abdomen and Pelvis with contrast (CPT[®] 74177) or MRI Abdomen (CPT[®] 74183) and Pelvis (CPT[®] 72197) without and with contrast • MRI Cervical/Thoracic/Lumbar Spine without and with contrast (CPT[®] 72156, CPT[®] 72157, and CPT[®] 72158)
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Angiosarcoma • Alveolar soft part sarcoma • All individuals with signs/symptoms of brain metastases 	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Grade of tumor in doubt following biopsy • Conventional imaging suggests solitary metastasis amenable to surgical resection 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
Desmoid Tumors	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • CT without contrast or with contrast of the affected body part • MRI without contrast or without and with contrast of the affected body part • Imaging of lung, lymph node, and metastatic site for these tumors is not indicated

Indication	Imaging Study
Dermatofibrosarcoma Protuberans (DFSP)	<p>ONE of the following:</p> <ul style="list-style-type: none">• CT without contrast or with contrast of the affected body part• MRI without contrast or without and with contrast of the affected body part• CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast for:<ul style="list-style-type: none">◦ Pulmonary symptoms◦ Abnormal Chest X-ray◦ Sarcomatous differentiation

Soft Tissue Sarcomas – Restaging/ Recurrence (ONC-12.3)

ON.SS.0012.3.A

v2.0.2024

Indication	Imaging Study
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • After preoperative radiotherapy • After surgical resection • After adjuvant radiotherapy 	<ul style="list-style-type: none"> • MRI without and with contrast or CT with contrast of affected body area • Chest or lymph node imaging is not indicated if no abnormality on previous imaging
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Differentiate tumor from radiation or surgical fibrosis • Determine response to neoadjuvant therapy • Confirm oligometastatic disease prior to curative intent surgical resection 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
<p>Chemotherapy response for individuals with measurable disease</p>	<ul style="list-style-type: none"> • CT with contrast or MRI without and with contrast of affected body area every 2 cycles
<p>Local recurrence suspected</p>	<ul style="list-style-type: none"> • Repeat all imaging for initial workup of specific histology and/or primary site
<p>Preoperative planning prior to resection</p>	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none"> • MRI without contrast or without and with contrast of involved area • CT (contrast as requested) of involved area

Indication	Imaging Study
Dermatofibrosarcoma Protuberans (DFSP)	<ul style="list-style-type: none">• CT without contrast or with contrast of the affected body part or MRI without contrast or without and with contrast of the affected body part• CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast for:<ul style="list-style-type: none">◦ Pulmonary symptoms◦ Abnormal chest x-ray◦ Sarcomatous differentiation

Soft Tissue Sarcomas Surveillance/ Follow-up (ONC-12.4)

ON.SS.0012.4.A

v2.0.2024

Indication	Imaging Study
<p>For any of the following:</p> <ul style="list-style-type: none"> • Retroperitoneal/intra-abdominal primary site • Angiosarcoma • Epithelioid sarcoma 	<p><u>ANY or ALL of the following every 3 months for 2 years, then every 6 months for 2 more years, then annually:</u></p> <ul style="list-style-type: none"> • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast or MRI without and with contrast of any other involved body areas
<p>Myxoid/round cell liposarcoma</p>	<p><u>ANY or ALL of the following every 3 months for 2 years, then every 6 months for 2 more years, then annually:</u></p> <ul style="list-style-type: none"> • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast or MRI without and with contrast of any other involved body areas • MRI Cervical/Thoracic/Lumbar Spine without and with contrast (CPT[®] 72156, CPT[®] 72157, and CPT[®] 72158)
<p>Low-grade/Stage I extremity or trunk, primary site</p>	<p><u>ANY or ALL of the following every 6 months for 5 years, then annually thereafter:</u></p> <ul style="list-style-type: none"> • Chest x-ray <ul style="list-style-type: none"> ◦ CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast is indicated for new findings on chest x-ray or new/worsening pulmonary signs/symptoms • CT with contrast, MRI without contrast, or MRI without and with contrast of primary site if primary site not easily evaluated by physical exam

Indication	Imaging Study
<p>ANY of the following:</p> <ul style="list-style-type: none"> Extremity/trunk primary site - grade II/stage II or higher Head/neck primary site 	<p><u>ANY or ALL of the following every 3 months for 2 years, then every 6 months for 2 more years, then annually:</u></p> <ul style="list-style-type: none"> CT with contrast, MRI without contrast, or MRI without and with contrast of primary site CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast CT with contrast or MRI without and with contrast of any other involved body areas
<p>ANY of the following:</p> <ul style="list-style-type: none"> Angiosarcoma Alveolar soft part sarcoma Cardiac sarcoma 	<p>In addition to the above studies:</p> <ul style="list-style-type: none"> MRI Brain without and with contrast (CPT[®] 70553) annually <p>For surveillance of individuals with known brain metastases, see: Brain Metastases (ONC-31.3)</p>
<p>Desmoid tumors</p>	<p><u>ONE of the following every 6 months for 3 years, then annually:</u></p> <ul style="list-style-type: none"> CT without contrast or with contrast of the affected body part MRI without contrast or without and with contrast of the affected body part
<p>Dermatofibrosarcoma Protuberans</p>	<ul style="list-style-type: none"> No routine imaging unless clinical signs/symptoms of recurrence

Gastrointestinal Stromal Tumor (GIST) (ONC-12.5)

ON.SS.0012.5.A

v2.0.2024

General Considerations

- GISTs are mesenchymal neoplasms of the gastrointestinal (GI) tract, mostly found in the stomach and upper small bowel, commonly metastasizing to the liver and abdominal cavity and primarily treated with surgery.
- Recurrence risk of GIST is estimated by prognostic model based on location, size of primary tumor, and mitotic rate per high power field (HPF). High-risk category includes any tumor >5 cm with >5 mitoses/50 HPF and any tumors >10 cm in size regardless of mitotic rate.

Indication	Imaging Study
Suspected/Diagnosis	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Initial Work-up/Staging	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast • MRI Abdomen without and with contrast (CPT[®] 74183) is indicated for evaluation of liver lesions that are equivocal on CT imaging or for preoperative assessment of liver • PET (CPT[®] 78815) is indicated for evaluation of inconclusive findings on conventional imaging
<u>Monitoring response to treatment (every 8 to 12 weeks) in either of the following:</u> <ul style="list-style-type: none"> • Unresectable primary disease • Metastatic disease 	<u>EITHER of the following:</u> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Abdomen without and with contrast (CPT[®] 74183) and MRI Pelvis without and with contrast (CPT[®] 72197)
Known or suspected recurrence	<ul style="list-style-type: none"> • <u>CT Abdomen and Pelvis with contrast (CPT[®] 74177)</u>

Indication	Imaging Study
<p><u>Any of the following:</u></p> <ul style="list-style-type: none"> • Prior evidence of chest disease • Signs or symptoms of chest disease 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260)
<p>Evaluation of inconclusive findings on conventional imaging</p>	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)
<p><u>Surveillance for any of the following:</u></p> <ul style="list-style-type: none"> • Incompletely resected • Metastatic disease • High-risk disease 	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) every 3 months for 3 years, then every 6 months for 2 years, and then annually
<p>Surveillance for all others</p>	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) every 6 months for 5 years, then annually

Bone Sarcomas – Initial Work-up/Staging (ONC-12.6)

ON.SS.0012.6.A

v2.0.2024

Indication	Imaging Study
<p>Chondrosarcoma</p> <ul style="list-style-type: none"> • Low-grade intra-compartmental • High-grade (grade II or grade III) • Clear cell • Extra-compartmental 	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none"> • MRI without contrast or without and with contrast of involved area • CT (contrast as requested) of involved area • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast
<p>Dedifferentiated chondrosarcoma</p>	<p>See: Osteogenic Sarcoma (OS) (PEDONC-9.3) for imaging recommendations</p>
<p>Mesenchymal chondrosarcoma</p>	<p>See: Ewing’s Sarcoma Family of Tumors (PEDONC-9.4) for imaging recommendations</p>
<p>Chordoma</p>	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none"> • MRI without contrast or without and with contrast of involved area • CT (contrast as requested) of involved area • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Cervical (CPT[®] 72156), Thoracic (CPT[®] 72157), and Lumbar (CPT[®] 72158) Spine without and with contrast • Bone scan (see also: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)) • PET may be approved for inconclusive conventional imaging

Bone Sarcomas – Restaging/Recurrence (ONC-12.7)

ON.SS.0012.7.A

v2.0.2024

Indication	Imaging Study
<p>Chondrosarcoma</p> <ul style="list-style-type: none"> • Low-grade intra-compartmental • High-grade (grade II or grade III) • Clear cell Extra-compartmental 	<p>ANY or ALL of the following, after completion of radiotherapy or every 2 cycles of chemotherapy:</p> <ul style="list-style-type: none"> • MRI without contrast or without and with contrast of involved area • CT (contrast as requested) of involved area • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast
<p>Dedifferentiated chondrosarcoma</p>	<p>See: Osteogenic Sarcoma (OS) (PEDONC-9.3) for imaging recommendations</p>
<p>Mesenchymal chondrosarcoma</p>	<p>See: Ewing’s Sarcoma Family of Tumors (PEDONC-9.4) for imaging recommendations</p>
<p>Chordoma</p>	<p>ANY or ALL of the following, after completion of radiotherapy or every 2 cycles of chemotherapy:</p> <ul style="list-style-type: none"> • MRI without contrast or without and with contrast of involved area • CT (contrast as requested) of involved area • Bone scan (see also: Nuclear Medicine (NM) Imaging in Oncology [ONC-1.3]) • PET may be approved for inconclusive conventional imaging

Bone Sarcomas – Surveillance/Follow-up (ONC-12.8)

ON.SS.0012.8.A

v2.0.2024

Indication	Imaging Study
<ul style="list-style-type: none"> • Grade I Chondrosarcoma • Intra-compartmental Chondrosarcoma 	<p>ANY or ALL of the following every 6 months for 2 years, then annually for 10 years:</p> <ul style="list-style-type: none"> • Plain x-ray of primary site <ul style="list-style-type: none"> ◦ MRI without and with contrast is indicated for new findings on plain x-ray or new/worsening clinical symptoms. • Chest x-ray <ul style="list-style-type: none"> ◦ CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast for new findings on chest x-ray, or new/worsening signs/symptoms
<ul style="list-style-type: none"> • Grade II or III Chondrosarcoma • Clear Cell Chondrosarcoma • Extra-compartmental Chondrosarcoma 	<p>ANY or ALL of the following every 6 months for 5 years, then annually for 10 years:</p> <ul style="list-style-type: none"> • Plain x-ray of primary site <ul style="list-style-type: none"> ◦ MRI without and with contrast is indicated for new findings on plain x-ray or new/worsening clinical symptoms. • Chest x-ray or CT Chest with (CPT[®] 71260) or CT Chest without (CPT[®] 71250) contrast
<p>Dedifferentiated chondrosarcoma</p>	<p>See: Osteogenic Sarcoma (OS) (PEDONC-9.3) for imaging recommendations</p>
<p>Mesenchymal chondrosarcoma</p>	<p>See: Ewing’s Sarcoma Family of Tumors (PEDONC-9.4) for imaging recommendations</p>

Indication	Imaging Study
Chordoma	<ul style="list-style-type: none">• Plain x-ray of primary site every 6 months for 5 years and then annually until year 10<ul style="list-style-type: none">◦ MRI without and with contrast is indicated for new findings on plain x-ray or new/worsening clinical symptoms.• Chest x-ray every 6 months for 5 years and then annually until year 10<ul style="list-style-type: none">◦ CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast may be obtained annually or for evaluation of any new findings on chest x-ray or new/worsening signs/symptoms

Benign Bone Tumors – General Considerations (ONC-12.9)

ON.SS.0012.9.A

v2.0.2024

- Variety of diagnoses, including osteoid osteochondroma, chondroblastoma, desmoplastic fibroma, Paget's disease, osteoid osteoma and others.
- Plain x-ray appearance is diagnostic for many benign bone tumors and advanced imaging is generally unnecessary except for preoperative planning.
- MRI without and with contrast is the primary modality for advanced imaging of bone tumors, and can be approved to help narrow differential diagnoses and determine whether biopsy is indicated.
- Some benign bone tumor types carry a risk of malignant degeneration over time, but routine advanced imaging surveillance has not been shown to improve outcomes for these individuals.
- MRI without and with contrast can be approved to evaluate new findings on Plain x-ray new/worsening clinical symptoms not explained by a recent Plain x-ray.
- There are no data to support the use of PET/CT in the evaluation of benign bone tumors, and PET requests should not be approved without biopsy confirmation of a malignancy.
- Other benign bone tumors should be imaged according to guidelines in **Lesion of Bone (MS-10.1)** in the General Musculoskeletal Imaging Guidelines or **Mass Involving Bone (including Lytic and Blastic Metastatic Disease) (PEDMS-3.4)** in the Pediatric Musculoskeletal Imaging Guidelines.

Benign Bone Tumors – Initial Work-up/ Staging (ONC-12.10)

ON.SS.0012.10.A

v2.0.2024

Indication	Imaging Study
Giant Cell Tumor of Bone (GCTB)	<p><u>ANY or ALL of the following:</u></p> <ul style="list-style-type: none">• MRI without contrast or without and with contrast of involved area• CT (contrast as requested) of involved area• CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast• Bone scan (see also: Nuclear Medicine (NM) in Oncology [ONC-1.3])
Enchondroma	<ul style="list-style-type: none">• MRI without contrast or without and with contrast of primary site

Benign Bone Tumors – Restaging/ Recurrence (ONC-12.11)

ON.ss.0012.11.A

v2.0.2024

Indication	Imaging Study
Giant Cell Tumor of Bone (GCTB)	<p><u>ANY or ALL of the following, after completion of radiotherapy or every 2 cycles of chemotherapy:</u></p> <ul style="list-style-type: none">• MRI without contrast or without and with contrast of involved area• CT (contrast as requested) of involved area• Bone scan (see also: Nuclear Medicine (NM) Imaging in Oncology [ONC-1.3])
Enchondroma	Plain films of primary site

Benign Bone Tumors – Surveillance/ Follow-up (ONC-12.12)

ON.SS.0012.12.A
v2.0.2024

Indication	Imaging Study
Giant Cell Tumor of Bone (GCTB)	<p><u>ANY or ALL of the following every 6 months for 4 years, then annually thereafter:</u></p> <ul style="list-style-type: none">• Plain x-ray of primary site<ul style="list-style-type: none">◦ MRI without and with contrast is indicated for new findings on plain x-ray or new/worsening clinical symptoms.• Chest x-ray<ul style="list-style-type: none">◦ CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast for new findings on chest x-ray, or new/worsening signs/symptoms.
Enchondroma	Plain films of primary site

References (ONC-12)

v2.0.2024

1. Mehren MV, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 – December 12, 2023. Soft Tissue Sarcoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Soft Tissue Sarcoma V3.2023 – December 12, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Biermann JS, Hirbe A, Agulnik M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024 – March 12, 2024. Bone cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Bone cancer V2.2024– March 12, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Von Mehren M, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – March 13, 2023. Gastrointestinal Stromal Tumors (GISTs), available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Gastrointestinal Stromal Tumors (GISTs) V1.2023 – March 13, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN™ Guidelines, go online to NCCN.org
4. Nishiguchi T, Mochizuki K, Ohsawa M, et al. Differentiating benign notochordal cell tumors from chordomas: radiographic features on MRI, CT, and tomography. *Am Jour Roentgenol*. 2011;196(3):644-650. doi:10.2214/AJR.10.4460.
5. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: a new paradigm for imaging. *Oncologist*. 2008;13:8-13. doi:10.1634/theoncologist.13-S2-8.
6. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. *J Natl Compr Canc Netw*. 2010;8(Suppl 2):S42-44.
7. Peng PD, Hyder O, Mavros MN, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. *Ann Surg Oncol*. 2012;19(13):4036-4042. doi:10.1245/s10434-012-2634-6.
8. Tseng WW, Amini B, Madewell JE. Follow-up of the soft tissue sarcoma patient. *J Surg Oncol*. 2015;111(5):641-645. doi:10.1002/jso.23814.
9. Grotz TE, Donohue JH. Surveillance strategies for gastrointestinal stromal tumors. *J Surg Oncol*. 2011;104(8):921-927. doi:10.1002/jso.21862.
10. Akram J, Wooler G, Lock-Andersen J. Dermatofibrosarcoma protuberans: clinical series, national Danish incidence data and suggested guidelines. *J Plast Surg Hand Surg*. 2014;48(1):67-73. doi:10.3109/2000656X.2013.812969.
11. Puri A, Gulia A, Hawaldar R, Ranganathan P, Badwe RA. Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. *Clin Orthop Relat Res*. 2014;472(5):1568-1575. doi:10.1007/s11999-013-3385-9.
12. Biermann JS, Adkins DR, Aqulnik M, et al. Bone cancer. *J Natl Compr Canc Netw*. 2013;11(6):688-723.

Pancreatic Cancer (ONC-13)

Guideline

- Pancreatic Cancer – General Considerations (ONC-13.0)
- Pancreatic Cancer – Screening Studies for Pancreatic Cancer (ONC-13.1)
- Pancreatic Cancer – Suspected/Diagnosis (ONC-13.2)
- Pancreatic Cancer – Initial Work-up/Staging (ONC-13.3)
- Pancreatic Cancer – Restaging/Recurrence (ONC-13.4)
- Pancreatic Cancer – Surveillance/Follow-up (ONC-13.5)
- References (ONC-13)

Pancreatic Cancer – General Considerations (ONC-13.0)

ON.PC.0013.0.A

v2.0.2024

- This guideline refers only to adenocarcinoma of the exocrine pancreas, which accounts for over 90% of pancreatic malignancies. This guideline may also be used for cancer of the Ampulla of Vater.
- Neuroendocrine and carcinoid tumors of the pancreas are not included in this guideline, see: **Neuroendocrine Cancers and Adrenal Tumors (ONC-15)**.

Pancreatic Cancer – Screening Studies for Pancreatic Cancer (ONC-13.1)

ON.PC.0013.1.A

v2.0.2024

- Detailed history of any known inherited syndrome in the individual and detailed family history in first- and second-degree relatives, including the age and lineage, is essential to guide screening recommendations. See table below for age- and risk-specific screening recommendations
- New onset of diabetes in individuals older than 50 has been recognized as a potential indicator of the development of pancreatic cancer. Approximately 1% of individuals in this category are diagnosed with cancer within 3 years. A prediction model has been established which identifies those individuals at greatest risk for pancreatic malignancy. The scoring system, known as ENDPAC (Enriching New-Onset Diabetes for Pancreatic Cancer) is based on 3 discriminatory factors, including change in blood glucose, change in weight, and age of onset at the time of the new diagnosis of diabetes. A score of >3 imparts an elevated risk of pancreatic cancer (3.6%), and these individuals should be screened. Screening is not indicated at this time for scores of 0-2.

Indications	Imaging Study
<p>Individuals who meet BOTH of the following criteria:</p> <ul style="list-style-type: none"> • One or more first- or second-degree relative affected with pancreatic cancer AND • Known mutation carrier of ONE of the following genes: <ul style="list-style-type: none"> ◦ Lynch Syndrome (MLH1, MSH2, or MSH6 gene mutations) ◦ BRCA1, BRCA2 (Familial Breast and Ovarian syndrome) ◦ PALB2 mutation ◦ ATM (Ataxia-Telangiectasia) 	<ul style="list-style-type: none"> • MRI Abdomen without and with contrast (CPT[®] 74183) starting at age 50 or 10 years earlier than the youngest affected family member, repeat annually

Indications	Imaging Study
<p><u>Individuals with family history of pancreatic cancer but no known genetic mutation:</u></p> <ul style="list-style-type: none"> Individuals with 2 relatives with pancreatic cancer where one is a first-degree relative Individuals with 3 or more relatives with pancreatic cancer 	<ul style="list-style-type: none"> MRI Abdomen without and with contrast (CPT[®] 74183) starting at age 45 or 10 years earlier than the youngest affected family member, repeat annually
<p>Pancreatic Cancer Kindred (individuals who have at least one first-degree relative with pancreatic cancer who in turn also has a first-degree relative with pancreatic cancer) and NO known genetic germline mutations</p>	<ul style="list-style-type: none"> MRI Abdomen without and with contrast (CPT[®] 74183) starting at age 50 or 10 years earlier than the youngest affected family member, repeat annually
<p>Hereditary Pancreatitis (PRSS1, CPA1, and CTSC gene mutations)</p>	<ul style="list-style-type: none"> MRI Abdomen without and with contrast (CPT[®] 74183) beginning at age 40 or 20 years after the first pancreatitis attack, repeat annually.
<p>Peutz-Jeghers Syndrome (LKB1/STK11 gene mutation)</p>	<ul style="list-style-type: none"> MRI Abdomen without and with contrast (CPT[®] 74183) starting at age 30, repeat annually
<p>CDKN2A mutation (also known as p16, p16INK4a, and MTS1, FAMM-Familial Atypical Multiple Melanoma and Mole Syndrome)</p>	<ul style="list-style-type: none"> MRI Abdomen without and with contrast or MRCP (CPT[®] 74183) beginning at age 40, repeat annually.
<p>Screening MRI reveals cystic lesion of the pancreas</p>	<ul style="list-style-type: none"> Repeat MRI Abdomen without and with contrast (CPT[®] 74183) in 6 months
<p>Screening MRI reveals indeterminate solid lesion</p>	<ul style="list-style-type: none"> CT Abdomen with contrast – pancreatic protocol (CPT[®] 74160) May repeat MRI Abdomen without and with contrast (CPT[®] 74183) in 3 months after the CT scan

Indications	Imaging Study
Screening MRI reveals pancreatic stricture and/or dilation ≥ 6 mm without a mass	<ul style="list-style-type: none">• CT Abdomen with contrast – pancreatic protocol (CPT[®] 74160)• May repeat MRI Abdomen without and with contrast (CPT[®] 74183) in 3 months after the CT scan
New onset diabetes in adults with ENDPAC score of ≥ 3	<ul style="list-style-type: none">• CT Abdomen without and with contrast (CPT[®] 74170) or MRI Abdomen without and with contrast (CPT[®] 74183) at baseline; if negative, can be repeated once after 6 months

Pancreatic Cancer – Suspected/ Diagnosis (ONC-13.2)

ON.PC.0013.2.A

v2.0.2024

Indication	Imaging Study
For any suspected symptoms only (e.g. epigastric pain, weight loss, pain radiating to back, etc.)	<ul style="list-style-type: none"> • Ultrasound (CPT[®] 76700 or CPT[®] 76705) • Also see: Epigastric Pain and Dyspepsia (AB-2.5)
Symptoms suspicious for pancreatic cancer AND any one of the following: <ul style="list-style-type: none"> • Abnormal labs (e.g. elevated CA 19-9, ALKP, bilirubin, or GGTP) • Abnormal physical exam findings (e.g. abdominal mass) • Abnormal or non-diagnostic ultrasound/ERCP 	Any ONE of the following: <ul style="list-style-type: none"> • CT Pancreatic Protocol (CT Abdomen with contrast with dual phase imaging, CPT[®] 74160) • MRI Abdomen without and with contrast (CPT[®] 74183)
Preoperative studies for potentially resectable tumors without confirmed histologic diagnosis	<ul style="list-style-type: none"> • See: Pancreatic Cancer – Initial Work-up/ Staging (ONC-13.3)

Pancreatic Cancer – Initial Work-up/ Staging (ONC-13.3)

ON.PC.0013.3.A

v2.0.2024

Indication	Imaging Study
All individuals	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with (CPT[®] 74177) or CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) • EUS
For any of the following: <ul style="list-style-type: none"> • Preoperative planning • CT insufficient to determine resectability • Evaluation of indeterminate liver lesions 	<ul style="list-style-type: none"> • MRI Abdomen without and with contrast (CPT[®] 74183)
No evidence of metastatic disease on CT or MRI AND any of the following high-risk features: <ul style="list-style-type: none"> • Borderline resectable disease • Markedly elevated CA 19-9 • Large primary tumor(s) • Enlarged regional lymph nodes 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Pancreatic Cancer – Restaging/ Recurrence (ONC-13.4)

ON.PC.0013.4.A

v2.0.2024

Indication	Imaging Study
For ANY of the following: <ul style="list-style-type: none"> • After neoadjuvant chemoradiation • Post-operative baseline • Suspected recurrence 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with (CPT[®] 74177) or CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) • CT with contrast of other involved or symptomatic areas
Unresectable disease or metastatic disease on chemotherapy	<u>Every 2 cycles of treatment (commonly every 6 to 8 weeks):</u> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with (CPT[®] 74177) or CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) • CT with contrast of other involved or symptomatic areas
Unexplained elevated liver enzymes or inconclusive recent CT abnormality	<ul style="list-style-type: none"> • MRI Abdomen without and with contrast (CPT[®] 74183)
If complete surgical resection was initial therapy	<ul style="list-style-type: none"> • See: <u>Pancreatic Cancer – Surveillance/Follow-up for surveillance imaging (ONC-13.5)</u>

Pancreatic Cancer – Surveillance/Follow-up (ONC-13.5)

ON.PC.0013.5.A
v2.0.2024

Indication	Imaging Study
All individuals	<p><u>Every 3 months for 2 years, then annually:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT® 71260) <p><u>And ANY ONE of the following:</u></p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT® 74177) • MRI Abdomen without and with contrast (CPT® 74183) and MRI Pelvis without and with contrast (CPT® 72197)
Measurable metastatic disease on maintenance therapy or being monitored off therapy	<p><u>Every 3 months for up to 5 years after completion of definitive treatment:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT® 71260) • CT Abdomen and Pelvis with contrast (CPT® 74177)

References (ONC-13)

v2.0.2024

1. Tempero MA, Malafa MP, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – December 13, 2023. Pancreatic Adenocarcinoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Pancreatic Adenocarcinoma V1.2024 – December 13, 2023. © 2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am. J. Gastroenterol.* 2015;110(2):223-262. doi:10.1038/ajg.2014.435.
3. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. *Gut.* 2013;62(3):339-347. doi:10.1136/gutjnl-2012-303108.
4. U.S. Preventive Services Task Force. *Screening for pancreatic cancer: recommendation statement.* Rockville, Maryland: Agency for Healthcare Research and Quality (AHRQ); 2004.
5. Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. *Ann Surg.* 2005;242(2):235-243.
6. Gemmel C, Eickhoff A, Helmstädter L, Riemann JF. Pancreatic cancer screening: state of the art. *Expert Rev Gastroenterol Hepatol.* 2009;3(1):89-96. doi:10.1586/17474124.3.1.89.
7. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. *Gastroenterology.* 2014;146(1):291-304. doi:10.1053/j.gastro.2013.11.004.
8. Tersmette AC, Petersen GM, Offerhaus GJ. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. *Clin Cancer Res.* 2001;7(3):738-44.
9. Tzeng CW, Abbott DE, Cantor SB et al. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. *Ann Surg Oncol.* 2013;20(7):2197-2203. doi:10.1245/s10434-013-2889-6.
10. Furman MJ, Lambert LA, Sullivan ME, Whalen GF. Rational follow-up after curative cancer resection. *Journal of Clinical Oncology.* 2013;31(9):1130-1133. doi:10.1200/JCO.2012.46.4438.
11. Tzeng C, Fleming J, Lee J, et al. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. *HPB.* 2012;14(6):365-372. doi:10.1111/j.1477-2574.2012.00445.x.
12. Sharma, A, Kandlakunta H, Nagpal SJS, et.al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes. *Gastroenterology.* 2018;155(3):730-739.
13. Goggins M, Overbeek KA, Brand R, et. al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening Consortium. *Gut.* 2020;69(1):7-17. doi:10.1136/gutjnl-2019-319352.

Upper GI Cancers (ONC-14)

Guideline

Hepatocellular Carcinoma (HCC) – General Considerations (ONC-14.1)
Hepatocellular Carcinoma (HCC) – Suspected/Diagnosis (ONC-14.2)
Hepatocellular Carcinoma (HCC) – Initial Work-up/Staging (ONC-14.3)
Hepatocellular Carcinoma (HCC) – Restaging/Recurrence (ONC-14.4)
Hepatocellular Carcinoma (HCC) – Surveillance/Follow-up (ONC-14.5)
Gallbladder and Biliary Tumors – Initial Work-up/Staging (ONC-14.6)
Gallbladder and Biliary Tumors – Restaging/Recurrence (ONC-14.7)
Gallbladder and Biliary Tumors – Surveillance/Follow-up (ONC-14.8)
Gastric Cancer – Initial Work-up/Staging (ONC-14.9)
Gastric Cancer – Restaging/Recurrence (ONC-14.10)
Gastric Cancer – Surveillance/Follow-up (ONC-14.11)
References (ONC-14)

Hepatocellular Carcinoma (HCC) – General Considerations (ONC-14.1)

ON.GI.0014.1.A

v2.0.2024

- A biopsy is not always required for the diagnosis of Hepatocellular carcinoma (HCC). A dedicated triple-phase CT or MRI may be obtained. MRI with contrast is the test of choice for the evaluation of liver masses. It offers soft tissue contrast resolution superior to CT as well as the possibility of using two different contrast agents, one of which is more blood flow based and the other which also is blood flow based and demonstrates hepatobiliary function (Eovist). Classical imaging findings include:
 - Arterial phase hyper-enhancement
 - Venous phase washout appearance
 - Capsule appearance
 - Threshold growth
- For individuals who are high-risk for developing HCC (cirrhosis, chronic Hepatitis B or current or prior HCC), if the liver lesion is >1 cm with 2 classic enhancements on triple-phase CT or MRI, the diagnosis is confirmatory and biopsy is not needed.
- For lesions less than 1 cm or with less than 2 classical enhancements or for any liver lesions in individuals who are not high-risk, a biopsy is needed for histological confirmation. PET/CT scan is considered experimental, investigational, or unproven for the diagnosis or staging of HCC

Hepatocellular Carcinoma (HCC) – Suspected/Diagnosis (ONC-14.2)

ON.GI.0014.2.A

v2.0.2024

- See: **Chronic Liver Disease, Cirrhosis and Screening for HCC (AB-26.1)** in the Abdomen Imaging Guidelines
- See: **Liver Lesion Characterization (AB-29.1)** in the Abdomen Imaging Guidelines

Hepatocellular Carcinoma (HCC) – Initial Work-up/Staging (ONC-14.3)

ON.GI.0014.3.A
v2.0.2024

Indication	Imaging Study
All individuals	<ul style="list-style-type: none">• CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) <p>And ONE of the following:</p> <ul style="list-style-type: none">• CT Abdomen with contrast (CPT[®] 74160)• CT Abdomen without and with contrast (CPT[®] 74170)• CT Abdomen and Pelvis with contrast (CPT[®] 74177) or without and with contrast (CPT[®] 74178)• MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast

Hepatocellular Carcinoma (HCC) – Restaging/Recurrence (ONC-14.4)

ON.GI.0014.4.A

v2.0.2024

Indication	Imaging Study
<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • After initial therapy • For suspected recurrence or new liver lesions • Individuals receiving systemic therapy (every 2 cycles) 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) <p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • CT Abdomen with contrast (CPT[®] 74160) • CT Abdomen without and with contrast (CPT[®] 74170) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) • MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
<p>Hepatocellular Carcinoma treated with embolization</p>	<ul style="list-style-type: none"> • CTA Abdomen (CPT[®] 74175) can be approved immediately prior to embolization <p><u>ONE of the following, immediately prior to and 1 month post-ablation:</u></p> <ul style="list-style-type: none"> • MRI Abdomen without and with contrast (CPT[®] 74183) • CT Abdomen without and with contrast (CPT[®] 74170) <p>See: Liver Metastases (ONC-31.2) for imaging studies indicated prior to and post-embolization</p>
<p>Hepatocellular Carcinoma awaiting liver transplant</p>	<ul style="list-style-type: none"> • See: Liver Transplant, Pre-Transplant (AB-42.1) in the Abdomen Imaging Guidelines

Hepatocellular Carcinoma (HCC) – Surveillance/Follow-up (ONC-14.5)

ON.GI.0014.5.A
v2.0.2024

Indication	Imaging Study
<p>Hepatocellular Carcinoma:</p> <ul style="list-style-type: none"> • Treated with surgical resection • Treated with embolization • Being monitored off therapy 	<p>Every 3 months for 2 years, then every 6 months until year <u>5</u>:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) <p>And ONE of the following:</p> <ul style="list-style-type: none"> • CT Abdomen with contrast (CPT[®] 74160) • CT Abdomen without and with contrast (CPT[®] 74170) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or without and with contrast (CPT[®] 74178) • MRI Abdomen (CPT[®] 74183) and Pelvis (CPT[®] 72197) without and with contrast
<p>Hepatocellular Carcinoma treated with liver transplant</p>	<ul style="list-style-type: none"> • See: Liver Transplant, Post-transplant Imaging (AB-42.3) in the Abdomen Imaging Guidelines

Gallbladder and Biliary Tumors – Initial Work-up/Staging (ONC-14.6)

ON.GI.0014.6.A
v2.0.2024

Indication	Imaging Study
All individuals	<ul style="list-style-type: none">CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) And ONE of the following: <ul style="list-style-type: none">CT Abdomen with contrast (CPT[®] 74160)CT Abdomen without and with contrast (CPT[®] 74170)CT Abdomen and Pelvis with contrast (CPT[®] 74177)MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
Inconclusive findings on conventional imaging	<ul style="list-style-type: none">PET/CT (CPT[®] 78815)

Gallbladder and Biliary Tumors – Restaging/Recurrence (ONC-14.7)

ON.GI.0014.7.A

v2.0.2024

Indication	Imaging Study
<p>ANY of the following:</p> <ul style="list-style-type: none">• After initial therapy• For suspected recurrence or new liver lesions• Individuals receiving systemic chemotherapy (every 2 cycles)	<ul style="list-style-type: none">• CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) <p>And ONE of the following:</p> <ul style="list-style-type: none">• CT Abdomen with contrast (CPT[®] 74160)• CT Abdomen and Pelvis with contrast (CPT[®] 74177)• MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
<p>Inconclusive findings on conventional imaging</p>	<ul style="list-style-type: none">• PET/CT (CPT[®] 78815)

Gallbladder and Biliary Tumors – Surveillance/Follow-up (ONC-14.8)

ON.GI.0014.8.A

v2.0.2024

Indication	Imaging Study
All individuals	<p><u>Every 6 months for 2 years, and then annually up to year 5:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) <p><u>And ONE of the following:</u></p> <ul style="list-style-type: none"> • CT Abdomen with contrast (CPT[®] 74160) • CT Abdomen without and with contrast (CPT[®] 74170) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
Biliary carcinoma treated with liver transplant	<p>See: <u>Liver Transplant, Post-transplant Imaging (AB-42.3)</u> in the Abdomen Imaging Guidelines</p>

Gastric Cancer – Initial Work-up/Staging (ONC-14.9)

ON.GI.0014.9.A
v2.0.2024

Indication	Imaging Study
All individuals	<ul style="list-style-type: none">• CT Chest with contrast (CPT[®] 71260)• CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Gastric cancer \geq T2 or higher with no metastatic disease by conventional imaging	<ul style="list-style-type: none">• PET/CT (CPT[®] 78815)

Gastric Cancer – Restaging/Recurrence (ONC-14.10)

ON.GI.0014.10.A

v2.0.2024

Indication	Imaging Study
<ul style="list-style-type: none"> • After initial therapy for presumed surgically resectable disease • Post curative chemoradiation being treated without surgery • For suspected recurrence 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177)
<p>Monitoring response to chemotherapy (every 2 cycles, ~every 6-8 weeks) for:</p> <ul style="list-style-type: none"> • Unresected primary disease • Metastatic disease 	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Chest with contrast (CPT[®] 71260) for: <ul style="list-style-type: none"> ◦ New/worsening pulmonary symptoms ◦ Abnormal chest x-ray findings ◦ Known prior pulmonary involvement
<p>New liver lesion(s) and primary site controlled</p>	<ul style="list-style-type: none"> • CT Abdomen without and with contrast (CPT[®] 74170) or MRI Abdomen without and with contrast (CPT[®] 74183)
<p>Inconclusive findings on conventional imaging</p>	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Gastric Cancer – Surveillance/Follow-up (ONC-14.11)

ON.GI.0014.11.A

v2.0.2024

Indication	Imaging Study
Stage I (treated with resection alone)	<ul style="list-style-type: none"> No routine imaging unless clinical signs/symptoms of recurrence
<p>ANY of the following:</p> <ul style="list-style-type: none"> Stage I treated with systemic therapy Stages II-III Stage IV - Metastatic disease (post definitive treatment of all measurable disease or being observed off therapy) 	<p>Every 6 months for 2 years, and then annually for 3 more years:</p> <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Measurable metastatic disease on maintenance therapy or being monitored off therapy	<p>Every 3 months for up to 5 years after completion of active treatment:</p> <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) CT Abdomen and Pelvis with contrast (CPT[®] 74177)

References (ONC-14)

v2.0.2024

1. Ajani JA, D'Amico TA, Bentrem DJ et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – March 10, 2023. Gastric cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Gastric cancer V1.2023 – March 10, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Benson AB, D'Angelica MI, Abrams T, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023—March 10, 2023, Hepatocellular Carcinoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf, Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Hepatocellular Carcinoma V1.2023 3/10/2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Benson AB, D'Angelica MI, Abrams T, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2023—May 10, 2023, Biliary Tract Cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf, Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Biliary Tract Cancers V2.2023 5/10/2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org
4. Vallböhmer D, Hölscher AH, Schnieder PM, et al. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. *J Surg Oncol*. 2010;102(2):135-140. doi:10.1002/jso.21592.
5. Zou H, Zhao Y. 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection: a meta-analysis. *Surg Oncol*. 2013;22(3):162-166. doi:10.1016/j.suronc.2013.05.001.
6. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. *J Hepatol*. 2014;60(6):1268-1289. doi:10.1016/j.jhep.2014.01.021.
7. Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. *Gut*. 2012;61(12):1657-1669. doi:10.1136/gutjnl-2011-301748.
8. Benson AB 3rd, D'Angelica MI, Abrams TA, et al. Hepatobiliary cancers, version 2.2014. *J Natl Compr Canc Netw*. 2014;12(8):1152-1182.

Neuroendocrine Cancers and Adrenal Tumors (ONC-15)

Guideline

- General Considerations (ONC-15.1)
- Gastrointestinal/Pancreatic Neuroendocrine Cancers – Suspected/Diagnosis (ONC-15.2)
- Gastrointestinal/Pancreatic Neuroendocrine Cancers – Initial Work-up/Staging (ONC-15.3)
- Gastrointestinal/Pancreatic Neuroendocrine Cancers – Restaging/Recurrence (ONC-15.4)
- Gastrointestinal/Pancreatic Neuroendocrine Cancers – Surveillance (ONC-15.5)
- Bronchopulmonary or Thymic Carcinoid – Initial Staging (ONC-15.6)
- Bronchopulmonary or Thymic Carcinoid – Restaging/Recurrence (ONC-15.7)
- Bronchopulmonary or Thymic Carcinoid – Surveillance (ONC-15.8)
- Adrenal Tumors – Suspected/Diagnosis (ONC-15.9)
- Adrenal Tumors – Initial Work-up/Staging (ONC-15.10)
- Adrenal Tumors – Restaging/Recurrence (ONC-15.11)
- Adrenal Tumors – Surveillance (ONC-15.12)
- Adrenocortical Carcinoma (ONC-15.13)
- References (ONC-15)

General Considerations (ONC-15.1)

ON.NA.0015.1.A

v2.0.2024

This guideline includes low-grade or well-differentiated carcinoid and endocrine tumors of the lung, thymus, pancreas, gastrointestinal tract or unknown primary site; including insulinoma, glucagonoma, VIPoma, gastrinoma, somatostatinoma and others as well as catecholamine-secreting tumors of the adrenal gland such as pheochromocytoma, paraganglioma, adrenocortical carcinoma, and others.

- For poorly-differentiated or high-grade small cell or large cell neuroendocrine tumors arising outside the lung or from an unknown primary site, see: **Extrathoracic Small Cell and Large Cell Neuroendocrine Tumors (ONC-31.8)**.
- For poorly-differentiated or high grade neuroendocrine tumors of the lung, see: **Small Cell Lung Cancer (ONC-7)**.
- Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma occurring in adults should be imaged according to **Neuroblastoma (PEDONC-6)** in the Pediatric Oncology Imaging Guidelines.
- Many are associated with Multiple Endocrine Neoplasia (MEN) familial syndromes.
– See: **Multiple Endocrine Neoplasias (MEN) (PEDONC-2.8)** in the Pediatric Oncology Imaging Guidelines for screening recommendations.
- Somatostatin receptor (SSR) based imaging is more sensitive and specific for evaluation of well-differentiated neuroendocrine tumors and may be performed using ¹¹¹In DTPA Octreotide scintigraphy or PET/CT scan with SSR radiotracers (such as ⁶⁸Ga-DOTATATE, ⁶⁸Ga-DOTATOC, or ⁶⁴Cu-DOTATATE). This study is not part of evaluation of poorly-differentiated or high-grade neuroendocrine tumors, which are imaged according to: **Extrathoracic Small Cell and Large Cell Neuroendocrine Tumors (ONC-31.8)**.

Gastrointestinal/Pancreatic Neuroendocrine Cancers – Suspected/ Diagnosis (ONC-15.2)

ON.NA.0015.2.A
v2.0.2024

Indication	Imaging Study
<ul style="list-style-type: none"> • Systemic symptoms strongly suggestive of functioning neuroendocrine tumor • Suspicious findings on other imaging studies • Unexplained elevation in ANY of the following: <ul style="list-style-type: none"> ◦ Chromogranin A ◦ 5HIAA ◦ Insulin ◦ VIP ◦ Glucagon ◦ Gastrin ◦ Substance P ◦ Serotonin ◦ Somatostatin 	<p>ANY of the following:</p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or without and with contrast (CPT[®] 74178) OR MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast • CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) • CT with contrast or MRI without and with contrast of any other symptomatic body areas

Indication	Imaging Study
<ul style="list-style-type: none"> Continued suspicion with negative/inconclusive CT or MRI 	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> Octreotide scan <ul style="list-style-type: none"> Any one of the following planar imaging codes - CPT[®] 78801, 78802, or 78804 AND Any one of the follow SPECT/SPECT-CT codes - CPT[®] 78803, 78830, 78831, 78832 PET/CT scan (CPT[®] 78815) with any ONE of the following SSR radiotracers: <ul style="list-style-type: none"> ⁶⁸Ga-DOTATATE ⁶⁸Ga-DOTATOC ⁶⁴Cu-DOTATATE

Gastrointestinal/Pancreatic Neuroendocrine Cancers – Initial Work- up/Staging (ONC-15.3)

ON.NA.0015.3.A
v2.0.2024

Indication	Imaging Study
GI or pancreatic neuroendocrine (carcinoid) tumors	<p><u>If not already done:</u></p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or without and with contrast (CPT[®] 74178) OR MRI Abdomen (CPT[®] 74183) and Pelvis (CPT[®] 72197) without and with contrast is indicated • CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250)
Inconclusive CT or MRI scans	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Octreotide scan (ANY ONE of the following): <ul style="list-style-type: none"> ◦ Any one of the following planar imaging codes - CPT[®] 78801, 78802, or 78804 AND ◦ Any one of the following SPECT/SPECT-CT codes - CPT[®] 78803, 78830, 78831, 78832 • PET/CT scan (CPT[®] 78815) with any ONE of the following SSR radiotracers: <ul style="list-style-type: none"> ◦ ⁶⁸Ga-DOTATATE ◦ ⁶⁸Ga-DOTATOC ◦ ⁶⁴Cu-DOTATATE

Indication	Imaging Study
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none">• Markers fail to normalize after complete resection AND CT/MRI and somatostatin-receptor based study are negative• Biopsy-proven neuroendocrine tumor of unknown primary site AND CT/ MRI and somatostatin-receptor based study are negative	<ul style="list-style-type: none">• FDG-PET/CT scan (CPT[®] 78815)

Gastrointestinal/Pancreatic Neuroendocrine Cancers – Restaging/ Recurrence (ONC-15.4)

ON.NA.0015.4.A
v2.0.2024

Indication	Imaging Study
All after surgical resection	<ul style="list-style-type: none"> See: Gastrointestinal/Pancreatic Neuroendocrine Cancers – Surveillance (ONC-15.5)
Unresectable/metastatic disease on treatment with somatostatin analogues	<ul style="list-style-type: none"> CT of involved body area no more frequently than every 3 months
Unresectable/metastatic disease on treatment with chemotherapy	<ul style="list-style-type: none"> CT of involved body area every 2 cycles (6 to 8 weeks)
Progression of symptoms or elevation of tumor markers	<ul style="list-style-type: none"> CT Chest without contrast (CPT[®] 71250) or CT Chest with contrast (CPT[®] 71260) <p>And ONE of the following:</p> <ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast

Indication	Imaging Study
Continued suspicion for recurrence with negative or inconclusive CT or MRI	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Octreotide scan: <ul style="list-style-type: none"> ◦ Any one of the following planar imaging codes - CPT[®] 78801, 78802, or 78804 AND ◦ Any one of the following SPECT/SPECT-CT codes - CPT[®] 78803, 78830, 78831, 78832 • PET/CT scan (CPT[®] 78815) with any ONE of the following SSR radiotracers: <ul style="list-style-type: none"> ◦ ⁶⁸Ga-DOTATATE ◦ ⁶⁸Ga-DOTATOC ◦ ⁶⁴Cu-DOTATATE
To assess candidacy for peptide receptor radionuclide therapy (PRRT) with Lutetium ¹⁷⁷ Lu-dotatate	<ul style="list-style-type: none"> • PET/CT scan (CPT[®] 78815) with any ONE of the following SSR radiotracers: <ul style="list-style-type: none"> ◦ ⁶⁸Ga-DOTATATE ◦ ⁶⁸Ga-DOTATOC ◦ ⁶⁴Cu-DOTATATE

Gastrointestinal/Pancreatic Neuroendocrine Cancers – Surveillance (ONC-15.5)

ON.NA.0015.5.A
v2.0.2024

Indication	Imaging Study
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Appendix carcinoid ≤2 cm, completely resected • Rectal carcinoid <1 cm, completely resected • Gastric carcinoid treated with complete endoscopic resection 	<ul style="list-style-type: none"> • Advanced imaging is not routinely indicated for surveillance
<p>Rectal carcinoid 1-2 cm, completely resected</p>	<ul style="list-style-type: none"> • MRI Pelvis without and with contrast (CPT[®] 72197) at 6 and 12 months post resection. If clear, no further surveillance imaging indicated
<p>All other GI neuroendocrine tumors (stomach, large and small intestine)</p>	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) once at 3 to 12 months postoperatively and annually for 3 years and then every 2 years up to year 10
<p>Unresected GI neuroendocrine tumors being monitored with observation alone</p>	<ul style="list-style-type: none"> • CT Abdomen with contrast (CPT[®] 74160) once at 3 to 12 months from initial diagnosis then annually up to year 10
<p>Pancreatic neuroendocrine tumors</p>	<ul style="list-style-type: none"> • CT Abdomen with contrast (CPT[®] 74160) once at 3 to 12 months postoperatively then annually up to year 10
<p>Unresected pancreatic neuroendocrine tumors being monitored with observation alone</p>	<ul style="list-style-type: none"> • CT Abdomen with contrast (CPT[®] 74160) once at 3 to 12 months from initial diagnosis then annually up to year 10

Indication	Imaging Study
Measurable metastatic disease on maintenance treatment or off therapy	<ul style="list-style-type: none">• CT of involved body area no more frequently than every 3 months

Bronchopulmonary or Thymic Carcinoid – Initial Staging (ONC-15.6)

ON.NA.0015.6.A
v2.0.2024

Indication	Imaging Study
Initial diagnosis	<p><u>If not already done:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen with contrast (CPT[®] 74160) or without and with contrast (CPT[®] 74170) <ul style="list-style-type: none"> ◦ If CT inconclusive, MRI Abdomen (CPT[®] 74183) without and with contrast is indicated
Inconclusive CT or MRI scans	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Octreotide scan (ANY ONE of the following): <ul style="list-style-type: none"> ◦ Any one of the following planar imaging codes - CPT[®] 78801, 78802, or 78804 AND ◦ Any one of the following SPECT/SPECT-CT codes - CPT[®] 78803, 78830, 78831, 78832 • PET/CT scan (CPT[®] 78815) with any ONE of the following SSR radiotracers: <ul style="list-style-type: none"> ◦ ⁶⁸Ga-DOTATATE ◦ ⁶⁸Ga-DOTATOC ◦ ⁶⁴Cu-DOTATATE

Indication	Imaging Study
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none">• Markers fail to normalize after complete resection AND CT/MRI and somatostatin-receptor based study are negative• Biopsy-proven neuroendocrine tumor of unknown primary site AND CT/MRI and somatostatin-receptor based study are negative	<ul style="list-style-type: none">• FDG-PET/CT scan (CPT[®] 78815)

Bronchopulmonary or Thymic Carcinoid – Restaging/Recurrence (ONC-15.7)

ON.NA.0015.7.A

v2.0.2024

Indication	Imaging Study
All after surgical resection	<ul style="list-style-type: none"> • See: Bronchopulmonary or Thymic Carcinoid - Surveillance (ONC-15.8)
Unresectable/metastatic disease on treatment with somatostatin analogues	<ul style="list-style-type: none"> • CT of involved body area no more frequently than every 3 months
Unresectable/metastatic disease on treatment with chemotherapy	<ul style="list-style-type: none"> • CT of involved body area every 2 cycles (6 to 8 weeks)
Progression of symptoms or elevation of tumor markers	<ul style="list-style-type: none"> • CT Chest without (CPT[®] 71250) or CT Chest with contrast (CPT[®] 71260) • <u>And ONE of the following:</u> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) • MRI Abdomen (CPT[®] 74183) and Pelvis (CPT[®] 72197) without and with contrast
Continued suspicion for recurrence with negative or inconclusive CT or MRI	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Octreotide scan <ul style="list-style-type: none"> ◦ Any one of the following planar imaging codes - CPT[®] 78801, 78802, or 78804 AND ◦ Any one of the following SPECT/SPECT-CT codes - CPT[®] 78803, 78830, 78831, 78832 • PET/CT scan (CPT[®] 78815) with any ONE of the following SSR radiotracers: <ul style="list-style-type: none"> ◦ ⁶⁸Ga-DOTATATE ◦ ⁶⁸Ga-DOTATOC ◦ ⁶⁴Cu-DOTATATE

Bronchopulmonary or Thymic Carcinoid – Surveillance (ONC-15.8)

ON.NA.0015.8.A

v2.0.2024

Indication	Imaging Study
Carcinoid tumors of lung or thymus	<ul style="list-style-type: none">CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) once at 3 to 12 months post resection and then annually for 3 years and then every 2 years up to year 10
Unresected primary tumors being monitored with observation alone	<ul style="list-style-type: none">CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) once at 3 to 12 months from initial diagnosis then annually for 3 years and then every 2 years up to year 10
Measurable metastatic disease on maintenance treatment or off therapy	<ul style="list-style-type: none">CT of involved body area no more frequently than every 3 months

Adrenal Tumors – Suspected/Diagnosis (ONC-15.9)

ON.NA.0015.9.A

v2.0.2024

- See: **Adrenal Cortical Lesions (AB-16.1)** in the Abdomen Imaging Guidelines for evaluation of indeterminate adrenal masses.
- Adrenal tumors that involve the adrenal medulla or neural crest tissue outside the adrenal gland include pheochromocytoma, paraganglioma, and paraganglioma
 - These tumors are imaged according to sections **ONC-15.10 through ONC-15.12**
 - Malignant adrenal tumors that involve the adrenal cortex are addressed in **Adrenocortical Carcinoma (ONC-15.13)**
- Adrenocortical carcinoma is imaged according to **Adrenocortical Carcinoma (ONC-15.13)**
- If concern for genetic predisposition syndrome such as MEN, neurofibromatosis, or Von Hippel-Lindau disease, see screening recommendations in **Screening Imaging and Cancer Predisposition Syndromes (PEDONC-2)** in the Pediatric Oncology Imaging Guidelines.

Adrenal Tumors – Initial Work-up/ Staging (ONC-15.10)

ON.NA.0015.10.A
v2.0.2024

Indication	Imaging Study
<p><u>For ANY of the following:</u></p> <ul style="list-style-type: none"> • Pheochromocytoma • Paraganglioma • Paraganglioneuroma 	<p><u>If not already done:</u></p> <ul style="list-style-type: none"> • CT Chest without (CPT[®] 71250) or CT Chest with contrast (CPT[®] 71260) <p><u>And ONE of the following (if not already done):</u></p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) • MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast • CT with contrast or MRI without and with contrast of any other symptomatic body areas
<p>Continued suspicion with negative/ inconclusive CT or MRI</p>	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Octreotide or MIBG scan: <ul style="list-style-type: none"> ◦ Any one of the following planar imaging codes - CPT[®] 78801, 78802, 78804 AND ◦ Any one of the following SPECT/SPECT-CT codes - CPT[®] 78803, 78830, 78831, 78832 • PET/CT scan (CPT[®] 78815) with any ONE of the following SSR radiotracers: <ul style="list-style-type: none"> ◦ ⁶⁸Ga-DOTATATE ◦ ⁶⁸Ga-DOTATOC ◦ ⁶⁴Cu-DOTATATE
<p>All above studies done and negative/ inconclusive</p>	<ul style="list-style-type: none"> • FDG-PET/CT scan (CPT[®] 78815)

Adrenal Tumors – Restaging/Recurrence (ONC-15.11)

ON.NA.0015.11.A

v2.0.2024

Indication	Imaging Study
If surgery is primary therapy	<ul style="list-style-type: none"> CT Abdomen with contrast (CPT[®] 74160) one time within first year post resection then go to surveillance recommendations
Recurrence, progression of symptoms, or elevation of tumor markers	<ul style="list-style-type: none"> CT Chest without contrast (CPT[®] 71250) or CT Chest with contrast (CPT[®] 71260) CT with contrast of involved areas <p>And ONE of the following:</p> <ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
Continued suspicion for recurrence with negative or inconclusive CT or MRI	<p>ONE of the following:</p> <ul style="list-style-type: none"> Octreotide scan (ANY ONE of the following): <ul style="list-style-type: none"> Any one of the following planar imaging codes - CPT[®] 78801, 78802, or 78804 AND Any one of the following SPECT/SPECT-CT codes - CPT[®] 78803, 78830, 78831, 78832 PET/CT scan (CPT[®] 78815) with any ONE of the following SSR radiotracers: <ul style="list-style-type: none"> ⁶⁸Ga-DOTATATE ⁶⁸Ga-DOTATOC ⁶⁴Cu-DOTATATE
All above studies done and negative/ inconclusive	<ul style="list-style-type: none"> FDG-PET/CT scan (CPT[®] 78815)

Adrenal Tumors – Surveillance (ONC-15.12)

ON.NA.0015.12.A

v2.0.2024

Indication	Imaging Study
All individuals	Once within 3-12 months post resection and then annually for 10 years: <ul style="list-style-type: none">• CT Chest with contrast (CPT[®] 71260) or without contrast (CPT[®] 71250)• CT Abdomen and Pelvis with contrast (CPT[®] 74177) or MRI Abdomen and Pelvis without and with contrast (CPT[®] 74183 and 72197)• CT with contrast of other involved body areas
Measurable metastatic disease being observed off therapy or on maintenance treatment	<ul style="list-style-type: none">• CT of involved body area no more frequently than every 3 months for up to 5 years after completion of definitive therapy and annually thereafter

Adrenocortical Carcinoma (ONC-15.13)

ON.NA.0015.13.A
v2.0.2024

Indication	Imaging Study
Initial Staging	<ul style="list-style-type: none"> • CT Chest without (CPT[®] 71250) or CT Chest with contrast (CPT[®] 71260) <p>And ONE of the following (if not already done):</p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) • MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
Suspected recurrence	<ul style="list-style-type: none"> • CT Chest without (CPT[®] 71250) or CT Chest with contrast (CPT[®] 71260) <p>And ONE of the following:</p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) • MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
<ul style="list-style-type: none"> • Solitary adrenal mass >4 cm on conventional imaging and plans for aggressive surgical resection • Inconclusive findings on conventional imaging 	<ul style="list-style-type: none"> • FDG PET/CT scan (CPT[®] 78815)
Surveillance after complete response to definitive treatment	<p>Annually for 5 years:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260), CT Abdomen with contrast (CPT[®] 74160), and CT of other involved body areas with contrast

Indication	Imaging Study
Measurable metastatic disease on maintenance therapy or being monitored off therapy	<p><u>Every 3 months for up to 5 years after completion of definitive therapy:</u></p> <ul style="list-style-type: none">• CT Chest with contrast (CPT[®] 71260), CT Abdomen and Pelvis with contrast (CPT[®] 74177), and CT with contrast of other involved body areas

References (ONC-15)

v2.0.2024

1. Bergsland E, Goldner WS, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – August 2, 2023. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Neuroendocrine and Adrenal tumors V1.2023 – August 2, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Qadan M, Ma Y, Visser BC, et al. Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors. *J Am Coll Surg*. 2014;218(2):188-195. doi:10.1016/j.jamcollsurg.2013.11.001.
3. Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2014;99(6):1915-1942. doi:10.1210/jc.2014-1498.
4. Ruys AT, Bennink RJ, van Westreenen HL, et al. FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma. *HPB (Oxford)*. 2011;13(4):256-262. doi:10.1111/j.1477-2574.2010.00280.x.
5. Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. *Endocr Relat Can*. 2013;20(2):187-196. doi:10.1530/ERC-12-0340.
6. Murray SE, Lloyd RV, Sippel RS, Chen H, Oltmann SC. Postoperative surveillance of small appendiceal carcinoid tumors. *Am J Surg*. 2014;207(3):342-345. doi:10.1016/j.amjsurg.2013.08.038.
7. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). *J Clin Endocrinol Metab*. 2012;97(9):2990-3011. doi:10.1210/jc.2012-1230.
8. Singh S, Moody L, Chan DL, et al. Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. *JAMA Oncol*. 2018;4(11):1597-1604. doi:10.1001/jamaoncol.2018.2428.

Colorectal and Small Bowel Cancer (ONC-16)

Guideline

- Colorectal Cancer – General Considerations (ONC-16.0)
- Colorectal Cancer – Suspected/Diagnosis (ONC-16.1)
- Colorectal Cancer – Initial Work-up/Staging (ONC-16.2)
- Colorectal Cancer – Restaging/Recurrence (ONC-16.3)
- Colorectal Cancer – Surveillance/Follow-up (ONC-16.4)
- Small Bowel Cancer – Initial Work-up/Staging (ONC-16.5)
- Small Bowel Cancer – Restaging/Recurrence (ONC-16.6)
- Small Bowel Cancer – Surveillance/Follow-up (ONC-16.7)
- References (ONC-16)

Colorectal Cancer – General Considerations (ONC-16.0)

ON.CC.0016.0.A

v2.0.2024

- Neuroendocrine tumors of the bowel are covered in: **Neuroendocrine Cancers and Adrenal Tumors. (ONC-15)**
- Appendiceal adenocarcinoma (including pseudomyxoma peritonei) follows imaging guidelines for colorectal cancer.
- For squamous cell carcinoma of the rectum, see: **Anal Carcinoma (ONC-24)**

Colorectal Cancer – Suspected/ Diagnosis (ONC-16.1)

ON.CC.0016.1.A

v2.0.2024

- See: **GI Bleeding (AB-22)** or **CT Colonography (CTC) (AB-25.1)** in the Abdomen Imaging Guidelines for evaluation of suspected colorectal malignancies.
- See: **Abnormal Findings on Endoscopy/Colonoscopy (AB-13.3)** in the Abdomen Imaging Guidelines for evaluation of abnormal findings on endoscopy/colonoscopy.
- If findings on colonoscopy are suspicious for colon cancer, see: **Colorectal Cancer – Initial Work-up/Staging (ONC-16.2)**

Colorectal Cancer – Initial Work-up/ Staging (ONC-16.2)

ON.CC.0016.2.A

v2.0.2024

Indication	Imaging Study
Carcinoma within a polyp that is completely removed	<ul style="list-style-type: none"> No advanced imaging needed
<ul style="list-style-type: none"> Biopsy proven invasive adenocarcinoma Colonoscopy findings suspicious for colon cancer 	<ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177)
<ul style="list-style-type: none"> Further evaluation of an inconclusive liver lesion seen on CT Potentially resectable liver metastases 	<ul style="list-style-type: none"> MRI Abdomen without and with contrast (CPT[®] 74183)
Rectal adenocarcinoma	<ul style="list-style-type: none"> MRI Pelvis without and with contrast (CPT[®] 72197) or MRI Pelvis without contrast (CPT[®] 72195) (can be obtained in addition to CT scans for initial staging)
Rectal adenocarcinoma with ANY one of the following: <ul style="list-style-type: none"> Rectal MRI is contraindicated Rectal MRI is inconclusive Superficial lesions 	<ul style="list-style-type: none"> Endorectal ultrasound (CPT[®] 76872)
ONE of the following: <ul style="list-style-type: none"> Isolated metastatic lesion(s) on other imaging and individual is a candidate for aggressive surgical resection or other localized treatment to metastasis for curative intent Inconclusive conventional imaging 	<ul style="list-style-type: none"> PET/CT (CPT[®] 78815)

Colorectal Cancer – Restaging/ Recurrence (ONC-16.3)

ON.CC.0016.3.A

v2.0.2024

Indication	Imaging Study
<ul style="list-style-type: none"> Complete resection Individuals receiving post-operative adjuvant chemotherapy 	<ul style="list-style-type: none"> See: Surveillance/Follow-up (ONC-16.4)
<p>Recurrence suspected</p>	<ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast
<p>After completion of planned neoadjuvant therapy</p>	<p><u>Prior to surgical resection in individuals with non-metastatic rectal cancer:</u></p> <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) and <p><u>Any ONE of the following:</u></p> <ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) CT Abdomen with contrast (CPT[®] 74160) and MRI Pelvis without and with contrast (CPT[®] 72197)
<p>Unresected primary disease or metastatic disease on chemotherapy</p>	<p><u>Every 2 cycles of chemotherapy treatment and at the completion of chemoradiotherapy:</u></p> <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) CT Abdomen and Pelvis with contrast (CPT[®] 74177) CT with contrast of other involved or symptomatic areas
<ul style="list-style-type: none"> Further evaluation of an inconclusive liver lesion seen on CT Potentially resectable liver metastases 	<ul style="list-style-type: none"> MRI Abdomen without and with contrast (CPT[®] 74183)

Indication	Imaging Study
<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Postoperative elevated or rising CEA or LFTs with negative recent conventional imaging • Isolated metastatic lesion(s) on other imaging and individual is a candidate for aggressive surgical resection or other localized treatment to metastasis for curative intent • Differentiate local tumor recurrence from postoperative and/or post-radiation scarring 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)
<p>New or worsening pelvic pain and recent CT imaging negative or inconclusive</p>	<ul style="list-style-type: none"> • MRI Pelvis without and with contrast (CPT[®] 72197)

Colorectal Cancer – Surveillance/Follow-up (ONC-16.4)

ON.CC.0016.4.A
v2.0.2024

Indication	Imaging/Lab Study
<p><u>Colon and rectal adenocarcinoma:</u></p> <ul style="list-style-type: none"> • Stage I 	<ul style="list-style-type: none"> • No routine advanced imaging indicated
<p><u>Colon and rectal adenocarcinoma:</u></p> <ul style="list-style-type: none"> • Stage II-III 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177) after completion of surgery and then annually for 5 years
<p><u>Colon and rectal adenocarcinoma:</u></p> <ul style="list-style-type: none"> • Stage IV or distant metastatic disease (post definitive treatment of all measurable disease or being observed off therapy) 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177) every 6 months for 2 years and then annually for 3 years
<p>Measurable metastatic disease on maintenance therapy</p>	<p><u>Every 3 months for up to 5 years after completion of active treatment:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
<p>Rectal cancer treated with transanal excision alone</p>	<p><u>Any one of the following every 6 months for 5 years:</u></p> <ul style="list-style-type: none"> • Endorectal ultrasound (CPT[®] 76872) • MRI Pelvis without and with contrast (CPT[®] 72197)
<p>Stage II-III rectal cancer treated with chemoradiation alone (no surgical treatment)</p>	<p><u>In addition to the above stage-specific surveillance:</u></p> <ul style="list-style-type: none"> • MRI Pelvis (CPT[®] 72197) without and with contrast every 6 months for 3 years

Indication	Imaging/Lab Study
Pseudomyxoma peritonei	<p><u>ONE of each of the following, every 3 months for first year, then every 6 months for 4 more years:</u></p> <ul style="list-style-type: none">• CT Chest with (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250)• CT Abdomen and Pelvis with contrast (CPT[®] 74177) or MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast

Small Bowel Cancer – Initial Work-up/ Staging (ONC-16.5)

ON.CC.0016.5.A
v2.0.2024

This section provides imaging guidelines for small bowel adenocarcinoma arising from the duodenum, jejunum, and ileum.

Indication	Imaging/Lab Study
Carcinoma within a polyp that is completely removed	<ul style="list-style-type: none">No advanced imaging needed
Invasive adenocarcinoma	<ul style="list-style-type: none">CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast<ul style="list-style-type: none">MRI Abdomen without and with contrast (CPT[®] 74183) and MRI Pelvis without and with contrast (CPT[®] 72197) if CT is inconclusive or cannot be performed

Small Bowel Cancer – Restaging/ Recurrence (ONC-16.6)

ON.CC.0016.6.A

v2.0.2024

Indication	Imaging Study
Complete resection	<ul style="list-style-type: none"> • See Surveillance below
Recurrence suspected	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast
Unresected primary disease or metastatic disease on chemotherapy	<p>Every 2 cycles of chemotherapy:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Further evaluation of an inconclusive liver lesion seen on CT	<ul style="list-style-type: none"> • MRI Abdomen without and with contrast (CPT[®] 74183)
<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Postoperative elevated or rising CEA or LFTs with negative recent conventional imaging • Isolated metastatic lesion(s) on other imaging and individual is a candidate for aggressive surgical resection or other localized treatment to metastasis for curative intent 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Small Bowel Cancer – Surveillance/ Follow-up (ONC-16.7)

ON.CC.0016.7.A
v2.0.2024

Indication	Imaging/Lab Study
Stage I-III	<ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast after completion of surgery, and then annually for 5 years
Stage IV - Metastatic disease (post definitive treatment of all measurable disease, or being observed off therapy)	<ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast every 6 months for 2 years and then annually for 3 years
Measurable metastatic disease on maintenance therapy	<p><u>Every 3 months for up to 5 years after completion of active treatment:</u></p> <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) CT Abdomen and Pelvis with contrast (CPT[®] 74177)

References (ONC-16)

v2.0.2024

1. Benson III AB, Venook AP, Adam M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – January 29, 2024. Colon cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Colon cancer V1.2024 – January 29, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Benson III AB, Venook AP, Adam M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – January 29, 2024. Rectal cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Rectal cancer V1.2024 – January 29, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Benson AB, Venook AP, Pedersen K, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024 – February 27, 2024. Small Bowel Adenocarcinoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Small Bowel Adenocarcinoma V2.2024 – February 27, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
4. ACR Appropriateness Criteria. Pretreatment Staging of Colorectal Cancer. Rev. 2011.
5. Bailey CE, Hu C-Y, You YN et al. Variation in positron emission tomography use after colon cancer resection. *J Oncol Pract*. 2015;11(3):e363-e372. doi:10.1200/JOP.2014.001933.
6. Lu YY, Chen JH, Ding HJ, Chien CR, Lin WY, Kao CH. A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET/CT. *Nucl Med commun*. 2012;33(11):1127-1133. doi:10.1097/MNM0b013e328357b2d9.
7. Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. *JAMA*. 2014;311(18):1863-1869. doi:10.1001/jama.2014.3740.
8. Steele SR, Chang GJ, Hendren S, et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. *Dis Colon Rectum*. 2015;58(8):713-725. doi:10.1097/DCR.0000000000000410.
9. van de Velde CJ, Boelens PG, Borrás JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. *Eur J Cancer*. 2014;50(1):e1-e34. doi:10.1016/j.ejca.2013.06.048.
10. Akce M, El-Rayes BF. Nonsurgical management of rectal cancer. *Journal of Oncology Practice*. 2019;15(3):123-131. doi:10.1200/JOP.18.00769.

Renal Cell Cancer (RCC) (ONC-17)

Guideline

Renal Cell Cancer (RCC) – General Considerations (ONC-17.0)

Renal Cell Cancer (RCC) – Suspected/Diagnosis (ONC-17.1)

Renal Cell Cancer (RCC) – Initial Work-up/Staging (ONC-17.2)

Renal Cell Cancer (RCC) – Restaging/Recurrence (ONC-17.3)

Renal Cell Cancer (RCC) – Surveillance (ONC-17.4)

References (ONC-17)

Renal Cell Cancer (RCC) – General Considerations (ONC-17.0)

ON.RC.0017.0.A

v2.0.2024

- PET considered experimental, investigational, or unproven for initial diagnosis, staging or restaging of renal cell cancer.
- A minority of adult individuals with renal cell cancer (RCC) will have translocations in TFE3 or TFEB, which have a different natural history than “adult type” RCC. Individuals of any age with TFE3 or TFEB translocated RCC should be imaged according to guidelines in **Pediatric Renal Cell Carcinoma (RCC) (PEDONC-7.4)** in the Pediatric Oncology Imaging Guidelines.
- Individuals of any age with Wilms tumor should be imaged according to guidelines in section **Unilateral Wilms Tumor (UWT) (PEDONC-7.2)** or **Bilateral Wilms Tumor (BWT) (PEDONC-7.3)** in the Pediatric Oncology Imaging Guidelines.
- Oncocytoma in individuals of all ages should be imaged according to these guidelines.

Renal Cell Cancer (RCC) – Suspected/ Diagnosis (ONC-17.1)

ON.RC.0017.1.A
v2.0.2024

Indication	Imaging Study
<ul style="list-style-type: none">Solitary renal mass suspicious for renal cell cancer	<ul style="list-style-type: none">See: Indeterminate Renal Lesion (AB-35.1) in the Abdomen Imaging Guidelines for evaluation of suspected renal malignanciesChest x-ray or CT Chest with contrast with (CPT® 71260) or without contrast (CPT® 71250)

Renal Cell Cancer (RCC) – Initial Work-up/Staging (ONC-17.2)

ON.RC.0017.2.A

v2.0.2024

Indication	Imaging study
<p>All individuals</p>	<p><u>If not done previously:</u></p> <ul style="list-style-type: none"> • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • CT Abdomen and Pelvis, contrast as requested
<p><u>ANY</u> of the following:</p> <ul style="list-style-type: none"> • Extension of tumor into the vena cava by other imaging • Inconclusive findings on CT 	<ul style="list-style-type: none"> • MRI Abdomen without and with contrast (CPT[®] 74183)
<p>Bone pain</p>	<ul style="list-style-type: none"> • Bone scan (See: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3))
<p><u>EITHER</u> of the following:</p> <ul style="list-style-type: none"> • Signs/symptoms suspicious for brain metastases • Newly diagnosed stage IV/ metastatic RCC 	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)

Renal Cell Cancer (RCC) – Restaging/ Recurrence (ONC-17.3)

ON.RC.0017.3.A

v2.0.2024

Indication	Imaging Study
Unresectable disease or metastatic disease on systemic therapy	<p><u>Every 2 cycles of treatment (commonly every 6 to 8 weeks):</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of other involved or symptomatic areas
Recurrence suspected	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
<p><u>EITHER of the following:</u></p> <ul style="list-style-type: none"> • Biopsy-proven recurrent/metastatic disease • Signs or symptoms concerning for brain metastases 	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)

Renal Cell Cancer (RCC) – Surveillance (ONC-17.4)

ON.RC.0017.4.A

v2.0.2024

Indication	Imaging Study
RCC on active surveillance of renal mass <1 cm	<p>ONE of the following, once within 6 months of surveillance initiation and annually thereafter:</p> <ul style="list-style-type: none"> • CT Abdomen without and with contrast (CPT[®] 74170) • MRI Abdomen without and with contrast (CPT[®] 74183) • See: Indeterminate Renal Lesion (AB-35.1) in the Abdomen Imaging Guidelines • Chest x-ray (in addition to abdominal imaging) <ul style="list-style-type: none"> ◦ CT Chest with contrast (CPT[®] 71260) or without contrast (CPT[®] 71250) may be obtained for one of the following: <ul style="list-style-type: none"> ▪ New chest x-ray abnormalities ▪ Pulmonary signs/symptoms
RCC on active surveillance of renal mass ≥1 cm	<p>One of the following, every 3 months for year 1, every 6 months for years 2 and 3 and annually thereafter:</p> <ul style="list-style-type: none"> • CT Abdomen without and with contrast (CPT[®] 74170) • MRI Abdomen without and with contrast (CPT[®] 74183) • Chest x-ray (in addition to abdominal imaging) <ul style="list-style-type: none"> ◦ CT Chest with contrast (CPT[®] 71260) or without contrast (CPT[®] 71250) may be obtained for one of the following: <ul style="list-style-type: none"> ▪ New chest x-ray abnormalities ▪ Pulmonary signs/symptoms

Indication	Imaging Study
<p>Follow up after post-ablation therapy of RCC</p>	<p><u>EITHER of the following, at 1 to 3 months, 6 months, and 12 months post-ablation and then annually thereafter:</u></p> <ul style="list-style-type: none"> • CT Abdomen without and with contrast (CPT[®] 74170) or • MRI Abdomen without and with contrast (CPT[®] 74183) <p>AND</p> <p>Annually for 5 years:</p> <ul style="list-style-type: none"> • Chest x-ray or CT Chest with contrast (CPT[®] 71260) or without contrast (CPT[®] 71250)
<p>Stage I RCC, after partial or radical nephrectomy</p>	<p><u>ONE of each of the following, 3 to 12 months post-resection:</u></p> <ul style="list-style-type: none"> • CT Chest with (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) • CT Abdomen with (CPT[®] 74160) or CT Abdomen without contrast (CPT[®] 74150) or MRI Abdomen without and with contrast (CPT[®] 74183) <p><u>Annually for 5 years:</u></p> <ul style="list-style-type: none"> • Chest x-ray or CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • Abdominal imaging with any ONE of the following: <ul style="list-style-type: none"> ◦ CT Abdomen with (CPT[®] 74160) or without (CPT[®] 74150) contrast ◦ MRI Abdomen without and with contrast (CPT[®] 74183)

Indication	Imaging Study
Stage II RCC, post-nephrectomy	<p><u>ONE of each of the following, 3 to 6 months post-resection:</u></p> <ul style="list-style-type: none"> • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • CT Abdomen with (CPT[®] 74160) or without (CPT[®] 74150) contrast or MRI Abdomen without and with contrast (CPT[®] 74183) <p><u>ONE of each of the following, every 6 months for 2 years, then annually until year 5:</u></p> <ul style="list-style-type: none"> • Chest x-ray or CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • Abdominal imaging with any ONE of the following: <ul style="list-style-type: none"> ◦ CT Abdomen with (CPT[®] 74160) or without (CPT[®] 74150) contrast ◦ MRI Abdomen without and with contrast (CPT[®] 74183)
Stage III RCC, post-nephrectomy	<p><u>ONE of each of the following, 3 to 6 months post-resection:</u></p> <ul style="list-style-type: none"> • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • CT Abdomen with (CPT[®] 74160) or without (CPT[®] 74150) contrast or MRI Abdomen without and with contrast (CPT[®] 74183) <p><u>ONE of each of the following, every 3 months for 3 years, then annually to year 5:</u></p> <ul style="list-style-type: none"> • CT Chest with (CPT[®] 71260) or without (CPT[®] 71250) contrast • CT Abdomen with (CPT[®] 74160) or without (CPT[®] 74150) contrast or MRI Abdomen without and with contrast (CPT[®] 74183)
Stage IV/metastatic disease on maintenance therapy or being observed off therapy	<p><u>Every 3 months for up to 5 years after completion of active treatment:</u></p> <ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast

References (ONC-17)

v2.0.2024

1. Motzer RJ, Jonasch E, Agarwal N, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – June 21, 2023. Kidney cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Kidney cancer V1.2024 – June 21, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. ACR Appropriateness Criteria. *Post-treatment follow up of renal cell carcinoma*. Rev. 2013.
3. Herts BR, Silverman SG, Hindman NM, et al. *Management of the incidental renal mass on CT: a white paper of the ACR incidental findings committee*. *J Am Coll Radiol*. 2018;15(2):264-273. doi:10.1016/j.jacr.2017.04.028.
4. Finelli A, Ismaila N, Bro B, et al. Management of small renal masses. American Society of Clinical Oncology clinical practice guideline. *Journal of Clinical Oncology*. 2017;35(6):668-680. doi:10.1200/JCO.2016.69.9645.
5. Davenport MS, Caoili EM, Cohan RH, et al. MRI and CT characteristics of successfully ablated renal masses: imaging surveillance after radiofrequency ablation. *AJR Am J Roentgenol*. 2009;192:1571-1578. doi:10.2214/AJR.08.1303.
6. Clark TW, Millward SF, Gervais DA, et al. Reporting standards for percutaneous thermal ablation of renal cell carcinoma. *J Vasc Interv Radiol*. 2009;20(7 Suppl):S409-S416. doi:10.1016/j.jvir.2009.04.013.
7. Rais-Bahrami S, Guzzo TJ, Jarrett TW, Kavoussi LR, Allaf ME. Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. *BJU Int*. 2009;103(10):1355-1358. doi:10.1111/j.1464-410X.2008.08242.x.
8. Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, Kao CH. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. *Cancer Imaging*. 2012 October;12:464-474. doi:10.1102/1470-7330.2012.0042.
9. Kim EH, Strobe SA. Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma. *Urol Oncol*. 2015;33(12):499-502. doi:10.1016/j.urolonc.2015.08.008.
10. Sankineni S, Brown A, Cieciera M, Choyke PL, Turkbey B. Imaging of renal cell carcinoma. *Urol Oncol*. 2016;34(3):147-155. doi:10.1016/j.urolonc.2015.05.020.
11. ACR Appropriateness Criteria. *Renal cell carcinoma staging*. Rev. 2015.
12. Campbell S, Uzzo R, Allaf M, et al. Renal mass and localized renal cancer: AUA guideline. *J Urol*. 2017;198(3):520-529. doi:10.1016/j.juro.2017.04.100.

Transitional Cell Cancer (ONC-18)

Guideline

Transitional Cell Cancer – General Considerations (ONC-18.0)

Transitional Cell Cancer – Suspected/Diagnosis (ONC-18.1)

Transitional Cell Cancer – Initial Work-up/Staging (ONC-18.2)

Transitional Cell Cancer – Restaging/Recurrence (ONC-18.3)

Transitional Cell Cancer – Surveillance/Follow-up (ONC-18.4)

References (ONC-18)

Transitional Cell Cancer – General Considerations (ONC-18.0)

ON.TS.0018.0.A

v2.0.2024

- Transitional cell cancers can include: tumors of the bladder, ureters, prostate, urethra, or renal pelvis. For primary cancer of the kidney, see: **Renal Cell Cancer (RCC) (ONC-17)**.
- Most common histology of bladder cancer is transitional cell (TCC) or urothelial carcinoma (UCC). Rare histologies include adenocarcinoma, squamous cell (imaged according to **Transitional Cell Cancer (ONC-18)**), or small cell (imaged according to **Extrathoracic Small Cell and Large Cell Neuroendocrine Tumors (ONC-31.8)**).
- Urachal cancer is rare type of bladder cancer; the most common histology is adenocarcinoma. These are imaged according to muscle invasive bladder cancer.
- PET not routinely indicated in transitional cell cancer with exception noted below in **Transitional Cell Cancer – Initial Work-up/Staging (ONC-18.2)**

Transitional Cell Cancer – Suspected/ Diagnosis (ONC-18.1)

ON.TS.0018.1.A

v2.0.2024

- See: **Hematuria and Hydronephrosis (AB-39)** in the Abdomen Imaging Guidelines for evaluation of suspected transitional cell malignancies.

Transitional Cell Cancer – Initial Work-up/Staging (ONC-18.2)

ON.TS.0018.2.A
v2.0.2024

Indication	Imaging Study
All individuals	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) <ul style="list-style-type: none"> ◦ MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast if contraindication to CT contrast • CT Abdomen and Pelvis without contrast (CPT[®] 74176) with retrograde pyelogram or renal ultrasound (CPT[®] 76770 or CPT[®] 76775) in individuals who cannot receive either CT or MRI contrast
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Muscle invasive bladder carcinoma • Urethral carcinoma • Urothelial carcinoma of the prostate 	<ul style="list-style-type: none"> • CT Chest without (CPT[®] 71250) or with (CPT[®] 71260) contrast
Individuals without metastatic disease, when requested by operating surgeon for operative planning	<ul style="list-style-type: none"> • CT with contrast or MRI without and with contrast of all operative sites
To evaluate inconclusive findings on conventional imaging	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Transitional Cell Cancer – Restaging/ Recurrence (ONC-18.3)

ON.TS.0018.3.A

v2.0.2024

Indication	Imaging Study
After definitive surgery	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen and Pelvis without and with contrast (CPT[®] 74178) for post-operative baseline
Recurrence suspicion	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or with and without contrast (CPT[®] 74178) • CT Chest with contrast (CPT[®] 71260) for ANY of the following: <ul style="list-style-type: none"> ◦ Signs/symptoms of pulmonary disease ◦ Abnormal chest x-ray ◦ Prior involvement of the chest
After neoadjuvant therapy and before resection	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and CT Urogram (CPT[®] 74178)
Monitoring therapy for metastatic disease	<p><u>Every 2 cycles of therapy:</u></p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Chest with contrast (CPT[®] 71260) for ANY of the following: <ul style="list-style-type: none"> ◦ Signs/symptoms of pulmonary disease ◦ Prior involvement of the chest ◦ Abnormal chest x-ray
To evaluate inconclusive findings on conventional imaging	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Transitional Cell Cancer – Surveillance/ Follow-up (ONC-18.4)

ON.TS.0018.4.A

v2.0.2024

Indication	Imaging Study
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Papillary urothelial neoplasm of low malignant potential • Low risk lesions <ul style="list-style-type: none"> ◦ Solitary Ta lesions ≤3cm • Intermediate risk lesions <ul style="list-style-type: none"> ◦ Low-grade >3 cm ◦ Low-grade multifocal ◦ T1 lesions ◦ High-grade solitary Ta ≤3cm 	<ul style="list-style-type: none"> • Advanced imaging is not routinely indicated for surveillance
<p><u>ANY of the following high-risk non-muscle invasive transitional cell carcinoma of the bladder or upper tracts:</u></p> <ul style="list-style-type: none"> • Multifocal high-grade lesions • High-grade lesions >3 cm • Superficial and minimally invasive (Tis and T1) • BCG unresponsive • Lymphovascular invasion • Prostatic urethral invasion 	<ul style="list-style-type: none"> • CT Urogram (CPT[®] 74178) every 2 years for 10 years <ul style="list-style-type: none"> ◦ MR Urogram (CPT[®] 74183 and CPT[®] 72197) may be obtained for renal insufficiency or CT dye allergy
<p>Non-muscle-invasive transitional carcinoma of the bladder treated with cystectomy</p>	<ul style="list-style-type: none"> • CT Urogram (CPT[®] 74178) at 3 and 12 months post-cystectomy, and then annually for years 2-5 <ul style="list-style-type: none"> ◦ MR Urogram (CPT[®] 74183 and CPT[®] 72197) may be obtained for renal insufficiency or CT dye allergy

Indication	Imaging Study
<p>Muscle invasive lower and upper genitourinary tumors treated with cystectomy, nephrectomy, or chemoradiation</p>	<p><u>Every 6 months for 2 years, then annually for 3 more years:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250), and CT Abdomen and Pelvis with contrast (CPT[®] 74177) or without and with contrast (CPT[®] 74178) <p>OR</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250), and MR Urogram (CPT[®] 74183 and CPT[®] 72197)
<p>Measurable metastatic disease on maintenance therapy or being monitored off therapy</p>	<p><u>Every 3 months for up to 5 years after completion of active treatment:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Urogram (CPT[®] 74178)
<p>Urethral cancers (high-risk T1 or greater) and urothelial carcinoma of the prostate</p>	<p><u>Every 6 months for 2 years, then annually:</u></p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or without and with contrast (CPT[®] 74178) <p>OR</p> <ul style="list-style-type: none"> • MR Urogram (CPT[®] 74183 and CPT[®] 72197) <p>AND</p> <ul style="list-style-type: none"> • Chest x-ray <ul style="list-style-type: none"> ◦ CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) if abnormal signs/symptoms of pulmonary disease or abnormal chest x-ray

References (ONC-18)

v2.0.2024

1. Flaig TW, Spiess PE, Abern M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – January 30, 2024. Bladder cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Bladder cancer V1.2024, January 30, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Verma S, Rajesh A, Prasad SR et al, Urinary bladder cancer: role of MR imaging. *Radiographics*. 2012;32(2):371-387. doi:10.1148/rg.322115125.
3. Lu YY, Chen JH, Liang JA. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systematic review and meta-analysis. *Eur J Radiol*. 2012;81(9):2411-2416. doi:10.1016/j.ejrad.2011.07.018.
4. Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. *Eur Urol*. 2014;65(4):778-792. doi:10.1016/j.eururo.2013.11.046.
5. Gakis G, Witjes JA, Comperat E, et al. EAU guidelines on primary urethral carcinoma. *Eur Urol*. 2013;64(5):823-830. doi:10.1016/j.eururo.2013.03.044.
6. Rouprêt M, Babjuk M, Compérat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. *Eur Urol*. 2013;63(6):1059-1071. doi:10.1016/j.eururo.2013.03.032.

Prostate Cancer (ONC-19)

Guideline

- Prostate Cancer – General Considerations (ONC-19.0)
- Suspected Prostate Cancer (ONC-19.1)
- Prostate Cancer – Initial Work-up/Staging (ONC-19.2)
- Prostate Cancer – Restaging/Recurrence (ONC-19.3)
- Prostate Cancer – Follow-up On Active Surveillance (ONC-19.4)
- Surveillance/Follow-up For Treated Prostate Cancer (ONC-19.5)
- References (ONC-19)

Prostate Cancer – General Considerations (ONC-19.0)

ON.PR.0019.0.UOH

v2.0.2024

- Prostate cancer screening begins at age 45 for individuals at average risk of prostate cancer. However, individuals at high-risk may begin screening at age 40. High-risk features include:
 - African ancestry
 - Germline mutations (BRCA1 or 2, HOXB13, ATM, CHEK2, or mismatch repair genes - MLH1, MSH2, MSH6, PMS2) that increase the risk of prostate cancer
 - Family history of first or second-degree relative with prostate, male breast, colorectal, pancreatic, endometrial or female breast cancer at age <45 years.
- Treatment of benign prostatic hyperplasia with 5- α reductase inhibitors (such as finasteride and dutasteride) can falsely reduce the measured PSA levels by 50%. Thus, the reported PSA level should be doubled when prostate cancer is suspected in individuals on these medications.
- Individuals with high-risk adverse clinical and pathological factors may benefit from a more aggressive diagnostic and therapeutic approach at the time of relapse after initial treatment. These factors include pre-treatment Gleason score of ≥ 8 , pre-treatment clinical stage of cT3b or higher, positive surgical margins, post-treatment PSA doubling time of <3 months, and an interval to biochemical failure of <3 years after initial treatment.
- PET/CT scan using ^{18}F -FDG radiotracer are considered investigational and experimental for evaluation of prostate cancer.
- ^{11}C Choline, ^{18}F -Fluciclovine (AXUMIN[®]), and PSMA-specific radiopharmaceuticals have recently gained FDA approval for evaluation of prostate cancer. Optimal detection rates for these radiotracers vary greatly with PSA levels. False positive rate is high and histological confirmation of positive sites is recommended.
- PSMA-specific PET radiopharmaceuticals that are currently FDA-approved and indicated in prostate cancer are: ^{68}Ga PSMA-11 (UCSF & UCLA), ^{18}F Piflufolastat (Pylarify[®]), ^{18}F Flotufolastat (Posluma[®]), and ^{68}Ga Gozetotide (Illuccix[®] and Locametz[®]).
- While early detection of low-volume recurrence after treatment of prostate cancer using PET/CT scans may influence therapeutic decisions, there is lack of evidence that this approach has any meaningful impact on overall survival.
- As high intensity focused ultrasound prostate ablation is considered investigational and experimental at this time, and advanced imaging for treatment planning and/or surveillance of high intensity focused ultrasound prostate ablation is not indicated.

- MR Spectroscopy (CPT[®] 76390) is considered investigational and experimental in the evaluation of prostate cancer at this time.
- As laser prostate ablation is considered investigational and experimental at this time, advanced imaging for treatment planning and/or surveillance of laser prostate ablation is not indicated.
- Monitoring an elevated prostate-specific antigen level (PSA) with serial MRI is not indicated for suspected prostate cancer.
- Requests for imaging based on PSA must provide a recent (within the last 60 days) PSA.

ISUP Prostate Cancer Grade Groups³⁰

Grade Group	Gleason Score	Gleason Pattern
1	≤6	≤3+3
2	7	3+4
3	7	4+3
4	8	4+4, 3+5, 5+3
5	9 or 10	4+5, 5+4, or 5+5

NCCN Initial Risk Stratification

- Very Low Risk
 - ALL of the following features are present:
 - Tumor not clinically palpable, but present on one or both lobes on biopsy (cT1a, cT1b, or cT1c)
 - PSA (ng/mL) <10
 - Gleason Grade Group = 1
 - <3 prostate biopsy cores positive, ≤50% cancer in each core
 - PSA Density <0.15 ng/mL/g
- Low Risk
 - ALL of the following features are present but does not qualify for very low risk:
 - Clinical T Stage = cT1-cT2a (palpable tumor limited to ≤1/2 of one side)
 - PSA (ng/mL) <10
 - Gleason Grade Group = 1
- Favorable Intermediate Risk
 - ALL of the following features are present:

- Gleason Grade Group = 1 or 2
- <50% biopsy cores positive (e.g., <6 of 12 cores)
- And only ONE of the following features is present:
 - Clinical T Stage = cT2b (tumor involves more than half of one lobe, but not both lobes) and cT2c (tumor involves both lobes)
 - PSA (ng/mL) = 10-20
- Unfavorable Intermediate Risk
 - Any one of the following are present:
 - Gleason grade group = 3
 - ≥50% biopsy cores positive (e.g., ≥6 of 12 cores)
 - Presence of at least two of the following three features:
 - PSA (ng/mL) = 10-20
 - Gleason Grade Group = 2 or 3
 - Clinical T Stage = cT2b (tumor involves more than half of one lobe, but not both lobes) and cT2c (tumor involves both lobes)
- High-risk
 - Only ONE of the following high-risk features is present:
 - Clinical T Stage = cT3a (unilateral or bilateral extra-prostatic extension that is not fixed and does not invade the seminal vesicles)
 - PSA (ng/mL) >20
 - Gleason Grade Group = 4 or 5
- Very High-risk
 - At least ONE of the following features is present:
 - Clinical T stage = cT3b-cT4 (extension into the seminal vesicles or invasion into adjacent structures)
 - Primary Gleason Pattern = 5
 - Gleason Grade Group = 4 or 5 in >4 cores
 - Presence of 2 or 3 high-risk features (noted above)

3D Rendering of MRI for MRI / Ultrasound Fusion Biopsy:

- When specific target lesion(s) is (are) detected on mpMRI (multi-parametric MRI) prostate and classified as PIRADS 4 or 5, 3D Rendering (CPT[®] 76377) to generate prostate segmentation data image set for target identification on MRI/Transrectal ultrasound (TRUS) fusion biopsy is approvable as:
 - Subsequent separate standalone request; or
 - As retrospective request for medical necessity.
- For MRI/TRUS fusion biopsy of a PIRADS 1-3 lesion, approval of 3D rendering at independent workstation (CPT[®] 76376 or CPT[®] 76377) can be considered on a case-by-case basis.

- If there is no target lesion identified on MRI then 3D rendering and MRI/TRUS fusion biopsy is generally not indicated.
- The 3D rendering for the TRUS component of the fusion is a part of the UroNav Fusion Equipment Software and an additional 3D code CPT[®] 76376 or CPT[®] 76377 should not be approved.

Suspected Prostate Cancer (ONC-19.1)

ON.PR.0019.1.A

v2.0.2024

Indication	Imaging Study
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Age 40-75 years with PSA >3 ng/ml or very suspicious DRE and ONE of the following high-risk features: <ul style="list-style-type: none"> ◦ African ancestry ◦ Germline mutations that increase the risk of prostate cancer ◦ Family history of first or second-degree relative with prostate, male breast, colorectal, pancreatic, endometrial or female breast cancer at age <45 years • Age 45-75 years and ONE of the following: <ul style="list-style-type: none"> ◦ PSA >3 ng/ml ◦ Very suspicious DRE • Age >75 years and ONE of the following: <ul style="list-style-type: none"> ◦ PSA ≥4 ng/ml ◦ Very suspicious DRE • At least one negative/non-diagnostic TRUS biopsy and ANY of the following: <ul style="list-style-type: none"> ◦ Rising PSA ◦ Abnormal DRE ◦ Need for confirmatory MR/US fusion biopsy 	<p>ANY of the following:</p> <ul style="list-style-type: none"> • Transrectal ultrasound (CPT[®] 76872) • TRUS-guided biopsy (CPT[®] 76942) • MRI Pelvis without and with contrast (CPT[®] 72197) or MRI Pelvis without contrast (CPT[®] 72195) if an MR/US guided fusion biopsy is planned • MRI/US fusion biopsy (CPT[®] 76942)
<ul style="list-style-type: none"> • PIRADS 4 or 5 lesion identified on recent diagnostic MRI Pelvis (CPT[®] 72195 or CPT[®] 72197) and planning for biopsy to be done by MRI/TRUS fusion technique 	<ul style="list-style-type: none"> • 3D Rendering (CPT[®] 76376 or CPT[®] 76377)

Indication	Imaging Study
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Multifocal (3 or more lesions) high-grade prostatic intraepithelial neoplasia (PIN) • Atypia on biopsy 	<ul style="list-style-type: none"> • Extended pattern rebiopsy within 6 months by TRUS-guided biopsy (CPT[®] 76942)
<ul style="list-style-type: none"> • Focal PIN (1-2 lesions) 	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • MRI Pelvis without contrast (CPT[®] 72195) • MRI Pelvis without and with contrast (CPT[®] 72197) • MRI/US fusion biopsy (CPT[®] 76942) • MRI guided biopsy (CPT[®] 77021)

Prostate Cancer – Initial Work-up/ Staging (ONC-19.2)

ON.PR.0019.2.A

v2.0.2024

Indication	Imaging Study
<p>Localized prostate cancer with any of the following risk groups (see: ONC-19.0 for definition of risk groups):</p> <ul style="list-style-type: none"> • Very low risk • Low risk • Favorable intermediate risk 	<p>Advanced imaging is not routinely indicated for initial staging</p> <p>If not already performed prior to biopsy, MRI Pelvis without and with contrast (CPT[®] 72197) is appropriate for any of the following:</p> <ul style="list-style-type: none"> • Prior to planned treatment (surgery and/or radiation therapy) • To establish candidacy for active surveillance
<p>Localized prostate cancer with any of the following risk groups (see: ONC-19.0 for definition of risk groups):</p> <ul style="list-style-type: none"> • Unfavorable intermediate risk • High-risk • Very high-risk 	<p>Any ONE of the following combinations, not all (may be obtained in addition to mpMRI prostate):</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260), CT Abdomen and Pelvis with contrast (CPT[®] 74177), and Bone scan • CT Chest with contrast (CPT[®] 71260), CT Abdomen with contrast (CPT[®] 74160), MRI Pelvis without and with contrast (CPT[®] 72197) if not previously performed, and Bone scan • PSMA PET/CT scan (CPT[®] 78815 or CPT[®] 78816) using any one of the following radiotracers: <ul style="list-style-type: none"> ◦ ⁶⁸Ga-PSMA-11 ◦ ¹⁸F Piflufolastat (Pylarify[®]) ◦ ⁶⁸Ga Gozetotide (Illuccix[®] and Locametz[®]) ◦ ¹⁸F Flotufolastat (Posluma[®])

Indication	Imaging Study
Known or clinically suspected metastatic prostate cancer (including prior to prostate biopsy)	CT Chest with contrast (CPT [®] 71260), CT Abdomen and Pelvis with contrast (CPT [®] 74177), and Bone scan
Inconclusive bone scan	CT with contrast or MRI without and with contrast of involved body site
<p>For ANY of the following:</p> <ul style="list-style-type: none"> • Inconclusive bone findings on both CT/MRI and bone scan • Conventional imaging studies (CT and bone scan) suggests oligo- or low volume metastatic disease that need further confirmation 	<ul style="list-style-type: none"> • <u>PET/CT scan (CPT[®] 78815 or CPT[®] 78816) using any one of the following radiotracers:</u> <ul style="list-style-type: none"> ◦ ¹⁸F Fluciclovine ◦ ¹¹C Choline ◦ ⁶⁸Ga-PSMA-11 ◦ ¹⁸F Piflufolastat (Pylarify[®]) ◦ ⁶⁸Ga Gozetotide (Illuccix[®] and Locametz[®]) ◦ ¹⁸F Flotufolastat (Posluma[®])

Prostate Cancer – Restaging/Recurrence (ONC-19.3)

ON.PR.0019.3.A

v2.0.2024

Indication	Imaging Study
<p>For ANY of the following:</p> <ul style="list-style-type: none"> • Obvious progression by DRE with plans for prostatectomy or radiation therapy • Repeat TRUS biopsy for rising PSA shows progression to a higher Gleason’s score with plans for prostatectomy or radiation therapy • Inconclusive findings on CT scan 	<ul style="list-style-type: none"> • MRI Pelvis without and with contrast (CPT[®] 72197)
<p><u>Non-metastatic prostate cancer previously treated with prostatectomy, radiation therapy, ablation, hormonal therapy or chemotherapy and any one of the following:</u></p> <ul style="list-style-type: none"> • Clinical suspicion of relapse/recurrence • PSA fails to become undetectable post prostatectomy • Palpable anastomotic recurrence • PSA rises above post-treatment baseline to >0.2 ng/mL but <0.5 ng/mL on two consecutive measurements 	<p>Any ONE of the following combinations:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260), CT Abdomen and Pelvis with contrast (CPT[®] 74177), and Bone scan (see: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3) for bone scan coding) • CT Chest with contrast (CPT[®] 71260), CT Abdomen with contrast (CPT[®] 74160), MRI Pelvis without and with contrast (CPT[®] 72197), and Bone scan (see: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3) for bone scan coding)

Indication	Imaging Study
<p><u>Non-metastatic prostate cancer previously treated with prostatectomy or radiation therapy, and all of the following are met:</u></p> <ul style="list-style-type: none"> • PSA rises on two consecutive measurements above post-treatment baseline and • PSA ≥ 0.5 ng/mL and • Individual is a candidate for salvage local therapy 	<p>Any ONE of the following:</p> <ul style="list-style-type: none"> • PSMA PET/CT scan (CPT[®] 78815 or CPT[®] 78816) with any of the following radiotracers: <ul style="list-style-type: none"> ◦ ⁶⁸Ga-PSMA-11 ◦ ¹⁸F Piflufolastat (Pylarify[®]) ◦ ¹⁸F Flotufolastat (Posluma[®]) ◦ ⁶⁸Ga Gozetotide (Illuccix[®] and Locametz[®]) • CT Chest with contrast (CPT[®] 71260), CT Abdomen and Pelvis with contrast (CPT[®] 74177), and Bone scan • CT Chest with contrast (CPT[®] 71260), CT Abdomen with contrast (CPT[®] 74160), MRI Pelvis without and with contrast (CPT[®] 72197), and Bone scan (see: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3) for bone scan coding
<p><u>Non-metastatic prostate cancer previously treated with prostatectomy or radiation therapy, and all of the following are met:</u></p> <ul style="list-style-type: none"> • PSA rises on two consecutive measurements above post-treatment baseline and • PSA ≥ 1 ng/mL and • Recent CT scan and bone scan are negative for metastatic disease and • Individual is a candidate for salvage local therapy 	<ul style="list-style-type: none"> • PET/CT scan (CPT[®] 78815 or CPT[®] 78816) using any ONE of the following radiotracers: <ul style="list-style-type: none"> ◦ ¹⁸F-Fluciclovine ◦ ¹¹C Choline

Indication	Imaging Study
<p><u>Suspected progression of known metastatic disease based on:</u></p> <ul style="list-style-type: none"> • New or worsening signs/symptoms • Rising PSA levels 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260), CT Abdomen and Pelvis with contrast (CPT[®] 74177), and Bone scan (see: <u>Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)</u> for bone scan coding) • CT with contrast of any involved or symptomatic body part
<p>Metastatic prostate cancer receiving treatment with chemotherapy</p>	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) and CT scan with contrast of any involved body part every 2 cycles (6 to 8 weeks) while on chemotherapy • Bone scan may be obtained every 3-6 months (see: <u>Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)</u> for bone scan coding)
<p>Metastatic prostate cancer receiving anti-androgen therapy</p>	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) and CT scan of any involved body part every 3 months while on anti-androgen therapy • Bone scan may be obtained every 3-6 months (see: <u>Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)</u> for bone scan coding)
<p>Previously treated metastatic prostate cancer progressed on conventional imaging and being considered for ¹⁷⁷Lu-PSMA-617 (Pluvicto[®]) treatment^{31, 32}</p>	<ul style="list-style-type: none"> • PSMA PET/CT scan (CPT[®] 78815 or CPT[®] 78816) with one of the following agents: <ul style="list-style-type: none"> ◦ ⁶⁸Ga PSMA-11 ◦ ¹⁸F Piflufolastat (Pylarify[®]) ◦ ⁶⁸Ga Gozetotide (Illuccix[®] and Locametz[®]) ◦ ¹⁸F Flotufolastat (Posluma[®])
<p>Prior to start of Xofigo (Radium-223) therapy</p>	<ul style="list-style-type: none"> • ONE time CT Chest, Abdomen, and Pelvis with contrast (CPT[®] 71260 and CPT[®] 74177)
<p>Inconclusive bone scan</p>	<ul style="list-style-type: none"> • CT with contrast or MRI without and with contrast of involved body site

Indication	Imaging Study
<p>For ANY of the following:</p> <ul style="list-style-type: none"> • Inconclusive bone findings on both CT/ MRI and bone scan • Conventional imaging studies (CT and bone scan) suggests oligo- or low volume metastatic disease that needs further confirmation 	<ul style="list-style-type: none"> • PET/CT scan (CPT[®] 78815 or CPT[®] 78816) using <u>any one of the following radiotracers</u>: <ul style="list-style-type: none"> ◦ ¹⁸F Fluciclovine ◦ ¹¹C Choline ◦ ⁶⁸Ga-PSMA-11 ◦ ¹⁸F Piflufolastat (Pylarify[®]) ◦ ⁶⁸Ga Gozetotide (Illuccix[®] and Locametz[®]) ◦ ¹⁸F Flotufolastat (Posluma[®])

Prostate Cancer – Follow-up On Active Surveillance (ONC-19.4)

ON.PR.0019.4.A

v2.0.2024

Active surveillance is being increasingly utilized in prostate cancer, and this therapeutic option involves regimented monitoring of an individual with known diagnosis of low risk prostate cancer for disease progression, without specific anticancer treatment. While being treated with active surveillance, an individual is generally considered a potential candidate for curative intent treatment approaches in the event that disease progression occurs.

It is important to distinguish active surveillance from watchful waiting (or observation), which is generally employed in individuals with limited life expectancy. Watchful waiting involves cessation of routine monitoring and treatment is initiated only if symptoms develop.

Current active surveillance guidelines suggest the following protocol:

- PSA every 6 months
- Digital Rectal Exam (DRE) every 12 months
- Repeat prostate biopsy every 12 months
- Repeat mpMRI (CPT[®] 72195 or CPT[®] 72197) no more often than every 12 months

Indication	Imaging Study
Routine monitoring on active surveillance protocol	<ul style="list-style-type: none"> • MRI Pelvis without (CPT[®] 72195) or without and with contrast (CPT[®] 72197) at initiation of active surveillance, and every 12 months thereafter
<p>For ANY of the following:</p> <ul style="list-style-type: none"> • Progression is suspected based on DRE changes or rising PSA and a recent TRUS biopsy was negative • Repeat TRUS biopsy shows progression to a higher Gleason score 	<ul style="list-style-type: none"> • MRI Pelvis without (CPT[®] 72195) or MRI Pelvis without and with contrast (CPT[®] 72197)

Indication	Imaging Study
Individuals on active surveillance who are noted to have progression and have plans to initiate treatment	<ul style="list-style-type: none"><li data-bbox="716 321 1317 394">• Imaging studies for initial staging as per <u>ONC-19.2</u>

Surveillance/Follow-up For Treated Prostate Cancer (ONC-19.5)

ON.PR.0019.5.A

v2.0.2024

Indication	Imaging Study
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none">• Asymptomatic or stable chronic symptoms• Stable DRE findings• Stable PSA levels	<ul style="list-style-type: none">• Advanced imaging is not routinely indicated for surveillance

References (ONC-19)

v2.0.2024

1. Schaeffer E, Srinivas S, Adra N, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2024 – March 8, 2024. Prostate cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Prostate cancer V3.2024 – March 8, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Moses KA, Sprenkle PC, Bahler C, et al. National Comprehensive Cancer Network (NCCN) Guidelines V2.2024 – March 6, 2024. Prostate Cancer Early Detection available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Prostate Cancer Early Detection V2.2024 – March 6, 2024 ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Jadvar H, Calais J, Fanti S, et al. Appropriate use criteria for prostate-specific membrane antigen PET imaging, Society for Nuclear Medicine and Molecular Imaging. <https://www.snmni.org/ClinicalPractice/content.aspx?ItemNumber=38657>.
4. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *Lancet*. 2020;395(10231):1208-1216. doi:10.1016/S0140-6736(20)30314-7.
5. Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with ¹⁸F-DCFPyL in prostate cancer patients (OSPREY). *J Urol*. 2021;206(1):52-61. doi:10.1097/JU.0000000000001698.
6. Artibani W, Porcaro AB, De Marco V, et al. Management of biochemical recurrence after primary curative treatment for prostate cancer: A review. *Urol Int*. 2018;100:251–262. doi:10.1159/000481438.
7. Zumsteg ZS, Spratt DE, Romesser PB, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. *Eur Urol*. 2015;67(6):1009-1016. doi:10.1016/j.eururo.2014.09.028.
8. Trabulsi EJ, Rumble RB, Jadvar H, et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. *J Clin Oncol*. 2020 Jan 15. doi:10.1200/JCO.19.02757 (Epub ahead of print).
9. Andriole G, Siegel B, LOCATE Study Group. PD60-12 Sites of prostate cancer recurrence delineated with 18F-Fluciclovod positron emission tomography in patients with negative or equivocal conventional imaging. *Journal of Urology*. 2019;201(4):e1100-e1101. doi:10.1097/01.JU.0000557289.21741.20.
10. ACR Appropriateness Criteria. Prostate cancer – pretreatment detection, surveillance, and staging. Rev. 2016.
11. Schoots IG, Nieboer D, Giganti F, Moore CM, Bangma CH, Roobol MJ. Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low risk prostate cancer? A systematic review and meta-analysis. *BJU Int*. 2018;122(6):946-958. doi:10.1111/bju.14358.
12. Mullins J, Bodenkamp D, Landis P, et al. Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed by active surveillance. *BJU Int*. 2013;111(7):1037-1045. doi:10.1111/j.1464-410X.2012.11641.x.
13. Sanda MG, Chen RC, Crispino T, et al. *AUA/ASTRO/SUO guidelines for clinically localized prostate cancer*. Linthicum, MD: American Urological Association; 2017.
14. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. *JAMA*. 2009;302(11):1202-1209. doi:10.1001/jama.2009.1348.
15. Chen RC, Rumble RB, Loblaw DA, et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology clinical practice guideline endorsement. *J Clin Oncol*. 2016;34(18):2182-2190. doi:10.1200/JCO.2015.65.7759.
16. Liu D, Lehmann HP, Frick KD, Carter HB. Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. *J Urol*. 2012;187(4):1241-1246. doi:10.1016/j.juro.2011.12.015.

17. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. *J Clin Oncol*. 2010;28(1):126-131. doi:10.1200/JCO.2009.24.2180.
18. Blomqvist L, Carlsson S, Gjertsson P, et al. Limited evidence for the use of imaging to detect prostate cancer: a systematic review. *Eur J Radiol*. 2014;83(9):1601–1606. doi:10.1016/j.ejrad.2014.06.028.
19. Schoots IG, Petrides N, Giganti F, et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. *Eur Urol*. 2015;67(4):627-636. doi:10.1016/j.eururo.2014.10.050.
20. Quentin M, Blondin D, Arsov C, et al. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen. *J Urol*. 2014;192(5):1374-1379. doi:10.1016/j.juro.2014.05.090.
21. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. *J Clin Oncol*. 2015;33(3):272-277. doi:10.1200/JCO.2014.55.1192.
22. Cooperberg MR. Long-term active surveillance for prostate cancer: answers and questions. *J Clin Oncol*. 2015;33(3):238-240. doi:10.1200/JCO.2014.59.2329.
23. Risko R, Merdan S, Womble PR, et al. Clinical predictors and recommendations for staging CT scan among men with prostate cancer. *Urology*. 2014;84(6):1329-1334. doi:10.1016/j.urology.2014.07.051.
24. Heck MM, Souvatzoglou M, Retz M, et al. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. *Eur J Nucl Med Mol Imaging*. 2014;41(4):694-701. doi:10.1007/s00259-013-2634-1.
25. Armstrong JM, Martin CR, Dechet C, et al. ¹⁸F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. *J Urol Onc*. 2020;38(7):636.e1-636.e6. doi:10.1016/j.urolonc.2020.03.021.
26. Baruch B, Lovrec P, Solanki A, et al. Fluorine 18 labeled fluciclovine PET/CT in clinical practice: factors affecting the rate of detection of recurrent prostate cancer. *AJR*. 2019;213(4):851-858. doi:10.2214/AJ.19.21153.
27. Marcus C, Butler P, Bagrodia A, et al. Fluorine-18-labeled fluciclovine PET/CT in primary and biochemical recurrent prostate cancer management. *AJR*. 2020:1-10. doi:10.2214/AJR.19.22404.
28. Trabulsi EJ, Rumble BR, Jadvar H, et. al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. *J Clin Oncol*. 2020;38:1963-1996. doi:10.1200/JCO.19.02757.
29. Lowrance WT, Breau RH, Chou R, et. al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. *J Urol*. 2021;205:14.
30. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. *Am J Surg Pathol*. 2016;40(2):244-52. doi:10.1097/PAS.0000000000000530.
31. FDA Oncology Center of Excellence. FDA approves Pluvicto for metastatic castration-resistant prostate cancer. 2022. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer>.
32. Sartor O, de Bono J, Chi KN, et. al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. *N Engl J Med*. 2021;385:1091-1103. doi:10.1056/NEJMoa2107322.

Testicular, Ovarian and Extragonadal Germ Cell Tumors (ONC-20)

Guideline

Testicular, Ovarian and Extragonadal Germ Cell Tumors – General Considerations (ONC-20.0)

Testicular, Ovarian and Extragonadal Germ Cell Tumors – Initial Work-Up/Staging (ONC-20.1)

Testicular, Ovarian and Extragonadal Germ Cell Tumors – Restaging/Recurrence (ONC-20.2)

Testicular, Ovarian and Extragonadal Germ Cell Tumors – Surveillance (ONC-20.3)

References (ONC-20)

Testicular, Ovarian and Extragenital Germ Cell Tumors – General Considerations (ONC-20.0)

ON.TO.0020.0.A

v2.0.2024

- This section applies to primary germ cell tumors occurring outside the central nervous system if individual's age >15 years at the time of initial diagnosis. Individuals age ≤15 years at diagnosis should be imaged according to pediatric guidelines in: **Pediatric Germ Cell Tumors (PEDONC-10)** in the Pediatric Oncology Imaging Guidelines.
- These guidelines are for germ cell tumors of the testicle, ovary and extragenital sites as well as malignant sex cord stromal tumors (granulosa cell and Sertoli-Leydig cell tumors).
- Requests for imaging must state the histologic type of the cancer being evaluated.
- Classified as pure seminomas (dysgerminomas, 40%) or Non-seminomatous germ cell tumors (NSGCT, 60%):
 - Pure seminomas are defined as pure seminoma histology with a normal serum concentration of alpha fetoprotein (AFP). Seminomas with elevated AFP are by definition Mixed.
 - Required for TNM staging are the tumor marker levels indicated by "S" (TNMS)
 - Mixed tumors are treated as NSGCTs, as they tend to be more aggressive.
 - The NSGCT histologies include:
 - Yolk-Sac tumors
 - Immature (malignant) teratomas
 - Choriocarcinomas (<1%)
 - Embryonal cell carcinomas (15% to 20%)
 - Endodermal Sinus Tumors (ovarian)
 - Combinations of all of the above (Mixed)
- MRI in place of CT scans to reduce risk of secondary malignancy is not supported by the peer-reviewed literature. CT scans are indicated for surveillance and are the preferred modality of imaging to assess for recurrence.
- PET/CT Scan is considered experimental, investigational, or unproven for evaluation of non-seminomatous germ cell tumors
- Active surveillance in testicular cancer refers to treatment with surgery (orchidectomy) alone without any additional post-operative treatment such as chemotherapy or radiotherapy

Testicular, Ovarian and Extragonadal Germ Cell Tumors – Initial Work-Up/ Staging (ONC-20.1)

ON.TO.0020.1.A
v2.0.2024

Indication	Imaging Study
Orchiectomy/oophorectomy is both diagnostic and therapeutic	<p>All individuals, following orchiectomy or oophorectomy:</p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
<p>For ANY of the following:</p> <ul style="list-style-type: none"> • Non-seminoma histology • Ovarian germ cell tumor • Abdominal lymphadenopathy noted on CT scan • Abnormal chest x-ray or signs/symptoms suggestive of chest involvement 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260)
Extragonadal Germ Cell Tumor	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177)

Testicular, Ovarian and Extragonadal Germ Cell Tumors – Restaging/ Recurrence (ONC-20.2)

ON.TO.0020.2.A
v2.0.2024

Indication	Imaging Study
Treatment response for stage II-IV individuals with measurable disease on CT	<ul style="list-style-type: none"> CT with contrast of previously involved body areas every 2 cycles
Seminoma with residual mass >3 cm after completion of chemotherapy	<ul style="list-style-type: none"> PET/CT (CPT[®] 78815)
End of therapy evaluation for NSGCT post chemotherapy or post retroperitoneal lymph node dissection (RPLND)	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Recurrence suspected, including increased tumor markers	<ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast Ultrasound (CPT[®] 76856 or CPT[®] 76857) of the remaining gonad if applicable
Unexplained pulmonary symptoms despite a negative chest x-ray, or new findings on chest x-ray	<ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260)
All others	<ul style="list-style-type: none"> See: Surveillance (ONC-20.3)

Testicular, Ovarian and Extragonadal Germ Cell Tumors – Surveillance (ONC-20.3)

ON.TO.0020.3.A
v2.0.2024

Indication	Imaging Study
Stage I Seminoma treated with orchiectomy alone (no radiotherapy or chemotherapy, also called active surveillance)	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) once at 4-6 months and 12 months post-orchiectomy, then every 6 months for years 2 and 3, and then annually until year 5
Stage I Seminoma treated with radiotherapy and/or chemotherapy	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) annually for 3 years
Stage IIA and non-bulky Stage IIB Seminomas treated with radiotherapy or chemotherapy	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) once at 3 months then once at 9-12 months after completion of therapy, then annually for 2 additional years

Indication	Imaging Study
<p>Bulky Stage IIB, IIC, and III Seminomas treated with chemotherapy</p>	<p><u>For individuals with ≤3 cm residual mass:</u></p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) every 4 months for 1 year, every 6 months for 1 year and then annually for 2 additional years <p><u>For individuals with >3 cm residual mass and negative PET scan:</u></p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) at 6 and 12 months after completion of therapy, then annually until year 5 <p><u>For individuals with thoracic disease:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) every 2 months for 1 year, then every 3 months for 1 year, then annually until year 5 after completion of therapy
<p>Stage IA Non-Seminomatous germ cell tumors treated with orchiectomy alone (without risk factors)</p>	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) every 6 months for 2 years and then annually for 1 additional year
<p>Stage IB Non-Seminomatous germ cell tumors treated with orchiectomy alone (with risk factors – lymphovascular invasion or invasion into spermatic cord/scrotum)</p>	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) every 4 months for 1 year, then every 6 months for 2 years, then annually until year 4
<p>Stage IA/IB Non-Seminomatous germ cell tumors treated with chemotherapy and/or primary RPLND</p>	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) annually for 2 years

Indication	Imaging Study
Stage II-III Non-Seminomatous germ cell tumors with complete response to chemotherapy +/- post-chemotherapy RPLND	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) once at 6, 12, 24 and 36 months after completion of therapy <p><u>For individuals with thoracic disease:</u></p> <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) every 6 months for 2 years, then annually until year 4 after completion of therapy
Stage IIA or IIB Non-Seminomatous germ cell tumors treated with post-primary RPLND <u>and</u> adjuvant chemotherapy	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) once at 4 months after completion of RPLND
Stage IIA or IIB Non-Seminomatous germ cell tumors treated with post-primary RPLND <u>without</u> adjuvant chemotherapy	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) or CT Abdomen with contrast (CPT[®] 74160) once at 3 to 4 months after completion of therapy and repeat annually for 1 additional year
All stages of ovarian dysgerminoma germ cell tumors	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) every 4 months for 1 year, every 6 months for 1 year and then annually for 3 years after completion of therapy
<p><u>All ovarian non-dysgerminoma germ cell tumors</u></p> <ul style="list-style-type: none"> Embryonal tumor Endodermal sinus tumor Immature teratoma Non-gestational choriocarcinoma 	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) every 4 months for 1 year, every 6 months for 1 year and then annually for 3 years after completion of therapy CT Chest with contrast (CPT[®] 71260) every 4 months for 1 year and every 6 months for 1 year after completion of therapy
<ul style="list-style-type: none"> Sex cord stromal tumors (male and female) Mature teratoma 	<ul style="list-style-type: none"> No routine advanced imaging indicated unless elevated tumor markers or clinical signs/symptoms of recurrence
Extragonadal germ cell tumors	<ul style="list-style-type: none"> CT of the involved region every 3 months for one year and every 6 months for one year.

References (ONC-20)

v2.0.2024

1. Gilligan T, Lin DW, Aggarwal R, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – January 26, 2023. Testicular cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Testicular cancer V1.2023 – January 26, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Armstrong DK, Alvarez RD, Backes FJ, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – January 17, 2024. Ovarian cancer, including fallopian tube cancer and primary peritoneal cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Ovarian cancer V1.2024 – January 17, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Salani R, Backes FJ, Fung MF, et al. Post treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. *Am J Obstet Gynecol.* 2011;204(6):466-478. doi:10.1016/j.ajog.2011.03.008.
4. Gershenson DM. Management of ovarian germ cell tumors. *J Clin Oncol.* 2007;25(20):2938-2943. doi:10.1200/JCO.2007.10.8738.
5. Colombo N, Parma G, Zanagnolo V, Insinga A. Management of ovarian stromal cell tumors. *J Clin Oncol.* 2007;25(20):2944-2951. doi:10.1200/JCO.2007.11.1005.
6. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of Borderline Ovarian Neoplasms. *J Clin Oncol.* 2007;25(20):2928-2937. doi:10.1200/JCO.2007.10.8076.
7. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. *Gynecol Oncol.* 2012;125(1):271-277. Doi:10.1016/j.ygyno.2011.12.418.
8. Kollmannsberger C, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. *J Clin Oncol.* 2015;33(1):51-57. doi:10.1200/JCO.2014.56.2116.
9. Oechsle K, Hartmann M, Brenner W, et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. *J Clin Oncol.* 2008;26(36):5930-5935. doi:10.1200/JCO.2008.17.1157.
10. Daugard G, Gundgaard MG, Mortensen MS, et al. Surveillance for stage I non seminoma testicular cancer: outcomes and long term follow-up in a population based cohort. *J. Clin Oncol.* 2014;32(34):3817-3823. doi:10.1200/JCO.2013.53.5831.
11. Zuniga A, Kakiashvili D, Jewett MA. Surveillance in stage I nonseminomatous germ cell tumours of the testis. *BJU Int.* 2009;104:1351-1356. doi:10.1111/j.1464-410X.2009.08858.x.

Ovarian Cancer (ONC-21)

Guideline

- Ovarian Cancer – General Considerations (ONC-21.0)
- Screening for Ovarian Cancer (ONC-21.1)
- Ovarian Cancer – Suspected/Diagnosis (ONC-21.2)
- Ovarian Cancer – Initial Work-Up/Staging (ONC-21.3)
- Ovarian Cancer – Restaging/Recurrence (ONC-21.4)
- Ovarian Cancer – Surveillance (ONC-21.5)
- References (ONC-21)

Ovarian Cancer – General Considerations (ONC-21.0)

ON.OC.0021.0.A

v2.0.2024

- Ovarian cancers include: epithelial ovarian cancers, ovarian cancers of low malignant potential and mixed Müllerian tumors, primary peritoneal and fallopian tube cancers.
 - There are five main types of epithelial ovarian cancers:
 - High-grade serous carcinoma (HGSC) (70%)
 - Endometrioid carcinoma (EC) (10%)
 - Clear cell carcinoma (CCC) (10%)
 - Mucinous carcinoma (MC) (3%)
 - Low-grade serous carcinoma (LGSC) (<5%)
- Borderline tumors (formerly referred to as tumors of low malignant potential) usually have some feature of carcinoma when they recur.
- Fallopian tube and primary peritoneal are usually serous carcinoma.
- Germ cell tumors and sex cord stromal tumors (granulosa cell tumors), are imaged according to **Testicular, Ovarian and Extragonadal Germ Cell Cancer (ONC-20)**.

Screening for Ovarian Cancer (ONC-21.1)

ON.OC.0021.1.A

v2.0.2024

Indication	Imaging/Lab Study
<p><u>High-Risk Factors:</u></p> <ul style="list-style-type: none"> • Family history of BRCA 1 or BRCA 2 mutations • Family history of ovarian cancer • Hereditary ovarian cancer syndrome that includes ovarian, breast, and/or endometrial and gastrointestinal cancers [Lynch II syndrome] in multiple members of two to four generations • Low parity • Decreased fertility • Delayed childbearing 	<ul style="list-style-type: none"> • Ovarian cancer screening is considered experimental & investigational and is not recommended. • Genetic counseling is recommended for women with an increased-risk family history (USPSTF, 2015)
<p>Known BRCA-1 or BRCA-2 mutation</p>	<ul style="list-style-type: none"> • Transvaginal ultrasound (CPT[®] 76830), combined with CA-125 for ovarian cancer screening may be considered annually starting at age 30, until risk-reducing salpingo-oophorectomy is performed

Ovarian Cancer – Suspected/Diagnosis (ONC-21.2)

ON.OC.0021.2.A

v2.0.2024

- See: **Complex Adnexal Masses (PV-5.3)** for imaging guidelines for evaluation of suspected ovarian malignancies
- Staging of ovarian cancer is primarily surgical and routine imaging is not indicated pre-operatively, unless it is obtained to evaluate specific signs/symptoms.
- To differentiate the origin of pelvic masses that are not clearly of ovarian origin, see: **Suspected Adnexal Mass (PV-5.1)**

Indication	Imaging/Lab Study
<ul style="list-style-type: none"> • Pelvic symptoms (pelvic pain, abdominal bloating) • Palpable pelvic mass 	<ul style="list-style-type: none"> • Transvaginal (TV) ultrasound imaging (CPT[®] 76830) and/or Pelvic ultrasound (CPT[®] 76856 or CPT[®] 76857)
<p>Ultrasound shows a complex and/or solid adnexal mass</p>	<ul style="list-style-type: none"> • See: Complex Adnexal Masses (PV-5.3)
<p>Ultrasound shows complex and/or solid adnexal mass suspicious for ovarian malignancy AND any of the following signs/symptoms concerning for metastatic disease:</p> <ul style="list-style-type: none"> • Ascites • Abdominal symptoms (distension, tenderness) • Elevated CA-125 • Elevated LFTs • Obstructive uropathy** 	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • **CT Abdomen and Pelvis without and with contrast (CT Urogram – CPT[®] 74178) may be approved only for symptoms of obstructive uropathy

Ovarian Cancer – Initial Work-Up/Staging (ONC-21.3)

ON.OC.0021.3.A
v2.0.2024

Indication	Imaging Study
Clinical stage II disease or higher	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Chest with contrast (CPT[®] 71260) for: <ul style="list-style-type: none"> ◦ Abnormal signs/symptoms of pulmonary disease ◦ Abnormal chest x-ray
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Primary peritoneal disease with biopsy-proven malignancy consistent with ovarian carcinoma • Elevated tumor markers with negative or inconclusive CT imaging 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Ovarian Cancer – Restaging/Recurrence (ONC-21.4)

ON.OC.0021.4.A

v2.0.2024

Indication	Imaging Study
Completely resected or definitively treated with chemotherapy and normal(ized) tumor markers	<ul style="list-style-type: none"> No advanced imaging needed
<p>ANY of the following:</p> <ul style="list-style-type: none"> Unresected disease Unknown preoperative markers Difficult or abnormal examination Elevated LFTs Elevated tumor markers (CA-125, inhibin) Signs or symptoms of recurrence 	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) CT Chest with contrast (CPT[®] 71260) for ANY of the following: <ul style="list-style-type: none"> Known prior thoracic disease New or worsening pulmonary symptoms New or worsening chest x-ray findings Rising tumor markers (CA-125, inhibin)
Monitoring response to treatment (every 2 cycles, or ~every 6 to 8 weeks)	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) CT Chest with contrast (CPT[®] 71260) for ANY of the following: <ul style="list-style-type: none"> Known prior thoracic disease New or worsening pulmonary symptoms New or worsening chest x-ray findings
<ul style="list-style-type: none"> CT negative or inconclusive and CA-125 continues to rise or elevated LFTs Conventional imaging failed to demonstrate tumor or if persistent radiographic mass with rising tumor markers 	<ul style="list-style-type: none"> PET/CT (CPT[®] 78815)

Ovarian Cancer – Surveillance (ONC-21.5)

ON.OC.0021.5.A
v2.0.2024

Indication	Imaging Study
Stages I-III	<ul style="list-style-type: none">Advanced imaging is not routinely indicated for surveillance
Measurable metastatic disease on maintenance therapy or being monitored off therapy	<p><u>Every 3 months for up to 5 years after completion of active treatment:</u></p> <ul style="list-style-type: none">CT Abdomen and Pelvis with contrast (CPT[®] 74177)CT with contrast of previously involved body areas

References (ONC-21)

v2.0.2024

1. Armstrong DK, Alvares RD, Backes FJ, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2023 – June 2, 2023. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer available at: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V2.2023 – June 2, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Daly MB, Pal T, AlHilli Z, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version V3.2023 – February 13, 2023. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Ovarian cancer V3.2023 – February 13, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Moyer VA, U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med.* 2012;157(12):900-904. doi:10.7326/0003-4819-157-11-201212040-00539.
4. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. *J Clin Oncol.* 2007;25(20):2928-2937. doi:10.1200/JCO.2007.10.8076.
5. ACR Appropriateness Criteria. *Ovarian cancer screening.* Rev. 2017.
6. Rosenthal AN, Fraser LSM, Phipott S. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study. *J Clin Oncol.* 2017;35(13):13:1411-1420. doi:10.1200/JCO.2016.69.9330.
7. Shinagare AB, O'Neill AC, Cheng S, et al. Advanced high-grade serous ovarian cancer: frequency and timing of thoracic metastases and the implications for chest imaging follow-up. *Radiology.* 2015;277(3):733-740. doi:10.1148/radiol.2015142467.
8. Musto A, Grassetto G, Marzola MC, et al. Management of epithelial ovarian cancer from diagnosis to restaging: an overview of the role of imaging techniques with particular regard to the contribution of 18F-FDG PET/CT. *Nucl Med Commun.* 2014;35(6):588-597. doi:10.1097/MNM.000000000000091.
9. Fischerova D, Burgetova A. Imaging techniques for the evaluation of ovarian cancer. *Best Pract Res Clin Obstet Gynaecol.* 2014;28(5):697-720. doi:10.1016/j.bpobgyn.2014.04.006.

Uterine Cancer (ONC-22)

Guideline

- Uterine Cancer – General Considerations (ONC-22.0)
- Uterine Cancer – Suspected/Diagnosis (ONC-22.1)
- Uterine Cancer – Initial Work-Up/Staging (ONC-22.2)
- Uterine Cancer – Restaging/Recurrence (ONC-22.3)
- Uterine Cancer – Surveillance (ONC-22.4)
- Gestational Trophoblastic Neoplasia (GTN) (ONC-22.5)
- References (ONC-22)

Uterine Cancer – General Considerations (ONC-22.0)

ON.UC.0022.0.A

v2.0.2024

- Gestational trophoblastic neoplasia (GTN) – see: **Molar Pregnancy and Gestational Trophoblastic Neoplasia (GTN) (PV-16.1)** in the Pelvic Imaging Guidelines.
- Most common cell type is adenocarcinoma. Uterine sarcomas are also imaged according to this guideline.
- Staging of uterine cancer is primarily surgical. Advanced imaging is not routinely indicated pre-operatively for laparoscopic/minimally invasive surgery unless initial staging criteria are met. Pelvic and para-aortic lymphadenectomy can still be performed.

Uterine Cancer – Suspected/Diagnosis (ONC-22.1)

ON.UC.0022.1.A

v2.0.2024

- See: **Abnormal Uterine Bleeding (PV-2.1)** in the Pelvic Imaging Guidelines for evaluation of suspected uterine malignancies.

Uterine Cancer – Initial Work-Up/Staging (ONC-22.2)

ON.UC.0022.2.A
v2.0.2024

Indication	Imaging Study
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Extra-uterine disease suspected • To assess local extent of tumor prior to fertility-sparing surgery for well-differentiated Stage IA (grade 1) uterine cancer • Poor surgical candidate (due to medical comorbidities) considering medical therapy 	<ul style="list-style-type: none"> • MRI Pelvis without and with contrast (CPT[®] 72197) • Transvaginal ultrasound (CPT[®] 76830) if MRI is contraindicated • Chest x-ray <ul style="list-style-type: none"> ◦ CT Chest with contrast (CPT[®] 71260) if chest x-ray is abnormal
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Abdominal symptoms or abnormal examination findings • Elevated LFTs • Other imaging studies suggest liver involvement 	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Abdomen with contrast (CPT[®] 74160)
<p><u>ANY of the following high-risk histologies:</u></p> <ul style="list-style-type: none"> • Papillary serous • Clear cell • High-grade/poorly differentiated endometrioid carcinoma • Uterine sarcomas: <ul style="list-style-type: none"> ◦ Carcinosarcoma ◦ Soft tissue sarcoma of the uterus ◦ Leiomyosarcoma ◦ Rhabdomyosarcoma ◦ Undifferentiated sarcoma ◦ Endometrial stromal sarcoma 	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast

Indication	Imaging Study
<p><u>Tumors detected incidentally or incompletely staged surgically and ANY of the following high-risk features:</u></p> <ul style="list-style-type: none">• Myoinvasion >50%• Cervical stromal involvement• Lymphovascular invasion• Tumor >2 cm	<ul style="list-style-type: none">• CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast
<p>Inconclusive findings on conventional imaging</p>	<ul style="list-style-type: none">• PET/CT scan (CPT[®] 78815)

Uterine Cancer – Restaging/Recurrence (ONC-22.3)

ON.UC.0022.3.A

v2.0.2024

Indication	Imaging Study
<ul style="list-style-type: none"> • Unresected disease • Medically inoperable disease • Incomplete surgical staging • Difficult or abnormal examination • Elevated LFTs or rising tumor markers • Signs or symptoms of recurrence 	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
<p><u>Monitoring response to chemotherapy (every 2 cycles, ~every 6-8 weeks) for:</u></p> <ul style="list-style-type: none"> • Unresected primary disease • Metastatic disease 	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Chest with contrast (CPT[®] 71260) for: <ul style="list-style-type: none"> ◦ New/worsening pulmonary symptoms ◦ Abnormal chest x-ray findings ◦ Known prior pulmonary involvement
<p><u>Any of the following:</u></p> <ul style="list-style-type: none"> • After fertility sparing treatment • Inconclusive CT scan findings 	<ul style="list-style-type: none"> • MRI Pelvis without and with contrast (CPT[®] 72197)
<ul style="list-style-type: none"> • Inconclusive findings on conventional imaging 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Uterine Cancer – Surveillance (ONC-22.4)

ON.UC.0022.4.A

v2.0.2024

Indication	Imaging Study
Stage I-III of uterine carcinoma	Advanced imaging is not routinely indicated for surveillance
Measurable metastatic disease on maintenance therapy or being monitored off therapy	<p><u>Every 3 months for up to 5 years after completion of definitive treatment:</u></p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved body areas
<p><u>All stages of uterine sarcoma:</u></p> <ul style="list-style-type: none"> • Soft tissue sarcoma of the uterus • Leiomyosarcoma • Adenosarcoma • Carcinosarcoma • Rhabdomyosarcoma • Undifferentiated sarcoma • Endometrial stromal sarcoma 	<p>CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177) every 3 months for 2 years, every 6 months for 3 years, and then every 1-2 years until year 10</p>

Gestational Trophoblastic Neoplasia (GTN) (ONC-22.5)

ON.UC.0022.5.A
v2.0.2024

- The most common form of gestational trophoblastic disease (GTD) is hydatidiform mole (HM), a benign form, also known as molar pregnancy.
 - See: **Molar Pregnancy and GTN (PV-16.1)**
- Gestational trophoblastic neoplastic disorders including a malignant form of GTD, and can present as invasive mole, choriocarcinoma, placental site trophoblastic tumor (PSTT), or epithelioid trophoblastic tumor (ETT). GTN cells are malignant and can metastasize to other organs such as lungs, brain, bone and vagina. These tumors have a high likelihood of cure and treatment with methotrexate usually allows for fertility preservation.
- Surveillance is generally with serial monitoring of HCG levels, and advanced imaging is reserved for high-risk histologies where HCG levels may not be a reliable marker.

Indication	Imaging Study
Initial staging	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
<p><u>EITHER of the following:</u></p> <ul style="list-style-type: none"> • Pulmonary metastases noted on CT scan • Signs/symptoms of CNS involvement 	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)
<p><u>EITHER of the following:</u></p> <ul style="list-style-type: none"> • Monitoring response to systemic therapy (every 2 cycles, i.e., 6-8 weeks) • Suspected progression 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)

Indication	Imaging Study
<p><u>Surveillance for any of the following high risk histologies:</u></p> <ul style="list-style-type: none">• Placental site trophoblastic tumor (PSTT)• Epithelioid trophoblastic tumor (ETT)	<p><u>Annually for 2 years:</u></p> <ul style="list-style-type: none">• CT Chest with contrast (CPT[®] 71260)• CT Abdomen and Pelvis with contrast (CPT[®] 74177)

References (ONC-22)

v2.0.2024

1. Abu-Rustum NR, Yashar CM, Arend R, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2023 – April 28, 2023. Uterine Neoplasms, available at: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Uterine Neoplasms 2.2023 – April 28, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Updates on uterine papillary serous carcinoma. *Expert Rev Obstet Gynecol*. 2009;4(6):647-657. doi:10.1586/eog.09.49.
3. Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. *Gynecol Oncol*. 2009;115(1):142-153. doi:10.1016/j.ygyno.2009.06.011.
4. Olawaiye AB, Boruta DM 2nd. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. *Gynecol Oncol*. 2009;113(2):277-283. doi:10.1016/j.ygyno.2009.02.003.
5. Salani R, Backes FJ, Fung MF et al. Post treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. *Am J Obstet Gynecol*. 2011;204(6):466-478. doi:10.1016/j.ajog.2011.03.008.
6. Reinhold C, Ueno Y, Akin EA, et. al. ACR Appropriateness Criteria® - Evaluation and follow-up of endometrial cancer. Available at <https://acsearch.acr.org/docs/69459/Narrative/>. American College of Radiology. Accessed 7/29/2020.
7. Abu-Rustum NR, Yashar CM, Bradley, K, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2021 – March 31, 2021. Gestational Trophoblastic Neoplasia, available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™ for Gestational Trophoblastic Neoplasia, March 31, 2021 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.

Cervical Cancer (ONC-23)

Guideline

- Cervical Cancer – General Considerations (ONC-23.0)
- Cervical Cancer – Suspected/Diagnosis (ONC-23.1)
- Cervical Cancer – Initial Work-Up/Staging (ONC-23.2)
- Cervical Cancer – Restaging/Recurrence (ONC-23.3)
- Cervical Cancer – Surveillance (ONC-23.4)
- References (ONC-23)

Cervical Cancer – General Considerations (ONC-23.0)

ON.CV.0023.0.A

v2.0.2024

- Primary histology for cervical cancer is squamous cell. Other, less common histologies are adenosquamous and adenocarcinoma. If biopsy is consistent with one of these less common histologies, it is necessary to clarify that tumor is not of primary uterine origin.
- If the primary histology is uterine in origin, follow imaging recommendations for uterine cancer, see: **Uterine Cancer (ONC-22)**.

Cervical Cancer – Suspected/Diagnosis (ONC-23.1)

ON.CV.0023.1.A

v2.0.2024

Indication	Imaging Study
All	<ul style="list-style-type: none">• Biopsy should be performed prior to imaging

Cervical Cancer – Initial Work-Up/ Staging (ONC-23.2)

ON.CV.0023.2.A

v2.0.2024

Indication	Imaging Study
Stage IB1 or higher stages	<p><u>ANY of the following combinations, not both:</u></p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815) <p>or</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Any size cervical cancer incidentally found in a hysterectomy specimen	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • To assess local extent of disease • To assess residual pelvic disease post-operatively • Inconclusive CT findings 	<ul style="list-style-type: none"> • MRI Pelvis without and with contrast (CPT[®] 72197)
Inconclusive findings on conventional imaging	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Cervical Cancer – Restaging/Recurrence (ONC-23.3)

ON.CV.0023.3.A

v2.0.2024

Indication	Imaging Study
Stage I treated with definitive surgery	<ul style="list-style-type: none"> See: Cervical Cancer – Surveillance (ONC-23.4)
Stage I-III treated with primary radiation therapy ± chemotherapy (no surgery)	<p>ANY of the following, not both:</p> <ul style="list-style-type: none"> PET/CT (CPT[®] 78815) at least 12 weeks after completion of treatment <p>OR</p> <ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast
<ul style="list-style-type: none"> After completion of primary non-surgical treatment (radiation therapy +/- chemotherapy) Inconclusive findings on CT scan 	<p>MRI Pelvis without and with contrast (CPT[®] 72197)</p>
Unresectable disease or metastatic disease on systemic treatment	<p>Every 2 cycles of treatment (commonly every 6 to 8 weeks):</p> <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) CT Abdomen and Pelvis with contrast (CPT[®] 74177) CT with contrast of other involved or symptomatic areas
Suspected or biopsy proven recurrence	<p>ANY of the following, not both:</p> <ul style="list-style-type: none"> PET/CT (CPT[®] 78815) <p>OR</p> <ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177)

Cervical Cancer – Surveillance (ONC-23.4)

ON.CV.0023.4.A

v2.0.2024

Indication	Imaging Study
Stage I disease treated with fertility sparing approach	<ul style="list-style-type: none">MRI Pelvis without and with contrast (CPT[®] 72197) at 6 months after surgery and then annually for 2 years
All individuals	<ul style="list-style-type: none">No routine advanced imaging needed in asymptomatic individuals.

References (ONC-23)

v2.0.2024

1. Abu-Rustum NR, Yashar CM, Arend R, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024 – February 23, 2024. Cervical Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Cervical Cancer V2.2024 – February 23, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Salani R, Backes FJ, Fung MF et al. Post treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. *Am J Obstet Gynecol*. 2011;204(6):466-478. doi:10.1016/j.ajog.2011.03.008.
3. Zanagnolo V, Ming L, Gadducci A, et al. Surveillance procedures for patients with cervical carcinoma: a review of the literature. *Int J Gynecol Cancer*. 2009;19(3):194-201. doi:10.1111/IGC.0b013e3181a130f3.
4. Elit L, Fyles AW, Devries MC, et al. Follow-up for women after treatment for cervical cancer: A systematic review. *Gynecol Oncol*. 2009;114(3):528-535. doi:10.1016/j.ygyno.2009.06.001.
5. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. *JAMA*. 2007;298(19):2289-2295. doi:10.1001/jama.298.19.2289.
6. Meads C, Davenport C, Malysiak S, et al. Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. *BJOG*. 2014;121(4):398-407. doi:10.1111/1471-0528.12488.
7. Chu Y, Zheng A, Wang F, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. *Nucl Med Commun*. 2014; 35(2):144-150. doi:10.1097/MNM.000000000000026.

Anal Cancer & Cancers of the External Genitalia (ONC-24)

Guideline

- Anal Carcinoma – General Considerations (ONC-24.0)
- Anal Carcinoma – Suspected/Diagnosis (ONC-24.1)
- Anal Carcinoma – Initial Work-up/Staging (ONC-24.2)
- Anal Carcinoma – Restaging/Recurrence (ONC-24.3)
- Anal Carcinoma – Surveillance (ONC-24.4)
- Cancers of External Genitalia – General Considerations (ONC-24.5)
- Cancers of External Genitalia – Initial Work-Up/Staging (ONC-24.6)
- Cancers of External Genitalia – Restaging/Recurrence (ONC-24.7)
- Cancers of External Genitalia – Surveillance (ONC-24.8)
- References (ONC-24)

Anal Carcinoma – General Considerations (ONC-24.0)

ON.AN.0024.0.A

v2.0.2024

- Most are squamous cell carcinomas, although some transitional and cloacogenic carcinomas are seen.
- Adenocarcinoma of the anal canal is managed as rectal cancer according to **Colorectal and Small Bowel Cancer (ONC-16)**
- Squamous cell carcinoma of the perianal region (up to 5 cm radius from the anal verge) are imaged according to anal carcinoma guidelines.
- Bowen's disease and Paget's disease of the perianal and perigenital skin are considered non-invasive/in-situ conditions and do not routinely require advanced imaging. See: **Non-Melanoma Skin Cancers – Initial Work-up/Staging (ONC-5.6)**

Anal Carcinoma – Suspected/Diagnosis (ONC-24.1)

ON.AN.0024.1.A

v2.0.2024

Indication	Imaging Study
All	• Advanced imaging prior to biopsy is not needed

Anal Carcinoma – Initial Work-up/ Staging (ONC-24.2)

ON.AN.0024.2.A

v2.0.2024

Indication	Imaging Study
All individuals	<ul style="list-style-type: none">• CT Chest with contrast (CPT[®] 71260) and <u>Any ONE of the following:</u>• CT Abdomen and Pelvis with contrast (CPT[®] 74177)• CT Abdomen with contrast (CPT[®] 74160) and MRI Pelvis without and with contrast (CPT[®] 72197)
<ul style="list-style-type: none">• Stage II-III Squamous Cell Carcinoma of the Anal Canal and no evidence of metastatic disease by conventional imaging• Inconclusive findings on conventional imaging	<ul style="list-style-type: none">• PET/CT (CPT[®] 78815)

Anal Carcinoma – Restaging/Recurrence (ONC-24.3)

ON.AN.0024.3.A

v2.0.2024

Indication	Imaging Study
Stage I treated with complete surgical resection	<ul style="list-style-type: none"> • See: Anal Carcinoma – Surveillance (ONC-24.4) for surveillance guidelines
Stages I, II and III – post chemoradiation evaluation	<p>Any ONE of the following:</p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
Metastatic (stage IV) disease	<ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) every 2 cycles (generally 6 to 8 weeks) on treatment • CT Chest with contrast (CPT[®] 71260) if Chest X-ray is abnormal or if symptoms of chest involvement
<ul style="list-style-type: none"> • Difficult or abnormal examination • Elevated LFTs • Signs or symptoms of recurrence • Biopsy proven recurrence 	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) with contrast and <p>Any ONE of the following:</p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
Inconclusive findings on conventional imaging	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Anal Carcinoma – Surveillance (ONC-24.4)

ON.AN.0024.4.A

v2.0.2024

Indication	Imaging Study
Stage I	<ul style="list-style-type: none"> • Advanced imaging is not routinely indicated for surveillance
<ul style="list-style-type: none"> • Stage II • Stage III • Local recurrence treated definitively 	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) with contrast or CT Chest without contrast (CPT[®] 71250) annually for 3 years • And ANY one of the following annually for three years: <ul style="list-style-type: none"> ◦ CT Abdomen and Pelvis with contrast (CPT[®] 74177) ◦ MRI Abdomen without and with contrast (CPT[®] 74183) and MRI Pelvis without and with contrast (CPT[®] 72197)
Stage IV – measurable metastatic disease on maintenance treatment or being observed off treatment	<p><u>Every 3 months for up to 5 years after completion of all treatment:</u></p> <ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) with contrast • CT Abdomen and Pelvis with contrast (CPT[®] 74177)

Cancers of External Genitalia – General Considerations (ONC-24.5)

ON.AN.0024.5.A

v2.0.2024

- These imaging guidelines are applicable for squamous cell carcinomas arising from the vulva, vagina, penis, urethra, and scrotum

Cancers of External Genitalia – Initial Work-Up/Staging (ONC-24.6)

ON.AN.0024.6.A

v2.0.2024

Indication	Imaging Study
<p>Clinical node negative vulvar cancer with ANY of the following:</p> <ul style="list-style-type: none"> • Lesion >2 cm • Any size with stromal invasion >1 mm 	<ul style="list-style-type: none"> • For planned sentinel lymph node (SLN) biopsy: Lymph system imaging (lymphoscintigraphy, CPT[®] 78195) <ul style="list-style-type: none"> ◦ SPECT/CT (CPT[®] 78830) is indicated as an add on code if requested
<p>For stage II or higher</p>	<p><u>ONE</u> of the following:</p> <ul style="list-style-type: none"> • CT Abdomen and Pelvis with contrast (CPT[®] 74177) OR • CT Abdomen with contrast (CPT[®] 74160) and MRI Pelvis without and with contrast (CPT[®] 72197) • CT Chest with contrast (CPT[®] 71260) is indicated only for: <ul style="list-style-type: none"> ◦ Signs/symptoms suggestive of chest involvement ◦ Abnormal findings on chest x-ray
<p>Inconclusive findings on conventional imaging</p>	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815)

Cancers of External Genitalia – Restaging/Recurrence (ONC-24.7)

ON.AN.0024.7.A

v2.0.2024

Indication	Imaging Study
<ul style="list-style-type: none"> Difficult or abnormal examination Elevated LFTs Signs or symptoms of recurrence Biopsy proven recurrence 	<ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) <p style="margin-left: 20px;"><u>And ANY one of the following:</u></p> <ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast
Individuals receiving systemic treatment	<ul style="list-style-type: none"> CT Abdomen and Pelvis with contrast (CPT[®] 74177) every 2 cycles (generally 6 to 8 weeks) during treatment and at the end of planned chemotherapy treatment CT Chest with contrast (CPT[®] 71260) if chest x-ray is abnormal or if symptoms of chest involvement
Inconclusive findings on conventional imaging	<ul style="list-style-type: none"> PET/CT (CPT[®] 78815)

Cancers of External Genitalia – Surveillance (ONC-24.8)

ON.AN.0024.8.A

v2.0.2024

Indication	Imaging Study
<ul style="list-style-type: none">All stages of vulvar and vaginal cancers	<ul style="list-style-type: none">Routine advanced imaging is not indicated for asymptomatic surveillance
<ul style="list-style-type: none">Penile Cancer: stage I-III A	<ul style="list-style-type: none">Routine advanced imaging is not indicated for asymptomatic surveillance
<ul style="list-style-type: none">Penile cancer: stages IIIB and higher	<ul style="list-style-type: none">CT Abdomen and Pelvis with contrast (CPT[®] 74177) every 3 months for year 1, and then every 6 months for year 2, then no further routine advanced imaging indicated

References (ONC-24)

v2.0.2024

1. Benson III AB, Venook AP, Al-Hawary MM, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2023 – April 28, 2023. Anal Carcinoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for anal carcinoma V2.2023– April 28, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Flaig TW, Spiess PE, Agarwal N. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – December 1, 2022. Penile Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Penile Cancer V1.2023 – December 1, 2022. ©2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Abu-Rustum NR, Yashar CM, Arend R. et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – December 22, 2022. Vulvar Cancer (Squamous Cell Carcinoma), available at: https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Vulvar Cancer (Squamous Cell Carcinoma) V1.2023 – December 22, 2022. ©2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
4. Bhuva NJ, Glynne-Jones R, Sonoda L, Wong WL, Harrison MK. To PET or not to PET? That is the question. Staging in anal cancer. *Ann Oncol.* 2012;23(8):2078-2082. doi:10.1093/annonc/mdr599.
5. Mistrangelo M, Pelosi E, Bellò M, et al. Role of positron emission tomography-computed tomography in the management of anal cancer. *Int J Radiat Oncol Biol Phys.* 2012;84(1):66-72. doi:10.1016/j.ijrobp.2011.10.048.
6. Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. *Ann Surg Oncol.* 2015;22(11):3574-3581. doi:10.1245/s10434-015-4391-9.
7. Moncrieff M, Pywell S, Snelling A, et. al. Effectiveness of SPECT/CT imaging for sentinel node biopsy staging of primary cutaneous melanoma and patient outcomes. *Ann Surg Oncol.* 2022;29(2):767-775. doi:10.1245/s10434-021-10911-4.
8. Quartuccio N, Garau LM, Arnone A, et. al. Comparison of 99mTc-labeled colloid SPECT/CT and planar lymphoscintigraphy in sentinel lymph node detection in patients with melanoma: a meta-analysis. *J Clin Med.* 2020;9(6):1680. doi:10.3390/jcm9061680.
9. Bennie G, Vorster M, Buscombe J, Sathekge M. The added value of a single-photon emission computed tomography-computed in sentinel lymph node mapping in patients with breast cancer and malignant melanoma. *World J Nucl Med.* 2015;14(01):41-46. doi:10.4103/1450-1147.150543

Multiple Myeloma and Plasmacytomas (ONC-25)

Guideline

Multiple Myeloma and Plasmacytomas – General Considerations (ONC-25.0)

Multiple Myeloma and Plasmacytomas – Suspected/Diagnosis (ONC-25.1)

Multiple Myeloma and Plasmacytomas – Initial Work-Up/Staging (ONC-25.2)

Multiple Myeloma and Plasmacytomas – Restaging/Recurrence (ONC-25.3)

Multiple Myeloma and Plasmacytomas – Surveillance (ONC-25.4)

References (ONC-25)

Multiple Myeloma and Plasmacytomas – General Considerations (ONC-25.0)

ON.MM.0025.0.A

v2.0.2024

- Multiple myeloma (MM) is a neoplastic disorder characterized by the proliferation of a single clone of plasma cells derived from B cells which grows in the bone marrow and adjacent bone, producing skeletal destruction.
- Multiple myeloma group of disorders can be classified as below, which influence imaging modality of choice.

Condition	Monoclonal protein	Bone marrow plasma cells	CRAB criteria**
Solitary Plasmacytoma (biopsy proven tumor containing plasma cells)	<3 gm/dL	Absent	Absent
Monoclonal Gammopathy of Unknown Significance (MGUS)	<3 gm/dL	<10%	Absent
Smoldering Myeloma (SMM) (stage I MM or asymptomatic MM)	≥3 gm/dL	10% - 60%	Absent
Multiple Myeloma (MM)	≥3 gm/dL	≥10%	Present

**CRAB criteria = hypercalcemia, renal insufficiency, anemia, lytic bony lesions

- Diagnosis and monitoring of response to therapy is primarily with laboratory studies that include urine and serum monoclonal protein levels, serum free light chain levels, LDH and beta-2 microglobulin. Routine advanced imaging to monitor response to treatment is not indicated.
- Rarely, (<5%), an individual may have Nonsecretory Myeloma, which does not produce measurable M-protein. These individuals require imaging as primary method to monitor disease.
- Other conditions that may present with Monoclonal Gammopathy include:
 - POEMS syndrome: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein and Skin Changes – may also have sclerotic bone lesions and Castleman’s disease. See: **Multiple Myeloma and Plasmacytomas – Initial Work-up/Staging (ONC-25.2)** for imaging recommendations.

- Waldenström’s Macroglobulinemia: IgM monoclonal protein along with bone marrow infiltration of small lymphocytes. See: **Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (ONC-27.10)** for imaging recommendations.
- Systemic Light chain Amyloidosis: light chain monoclonal protein in serum or urine with clonal plasma cells in bone marrow, systemic involvement of the kidneys, liver, heart, gastrointestinal tract or peripheral nerves due to amyloid deposition. See: **Multiple Myeloma and Plasmacytomas – Initial Work-up/Staging (ONC-25.2)** and **Cardiac Amyloidosis (CD-3.8)** for imaging recommendations for systemic light chain amyloidosis.

Multiple Myeloma and Plasmacytomas – Suspected/Diagnosis (ONC-25.1)

ON.MM.0025.1.A

v2.0.2024

Indication	Imaging Study
All	• X-ray skeletal series

Multiple Myeloma and Plasmacytomas – Initial Work-Up/Staging (ONC-25.2)

ON.MM.0025.2.A

v2.0.2024

Indication	Imaging Study
<p>ANY of the following:</p> <ul style="list-style-type: none"> Abnormal skeletal survey Abnormal myeloma labs Signs/symptoms of multiple myeloma 	<ul style="list-style-type: none"> Whole-body low-dose skeletal CT (CPT[®] 76497)
<p>ANY of the following:</p> <ul style="list-style-type: none"> If skeletal CT is negative, inconclusive, or not feasible Suspected solitary bone/osseous plasmacytoma 	<p>ONE of the following:</p> <ul style="list-style-type: none"> MRI Bone Marrow Blood Supply (CPT[®] 77084) MRI Cervical (CPT[®] 72141), Thoracic (CPT[®] 72146), Lumbar spine (CPT[®] 72148), and Pelvis (CPT[®] 72195) without contrast MRI Cervical (CPT[®] 72156), Thoracic (CPT[®] 72157), Lumbar spine (CPT[®] 72158), and Pelvis (CPT[®] 72197) without and with contrast CT contrast as requested of a specific area to determine radiotherapy or surgical candidacy, or for suspected extra-osseous plasmacytoma

Indication	Imaging Study
<p><u>ANY of the following (after above tests completed):</u></p> <ul style="list-style-type: none"> • Determine if plasmacytoma is truly solitary • Suspected extra-osseous plasmacytomas • Suspected progression of MGUS or SMM to a more malignant form and CT/ MRI imaging are negative • Whole-body skeletal CT and MRI Bone Marrow are negative, inconclusive, or not feasible 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Systemic light chain amyloidosis • POEMS syndrome 	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and • CT Abdomen and Pelvis with contrast (CPT[®] 74177)

Multiple Myeloma and Plasmacytomas – Restaging/Recurrence (ONC-25.3)

ON.MM.0025.3.A

v2.0.2024

Indication	Imaging Study
<p>Extra-osseous plasmacytoma response to initial therapy</p>	<p>ONE of the following:</p> <ul style="list-style-type: none"> • CT of any previously involved area, contrast as requested • MRI of any previously involved area, contrast as requested
<p>Known spine involvement with new neurological signs/symptoms or worsening pain</p>	<ul style="list-style-type: none"> • MRI Cervical (CPT[®] 72156), Thoracic (CPT[®] 72157), Lumbar spine (CPT[®] 72158) without and with contrast
<p><u>Treatment response assessment</u></p> <ul style="list-style-type: none"> • After completion of primary therapy • Non-secretory multiple myeloma • To determine therapy response with inconclusive labs 	<p>ONE of the following:</p> <ul style="list-style-type: none"> • Whole-body low-dose skeletal CT scan (CPT[®] 76497) • MRI Bone Marrow Blood Supply (CPT[®] 77084) • MRI Cervical (CPT[®] 72141), Thoracic (CPT[®] 72146), Lumbar spine (CPT[®] 72148), and Pelvis (CPT[®] 72195) without contrast • MRI Cervical (CPT[®] 72156), Thoracic (CPT[®] 72157), Lumbar spine (CPT[®] 72158), and Pelvis (CPT[®] 72197) without and with contrast • MRI without contrast, or MRI without and with contrast for any previously involved bony area or symptomatic area
<p>CAR-T cell therapy</p>	<p><u>Once before treatment and once 30-60 days after completion of treatment:</u></p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)

Indication	Imaging Study
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Suspected relapse/recurrence • Suspected progression of MGUS or SMM to a more malignant form 	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • Whole-body low-dose skeletal CT (CPT[®] 76497) • MRI Bone Marrow Blood Supply (CPT[®] 77084) • MRI Cervical (CPT[®] 72141), Thoracic (CPT[®] 72146), Lumbar spine (CPT[®] 72148), and Pelvis (CPT[®] 72195) without contrast • MRI Cervical (CPT[®] 72156), Thoracic (CPT[®] 72157), Lumbar spine (CPT[®] 72158), and Pelvis (CPT[®] 72197) without and with contrast • MRI without contrast, or MRI without and with contrast for any previously involved bony area or symptomatic area
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Negative PET will allow change in management from active treatment to maintenance or surveillance. • Inconclusive findings on conventional imaging 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
<p>Stem cell transplant recipients</p>	<p><u>ONE of the following, once before transplant and once within 30-100 days after transplant:</u></p> <ul style="list-style-type: none"> • Whole-body low-dose skeletal CT scan (CPT[®] 76497) • MRI Bone Marrow Blood Supply (CPT[®] 77084) • MRI Cervical (CPT[®] 72141), Thoracic (CPT[®] 72146), Lumbar spine (CPT[®] 72148), and Pelvis (CPT[®] 72195) without contrast • MRI Cervical (CPT[®] 72156), Thoracic (CPT[®] 72157), Lumbar spine (CPT[®] 72158), and Pelvis (CPT[®] 72197) without and with contrast

Multiple Myeloma and Plasmacytomas – Surveillance (ONC-25.4)

ON.MM.0025.4.A

v2.0.2024

Indication	Study
<ul style="list-style-type: none">• Plasmacytomas• Smoldering myeloma• Multiple myeloma	<p>ANY ONE of the following annually for 5 years:</p> <ul style="list-style-type: none">• Whole-body low-dose skeletal CT (CPT[®] 76497)• MRI Bone Marrow Blood Supply (CPT[®] 77084)

References (ONC-25)

v2.0.2024

1. Kumar SK, Callander NS, Adekola K, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 – December 8, 2022. Myeloma, available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Myeloma V3.2023 – December 8, 2022. ©2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M, Lonial S. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. *The Lancet*. 2019;20(6):PE302-E312. doi:10.1016/S1470-2045(19)30309-2.
3. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. *N Engl J Med*. 2007;356:2582-2590. doi:10.1056/NEJMoa070389.
4. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. *Leukemia*. 2009;23(9):1545-1556. doi:10.1038/leu.2009.89.
5. ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, version 10.3. Reston, VA: American College of Radiology; 2018.
6. Mulligan ME, Badros AZ. PET/CR and MR imaging in myeloma. *Skeletal Radiol*. 2007;36(1):5-16. doi:10.1007/s00256-006-0184-3.
7. Dimopoulos MA, Hillengrass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. *J Clin Oncol*. 2015;33(6):657-664. doi:10.1200/JCO.2014.57.9961.
8. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. *Leukemia*. 2009;23(9):1545-1556. doi:10.1038.leu.2008.89.
9. Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. 18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. *Clin Exp Med*. 2015;15(1):1-18. doi:10.1007/s10238-014-0308-3.
10. Ferraro R, Agarwal A, Martin-Macintosh EL, Peller PJ, Subramaniam RM. MR imaging and PET/CT in diagnosis and management of multiple myeloma. *Radiographics*. 2015;35(2):438-454. doi:10.1148/rg.352140112.
11. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. *Mayo Clin Proc*. 2016;91(1):101-119. doi:10.1016/j.mayocp.2015.11.007.
12. Westerland O, Amlani A, Kelly-Morland C, et al. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. *Eur J Nucl ed Mol Imaging*. 2021. doi:10.1007/s00259-020-05182-2

Leukemias, Myelodysplasia and Myeloproliferative Neoplasms (ONC-26)

Guideline

Leukemias, Myelodysplasia and Myeloproliferative Neoplasms – General Considerations (ONC-26.1)

Acute Leukemias (ONC-26.2)

Chronic Myeloid Leukemias, Myelodysplastic Syndrome and Myeloproliferative Disorders (ONC-26.3)

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (ONC-26.4)

References (ONC-26)

Leukemias, Myelodysplasia and Myeloproliferative Neoplasms – General Considerations (ONC-26.1)

ON.LM.0026.1.A

v2.0.2024

- PET imaging is considered investigational, experimental, or unproven for all indications in acute lymphoblastic leukemia, acute myeloid leukemia, and chronic myeloid leukemia.
- Routine advanced imaging is not indicated for the evaluation and management of Hairy cell leukemia in the absence of specific localizing clinical symptoms.

Acute Leukemias (ONC-26.2)

ON.LM.0026.2.A

v2.0.2024

- Imaging indications for acute lymphoblastic leukemia in adult individuals are identical to those for pediatric individuals. See: **Acute Lymphoblastic Leukemia (ALL) (PEDONC-3.2)** in the Pediatric Oncology Imaging Guidelines.
- Imaging indications for acute myeloid leukemia in adult individuals are identical to those for pediatric individuals. See: **Acute Myeloid Leukemia (AML) (PEDONC-3.3)** in the Pediatric Oncology Imaging Guidelines.

Chronic Myeloid Leukemias, Myelodysplastic Syndrome and Myeloproliferative Disorders (ONC-26.3)

ON.LM.0026.3.A

v2.0.2024

- Routine advanced imaging is not indicated in the evaluation and management of chronic myeloid leukemias, myelodysplastic syndromes or myeloproliferative disorders in the absence of specific localizing clinical symptoms or clearance for hematopoietic stem cell transplantation.
- See: **Hematopoietic Stem Cell Transplantation (ONC-29)** for imaging guidelines related to transplant.
- For work-up of elevated blood counts, see: **Paraneoplastic Syndromes – General Considerations (ONC-30.3)**.

Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (ONC-26.4)

ON.LM.0026.4.A

v2.0.2024

- PET imaging is not indicated in the evaluation of CLL/SLL with the exception of suspected Richter’s transformation (See Suspected transformation, below).
- CLL/SLL is monitored with serial laboratory studies. Routine advanced imaging is not indicated for monitoring treatment response or surveillance, except when initial studies reveal bulky disease involvement.
- Bulky disease is defined as lymph node mass >10 cm or spleen >6 cm below costal margin

Indication	Imaging Study
Initial Staging/Diagnosis	<ul style="list-style-type: none"> • Advanced imaging is not routinely indicated for initial evaluation of asymptomatic individuals
<p>For ANY of the following:</p> <ul style="list-style-type: none"> • Bulky lymph node mass (>10 cm) • Splenomegaly >6 cm below costal margin • Presence of B symptoms • Progressive anemia and thrombocytopenia • Prior to planned systemic therapy 	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Treatment Response	<ul style="list-style-type: none"> • For individuals with bulky nodal disease at diagnosis, CT with contrast of previously involved area(s) every 2 cycles of therapy • Routine imaging is not indicated for individuals without bulky nodal disease at diagnosis
End of Therapy Evaluation	<ul style="list-style-type: none"> • For individuals with bulky nodal disease at diagnosis, CT with contrast of previously involved area(s)

Indication	Imaging Study
Suspected Progression	<p><u>ANY or ALL of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s)
<p><u>Suspected transformation (Richter's) from a low-grade lymphoma to a more aggressive type based on one or more of the following:</u></p> <ul style="list-style-type: none"> • New B symptoms • Rapidly growing lymph nodes • Extranodal disease develops • Significant recent rise in LDH above normal range 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
Surveillance	<p><u>For individuals with bulky nodal disease at diagnosis, every 6 months for two years, then annually:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s) <p>Routine imaging is not indicated for individuals without bulky nodal disease at diagnosis</p>

References (ONC-26)

v2.0.2024

1. Wierda WG, Brown J, Abramson JS, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 – June 12, 2023. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V3.2023 – June 12, 2023. © 2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Conte MJ, Bowen DA, Wiseman GA, et al. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. *Leuk Lymphoma*. 2014;55(9):2079-2084. doi:10.3109/10428194.2013.869801.
3. Mauro FR, Chauvie S, Paoloni F, et al. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. *Leukemia*. 2015;29(6):1360-1365. doi:10.1038/leu.2015.21.
4. Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. *JAMA*. 2014;312(21):2265-2276. doi:10.1001/jama.2014.14553.
5. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: focus on clinical practice. *Mayo Clin Proc*. 2016;91(2):259-272. doi:10.1016/j.mayocp.2015.11.011.
6. American Society of Hematology. Choosing Wisely: Don't perform baseline or routine surveillance computed tomography (CT) scans in patients with asymptomatic, early-stage chronic lymphocytic leukemia (CLL). 2014. <https://www.choosingwisely.org/clinician-lists/american-society-hematology-baseline-or-routine-surveillance-ct-scans-for-asymptomatic-early-stage-chronic-lymphocytic-leukemia/>.

Non-Hodgkin Lymphomas (ONC-27)

Guideline

- Non-Hodgkin Lymphomas – General Considerations (ONC-27.1)
- Diffuse Large B Cell Lymphoma (DLBCL) (ONC-27.2)
- Follicular Lymphoma (ONC-27.3)
- Marginal Zone Lymphomas (ONC-27.4)
- Mantle Cell Lymphoma (ONC-27.5)
- Burkitt’s Lymphomas (ONC-27.6)
- Lymphoblastic Lymphomas (ONC-27.7)
- T Cell Lymphomas (ONC-27.8)
- Post-Transplant Lymphoproliferative Disorders (ONC-27.9)
- Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (ONC-27.10)
- References (ONC-27)

Non-Hodgkin Lymphomas – General Considerations (ONC-27.1)

ON.NH.0027.1.A

v2.0.2024

- Lymphoma is often suspected when individuals have any of the following:
 - Bulky lymphadenopathy (lymph node mass >10 cm in size), hepatomegaly or splenomegaly
 - The presence of systemic symptoms (fever, drenching night sweats or unintended weight loss of >10%, called “B symptoms”)
- Individuals with AIDS-related lymphoma should be imaged according to the primary lymphoma histology
- See: **Castleman’s Disease (unicentric and multicentric) (ONC-31.11)** for guidelines covering Castleman’s disease.
- See: **Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (ONC-26.4)** for guidelines covering Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL).

Indication	Imaging Study
<p><u>Biopsy proven lymphoma or suspected lymphoma with one of the following:</u></p> <ul style="list-style-type: none"> • Bulky lymphadenopathy (LN mass >10 cm) • Hepatomegaly • Splenomegaly • B symptom: Unexplained fever, drenching night sweats, unintended weight loss >10% total body weight 	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast <ul style="list-style-type: none"> ◦ MRI without and with contrast for individuals who cannot tolerate CT contrast due to allergy or impaired renal function
<p>Signs or symptoms of disease involving the neck</p>	<ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491)
<p>Signs or symptoms suggesting CNS involvement with lymphoma.</p>	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) • See: CNS Lymphoma (also known as Microglioma) (ONC-2.7)

Indication	Imaging Study
Known or suspected bone involvement with lymphoma	<ul style="list-style-type: none"> • MRI without and with contrast of symptomatic or previously involved bony areas <ul style="list-style-type: none"> ◦ Bone scan is inferior to MRI for evaluation of known or suspected bone involvement with lymphoma
Determine a more favorable site for biopsy when a relatively inaccessible site is contemplated	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) <ul style="list-style-type: none"> ◦ PET/CT is not indicated for all other indications prior to histological confirmation of lymphoma
CAR-T cell therapy	<p><u>Once before treatment and once 30-60 days after completion of treatment:</u></p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 and CPT[®] 78816)

Diffuse Large B Cell Lymphoma (DLBCL) (ONC-27.2)

ON.TO.0027.2.A

v2.0.2024

- Grey zone lymphomas, primary mediastinal B cell lymphomas, Grade 3 (high) follicular lymphoma, double-hit or triple-hit lymphomas, and primary cutaneous diffuse large B cell lymphoma should also be imaged according to these guidelines.

Indication	Imaging Study
Initial Staging/ Diagnosis	<p><u>ONE of the following may be approved:</u></p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) <p>OR</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Treatment response for all stages	<p><u>ANY one of the following may be approved, not both:</u></p> <ul style="list-style-type: none"> • CT with contrast of previously involved area(s) may be approved every 2 cycles (6-8 weeks) of therapy <p>Or</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) after 3-4 cycles of chemotherapy
End of Chemotherapy and/or Radiation Therapy Evaluation	<p><u>ANY or ALL of the following may be approved:</u></p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) may be approved at the end of chemotherapy and again at the end of radiation • CT with contrast of previously involved area(s)
Suspected Recurrence	<p><u>ANY or ALL of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s) • PET/CT can be considered in rare circumstances (e.g. bone involvement).

Indication	Imaging Study
Biopsy-proven recurrence	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
CAR-T cell therapy	<p>Once before treatment and once 30-60 days after completion of treatment:</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
<p><u>Surveillance for ANY of the following:</u></p> <ul style="list-style-type: none"> • All stages of DLBCL • Relapsed lymphoma • Primary mediastinal large B cell lymphoma • Primary cutaneous diffuse large B cell lymphoma 	<ul style="list-style-type: none"> • <u>Every 6 months for 2 years after completion of treatment:</u> <ul style="list-style-type: none"> ◦ CT Chest with contrast (CPT[®] 71260) ◦ CT Abdomen and Pelvis with contrast (CPT[®] 74177) ◦ CT with contrast of previously involved area(s)

Follicular Lymphoma (ONC-27.3)

ON.NH.0027.3.A

v2.0.2024

- This section applies to follicular lymphomas with WHO grade of 1 (low) or 2 (intermediate) and primary cutaneous follicle center lymphoma. Grade 3 (high) follicular lymphomas should be imaged according to guidelines found in: **Diffuse Large B Cell Lymphoma (DLBCL) (ONC-27.2)**.

Indication	Imaging Study
Initial Staging/Diagnosis	<p><u>ANY or ALL of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
<p><u>For ANY of the following:</u></p> <ul style="list-style-type: none"> • If radiation therapy is being considered for stage I or II disease • If systemic therapy is planned • Pediatric-type follicular lymphoma in adults 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
Treatment Response	<ul style="list-style-type: none"> • CT with contrast of previously involved area(s) every 2 cycles of therapy
End of Therapy Evaluation	<p><u>ONE of the following may be approved:</u></p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) <p>OR</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s)

Indication	Imaging Study
Suspected Recurrence	<p><u>ANY or ALL of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s)
<p><u>Suspected transformation (Richter’s) from a low grade lymphoma to a more aggressive type based on one or more of the following:</u></p> <ul style="list-style-type: none"> • New B symptoms • Rapidly growing lymph nodes • Extranodal disease develops • Significant recent rise in LDH above normal range 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
<p><u>Surveillance for ANY of the following:</u></p> <ul style="list-style-type: none"> • After completion of active treatment • On maintenance treatment • Observation without any treatment 	<p><u>For all stages, every 6 months for two years, then annually:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s)
Surveillance of pediatric-type follicular lymphoma in adults	Advanced imaging is not indicated routinely after complete response

Marginal Zone Lymphomas (ONC-27.4)

ON.NH.0027.4.A
v2.0.2024

- MALT lymphomas in any location and primary cutaneous marginal zone lymphoma should also be imaged according to these guidelines
- Splenic Marginal Zone Lymphoma is diagnosed with splenomegaly, peripheral blood flow cytometry and bone marrow biopsy. Splenectomy is diagnostic and therapeutic. PET scan is not routinely indicated prior to splenectomy.

Indication	Imaging Study
Initial Staging/ Diagnosis	<p><u>ANY or ALL of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
<p><u>EITHER of the following:</u></p> <ul style="list-style-type: none"> • If radiation therapy is being considered for stage I or II disease • If systemic therapy is planned 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
Treatment Response	<ul style="list-style-type: none"> • CT with contrast of previously involved area(s) every 2 cycles of therapy
End of Therapy Evaluation	<p><u>ONE of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT with contrast of previously involved area(s) • PET/CT (CPT[®] 78815 or CPT[®] 78816)
Suspected Recurrence	<p><u>ANY or ALL of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s) • PET/CT can be considered in rare circumstances (e.g. bone involvement).

Indication	Imaging Study
<p><u>Surveillance of all stages of nodal marginal zone lymphoma for any of the following:</u></p> <ul style="list-style-type: none"> • After completion of active treatment • On maintenance treatment • Observation without any treatment 	<p><u>Every 6 months for two years, then annually:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s)
<p>Surveillance of all stages of extranodal marginal zone lymphoma</p>	<p>Advanced imaging is not routinely indicated for surveillance of asymptomatic individuals</p>

Mantle Cell Lymphoma (ONC-27.5)

ON.NH.0027.5.A
v2.0.2024

Indication	Imaging Study
Initial Staging/Diagnosis	<p><u>ONE of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177) <p>OR</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
Treatment Response	<ul style="list-style-type: none"> • CT with contrast of previously involved area(s) every 2 cycles of therapy • PET/CT is not indicated for monitoring treatment response but can be considered in rare circumstances when CT did not show disease (e.g. bone).
End of Therapy Evaluation	<p><u>ONE of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT with contrast of previously involved area(s) • PET/CT (CPT[®] 78815 or CPT[®] 78816)
Suspected Recurrence	<p><u>ANY or ALL of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s) • PET/CT can be considered in rare circumstances (e.g. bone involvement).
Surveillance for all stages	<p><u>Every 6 months for 2 years, and then annually:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s)

Burkitt's Lymphomas (ONC-27.6)

ON.NH.0027.6.A
v2.0.2024

Indication	Imaging Study
Initial Staging/Diagnosis	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Treatment Response	<ul style="list-style-type: none"> • CT with contrast of previously involved area(s) every 2 cycles of therapy • PET/CT is not indicated for monitoring treatment response but can be considered in rare circumstances when CT did not show disease (e.g. bone).
End of Therapy Evaluation	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) may be approved at the end of chemotherapy and again at the end of radiation • CT with contrast of previously involved area(s)
Suspected Recurrence	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s) • PET/CT can be considered in rare circumstances (e.g. bone involvement).
Surveillance	<p>Every 6 months for 2 years after completion of treatment:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)

Lymphoblastic Lymphomas (ONC-27.7)

ON.NH.0027.7.A

v2.0.2024

- Individuals with lymphoblastic lymphoma (even those with bulky nodal disease) are treated using the leukemia treatment plan appropriate to the cell type (B or T cell). Imaging indications in adult individuals are identical to those for pediatric individuals. See: **Acute Lymphoblastic Leukemia (ALL) (PEDONC-3.2)** in the Pediatric Oncology Imaging Guidelines.

T Cell Lymphomas (ONC-27.8)

ON.NH.0027.8.A

v2.0.2024

- Includes Peripheral T-Cell Lymphomas, Mycosis Fungoides/Sézary Syndrome, Anaplastic Large Cell Lymphoma (ALCL) including breast implant-associated ALCL, Angioimmunoblastic lymphoma, and Primary Cutaneous CD30+T Cell Lymphoproliferative Disorders

Indication	Imaging Study
Initial Staging/ Diagnosis	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> PET/CT (CPT[®] 78815 or CPT[®] 78816) CT Chest with contrast (CPT[®] 71260) CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Breast implant-associated ALCL	<p>In addition to the above initial staging studies:</p> <ul style="list-style-type: none"> Ultrasound Breast (CPT[®] 76641 or CPT[®] 76642) <ul style="list-style-type: none"> MRI Breast (CPT[®] 77049) may be indicated for evaluation of inconclusive ultrasound findings
Treatment Response	<p>Any ONE of the following may be approved after 3-4 cycles:</p> <ul style="list-style-type: none"> PET/CT (CPT[®] 78815 or 78816) <p>or</p> <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260), and CT Abdomen and Pelvis with contrast (CPT[®] 74177) and CT with contrast of previously involved area(s)
End of Therapy Evaluation	<p>Any ONE of the following may be approved at the end of chemotherapy and again at the end of radiation therapy:</p> <ul style="list-style-type: none"> PET/CT (CPT[®] 78815 or CPT[®] 78816) <p>or</p> <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260), and CT Abdomen and Pelvis with contrast (CPT[®] 74177), and CT with contrast of previously involved area(s)

Indication	Imaging Study
Suspected Recurrence	<p><u>ANY or ALL of the following may be approved:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s) • PET/CT can be considered in rare circumstances (e.g., bone involvement).
Surveillance, all stages	<p><u>Every 6 months for 2 years, then annually for 5 years:</u></p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260), CT Abdomen and Pelvis with contrast (CPT[®] 74177), and CT of previously involved areas

Post-Transplant Lymphoproliferative Disorders (ONC-27.9)

ON.NH.0027.9.A

v2.0.2024

- Post-transplant lymphoproliferative disorder (PTLD) or viral-associated lymphoproliferative disorder can rarely occur following solid organ or hematopoietic stem cell transplantation, or in primary immunodeficiency. When reduction of immunosuppression is unsuccessful, these are often treated with chemoimmunotherapy similar to high-grade NHL.
- This section applies to Monomorphic (B-cell type) PTLD and Polymorphic PTLD.
- For Hodgkin-lymphoma subtype of PTLD, see: **Hodgkin Lymphomas (ONC-28)** for imaging recommendations.

Indication	Imaging Study
Initial Staging/ Diagnosis	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Treatment Response	<p>ANY or ALL of the following may be approved after 4 weeks of reducing immunosuppression or every 2 cycles (6-8 weeks) of chemo/immunotherapy:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260), and • CT Abdomen and Pelvis with contrast (CPT[®] 74177), and • CT with contrast of previously involved area(s)
End of Therapy Evaluation	<p>ANY one of the following may be approved at the end of treatment:</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) <p>or</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260), and • CT Abdomen and Pelvis with contrast (CPT[®] 74177), and • CT with contrast of previously involved area(s)

Indication	Imaging Study
Suspected recurrence	<ul style="list-style-type: none">• CT Chest with contrast (CPT[®] 71260)• CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Surveillance	Advanced imaging is not routinely indicated for surveillance

Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (ONC-27.10)

ON.NH.0027.10.A
v2.0.2024

Indication	Imaging Study
Initial Staging/Diagnosis	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Treatment Response	<ul style="list-style-type: none"> • CT with contrast of previously involved area(s) every 2 cycles of therapy
End of Therapy Evaluation	<ul style="list-style-type: none"> • CT with contrast of previously involved area(s)
Suspected Recurrence	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s)
Surveillance	Advanced imaging is not routinely indicated for surveillance

References (ONC-27)

v2.0.2024

1. Zelenetz AD, Gordon LI, Abramson JS, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – January 18, 2024. B-cell lymphomas, available at: https://www.nccn.org/professionals/physician_gls/pdf/B-CELL.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for B-cell lymphomas V1.2024 – January 18, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Horwitz SM, Ansell S, Ai WZ, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – December 21, 2023. T-cell lymphomas, available at: https://www.nccn.org/professionals/physician_gls/pdf/T-CELL.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for T-cell lymphomas V1.2024 – December 21, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment for Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol.* 2014;32(27):3059-3067. doi:10.1200/JCO.2013.54.8800.
4. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *J Clin Oncol.* 2014;32(27):3048-3058. doi:10.1200/JCO.2013.53.5229.
5. Thompson CA, Ghesquieres H, Maurer MJ, et al. Utility of routine post-therapy surveillance imaging in diffuse Large B-Cell Lymphoma. *J Clin Oncol.* 2014;32(31):3506-3512. doi:10.1200/JCO.2014.55.7561.
6. El-Galaly TC, Jakobsen LH, Hutchings M, et al. Routine imaging for diffuse Large B-Cell Lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. *J Clin Oncol.* 2015;33(34):3993-3998. doi:10.1200/JCO.2015.62.0229.
7. Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse Large B-Cell Lymphoma in first remission. *J Clin Oncol.* 2015;33(13):1467-1474. doi:10.1200/JCO.2014.58.5729.
8. Mamot C, Klingbiel D, Hitz F, et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). *J Clin Oncol.* 2015;33(23):2523-2529. doi:10.1200/JCO.2014.58.9846.
9. Mylam KJ, Nielsen AL, Pedersen LM, Hutchings M. Fluorine-18-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma. *PET Clin.* 2014;9(4):443-455. doi:10.1016/j.cpet.2014.06.001.
10. Avivi I, Zilberlicht A, Dann EJ, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. *Am J Hematol.* 2013;88(5):400-405. doi:10.1002/ajh.23423.
11. Ulrich Dürsen, Stefan Müller, Bernd Hertenstein, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. *J Clin Oncol.* 2018;36(20):2024-2034. doi:10.1200/JCO.2017.76.8093.

Hodgkin Lymphoma (ONC-28)

Guideline

Hodgkin Lymphoma – General Considerations (ONC-28.1)

Classical Hodgkin Lymphoma (ONC-28.2)

Nodular Lymphocyte – Predominant Hodgkin Lymphoma (ONC-28.3)

References (ONC-28)

Hodgkin Lymphoma – General Considerations (ONC-28.1)

ON.HL.0028.1.A

v2.0.2024

- Lymphoma is often suspected when individuals have any of the following:
 - Bulky lymphadenopathy (lymph node mass >10 cm in size), hepatomegaly or splenomegaly
 - The presence of systemic symptoms (fever, drenching night sweats or unintended weight loss of >10%, called “B symptoms”)
- Individuals with AIDS-related lymphoma should be imaged according to the primary lymphoma histology
- The **Deauville Criteria** are internationally accepted criteria, which utilize a five-point scoring system for the FDG avidity of a Hodgkin's lymphoma or Non-Hodgkin's lymphoma tumor mass as seen on FDG PET.
 - Score 1: No uptake above the background
 - Score 2: Uptake ≤mediastinum
 - Score 3: Uptake >mediastinum but ≤liver
 - Score 4: Uptake moderately increased compared to the liver at any site
 - Score 5: Uptake markedly increased compared to the liver at any site
 - Score X: New areas of uptake unlikely to be related to lymphoma

Indication	Imaging Study
<p><u>Biopsy proven lymphoma or suspected lymphoma with one of the following:</u></p> <ul style="list-style-type: none"> • Bulky lymphadenopathy (LN mass >10 cm) • Hepatomegaly • Splenomegaly • B symptom: Unexplained fever, drenching night sweats, unintended weight loss >10% total body weight 	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast <ul style="list-style-type: none"> ◦ MRI without and with contrast for individuals who cannot tolerate CT contrast due to allergy or impaired renal function
<p>Signs or symptoms of disease involving the neck</p>	<ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491)

Indication	Imaging Study
Signs or symptoms suggesting CNS involvement with lymphoma	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) • See: CNS Lymphoma (also known as Microglioma) (ONC-2.7)
Known or suspected bone involvement with lymphoma	<ul style="list-style-type: none"> • MRI without and with contrast of symptomatic or previously involved bony areas <ul style="list-style-type: none"> ◦ Bone scan is inferior to MRI for evaluation of known or suspected bone involvement with lymphoma
Determine a more favorable site for biopsy when a relatively inaccessible site is contemplated	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) <ul style="list-style-type: none"> ◦ PET/CT is medically unnecessary for all other indications prior to histological confirmation of lymphoma
CAR-T cell therapy	<p>Once before treatment and once 30-60 days after completion of treatment:</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)

Classical Hodgkin Lymphoma (ONC-28.2)

ON.HL.0028.2.A

v2.0.2024

- This section applies to nodular sclerosis, mixed cellularity, lymphocyte-depleted and lymphocyte-rich subtypes of Hodgkin lymphoma.

Indication	Imaging Study
Initial Staging/Diagnosis	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) • CT Neck with contrast (CPT[®] 70491) • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Treatment Response	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) as frequently as every 2 cycles
End of Chemotherapy and/or Radiation Therapy Evaluation	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) may be approved at the end of chemotherapy and again at the end of radiation (at least 12 weeks after completion of radiation therapy)
Suspected Recurrence	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s)
Biopsy proven recurrence	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)

Indication	Imaging Study
Surveillance	<p><u>ANY or ALL of the following may be approved every 6 months for 2 years after completion of therapy:</u></p> <ul style="list-style-type: none">• CT Neck with contrast (CPT[®] 70491)• CT Chest with contrast (CPT[®] 71260)• CT Abdomen and Pelvis with contrast (CPT[®] 74177)• CT with contrast of previously involved area(s) <p><u>In addition to the above studies:</u></p> <ul style="list-style-type: none">• A single follow-up PET/CT may be approved at three months if end of therapy PET/CT shows Deauville 4 or 5 FDG avidity

Nodular Lymphocyte – Predominant Hodgkin Lymphoma (ONC-28.3)

ON.HL.0028.3.A

v2.0.2024

Indication	Imaging Study
Initial Staging/Diagnosis	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) • CT Neck with contrast (CPT[®] 70491) • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177)
Treatment Response	<ul style="list-style-type: none"> • CT with contrast of previously involved areas as frequently as every 2 cycles
End of Chemotherapy and/or Radiation Therapy Evaluation	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816) may be approved at the end of chemotherapy and again at the end of radiation (at least 12 weeks after completion of radiation therapy)
Suspected Recurrence	<p>ANY or ALL of the following may be approved:</p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s)
Biopsy proven recurrence	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)

Indication	Imaging Study
<p><u>Suspected transformation (Richter’s) from a low-grade lymphoma to a more aggressive type based on one or more of the following:</u></p> <ul style="list-style-type: none"> • New B symptoms • Rapidly growing lymph nodes • Extranodal disease develops • Significant recent rise in LDH above normal range 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
<p>Surveillance</p>	<p><u>ANY or ALL of the following may be approved every 6 months for 2 years after completion of therapy:</u></p> <ul style="list-style-type: none"> • CT Neck with contrast (CPT[®] 70491) • CT Chest with contrast (CPT[®] 71260) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT with contrast of previously involved area(s) <p><u>In addition to the above studies:</u></p> <ul style="list-style-type: none"> • A single follow-up PET/CT may be approved at three months if end of therapy PET/CT shows Deauville 4 or 5 FDG avidity

References (ONC-28)

v2.0.2024

1. Hoppe RT, Advani RH, Ambinder RF, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2023 – November 8, 2022. Hodgkin lymphoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Hodgkins Lymphoma V2.2023 – November 8, 2022. ©2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment for Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol.* 2014;32(27):3059-3067. doi:10.1200/JCO.2013.54.8800.
3. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *J Clin Oncol.* 2014;32(27):3048-3058. doi:10.1200/JCO.2013.53.5229.
4. Pingali SR, Jewell SW, Havlat L, et al. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. *Cancer.* 2014;120:2122-2129.
5. Ha CS, Hodgson DC, Advani R, et al. Follow-up of Hodgkin lymphoma. ACR Appropriateness Criteria® 2014;1-16.
6. Picardi M, Pugliese N, Cirillo, M et al. Advanced-stage Hodgkin lymphoma: US/Chest radiography for detection of relapse in patients in first complete remission—a randomized trial of routine surveillance imaging procedures. *Radiology.* 2014;272:262-274.
7. Gallamini A, and Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: a compass of a safe navigation in clinical trials? *Blood.* 2012;120(25):4913-4920.
8. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. *J Nucl Med.* 2013; 54(5):683-690.
9. Gallamini A, Barrington SF, Biggi, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. *Haematologica.* 2014; 99(6):1107-1113.
10. El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. *Haematologica.* 2012;97(6):931-936.

Hematopoietic Stem Cell Transplantation (ONC-29)

Guideline

General Considerations for Stem Cell Transplant (ONC-29.1)
Reference (ONC-29)

General Considerations for Stem Cell Transplant (ONC-29.1)

ON.HT.0029.1.A

v2.0.2024

Transplant Types:

Allogeneic (“allo”): The donor and recipient are different people, and there are multiple types depending on the source of the stem cells and degree of match between donor and recipient. This is most commonly used in diseases originating in the hematopoietic system, such as leukemias and lymphomas, and bone marrow failure syndromes or metabolic disorders. Common types are:

- Matched sibling donor (MSD or MRD): Donor and recipient are full siblings and HLA-matched
- Matched unrelated donor (MUD): Donor and recipient are HLA matched but not related to each other
- Cord blood: Donor stem cells come from frozen umbilical cord blood not related to the recipient, sometimes from multiple different donors at once
- Haploidentical transplant (haplo): Donor is a half-HLA match to the recipient, usually a parent

Autologous (“auto”): The donor and recipient are the same person. The process involves delivery of high dose chemotherapy that is ablative to the bone marrow, followed by an infusion of one’s own harvested stem cells.

Allogeneic HSCT results in a much greater degree of immunosuppression than autologous HSCT because of the need to allow the new immune system to chimerize with the recipient’s body. Immune reconstitution commonly takes more than a year for individuals who receive allogeneic HSCT, and individuals remain at high- risk for invasive infections until that has occurred.

Pre-Transplant Imaging in HSCT:

- Pre-transplant imaging in HSCT generally takes place within 30 days prior to transplant and involves a reassessment of the individual’s disease status as well as infectious disease clearance.

Indication	Imaging
Immediate pre-transplant period	<ul style="list-style-type: none"> Chest x-ray <ul style="list-style-type: none"> CT Chest with contrast (CPT[®] 71260) or CT Chest without contrast (CPT[®] 71250) for new findings on chest x-ray, or new/worsening signs/symptoms CT Sinus (CPT[®] 70486) for any clinical signs or symptoms
Assess cardiac function	<ul style="list-style-type: none"> Echocardiogram (CPT[®] 93306, CPT[®] 93307 or CPT[®] 93308) <ul style="list-style-type: none"> MUGA scan (CPT[®] 78472) may be indicated in specific circumstances, see: Oncologic Indications for Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD) (CD-12.1) in the Cardiac Imaging Guidelines
Assess pulmonary function	<ul style="list-style-type: none"> Pulmonary function tests
Assess primary disease status	<ul style="list-style-type: none"> See disease-specific guidelines for end of therapy response assessment

Post-Transplant Imaging in HSCT:

- There are many common complications from HSCT, including infection, acute and chronic graft versus host disease (GVHD), hepatic sinusoidal obstruction syndrome, restrictive lung disease, among others.
- Disease response generally takes place at ~Day +30 (autos and some allos) or ~Day +100 (allos) post-transplant.

Indication	Imaging
Assess known or suspected HSCT complications	<ul style="list-style-type: none"> Site-specific imaging should generally be approved
Suspected hepatic GVHD (elevated liver enzymes)	<ul style="list-style-type: none"> Abdominal US (CPT[®] 76700 or CPT[®] 76705)
Suspected Bronchiolitis Obliterans Syndrome (BOS)	<ul style="list-style-type: none"> CT Chest without contrast (CPT[®] 71250)

Indication	Imaging
Assess primary disease status post-transplant	<ul style="list-style-type: none">• See disease-specific guidelines for end of therapy evaluation and surveillance
Individuals receiving tandem auto transplants (2-4 autos back-to-back, spaced 6 to 8 weeks apart)	<ul style="list-style-type: none">• Guideline recommended imaging can be repeated after each transplant

Reference (ONC-29)

v2.0.2024

1. Loren AW, Mielcarek M, Bolaños-Meade J, et. al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – March 31, 2023. Hematopoietic Cell Transplantation, available at: https://www.nccn.org/professionals/physician_gls/pdf/hct.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Hematopoietic Cell Transplantation V1.2023 – March 31, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines[®] and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines[®], go online to NCCN.org.

Medical Conditions with Cancer in the Differential Diagnosis (ONC-30)

Guideline

Fever of Unknown Origin (FUO) (ONC-30.1)
Unexplained Weight Loss (ONC-30.2)
Paraneoplastic Syndromes (ONC-30.3)
References (ONC-30)

Fever of Unknown Origin (FUO) (ONC-30.1)

ON.MC.0030.1.A

v2.0.2024

- FUO is defined as a persistent fever $\geq 101^{\circ}\text{F}$ and ≥ 3 weeks with unidentified cause.
- While fever is a classic “B” symptom of advanced lymphoma, a cancer-related fever presenting in isolation without any other signs or symptoms of neoplastic disease is rare.

Indication	Imaging Study
If physical examination, Chest X-ray, and laboratory studies are non-diagnostic	<ul style="list-style-type: none"> • Echocardiogram (CPT[®] 93306) • Abdominal ultrasound (CPT[®] 76700) • MRI Brain without and with contrast (CPT[®] 70553)
Above studies (including PE/ENT exam, pelvic exam, and DRE with laboratory studies) have failed to demonstrate site of infection	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast • Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s): CPT[®] 78800, CPT[®] 78801, or CPT[®] 78802, CPT[®] 78804, CPT[®] 78803 or CPT[®] 78831 (SPECT), or CPT[®] 78830, or CPT[®] 78832 (SPECT/CT)
“B” symptoms	<ul style="list-style-type: none"> • See: Non-Hodgkin Lymphomas (ONC-27)
Any CNS sign/symptom accompanied by fever	<ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553)
All individuals	<ul style="list-style-type: none"> • PET is not indicated in the work-up of individuals with FUO

Unexplained Weight Loss (ONC-30.2)

ON.MC.0030.2.A

v2.0.2024

- Unintentional weight loss is defined as loss of ≥ 10 lbs. or $\geq 5\%$ of body weight over 6 months or less, without an identifiable reason.
- Initial workup for all individuals may include appropriate detailed history, physical exam, baseline laboratory studies (e.g., CBC, CMP, HgbA1c, ESR/CRP, infectious workup, stool hemoccult, endocrine evaluation to rule out thyroid, pituitary, or gonadal dysfunction, etc.), chest x-ray, age-appropriate cancer screening, and neurological evaluation to rule out depression/dementia.
- Additional workup is directed to evaluate specific signs, symptoms, red flags, or abnormalities detected on initial workup. See condition-specific imaging guidelines for additional details.
- PET is not appropriate in the work-up of individuals with unexplained weight loss.

Indication	Imaging Study
CNS symptoms or abnormal pituitary hormones	• MRI Brain or Sella Turcica without and with contrast (CPT [®] 70553)
Abnormal thyroid function	• Thyroid ultrasound (CPT [®] 76536)
Abnormal liver function	• Abdominal ultrasound (CPT [®] 76700)
Abnormal kidney function	• Ultrasound kidney and bladder (CPT [®] 76770 or CPT [®] 76775)
Suspected cardiac dysfunction	• Echocardiogram (CPT [®] 93306)
Non-smokers	• Chest x-ray <ul style="list-style-type: none"> ◦ CT Chest with contrast (CPT[®] 71260) to evaluate abnormalities on chest x-ray
Current or former smokers	• CT Chest with contrast (CPT [®] 71260)
Dysphagia or early satiety	• See: Dysphagia and Esophageal Disorders (NECK-3)
GI bleeding	• See: GI Bleeding (AB-22)
Abdominal pain without red flag signs	See: Abdominal Pain (AB-2)

Indication	Imaging Study
<p><u>Suspected pancreatic cancer in individuals aged ≥60 years with weight loss and at least one of the following¹³:</u></p> <ul style="list-style-type: none"> • Diarrhea • Back pain • Abdominal pain • Nausea/vomiting • Constipation • New onset diabetes • Abnormal labs (CA 19-9, LFTs) • Non-diagnostic or negative abdominal ultrasound 	<p>Any ONE of the following may be obtained:</p> <ul style="list-style-type: none"> • CT Abdomen with contrast (CPT[®] 74160) • CT Abdomen and Pelvis with contrast (CPT[®] 74177) • MRI Abdomen without and with contrast (CPT[®] 74183) <p>See also: <u>Epigastric Pain and Dyspepsia (AB-2.5)</u></p>
<p>If all of the above do not identify cause of weight loss</p>	<p>Any of the following, if not previously performed:</p> <ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) • CT Abdomen and Pelvis (CPT[®] 74177) with contrast

Paraneoplastic Syndromes (ONC-30.3)

ON.MC.0030.3.A

v2.0.2024

- Paraneoplastic syndromes are metabolic and neuromuscular disturbances. These syndromes are not directly related to a tumor or to metastatic disease. There may be a lead time between initial finding of a possible paraneoplastic syndrome and appearance of the cancer with imaging. Limited studies suggest annual imaging for 2 years after diagnosis of possible paraneoplastic syndrome may detect cancer, however benefit after 2 years is not well documented.
- The following are the most common symptoms of paraneoplastic syndromes known to arise from various malignancies:
 - Hypertrophic Pulmonary Osteoarthropathy: Often presents as a constellation of rheumatoid-like polyarthritis, periostitis of long bones, and clubbing of fingers and toes
 - Amyloidosis
 - Hypercalcemia
 - Hypophosphatemia
 - Cushing's Syndrome
 - Somatostatinoma syndrome (vomiting, abdominal pain, diarrhea, cholelithiasis)
 - Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
 - Polymyositis/dermatomyositis
 - Opsoclonus
 - Paraneoplastic sensory neuropathy
 - Subacute cerebellar degeneration
 - Eaton-Lambert syndrome (a myasthenia-like syndrome)
 - Second event of unprovoked thrombosis
 - Disseminated Intravascular Coagulation
 - Migratory thrombophlebitis
 - Polycythemia
 - Chronic leukocytosis and/or thrombocytosis
 - Elevated tumor markers
 - Cryptogenic stroke (see also: **HD-21.3**)
- See: **Muscle Disorders (PN-6)** in the Peripheral Nerve Disorders Imaging Guidelines.
- See: **Multiple Myeloma and Plasmacytomas (ONC-25)** for evaluation of possible multiple myeloma.

Indication	Imaging Study
Initial evaluation	<ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast
<p>ANY of the following:</p> <ul style="list-style-type: none"> Abnormality on conventional imaging difficult to biopsy Inconclusive conventional imaging Documented paraneoplastic antibody and conventional imaging fails to demonstrate primary site 	<ul style="list-style-type: none"> PET/CT (CPT[®] 78815 or CPT[®] 78816)
Subsequent evaluation for known paraneoplastic syndrome	<ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast may be repeated every 6 months for 2 years after initial imaging for Lambert-Eaton Myasthenia syndrome CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast may be repeated every 6 months for 4 years for all other paraneoplastic syndromes
Systemic mastocytosis	<p>ANY ONE of the following:</p> <ul style="list-style-type: none"> CT Abdomen and Pelvis (CPT[®] 74177) with contrast MRI Abdomen (CPT[®] 74183) and MRI Pelvis (CPT[®] 72197) without and with contrast is indicated PET/CT scan is not indicated for evaluation of mastocytosis
First episode of unprovoked DVT/VTE	<ul style="list-style-type: none"> Imaging to evaluate for malignancy is not indicated
Second unprovoked DVT/PE	<ul style="list-style-type: none"> Imaging may be considered in the setting of a negative work-up for inherited thrombophilia and antiphospholipid syndrome
<p>Thyroid US is recommended for elevated CEA, and upper/lower endoscopy is recommended for elevated CEA or CA 19-9.</p>	

References (ONC-30)

v2.0.2024

1. Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for occult cancer in unprovoked venous thromboembolism. *N Engl J Med*. 2015 June;373:697-704. doi:10.1056/NEJMoa1506623.
2. Sioka C, Fotopoulos A, Kyritsis AP. Paraneoplastic neurological syndromes and the role of PET imaging. *Oncology*. 2010;78(2):150–156. doi:10.1159/000312657.
3. Schramm N, Rominger A, Schmidt C, et al. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT. *Eur J Nucl Med Mol Imaging*. 2013;40(7):1014-1024. doi:10.1007/s00259-013-2372-4.
4. Qiu L, Chen Y. The role of 18F-FDG PET or PET/CT in the detection of fever of unknown origin. *Eur J Radiol*. 2012;81(11):3524-3529. doi:10.1016/j.ejrad.2012.05.025.
5. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. *Mayo Clin Proc*. 2010;85(9):838-854. doi:10.4065/mcp.2010.0099.
6. Wong CJ. Involuntary weight loss. *Med Clin North Am*. 2014;98(3):625-43. doi:10.1016/j.mcna.2014.01.012.
7. Titulaer MJ, Soffieti R, Dalmau J, et al. Screening of tumours in paraneoplastic syndromes: report of an EFNS task force. *Eur J Neurol*. 2011;18(1):19–e3. doi:10.1111/j.1468-1331.2010.03220.x.
8. Lancaster E. Paraneoplastic disorders. *Continuum (Minneapolis)*. 2017;23(6, Neuro-oncology):1653-1679. doi:10.1212/CON.0000000000000542.
9. Gerds AT, Gotlib J, Ali H, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2022 – April 14, 2022. Systemic Mastocytosis, available at: https://www.nccn.org/professionals/physician_gls/pdf/mastocytosis.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Systemic Mastocytosis V1.2022 – April 14, 2022. ©2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
10. Saver JL. Cryptogenic stroke. *N Engl J Med*. 2016;374:2065-2074. doi:10.1056/NEJMcp1503946.
11. Schwarzbach CJ, Schaefer A, Ebert A, et al. Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. *Stroke*. 2012;43(11):3029-3034. doi:10.1161/STROKEAHA.112.658625.
12. Kamel H, Merkler AE, Iadecola C, Gupta A, Navi B. Tailoring the approach to embolic stroke of undetermined source: a review. *JAMA Neurol*. 2019;76(7):855-861. doi:10.1001/jamaneurol.2019.0591.
13. National Institute for Health and Care Excellence (NICE). Upper gastrointestinal tract cancers. In: Suspected cancer: recognition and referral. 2015. <https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer#upper-gastrointestinal-tract-cancers>

Metastatic Cancer, Carcinoma of Unknown Primary Site, and Other Types of Cancer (ONC-31)

Guideline

- General Guidelines (ONC-31.0)
- Lung Metastases (ONC-31.1)
- Liver Metastases (ONC-31.2)
- Brain Metastases (ONC-31.3)
- Adrenal Gland Metastases (ONC-31.4)
- Bone (Including Non-Vertebral) Metastases (ONC-31.5)
- Spinal/Vertebral Metastases (ONC-31.6)
- Carcinoma of Unknown Primary Site (ONC-31.7)
- Extrathoracic Small Cell and Large Cell Neuroendocrine Tumors (ONC-31.8)
- Primary Peritoneal Mesothelioma (ONC-31.9)
- Kaposi's Sarcoma (ONC-31.10)
- Castleman's Disease (Unicentric and Multicentric) (ONC-31.11)
- References (ONC-31)

General Guidelines (ONC-31.0)

ON.UP.0031.0.A

v2.0.2024

- Guideline sections **Lung Metastases (ONC-31.1)** through **Bone (Non-Vertebral) Metastases (ONC-31.5)** should only be used for individuals with metastatic cancer in the following circumstances:
 - The primary diagnosis section does not address a particular metastatic site that is addressed in these sections
 - The cancer type is rare and does not have its own diagnosis-specific imaging guidelines

Lung Metastases (ONC-31.1)

ON.UP.0031.1.A
v2.0.2024

Indication	Imaging Study
New or worsening signs or symptoms suggestive of metastatic lung involvement or new or worsening chest x-ray abnormality	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) • CT Chest without contrast (CPT[®] 71250) can be approved if there is a contraindication to CT contrast or only parenchymal lesions are being evaluated
Chest wall or brachial plexus involvement	<ul style="list-style-type: none"> • MRI Chest without and with contrast (CPT[®] 71552)
<p><u>ONE of the following and no diagnosis-specific guideline regarding PET imaging:</u></p> <ul style="list-style-type: none"> • Lung nodule(s) ≥8 mm • Confirm solitary metastasis amenable to resection on conventional imaging 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815) • When primary cancer known, PET request should be reviewed by primary cancer guideline
Previous or current malignancy and pulmonary nodule(s) that would reasonably metastasize to the lungs	<ul style="list-style-type: none"> • CT Chest with contrast (CPT[®] 71260) at 3, 6, 12, and 24 months from the first study

Liver Metastases (ONC-31.2)

ON.UP.0031.2.A

v2.0.2024

- Ablation of liver metastases or primary HCC may be performed utilizing chemical, chemotherapeutic, radiofrequency, or radioactive isotope. Regardless of the modality of ablation, PET is not indicated for assessing response to this mode of therapy.

Indication	Imaging Study
New or worsening signs or symptoms suggestive of metastatic liver involvement or new elevation in LFTs	<ul style="list-style-type: none"> • CT Abdomen with (CPT[®] 74160) or without and with (CPT[®] 74170) contrast
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Considering limited resection • Inconclusive CT findings 	<ul style="list-style-type: none"> • MRI Abdomen without and with contrast (CPT[®] 74183)
<p>ONE of the following and no diagnosis-specific guideline regarding PET imaging:</p> <ul style="list-style-type: none"> • Confirm solitary metastasis amenable to resection on conventional imaging • LFT's and/or tumor markers continue to rise and CT and MRI are negative 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815) <ul style="list-style-type: none"> ◦ When primary cancer known, PET request should be reviewed by primary cancer guideline
Monitoring of liver metastases that have been surgically resected	<ul style="list-style-type: none"> • Review according to primary cancer guideline
Evaluation of hepatic artery chemotherapy infusion or TACE (transarterial chemoembolization)	<p>ONE of the following studies, if not previously done:</p> <ul style="list-style-type: none"> • CT Abdomen without and with contrast (CPT[®] 74170) • MRI Abdomen without and with contrast (CPT[®] 74183)

Indication	Imaging Study
<p>Evaluation for hepatic artery radioembolization with Y-90 radioactive spheres (TheraSphere or SIR Spheres) for liver metastases or primary liver tumors</p>	<p>To assess hepatic vascular anatomy before the procedure, any ONE of the following:</p> <ul style="list-style-type: none"> • 3D Rendering (CPT[®] 76377) if conventional hepatic angiogram is being performed • CTA Abdomen (CPT[®] 74175) <p><u>ONE of the following studies may be approved PRE-treatment based upon provider preference:</u></p> <ul style="list-style-type: none"> • Liver Imaging Planar (CPT[®] 78201) • Radiopharmaceutical Localization Limited Area (CPT[®] 78800 or CPT[®] 78801) • SPECT or SPECT/CT (CPT[®] 78803, 78831, 78830, or 78832) <p><u>ONE of the following studies may be approved POST-treatment based upon provider preference:</u></p> <ul style="list-style-type: none"> • Liver Planar Imaging (CPT[®] 78201) • Radiopharmaceutical Localization Limited Area (CPT[®] 78800 or CPT[®] 78801) • SPECT or SPECT/CT (CPT[®] 78803, 78831, 78830, or 78832) <p>Please note: liver-lung shunt calculation is included in the pre-treatment Liver Scan and does not require additional Lung Perfusion Scan</p>
<p>Monitoring of ablated liver metastases or primary tumors</p>	<p><u>ONE of the following, immediately prior to ablation, 1 month post-ablation, then every 3 months for 2 years, and then every 6 months until year 5:</u></p> <ul style="list-style-type: none"> • CT Abdomen without and with contrast (CPT[®] 74170) • MRI Abdomen without and with contrast (CPT[®] 74183)

Brain Metastases (ONC-31.3)

ON.UP.0031.3.A
v2.0.2024

Indication	Imaging Study
Individual with cancer and signs or symptoms of CNS disease or known brain metastasis with new signs or symptoms.	<ul style="list-style-type: none"> MRI Brain without and with contrast (CPT[®] 70553)
To determine candidacy for SRS, and a diagnostic thin-slice MRI Brain has not been performed in the preceding 30 days	<ul style="list-style-type: none"> MRI Brain without and with contrast (CPT[®] 70553)
Stereotactic radiosurgery planning	<ul style="list-style-type: none"> Unlisted MRI for treatment planning purposes (CPT[®] 76498)
Monitoring of brain metastases treated with surgery or radiation therapy	<p><u>Post-treatment, then every 3 months for 1 year and every 6 months thereafter:</u></p> <ul style="list-style-type: none"> MRI Brain without and with contrast (CPT[®] 70553) <p>***Individuals treated with stereotactic radiosurgery alone may have MRI Brain without and with contrast (CPT[®] 70553) immediately after stereotactic radiosurgery, then every 2 months for the first year, and then every 6 months thereafter</p>
Brain metastases treated with radiation therapy, with recent MRI Brain indeterminate in distinguishing radiation necrosis vs. tumor progression	<ul style="list-style-type: none"> MRI Perfusion imaging (CPT[®] 70553)

Indication	Imaging Study
Brain metastases treated with radiation therapy, with recent MRI Brain and MR Perfusion studies both unable to distinguish radiation necrosis vs. tumor progression	<ul style="list-style-type: none"> • PET Metabolic Brain (CPT[®] 78608)
<p><u>Any of the following:</u></p> <ul style="list-style-type: none"> • Solitary brain metastasis suspected in individual with prior diagnosis of cancer and no diagnosis-specific guideline regarding PET imaging • Brain metastases and no known primary tumor 	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast • Mammography for female individuals • PET/CT (CPT[®] 78815 or CPT[®] 78816) is indicated for ANY of the following: <ul style="list-style-type: none"> ◦ Inconclusive conventional imaging ◦ Confirm either stable systemic disease or absence of other metastatic disease ◦ When primary cancer known, PET request should be reviewed by primary cancer guideline
Primary brain tumors	See: <u>Primary Central Nervous System Tumors (ONC-2)</u>
MR Spectroscopy (CPT [®] 76390) is considered investigational and experimental for evaluation of metastatic brain cancer	

Adrenal Gland Metastases (ONC-31.4)

ON.UP.0031.4.A

v2.0.2024

Indication	Imaging Study
Differentiate benign adrenal adenoma from metastatic disease	<ul style="list-style-type: none"> • See: Adrenal Cortical Lesions (AB-16.1) in the Abdomen Imaging Guidelines
<p><u>Known cancer and no known systemic metastases:</u></p> <ul style="list-style-type: none"> • New adrenal mass • Enlarging adrenal mass • Inconclusive findings on recent CT 	<p>If not done previously, <u>ANY</u> of the following may be obtained:</p> <ul style="list-style-type: none"> • CT Abdomen without contrast (CPT[®] 74150) • CT Abdomen without and with contrast (CPT[®] 74170, adrenal protocol) • MRI Abdomen without contrast (CPT[®] 74181) • MRI Abdomen without and with contrast (CPT[®] 74183) • CT-directed needle biopsy (CPT[®] 77012)
<p><u>One of the following and no diagnosis-specific guideline regarding PET imaging:</u></p> <ul style="list-style-type: none"> • Biopsy is not feasible or is non-diagnostic • Isolated metastasis on conventional imaging and individual is a candidate for aggressive surgical management 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815) <p>When primary cancer known, PET request should be reviewed by primary cancer guideline</p>
Known extra-adrenal malignancy and undiagnosed adrenal mass being monitored off treatment	See: Phases of Oncology Imaging and General Phase-Related Considerations (ONC-1.2)

Bone (Including Non-Vertebral) Metastases (ONC-31.5)

ON.UP.0031.5.A

v2.0.2024

Indication	Imaging Study
<p><u>ANY of the following in an individual with a current or prior malignancy:</u></p> <ul style="list-style-type: none"> • Bone pain • Rising tumor markers • Elevated alkaline phosphatase 	<ul style="list-style-type: none"> • Bone scan supplemented by plain x-rays is the initial diagnostic imaging study of choice (see: Nuclear Medicine (NM) Imaging in Oncology [ONC-1.3])
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Bone scan is not feasible or readily available • Bone scan is equivocal or indeterminate • Continued suspicion despite negative/inconclusive bone scan or other imaging modalities • Soft tissue component suspected on other imaging modalities • Differentiate neoplastic disease from Paget's disease of the bone 	<p><u>ANY one of the following:</u></p> <ul style="list-style-type: none"> • MRI without and with contrast of the involved body site • CT without or with contrast of the involved body site
<p>Bone metastases suspected and both bone scan and either CT or MRI are inconclusive</p>	<ul style="list-style-type: none"> • ¹⁸F-FDG-PET/CT (CPT[®] 78815 or CPT[®] 78816)
<p>Suspected metastatic bone disease and negative work-up for myeloma</p>	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast
<p>No prior cancer history with suspected pathologic fracture on plain x-ray</p>	<ul style="list-style-type: none"> • See: <u>Carcinoma of Unknown Primary Site (ONC-31.7)</u>

Spinal/Vertebral Metastases (ONC-31.6)

ON.UP.0031.6.A

v2.0.2024

- Individuals with stage IV cancer with new onset back pain can forgo a bone scan (and plain films) in lieu of an MRI with and without contrast of the spine.

Indication	Imaging Study
<p><u>Known cancer history and spinal cord compression suspected based on signs/symptoms of neurological compromise, including, but not limited to:</u></p> <ul style="list-style-type: none"> Unexpected, sudden loss of bowel or bladder control Sudden loss of ability to ambulate Complete loss of pinprick sensation corresponding to a specific vertebral level Loss of pain at a site that had previously been refractory to pain management 	<p>MRI Cervical (CPT[®] 72156), MRI Thoracic (CPT[®] 72157), and MRI Lumbar Spine (CPT[®] 72158) without and with contrast OR without contrast</p> <ul style="list-style-type: none"> CT Cervical (CPT[®] 72126), CT Thoracic (CPT[®] 72129), and CT Lumbar (CPT[®] 72132) Spine if MRI is contraindicated

Indication	Imaging Study
<p><u>Individual with a known history of cancer and ANY of the following:</u></p> <ul style="list-style-type: none"> • Metastatic or stage IV cancer with new or worsening back pain • Back pain and suspicion of spinal malignancy based on any one of the following: <ul style="list-style-type: none"> ◦ Night pain ◦ Age >70 years ◦ Uncontrolled or unintentional weight loss ◦ Pain unrelieved by change in position ◦ Severe and worsening spinal pain despite a reasonable (generally after 1 week) trial of provider-directed treatment with re-evaluation 	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • MRI of the relevant spinal level without contrast • MRI of the relevant spinal level without and with contrast • CT of the relevant spinal level without contrast • CT Myelogram of the relevant spinal level
<p><u>Monitoring untreated vertebral metastases</u></p>	<p><u>One of the following, every 3 months for 1 year:</u></p> <ul style="list-style-type: none"> • MRI without and with contrast of the involved spinal level • CT without or with contrast of the involved spinal level <p>**Imaging beyond 1 year is based on any new clinical signs/symptoms</p>
<p><u>Monitoring metastases within the spine treated with surgery and/or radiation therapy</u></p>	<p><u>One of the following, once within 3 months post-treatment, and then every 3 months for 1 year:</u></p> <ul style="list-style-type: none"> • MRI without and with contrast of the involved spinal level • CT without or with contrast of the involved spinal level <p>**Imaging beyond 1 year is based on any new clinical signs/symptoms</p>

Indication	Imaging Study
<p>Leptomeningeal involvement with cancer</p>	<p><u>Suspected:</u></p> <ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) and MRI Cervical (CPT[®] 72156), Thoracic (CPT[®] 72157), and Lumbar spine (CPT[®] 72158) without and with contrast • CT Cervical (CPT[®] 72127), Thoracic (CPT[®] 72130), and Lumbar Spine (CPT[®] 72133) without and with contrast can be approved if MRI is contraindicated or not readily available <p><u>On active treatment:</u></p> <ul style="list-style-type: none"> • MRI Brain without and with contrast (CPT[®] 70553) and MRI Cervical (CPT[®] 72156), Thoracic (CPT[®] 72157), and Lumbar spine (CPT[®] 72158) without and with contrast every 2 cycles • CT with or without contrast of the involved spinal level if MRI is contraindicated <p><u>Once treatment completed:</u></p> <ul style="list-style-type: none"> • Routine advanced imaging not indicated for surveillance in asymptomatic individuals

Carcinoma of Unknown Primary Site (ONC-31.7)

ON.UP.0031.7.A
v2.0.2024

General Considerations

- Defined as carcinoma found in a lymph node or in an organ known not to be the primary for that cell type (e.g., adenocarcinoma arising in the brain or in a neck lymph node).
- This guideline also applies to a pathologic fracture that is clearly due to metastatic neoplastic disease in an individual without a previous cancer history.
- Detailed history and physical examination including pelvic and rectal exams and laboratory tests to be performed before advanced imaging.
- Individuals presenting with a thoracic squamous cell carcinoma described as metastatic appearing on chest imaging, or in lymph nodes above the clavicle, should undergo a detailed head and neck examination by a clinician skilled in laryngeal and pharyngeal examinations, especially in smokers.
- Individuals with suspected unknown primary based on only suspicious lytic bone lesions should be considered for serum protein electrophoresis (SPEP); urine protein electrophoresis (UPEP) and serum free light chains prior to consideration of extensive imaging.

Indication	Imaging Study
Carcinoma found in a lymph node or in an organ known not to be primary	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Neck with contrast (CPT[®] 70491) if cervical or supraclavicular involvement • CT with contrast or MRI without and with contrast of any other symptomatic site • For female individuals: <ul style="list-style-type: none"> ◦ Diagnostic (not screening) mammogram and full pelvic exam ◦ MRI Breasts Bilateral (CPT[®] 77049) if pathology consistent with breast primary and mammogram is inconclusive

Indication	Imaging Study
Sebaceous carcinoma of the skin (can be associated with underlying primary malignancy)	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177) • CT Neck with contrast (CPT[®] 70491) if cervical or supraclavicular involvement • CT with contrast or MRI without and with contrast of any other symptomatic site
Axillary adenocarcinoma	<ul style="list-style-type: none"> • Diagnostic (not screening) mammogram and full pelvic exam • MRI Breasts Bilateral (CPT[®] 77049) if pathology consistent with breast primary and mammogram is inconclusive • If the above are non-diagnostic for primary site: <ul style="list-style-type: none"> ◦ CT Neck (CPT[®] 70491), CT Chest (CPT[®] 71260), and CT Abdomen (CPT[®] 74160) with contrast ◦ CT with contrast or MRI without and with contrast of any other symptomatic site
Carcinoma found within a bone lesion	<ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis with contrast (CPT[®] 74177) • Bone Scan (see: ONC-1.3) • CT with contrast or MRI without and with contrast of any symptomatic site
<p>ANY of the following:</p> <ul style="list-style-type: none"> • Above studies have failed to demonstrate site of primary • CT scans reveal isolated metastatic disease for which definitive curative therapy is planned 	<ul style="list-style-type: none"> • PET/CT (CPT[®] 78815 or CPT[®] 78816)
Post-treatment surveillance	<ul style="list-style-type: none"> • Advanced imaging is not indicated for routine surveillance of asymptomatic individuals after treatment completion

Extrathoracic Small Cell and Large Cell Neuroendocrine Tumors (ONC-31.8)

ON.UP.0031.8.A

v2.0.2024

All poorly-differentiated or high-grade, small cell and large cell neuroendocrine tumors arising outside the lungs or of unknown primary origin are imaged according to these guidelines.

Indication	Imaging Study
Initial staging	<ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast
Inconclusive findings on conventional imaging studies	<ul style="list-style-type: none"> PET/CT (CPT[®] 78815)
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> Poorly differentiated neuroendocrine cancers of the head or neck Signs or symptoms of CNS involvement 	<ul style="list-style-type: none"> MRI Brain without and with contrast (CPT[®] 70553)
Restaging during treatment	<ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) and any known sites of disease with contrast every 2 cycles
Suspected Recurrence	<p><u>ANY or ALL of the following are indicated:</u></p> <ul style="list-style-type: none"> CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast MRI Brain without and with contrast (CPT[®] 70553) Bone scan (See: Nuclear Medicine (NM) Imaging in Oncology (ONC-1.3)) PET imaging is generally not indicated but can be considered for rare circumstances.

Indication	Imaging Study
Surveillance	<ul style="list-style-type: none">• CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast every 3 months for 1 year, then every 6 months for 4 additional years and then annually

Primary Peritoneal Mesothelioma (ONC-31.9)

ON.UP.0031.9.A

v2.0.2024

Indication	Imaging Study
Initial staging	<ul style="list-style-type: none">• CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast• PET/CT (CPT[®] 78815) if there is no evidence of metastatic disease or conventional imaging is inconclusive
Recurrence/ Restaging	<ul style="list-style-type: none">• If there is known prior disease, CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast• PET for inconclusive finding on conventional imaging
Surveillance	<ul style="list-style-type: none">• CT Abdomen and Pelvis with contrast (CPT[®] 74177) every 3 months for 2 years, then every year of life

Kaposi's Sarcoma (ONC-31.10)

ON.UP.0031.10.A

v2.0.2024

Indication	Imaging Study
Kaposi's Sarcoma	<ul style="list-style-type: none">Advanced imaging is not generally indicated since disease is generally localized to skin.CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast can be approved at initial diagnosis. If initial scans are negative then future imaging would be based on signs or symptoms.

Castleman’s Disease (Unicentric and Multicentric) (ONC-31.11)

ON.UP.0031.11.A

v2.0.2024

Indication	Imaging Study
Initial staging	<ul style="list-style-type: none"> • Either CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast or PET/CT (CPT[®] 78815) • CT Neck with contrast (CPT[®] 70491) if cervical or supraclavicular involvement • If CT scans were utilized initially and suggested unicentric disease, and surgical resection is being considered, PET/CT (CPT[®] 78815) can be approved to confirm unicentric disease • If unicentric disease is surgically removed, proceed to Surveillance section
<p><u>Restaging:</u></p> <ul style="list-style-type: none"> • Multicentric disease or surgically unresected unicentric disease on chemotherapy 	<p><u>ONE of the following every 2 cycles:</u></p> <ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast • PET/CT (CPT[®] 78815)
<p><u>ANY of the following:</u></p> <ul style="list-style-type: none"> • Suspected recurrence • Recurrent B symptoms • Rising LDH/IL-6/VEGF levels 	<p><u>ONE of the following:</u></p> <ul style="list-style-type: none"> • CT Chest (CPT[®] 71260) and CT Abdomen and Pelvis (CPT[®] 74177) with contrast • PET/CT (CPT[®] 78815)
Surveillance	<ul style="list-style-type: none"> • CT with contrast of involved areas no more than every 6 months up to 5 years

References (ONC-31)

v2.0.2024

1. Ettinger DS, Stevenson MM, Ahn D, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 – December 21, 2022. Occult primary, available at: https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Occult Primary V3.2023 – December 21, 2022 ©2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
2. Nabors BL, Portnow J, Baehring J, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – March 24, 2023. Central Nervous System Cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for CNS Cancer V1.2023 – March 24, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
3. Zelenetz AD, Gordon LI, Abramson JS, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 5.2023 – July 7, 2023. B-cell lymphomas, available at: https://www.nccn.org/professionals/physician_gls/pdf/B-CELL.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for B-cell lymphomas V5.2023 – July 7, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
4. Mayo-Smith WM, Song JH, Boland GL, et al. Management of incidental adrenal masses: a white paper of the ACR Incidental Findings Committee. *J Am Coll Radiol*. 2017;14(8):1038-1044. doi:10.1016/j.jacr.2017.05.001.
5. ACR Appropriateness Criteria®. *Incidentally discovered adrenal mass*. Rev. 2012.
6. Braat AJ, Smits ML, Braat MN, et al. 90Y hepatic radioembolization: an update on current practice and recent developments. *J Nucl Med*. 2015;56(7):1079–1087. doi:10.2967/jnumed.115.157446.
7. Pawaskar AS, Basu S. Role of 2-fluoro-2-deoxyglucose PET/computed tomography in carcinoma of unknown primary. *PET Clin*. 2015;10(3):297-310. doi:10.1016/j.cpet.2015.03.004.
8. Avram AM. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. *J Nucl Med*. 2012;53(5): 754-764. doi:10.2967/jnumed.111.104133.
9. Mayo-Smith WW, Song JH, Boland GL, et al. Management of incidental adrenal masses: a white paper of the ACR Incidental Findings Committee. *J Am Coll Radiol*. 2017;14(8):1038-1044. doi:10.1016/j.jacr.2017.05.001.
10. Vaidya A, Hamrahan A, Bancos I, Fleseriu M, Ghayee HK. The evaluation of incidentally discovered adrenal masses. *Endocrine Practice*. 2019;25(2):178-192. doi: 10.4158/DSCR-2018-0565.
11. Bergsland E, Goldner WS, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – August 2, 2023. Neuroendocrine and Adrenal Tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Neuroendocrine and Adrenal Tumors V1.2023 – August 2, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
12. Furuse M, Nonoguchi N, Yamada K, et al. Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review. *Radiat Oncol*. 2019;14(28). doi:10.1186/s13014-019-1228-x.
13. American College of Radiology. ACR practice parameter for the performance of stereotactic radiosurgery. 2016; <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/stereobrain.pdf>

14. Soffiotti R, Abacioglu U, Baumert B, et. al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). *Neuro-Oncology*. 2017;19(2):162-174. doi:10.1093/neuonc/now241.
15. Mehrabian H, Detsky J, Soliman H, Sahgal A, Stanisiz GJ. Advanced magnetic resonance imaging techniques in management of brain metastases. *Front Oncol*. 2019;9(440). doi:10.3389/fonc.2019.00440.
16. Murthy R, Nunez R, Szklaruk J, et. al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations and potential complications. *RadioGraphics*. 2005;25:S41–S55. doi:10.1148/rg.25si055515.
17. Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. *Semin Intervent Radiol*. 2013;30(1):3-11. doi:10.1055/s-0033-1333648.

Policy History and Instructions for Use

Guideline

Policy History and Instructions for Use

Policy History and Instructions for Use

Policy History and Instructions for Use v2.0.2024

Instructions for Use

This Medical Policy provides assistance in interpreting United HealthCare Services, Inc. standard benefit plans. When deciding coverage, the federal, state (Ohio Administrative Code [OAC]) or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state (OAC) or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state (OAC) or contractual requirements for benefit plan coverage govern.

Before using this policy, please check the federal, state (OAC) or contractual requirements for benefit plan coverage. United HealthCare Services, Inc. reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

United HealthCare Services, Inc. uses InterQual[®] for the primary medical/surgical criteria, and the American Society of Addiction Medicine (ASAM) for substance use, in administering health benefits. If InterQual[®] does not have applicable criteria, United HealthCare Services, Inc. may also use United HealthCare Services, Inc.'s Medical Policies, Coverage Determination Guidelines, and/or Utilization Review Guidelines that have been approved by the Ohio Department for Medicaid Services. The United HealthCare Services, Inc.'s Medical Policies, Coverage Determination Guidelines, and Utilization Review Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Policy History/Revision Information

Date	Summary of Changes
02/01/2024	Annual evidence-based updates
07/01/2024	Interim evidence-based updates and minor editorial updates